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Abstract 
Human spermatozoa cryopreservation is currently the only method that offers men 
with cancer some insurance against iatrogenic clinical interventions. Unfortunately, 
semen quality before cryopreservation and following thawing proves highly 
variable. This has negative implications for both fertility preservation and future 
assisted conception treatment choice, which itself proves highly variable. There is 
a general lack of data on the men who require the local service, and those men 
who use their stored gametes. There is uncertainty concerning the outcome 
measures used to evaluate sample quality; the threshold limits for selecting 
assisted conception treatment; the cryopreservation method itself; and how an 
individual patient or ejaculate will respond to sperm cryopreservation. 
 
The aim of this research was to characterise a population of men with cancer 
referred for sperm cryopreservation, and to define and quantify the sources of 
uncertainty that limit fertility insurance and future assisted conception choice. It 
was found that an innovative quality tool and computer assisted semen analysis 
had potential to improve the analysis of sperm quality, and that a unique freezing 
receptacle could improve that quality. Men with testicular or prostate cancer, poor 
semen quality or poor living conditions were more likely to need additional 
samples frozen. For men with cancer, motile count recovery following sperm 
cryopreservation may indicate the severity of their disease. In addition, there was 
evidence that intra cytoplasmic sperm injection is being used unnecessarily for 
cancer patients. Although the numbers of men with cancer seeking the service is 
dramatically increasing, currently we are not storing enough sperm to meet the 
needs of most cancer patients who use their stored samples. The findings in this 
thesis highlight the need for change to current practice and policy for sperm 
banking for cancer patients in the National Health Service.  
  
3 
 
Contents Page 
Abstract………… ................................................................................................................ 2 
Contents Page ................................................................................................................. 3 
Declaration and Word Count ........................................................................................... 6 
List of Tables …………………………………………………………………………………………………………7 
List of Figures ................................................................................................................ 12 
Acknowledgements and Dedication ............................................................................. 20 
Overall Aim, Hypothesis and Objectives...................................................................... 22 
Chapter 1 Introduction............................................................................................. 24 
1.1 Literature Search .............................................................................................. 24 
1.2 Spermatozoa Cryopreservation ........................................................................ 24 
1.2.1 Introduction................................................................................................... 24 
1.2.2 Sperm Banking for Cancer Patients .............................................................. 26 
1.2.3 Regulation of Sperm Cryopreservation ......................................................... 28 
1.2.4 Cryopreservation Related Spermatozoa Injury ............................................. 31 
1.2.5 Assisted Conception with Cryopreserved Spermatozoa................................ 33 
1.2.6 The Rise of ICSI ........................................................................................... 35 
1.2.7 Spermatozoa Cryopreservation Variance ..................................................... 37 
1.3 Semen Analysis................................................................................................ 41 
1.3.1 Introduction................................................................................................... 41 
1.3.2 Spermatozoa Counting ................................................................................. 45 
1.3.3 Motility .......................................................................................................... 48 
1.3.4 Morphology................................................................................................... 51 
1.3.5 Reference Limits .......................................................................................... 55 
1.4 Variance ........................................................................................................... 57 
1.4.1 Introduction................................................................................................... 57 
1.4.2 Measurement Uncertainty ............................................................................. 57 
1.4.3 Semen Analysis Variance ............................................................................. 60 
1.4.4 Biological Variance, Lifestyle and Environmental Factors ............................. 64 
  
4 
 
Chapter 2 Trends in a London NHS Sperm Bank for Men with Cancer ................ 66 
2.1 Introduction ...................................................................................................... 66 
2.2 Methods ........................................................................................................... 67 
2.3 Results ............................................................................................................. 70 
2.4 Discussion ........................................................................................................ 77 
Chapter 3 Measurement Uncertainty in Semen Analysis ...................................... 83 
3.1 Introduction ...................................................................................................... 83 
3.2 Methods ........................................................................................................... 84 
3.3 Results ............................................................................................................. 88 
3.4 Discussion ........................................................................................................ 98 
Chapter 4 CASA: A Solution to High Measurement Uncertainty ........................ 104 
4.1 Introduction .................................................................................................... 104 
4.2 Methods ......................................................................................................... 105 
4.2.1 General Methods and statistics ................................................................... 105 
4.2.2 Methods Part A: CASA Count ..................................................................... 107 
4.2.3 Methods Part B: CASA Motility ................................................................... 113 
4.2.4 Methods Part C: CASA Morphology ........................................................... 117 
4.3 Results ........................................................................................................... 121 
4.3.1 Part A: CASA Count ................................................................................... 121 
4.3.2 Results Part B: CASA Motility ..................................................................... 136 
4.3.3 Results Part C: CASA Morphology ............................................................. 146 
4.4 Discussion ...................................................................................................... 157 
4.4.1 Part A: CASA Count ................................................................................... 157 
4.4.2 Discussion Part B: CASA Motility ................................................................ 160 
4.4.3 Discussion Part C: CASA Morphology ........................................................ 164 
4.4.4 CASA Validation Conclusion ...................................................................... 167 
Chapter 5 Uncertainty of Threshold Values for Assisted Conception ............... 169 
5.1 Introduction .................................................................................................... 169 
5.2 Methods ......................................................................................................... 170 
  
5 
 
5.3 Results IUI Threshold Values ......................................................................... 178 
5.4 Results IVF / ICSI Threshold Values .............................................................. 189 
5.5 Discussion ...................................................................................................... 196 
Chapter 6 Egg Yolk and the CoolCell ................................................................... 205 
6.1 Introduction .................................................................................................... 205 
6.2 Methods ......................................................................................................... 206 
6.3 Results ........................................................................................................... 211 
6.4 Discussion ...................................................................................................... 220 
Chapter 7 Cryopreservation Uncertainty and Prediction .................................... 226 
7.1 Introduction .................................................................................................... 226 
7.2 Methods ......................................................................................................... 227 
7.3 Results ........................................................................................................... 233 
7.4 Discussion ...................................................................................................... 248 
Chapter 8 General Discussion .............................................................................. 256 
8.1 Original Contribution to Knowledge ................................................................ 256 
8.2 Implications for Practice and Policy ................................................................ 259 
8.3 Limitations ...................................................................................................... 264 
8.4 Theoretical Implications and Future Work....................................................... 265 
8.5 Final Conclusion ............................................................................................. 269 
References………………………………………………………………………………………………………… 270 
Appendices……………………………………………………………………………………………………….. 288 
9.1 Appendix A Chapter Three Supplementary Results ........................................ 288 
9.2 Appendix B Chapter Four Supplementary Results .......................................... 290 
9.3 Appendix C Chapter Five Supplementary Results .......................................... 291 
9.4 Appendix D Chapter Seven Supplementary Results ....................................... 295 
9.5 Appendix E Ethics Committee Favourable Opinion ........................................ 308 
9.6 Appendix F URP16 Form for Ethics ................................................................ 311 
 Journal Publications from this Thesis ...................................................................... 313 
 
  
6 
 
Declaration and Word Count 
 
 
Whilst registered as a candidate for this PhD  
I have not been registered for any other research award.  
 
 
The results and conclusions embodied in this thesis are the work of  
Chey Gordon Dearing 
 and have not been submitted for any other academic award 
 
 
 
 
 
 
 
Word Count: 39526 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
7 
 
List of Tables 
Table 1-1 Published sperm banking studies for men with cancer. ................................... 26 
Table 1-2 Relevant UK legal requirements for sperm cryopreservation from the Human 
Fertilisation and Embryology Authorities Code of Practice. .............................................. 30 
Table 1-3 ART success with cryopreserved sperm .......................................................... 34 
Table 1-4 Semen analysis and fertility outcome measures. ............................................. 42 
Table 1-5 CASA and fertility outcome measures. ............................................................ 44 
Table 1-6 WHO guidelines for grading sperm as “Normal” .............................................. 51 
Table 1-7 Indices of sperm abnormality and prognostic potential. ................................... 52 
Table 1-8 Bottom up MU calculation for semen analysis clinical laboratories .................. 59 
Table 1-9 Top down MU calculation for clinical laboratories ............................................ 59 
Table 1-10 Evidence for poor semen analysis methodology ............................................ 61 
Table 1-11 Between-operator variance in semen analysis ............................................... 63 
Table 2-1 Past, current and projected cost of storing sperm based on numbers of new 
patients and the cost of storage in line with an inflation measure (4%). ........................... 71 
Table 2-2 Median semen analysis parameter values of first ejaculates of men with cancer 
(n=3062) compared by specific cancer diagnosis. ........................................................... 74 
Table 2-3 Semen analysis parameter percentiles for men with cancer (n=3062) compared 
with the WHO 2010 reference values. .............................................................................. 74 
Table 2-4 Percentiles of pre-freeze semen characteristics from men with cancer (n=183) 
are compared by ART selection with frozen / thawed sperm. ........................................... 76 
Table 3-1 Sperm count and D class WHO motility drift within operators and bias between-
operators compared before and after IQCT introduction. ................................................. 91 
Table 3-2 WHO motility classes median results from 500 patients for each of four 
operators post IQCT. ....................................................................................................... 93 
Table 4-1 steps, chemicals and timings used for Papanicolaou stain steps ................... 118 
Table 4-2 Chemicalsfor Papanicolaou stain. .................................................................. 119 
Table 4-3 Precision of CASA single field analysis. ......................................................... 125 
Table 4-4 Effects of sperm motility on single field CV% ................................................. 125 
Table 4-5 CV% summary from CASA multiple field analysis ......................................... 126 
Table 4-6 Sperm motility and multiple field CV% ........................................................... 126 
Table 4-7 Effects of field number on CV% using one, three and five fields of analysis .. 126 
Table 4-8 Segre-Silberberg effects on Leja 20µm Chambers area bias. ........................ 131 
  
8 
 
Table 4-9 ANOVA of Leja 20µm chambers area bias on immotile sperm. ..................... 132 
Table 4-10 CASA comparison with Neubauer for clinical decisions. .............................. 133 
Table 4-11 CASA comparison with Leja 20µm for clinical decisions. ............................. 134 
Table 4-12 Corrected count CASA method comparison with Leja 20µm for clinical 
decisions. ...................................................................................................................... 134 
Table 4-13 Audit of compliance to WHO guidelines for sperm counting. ........................ 135 
Table 4-14 CV% on Single Sperm Motility using CASA. ................................................ 143 
Table 4-15 Single Slide CV% on Sperm CASA Motility using CASA. ............................. 144 
Table 4-16 Between-slide CV% on Sperm Motility using CASA. .................................... 144 
Table 4-17 Phantom Motility with CASA ........................................................................ 145 
Table 4-18 CV% on single sperm morphology using CASA. .......................................... 153 
Table 4-19 Single slide CV% on head morphology using CASA. ................................... 154 
Table 4-20 Between-slide CV% on sperm morphology using CASA. ............................. 154 
Table 5-1 Semen ejaculate (n=191) characteristics from men (n=102) who achieved a 
pregnancy with their partner from IUI are compared with ejaculates (n=823) from men 
(n=469) who failed to achieve a pregnancy. ................................................................... 178 
Table 5-2 Percentiles of whole ejaculate (n=191) characteristics from men (n=102) who 
achieved a pregnancy with their partner from IUI are compared with ejaculates (n=823) 
from men (n=469) who failed to achieve a pregnancy. ................................................... 179 
Table 5-3 Percentile IUI inseminate (n=191) characteristics from men (102) who achieved 
a pregnancy with their partner from IUI are compared with inseminates (n=823) from men 
(n=469) who failed to achieve a pregnancy. ................................................................... 179 
Table 5-4 ROC analysis results for IUI failure comparing the cycle (n=191 pregnant, 823 
non-pregnant), the couple (n=101 pregnant, 469 non-pregnant) and first cycles only (n=55 
pregnant, 516 non-pregnant). ........................................................................................ 180 
Table 5-5 Percentile semen (n=191) characteristics of men (n=102) who were successful 
with IUI are compared with the WHO 2010 reference values (Cooper et al., 2010). ....... 183 
Table 5-6 Cut off values, sensitivity,  specificity and odds ratio of treatment failure for four 
parameters calculated from 55 first cycle ejaculates from men who achieved a pregnancy 
and 516 first cycle ejaculates from men who failed to conceive with IUI. ........................ 184 
Table 5-7 Significant or close to significance ROC analysis results using individual and 
combined clusters to predict pregnancy with IUI ............................................................ 186 
Table 5-8 CASA motility variables with the largest significant ROC areas with cut off 
values and corresponding specificity and sensitivity. ..................................................... 187 
Table 5-9 ROC analysis results of sperm head dimension measurements and associated 
distribution measurements for predicting pregnancy. ..................................................... 188 
Table 5-10 Percentile parameters from fertility work up semen ejaculates (n=238) from 
men who achieved a pregnancy with IVF from subsequent ejaculates. .......................... 190 
  
9 
 
Table 5-11 Percentile parameters from swim up (n=232) and density gradients (n=44) 
from fertility work up semen ejaculates from men who achieved a pregnancy with IVF from 
subsequent ejaculates. .................................................................................................. 190 
Table 5-12 Area under the curve for ROC analysis of IVF pregnancy (n=152 pregnant, 
222 not pregnant) with 95% confidence intervals and significance for semen analysis and 
ejaculate parameters predicting IVF success in woman (≤ 40). ...................................... 191 
Table 5-13 Percentile parameters from fertility work up semen ejaculates (n=212) from 
men who achieved a pregnancy with ICSI from subsequent ejaculates. ........................ 192 
Table 5-14 Percentile parameters of swim up (n=189) and density gradients (n=119) from 
fertility work up semen ejaculates from men who achieved a pregnancy with ICSI from 
subsequent ejaculates. .................................................................................................. 193 
Table 5-15 ROC analysis results of cluster analysis for IVF success (n=33 pregnant, 35 
non pregnant) with female  >40 excluded. ..................................................................... 194 
Table 5-16 ROC analysis results from semen parameters in predicting ≥ 40% fertilisation 
of mature eggs collected. ............................................................................................... 195 
Table 5-17 Percentile value cut off values with ROC sensitivity, specificity for ejaculate 
total progressive motile count to achieve ≥ 40% fertilisation with mature eggs. .............. 195 
Table 6-1 Median post-thaw results from 16 repeat experiments with pooled semen 
comparing our current in use SFM process validated method and the TYB manufacturers 
recommended method. .................................................................................................. 211 
Table 6-2 Matched paired aliquots of pooled semen frozen with SFM and TYB in 
CoolCells at -800C ......................................................................................................... 214 
Table 6-3 Median thaw parameters are presented from patients samples (n=80) split and 
frozen by using the process validated SFM method and the TYB CoolCell method. ...... 216 
Table 7-1 Percentile distributions of TMC and PMC before and after cryopreservation for 
ejaculates from patients with cancer (n=822) and non-cancer (n=226). ......................... 233 
Table 7-2 Median SCA CASA motility descriptors for cancer patients ejaculates (n=521) 
post-thaw and non-cancer patient ejaculates (n=226) pre-freeze and post-thaw. ........... 234 
Table 7-3 Percentage of cancer patients ejaculates (n=521) and non-cancer patient 
ejaculates (n=226) within local reference range CASA IUI cut-off values. ...................... 234 
Table 7-4 Maximum possible post-thaw fertility treatment cycles calculated by ejaculate 
number. ......................................................................................................................... 236 
Table 7-5 Correlations between deprivation indices and post-thaw semen analysis 
parameters and recovery for first ejaculates (n=217) from cancer patients. ................... 237 
Table 7-6 Correlations between-ejaculate cancer post-thaw variance and deprivation 
indices (n=246). ............................................................................................................. 238 
Table 7-7 Correlations between post-thaw variance in cancer patients and years of 
storage and patient age at storage (n=246). .................................................................. 239 
Table 7-8 Logistic regression results for mortality of cancer patients. ............................ 241 
Table 7-9 Correlations between percentage motile sperm count recoveries following 
sperm cryopreservation and patient data, variance and deprivation. .............................. 242 
  
10 
 
Table 7-10 Correlations between semen cell cholesterol and semen parameters.......... 244 
Table 7-11 Logistic regression of TMC recovery (≥ 30%) .............................................. 246 
Table 9-1 Dunns multiple comparison test results for sperm counts before IQCT. ......... 288 
Table 9-2 Dunns multiple comparison test results for sperm counts post IQCT. ............ 288 
Table 9-3 Spearman correlation coefficients and significance for semen parameters, IUI 
PMC and IUI TMC ......................................................................................................... 291 
Table 9-4 Spearman correlation coefficients and significance for semen whole ejaculate 
parameters and IUI PMC and IUI TMC. ......................................................................... 291 
Table 9-5 Density gradient (DG) cluster centres for VAP/LIN k mean clusters from sperm 
tracks (n=24500) from IUI preparations (n=20) that resulted in a pregnancy. ................. 291 
Table 9-6 Semen (SEM) cluster centres for VAP/LIN K mean clusters from sperm tracks 
(n=19800) from semen samples (n=16) that resulted in an IUI pregnancy. .................... 292 
Table 9-7 IUI patients semen samples (n=110, pregnant=20, non-pregnant=90) were 
compared for the percentage of sperm within each cluster using previously identified 
cluster centres. .............................................................................................................. 292 
Table 9-8 Significant and close to significant ROC predictors of pregnancy from VLC 
distribution measures for IUI patients (n=100, pregnant=20, non-pregnant=80). ............ 292 
Table 9-9 Significant and close to significant ROC predictors of pregnancy from WOB 
distribution measures for IUI patients (n=100, pregnant=20, non-pregnant=80). ............ 293 
Table 9-10 Significant and close to significant ROC predictors of pregnancy from ALH 
distribution measures for IUI patients (n=100, pregnant=20, non-pregnant=80). ............ 293 
Table 9-11 Significant and close to significant ROC predictors of pregnancy from BCF 
distribution measures for IUI patients (n=100, pregnant=20, non-pregnant=80). ............ 293 
Table 9-12 Significant and close to significant ROC predictors of pregnancy from UCV 
distribution measures for IUI patients (n=100, pregnant=20, non-pregnant=80). ............ 293 
Table 9-13 SCA CASA morphology sperm head measurements (n=3590) from fertile men 
(n-12). ............................................................................................................................ 294 
Table 9-14 Median percentages of patient sperm within fertility clusters pre-freeze and 
post-freeze for non-cancer patient ejaculates (n=226) and post-freeze for cancer patients 
ejaculates (n=521). ........................................................................................................ 295 
Table 9-15 Median deprivation indices for cancer patients (n=217) and non-cancer 
patients (n=221). ............................................................................................................ 295 
Table 9-16 Correlations between deprivation indices and semen analysis parameters for 
all ejaculates (n=642) and cancer ejaculates (n=421). ................................................... 296 
Table 9-17 Correlations between deprivation indices and post freeze parameters and 
recovery for all ejaculates (n=642), cancer ejaculates (n=421) and non-cancer ejaculates 
(221). ............................................................................................................................. 297 
Table 9-18 Between-ampoule within-ejaculate parameter variance correlations for cancer 
ejaculates post freeze (n=325). ...................................................................................... 298 
  
11 
 
Table 9-19 Between-ejaculate within patient semen parameter variance correlations post 
freeze (n=255) ............................................................................................................... 298 
Table 9-20 Between-patient semen parameter variance correlations post-thaw (n=221).
 ...................................................................................................................................... 299 
Table 9-21 Correlations between pre freeze semen and post freeze between-ejaculate 
variance in cancer patients (n=255). .............................................................................. 301 
Table 9-22 Correlations between pre freeze semen variance and post freeze between-
patient variance in cancer patients (n=221). .................................................................. 301 
Table 9-23 ROC area under the graph and significance of sperm count and motility 
grading as predictors of post freeze TMC and PMC recovery. ....................................... 302 
Table 9-24 CASA clusters and motility descriptor variables as predictors of post freeze 
TMC recovery. ............................................................................................................... 303 
Table 9-25 CASA clusters and motility descriptor variables as predictors of thaw PMC 
recovery. ........................................................................................................................ 304 
Table 9-26 Post freeze motility correlations with pre-freeze motility measures. ............. 305 
Table 9-27 Significant ROC area under the curve predicting poor freezers from pre freeze 
parameters .................................................................................................................... 306 
Table 9-28 Correlations between deprivation indices and cholesterol measurements in 
semen and seminal plasma. .......................................................................................... 307 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
12 
 
List of Figures 
Figure 2-1 New referrals, cancer incidence and patient ages. ............................. 71 
Figure 2-2 Frozen sample usage rates. ............................................................... 73 
Figure 2-3 ART treatment selected with cryopreserved sperm 1994-2009. ......... 75 
Figure 3-1 Photos of IQCT ................................................................................... 89 
Figure 3-2 D motility patient results from a single BMS plotted by month over two 
years prior to IQCT. .............................................................................................. 91 
Figure 3-3 D Motility results generated by one BMS plotted in consecutive batches 
of 200. ................................................................................................................... 92 
Figure 3-4 Pre and post IQCT compared for D motility. ....................................... 92 
Figure 3-5 The distributions of WHO grades of sperm motility for four Andrology 
BMS staff are compared. ...................................................................................... 94 
Figure 3-6 Within-laboratory precision profile for WHO motility. ........................... 95 
Figure 3-7 Between-laboratory variance recorded from 24 NEQAS reports. ....... 96 
Figure 3-8 Precision profile of between BMS sperm counts. ................................ 96 
Figure 3-9 Precision profile for morphology.......................................................... 97 
Figure 4-1 Improved Neubauer for sperm counting. ........................................... 108 
Figure 4-2 Leja 20µm chamber for sperm counting. .......................................... 109 
Figure 4-3 Areas counted on the Leja 20µm chamber. ...................................... 112 
Figure 4-4 CASA motility parameters. ................................................................ 114 
Figure 4-5 Accuracy of latex beads counts using CASA using three and five fields 
of analysis. .......................................................................................................... 121 
Figure 4-6 Correlation of manual counting methods with CASA for 352 patient’s 
samples. ............................................................................................................. 122 
Figure 4-7 Bland-Altman of CASA count and the Neubauer Chamber. .............. 123 
Figure 4-8 Bland-Altman of CASA count and the Leja 20µm Chamber.............. 123 
Figure 4-9 Bland-Altman of CASA counts <40x106 and Neubauer. ................... 123 
Figure 4-10 Correlation of counts < 30x106 ........................................................ 124 
Figure 4-11 Bland-Altman of counts < 30x106 between manually counting from the 
CASA screen and the Leja 20µm chamber. ........................................................ 124 
Figure 4-12 Motile sperm precision profile with three fields of analysis. ............. 127 
  
13 
 
Figure 4-13 Motile sperm precision profile with five fields of analysis. ............... 127 
Figure 4-14 Linearity of CASA counts of motile sperm in semen. ...................... 128 
Figure 4-15 Linearity of CASA counts of motile sperm in media. ....................... 128 
Figure 4-16 Linearity of CASA counts of immotile sperm in media. ................... 129 
Figure 4-17 CASA compared with BMS and NEQAS. ........................................ 130 
Figure 4-18 Increased mean recovery with a high concentration of NCOS and 
debris. ................................................................................................................. 133 
Figure 4-19 Comparison with Leja 20µm using dual CASA methods. ................ 135 
Figure 4-20 Correlations of manual WHO motility and CASA ............................ 136 
Figure 4-21 Bland-Altman of manual WHO motility and CASA. ......................... 137 
Figure 4-22 A class motility, manual method, consensus and CASA compared.
 ............................................................................................................................ 138 
Figure 4-23 B class motility, manual method, consensus and CASA compared.
 ............................................................................................................................ 138 
Figure 4-24 C class motility, manual method, consensus and CASA compared.
 ............................................................................................................................ 139 
Figure 4-25 D class motility, manual method, consensus and CASA compared.
 ............................................................................................................................ 139 
Figure 4-26 Correlations of manual WHO motility and CASA. ........................... 140 
Figure 4-27 Bland-Altman of manual WHO motility and CASA. ......................... 141 
Figure 4-28 Precision profiles for manual WHO motility and CASA. .................. 142 
Figure 4-29 Precision profiles for SCA by field number. ..................................... 142 
Figure 4-30 Precision profiles for CASA WHO motility categories by sperm count.
 ............................................................................................................................ 143 
Figure 4-31 SEM Images A. The resolving power of SEM allows great clarity. .. 146 
Figure 4-32 SEM Images B. Some sperm are difficult to measure due to debris or 
other cells ........................................................................................................... 147 
Figure 4-33 Images from CASA morphology...................................................... 148 
Figure 4-34 Dependency of focus on CASA morphology measurement. ........... 149 
Figure 4-35 Q-Q plots of CASA head measurements compared against SEM. . 150 
Figure 4-36 Q-Q plots of CASA midpiece measurements compared with SEM. 151 
Figure 4-37 Scatter plots of CASA and SEM difference for individual patients. . 152 
  
14 
 
Figure 4-38 Correlations of CASA against SEM for individual patients. ............. 153 
Figure 4-39 UK NEQAS results using SCA. ....................................................... 155 
Figure 4-40 Blind morphology results from four trained BMS ............................. 156 
Figure 5-1 ROC analysis of sperm count, ejaculate count and inseminate count 
parameters by cycle. ........................................................................................... 181 
Figure 5-2 Cycle number, female age and TMC. ............................................... 182 
Figure 5-3 CASA VAP / LIN clusters from a Fertile Population. ......................... 185 
Figure 5-4 Female Age and IVF and ICSI Treatment Success. ......................... 189 
Figure 5-5 ROC curves for CASA motility vs manual motility for IVF success. .. 192 
Figure 6-1 VAP vs LIN of sperm tracks from 10 pooled semen experiments 
comparing SFM and TYB. ................................................................................... 212 
Figure 6-2 The CoolCell. .................................................................................... 213 
Figure 6-3 Ice nucleation temperature and the CoolCell. ................................... 214 
Figure 6-4 Additions of LN2 to the central space of the CoolCell. ....................... 215 
Figure 6-5 Non-linear regression lines of VAP vs LIN percentiles 
(10th,25th,50th,75th,90th) from 80 patients comparing SFM and TYB CoolCell 
methods. ............................................................................................................. 217 
Figure 6-6 Pre-processing storage temperature and time effects on CASA motility.
 ............................................................................................................................ 218 
Figure 6-7 Sperm motility and CPA addition speed. ........................................... 219 
Figure 6-8 Ambient temperature risk to frozen semen during audit activities. .... 219 
Figure 7-1 Predicted sources of variance ........................................................... 231 
Figure 7-2 Changes in VAP/LIN clusters with cryopreservation. ........................ 235 
Figure 7-3 Maximum number of ART cycles per ejaculate for cancer and non-
cancer patients post-thaw ................................................................................... 235 
Figure 7-4 Median post-thaw variance within-ejaculate, between-ejaculate and 
between-patient. ................................................................................................. 237 
Figure 7-5 95th percentile of analytical variance in comparison with post-thaw 
variance measures. ............................................................................................. 240 
Figure 7-6 Linear regression line between sperm count and semen cell cholesterol 
(n=101). .............................................................................................................. 245 
Figure 7-7 Post-thaw motility by semen cell cholesterol ratio. ............................ 245 
  
15 
 
Figure 9-1 Difference between-operator using manual semen analysis to estimate 
WHO D class motility. ......................................................................................... 288 
Figure 9-2 Q-Q plots of the percentiles of D motility comparing pre and post IQCT.
 ............................................................................................................................ 289 
Figure 9-3 Correlation of Neubauer and CASA for 192 patient’s samples. ........ 290 
Figure 9-4 Correlation of Leja 20µm manual method with CASA for 160 patient’s 
samples. ............................................................................................................. 290 
Figure 9-5 IUI and cancer patients between-ejaculate variance compared for 
semen volume and sperm count. ........................................................................ 299 
Figure 9-6 IUI and cancer patients between-ejaculate variance compared for 
progressive motility, total motility, TMC and PMC. .............................................. 300 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
16 
 
List of Abbreviations 
ABVD Adriamycin, Bleomycin, Vinblastine and Dacarbazine 
ALH Amplitude of Lateral Head Displacement 
ANOVA Analysis of Variance 
ART Assisted Reproductive Technology 
ATP Adenosine Tri-Phosphate 
BCF Beat-Cross Frequency 
BMS Biomedical Scientist 
cAMP cyclic Adenosine Mono-Phosphate 
CASA Computer Assisted Semen Analysis 
CASP Critical Appraisal Skills Programme 
CE Communauté Européenne / Conformité Européenne 
COP Code of Practice 
CPA Cryo-Protective Agent 
CPA Clinical Pathology Accreditation 
CV Coefficient of Variation 
DG Density Gradient 
DNA Deoxyribio Nucleic Acid 
DPX Di-N-Butyle Phthalate in Xylene 
  
17 
 
ETD European Tissue Directive 
EQA External Quality Control 
ETD European Tissue Directives 
GUM Guide to Uncertainty of Measurement 
HCPC Health and Care Professions Council 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HFEA Human Fertility Embryonic Agency 
HIV Human Immunodeficiency Virus 
HTA Human Tissue Act 
HTLV Human T-Lymphotropic Virus 
ICSI Intra Cytoplasmic Sperm Injection 
IQCT Internal Quality Control Tool 
ISO International Organisation of Standardisation 
IQC Internal Quality Control 
IUI Intrauterine Insemination 
IVF In Vitro Fertilization 
KS Kolmogorov-Smirnov 
LIN Linearity 
LN2 Liquid Nitrogen 
MAI Multiple Anomalies Index 
  
18 
 
MAR Mixed Agglutination Reaction 
MESH Medical Subject Headings 
MOPP Nitrogenmustard, Oncovin, Procarbazine and Prednison 
MSOME Motile Sperm Organelle Morphology Examination  
MU Measurement of Uncertainty 
NCOS Nucleated Cells Other than Sperm 
NEQAS National External Quality Assessment Service 
NHS National Health Service 
NICE National Institute of Clinical Excellence 
PAP Papanicolaou 
PMC Progressive Motile Count 
QC Quality Control 
QQ Quartile Quartile 
RBC Red Blood Cell 
RCP Royal College of Physicians 
ROC Receiver Operator Characteristic 
ROS Reactive Oxygen Species 
CASP Critical Appraisal Skills Programme 
SCA Sperm Class Analyser 
SD Standard Deviation 
  
19 
 
SDI Sperm Deformity Index 
SEM Scanning Electron Microscopy 
SFM Sperm Freezing Medium 
SOD Super Oxide Dismutase 
SPF Specific Pathogen Free 
SS Segre-Silberberg 
STR Straightness 
SWT Swim Migration Test 
TMC Total Motile Count 
TYB Test Yolk Buffer 
TZI Teratozoospermia Index 
UCV Uncurving Velocity 
UK United Kingdom 
VAP Average Path Velocity 
VCL Curvilinear Velocity 
VSL Straight-Line Velocity 
WHO World Health Organisation 
WMUH West Middlesex University Hospital 
WOB Wobble 
 
 
 
  
20 
 
 
Acknowledgements and Dedication 
I would like to express my sincere gratitude to Dr Kevin Lindsay, who encouraged 
me to begin the journey and supervised both my MSc and this PhD and whose 
depth of knowledge has always inspired me. I would like to convey my deep 
appreciation to my primary Portsmouth supervisor, Dr Sally Kilburn for her 
excellent supervision and continued support throughout this thesis. 
 
I would also like to thank my secondary supervisors, Professor Matt Guile and Dr 
Bernard Higgins, for their advice and support. I would also like to acknowledge the 
kind advice of Dr Rhiannon Lloyd, Dr Allan Pacey and Dr Matthew Tomlinson. 
 
My sincerest gratitude to the patients of the Andrology Laboratory who volunteered 
samples, and the staff who allowed me the time to conduct and disseminate this 
research. In particular of the staff I also acknowledge Dr Kevin Lindsay for his 
unwavering support, Mrs Ivy Floyd for compiling the IUI spreadsheet, Ms Danielle 
Breen who conducted the telephone interviews with past patients, Dr Tim Ryder 
and Mrs Margeret Mobberley, who provided the electron microscope service and 
Ms Sarah Stephens for her flawless proofreading. 
 
I extend my profound thanks to my wife, Dr Anita Jagroop-Dearing for her advice, 
support and encouragement during this thesis and in gaining my first publication. 
Lastly but certainly not least I would like to acknowledge my three young 
daughters Georgia, Miah and Holly who kept me sane and constantly reminded 
me of my most important role. 
 
 
 
  
21 
 
Dissemination List 
Poster Presentations  
 
 CoolCell with a CE marked test yolk buffer for human sperm 
cryopreservation: reduced variance and improved post-thaw motility. CG 
Dearing, A Bradshaw, J Ramsay, KS Lindsay. BAS Annual Meeting.  
September 2013. 
 
 Which semen parameters at fertility treatment workup best predict IVF 
fertilisation rate? N Bartlett, CG Dearing, MJ Perez, G Trew, S Lavery. ACE 
conference, Sheffield, January 2014. 
 
Oral Presentations 
 
 Semen Analysis; Practice, Problems and Future Developments.  Imperial 
College MSc Reproductive Science Class, September 2013. 
 
Accepted Original Articles 
 
 Validation of the sperm class analyser CASA system for sperm counting in 
a busy diagnostic semen analysis laboratory. CG Dearing, S Kilburn, KS 
Lindsay. Human Fertility, 2014. 17(1), 37-44. 
 
 Trends and usage in a London National Health Service sperm bank for 
cancer patients. CG Dearing, D Breen, A Bradshaw, J Ramsay, KS 
Lindsay. Human Fertility, 2014. Published Early Online 02/09/2014. 
 
 CoolCell with a CE marked test yolk buffer for human sperm 
cryopreservation: reduced variance and improved post-thaw motility. CG 
Dearing, J Ramsay, KS Lindsay. Human Fertility, Accepted with minor 
revision May 2014. 
 
Planned Original Articles 
 
 Subjectivity of WHO motility estimations and measurement uncertainty; 
Should CASA be mandatory for clinical laboratories? CG Dearing, KS 
Lindsay. 
 
 Value of semen analysis at fertility workup for predicting IVF outcomes. CG 
Dearing, N Bartlett, MJ Perez, G Trew, S Lavery KS Lindsay. 
 
 A simple rapid sperm membrane cholesterol method which predicts human 
sperm cryopreservation post-thaw variance. CG Dearing, KS Lindsay.  
 
 Time to ditch HFEA storage review? CG Dearing, KS Lindsay. 
  
22 
 
Overall Aim, Hypothesis and Objectives 
Aim 
The aim of this research is to characterise a population of men with cancer 
requiring sperm cryopreservation and to define and quantify the sources of 
uncertainty that limit their levels of fertility insurance and future assisted 
conception choices. 
 
Hypotheses 
Defining the magnitudes of non-biological variance and reducing their impact will 
allow variance from biological sources to be identified. This will improve prediction 
of assisted conception outcomes and post-thaw responses. Thus, it will be 
possible to establish an evidence base to guide the quantity of sperm to be stored 
allowing the selection of appropriate ART treatments with cryopreserved sperm.  
 
Objectives 
1. Characterise the local cohort of men with cancer who require the sperm 
cryopreservation service, specifically including; 
a. The numbers and demographic characteristics of patients referred. 
b. The proportions of patients who use their stored samples.  
c. The effect of specific cancer diagnosis on semen quality. 
d. The assisted conception treatments being selected. 
e. The identification of trends. 
 
2. Review semen analysis variance for the laboratory studied. 
a. Determine and quantify the sources of variance for semen analysis. 
b. Fully validate the Sperm Class Analyser (SCA). 
c. Determine and quantify sources of variance for SCA. 
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3. Review and reducing variance associated from the cryopreservation method. 
a. Explore sources of variance during storage. 
b. Explore novel technologies and / or cryopreservation media. 
 
4. Provide local ART semen analysis threshold values for; 
a. Patients who attended the Andrology laboratory for IUI preparation. 
b. Patients producing ejaculates for fertility workup prior to IVF or ICSI.  
c. (Calculate) the number of ART cycles available to cryopreservation. 
d. Patients from the quantity of ejaculates currently being stored. 
 
5. Explore the relationships between variance and cryopreservation including; 
a. The variance of post-thaw quality within and between-patients. 
b. Factors associated with cryopreservation variance. 
c. Prediction of post-thaw quality using methods available to NHS 
laboratories.  
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Chapter 1 Introduction 
 
 
1.1 Literature Search 
 
A wide range of literature was searched for including reviews, primary qualitative 
and quantitative research and grey literature of high relevance. The literature 
search strategy consisted of a rigorous search for articles published in English 
between 1990 and 2014 on the computerised databases Medline, PubMed, Web 
of Knowledge, PsycInfo and Google Scholar. Medical Subject Headings (MESH) 
were used where available. Specific search terms included; spermatozoa, semen, 
cryoprotective, bank, cryopreservation, cancer, drug, therapy, chemotherapy, 
infertility, male, analysis, cell, count, motility, morphology, computer-assisted, 
measurement, uncertainty. Search terms were combined into the search strategy 
using the Boolean operators “AND” and “OR”. The results of the computerised 
searches were collated, duplicates removed and the abstracts reviewed for 
relevance and suitability. Identified key papers were evaluated using the principles 
of the Critical Appraisal Skills Programme (CASP) tools (CASP, 2006). Additional 
studies were identified using forward and backward citation searching from key 
papers. 
 
1.2 Spermatozoa Cryopreservation 
 
1.2.1 Introduction 
 
Sperm cryopreservation has been at least a theoretical science from as early as 
1600 (Sherman, 1973), though the first documented empirical investigation of the 
effects of cold temperatures on cells is from the late 1700’s (Luyet & Gehenio, 
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1940). The most famous experiment occurred In 1776 when Lazzaro Spallanzani,  
priest and scientist, froze stallion sperm with snow and observed motility recover 
on warming (Spallanzani & Di Pietro, 1780). However, it took a further two 
centuries, two major discoveries and serendipity to make the advances that 
allowed the techniques as they are known today to become possible. Luyet and 
Hodapp in the late 1930’s made a major breakthrough by successfully recovering 
frog sperm after plunging into Liquid Nitrogen (LN2) (Luyet & Hodapp, 1938). 
Unfortunately, this freezing technique proved to be extremely variable as the 
required freezing and thawing rates are exceptionally difficult to achieve. The 
focus thus turned to successful sperm cryopreservation with slower freezing rates. 
The crucial breakthrough occurred in 1949 with the discovery of the cryoprotective 
actions of glycerol (Polge et al., 1949), although the actual discovery was an 
accident with a mislabelled bottle. 
 
Sperm cryopreservation became medically useful as glycerol allowed achievable 
freezing rates while LN2 provided storage temperatures that were lower than the 
glass transition temperature of water. The “glassy” state has enormous viscosity 
and so halts all biochemical reactions. For practical purposes sperm stored at this 
temperature remain in “suspended animation” for the duration of storage. This has 
allowed human sperm cryopreservation to become useful in several distinct ways; 
to protect the fertility of men before iatrogenic treatment or vasectomy or 
dangerous occupation is undertaken, for donor semen uses, as part of Assisted 
Reproductive Technologies (ART), for logistical benefit and for minimising 
infectious disease transmission.   
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1.2.2 Sperm Banking for Cancer Patients 
 
Sperm cryopreservation is currently the only method offering men insurance 
against iatrogenic treatments, most notably benefiting men with cancer requiring 
clinical interventions (Pacey, 2007). As such, current United Kingdom (UK) 
guidelines (R.C.P., 2007, N.I.C.E., 2013) agree that sperm banking should be 
universally available and fully funded on the National Health Service (NHS). 
However, while cancer patients do use their banked samples in assisted 
conception, the number doing so represent only a fraction of the total who initially 
store (Table 1-1). 
 
Table 1-1 Published sperm banking studies for men with cancer. 
Banked 
(N) 
Time Covered 
(years) 
Age 
(years) 
Used 
(%) 
Pregnancies 
(N) 
Births 
(N) 
Reference 
1158 1999-2003 14-56 NR NR NR (Rives et al., 2012) 
1080 1995-2009 13-65 6.3 32 27 (Bizet et al., 2012) 
1042 1997-2007 NR 7.9 32 NR (Freour et al., 2012) 
833 1978-2000 NR 7.7 39 29 (Kelleher et al., 2001) 
686 1986-2001 15-53 5.2 14 12 (Ragni et al., 2003) 
559 1995-2006 13-64 5 15 11 (Crha et al., 2009) 
557 1983-2004 14-57 7.5 27 25 (Van Casteren et al., 2008) 
422 1983-2002 15-45 6.9 16 14 (Magelssen et al., 2005) 
367 2002-2005 NR 8.4 16 NR (Selk et al., 2009) 
318 1982-2001 NR 9.7 15 11 (Agarwal et al., 2004) 
306 1989-2000 14-55 3.6 9 9 (Lass et al., 2001) 
225 1989-1997 15-56 2.7 6 3 (Lass et al., 1998) 
184 1991-2004 15-58 16.3 16 12 (Meseguer et al., 2006) 
180 1995-2009 13-18 NR NR NR (Keene et al., 2012) 
164 1993-2003 13-58 3.7 2 2 (Chung et al., 2004) 
122 1978-1990 16-44 27 9 11 (Blackhall et al., 2002) 
NR=Not Recorded 
 
The table summarises studies reporting the number of patients who store sperm, patient ages, the percentage 
of the total who used their stored samples and the ART fertility outcomes with those samples. 
 
While published use rates are low, figures rely on follow up time frames that may 
not fully estimate the number of patients who do use their sperm  (Dearing et al., 
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2014a). Moreover, historical storage rates and use may not be comparable with 
current and future demands as sperm cryopreservation has not been offered to 
men with cancer in the past as routinely as it could be (Pacey et al., 2013). Sperm 
cryopreservation and usage rates are also likely to increase as cancer survival 
rates increase because with increased survival patients become more concerned 
about quality-of-life issues such as fertility preservation (Agarwal & Allamaneni, 
2005). Also, the benefit from sperm banking cannot be measured solely on the 
numbers of patients who go on to use their stored samples. Many men, particularly 
those who initiate sperm storage themselves, gain significant psychological benefit 
from banking sperm including a positive outlook for survival (Saito et al., 2005, 
Eiser et al., 2011, Pacey & Eiser, 2011). 
 
The poor semen quality of men with cancer referred for sperm storage is well 
established, with certain cancers associated with both specific and more profound 
detrimental effects (Agarwal, 2000, Trottmann et al., 2007, Dohle, 2010, van 
Casteren et al., 2010, Dearing et al., 2014a). Apart from testicular cancer, which is 
particularly associated with a pronounced reduction in sperm counts (Bahadur et 
al., 2005, van Casteren et al., 2010, Bizet et al., 2012, Freour et al., 2012, Dearing 
et al., 2014a) due to negative effects on spermatogenesis (Ho et al., 1992), the 
causes of poor semen quality in cancer patients are not well understood. 
Hypothesised pre-existing defects, systemic cancer effects including malnutrition 
or stress, associated metabolic / endocrine problems including bioactive 
substances or cytokines produced by tumors, hypothalamus / pituitary gland 
tumour cell invasion and immunological disturbances have all been suggested 
(Agarwal & Allamaneni, 2005, Trottmann et al., 2007, Dohle, 2010).  
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The risk of infertility from the combined effects of cancer and cancer treatment can 
be almost certain for some conditions and treatments (for review see (Dohle, 
2010, Góngora-Rodrígueza et al., 2014)). For example, 90% of Hodgkin’s patients 
who receive greater than three cycles of Nitrogenmustard, Oncovin, Procarbazine 
and Prednison (MOPP) demonstrate azoospermia over one year after treatment 
(Lee et al., 2006). Even for the few patients who do re-establish spermatogenesis 
after MOPP, recovery may take longer than 10 years (Marmor & Duyck, 1995). At 
the other extreme, 90% of patients following  Adriamycin, Bleomycin, Vinblastine 
and Dacarbazine (ABVD), which has now largely superseded MOPP, have normal 
sperm counts after one year (Tal et al., 2000). However, while the majority of 
patients will recover at least partial spermatogenesis following treatment (Bahadur 
et al., 2005, Pacey, 2007), it is not possible to predict accurately how any 
individual will respond to any given treatment. It should also be noted that men 
should only store sperm in the window between diagnosis and beginning cancer 
treatment. Men undergoing cancer treatments are at risk of producing sperm with 
mutated DNA damage and chromosomal abnormalities that potentially may be 
transmitted to offspring (for review see (Choy & Brannigan, 2013)). Related to this 
concern is the recent, and by far the largest powered study of its kind, accessing 
the risk of birth anomalies in offspring from male cancer survivors (Ståhl et al., 
2011). This study on 1.8 million singletons born in Denmark and Sweden over a 10 
year period found a paternal history of cancer was associated with an increased 
risk of major congenital malformations. 
 
1.2.3 Regulation of Sperm Cryopreservation 
 
In the UK, sperm storage is subject to both national and European statutes 
associated with material that can be used for medical treatments. Specific statutes 
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include the Human Fertilisation and Embryology Act 1990; modified 2008, the 
Human Tissue Act (HTA), and European Tissue Directives (ETD). While all three 
statutes provide aspects to the total legal framework for sperm cryopreservation, 
the vast majority is provided by the Human Fertilisation and Embryology Act. This 
1990 act created the Human Fertilisation and Embryology Authority (HFEA) which 
at the time was the first body of its kind in the world. The HFEA is an independent 
regulator for ART treatment and research in the UK, and regulates all aspects of 
human sperm cryopreservation. HFEA regulation is achieved through licensing 
and through the Code of Practice (COP) which “is intended to help and encourage 
licensed centres to understand and comply with their legal requirements. It also 
gives guidance on how centres are expected to go about meeting those 
requirements.” The code of practice outlines the legal requirements specifically for 
sperm cryopreservation (Table 1-2). 
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Table 1-2 Relevant UK legal requirements for sperm cryopreservation from the Human Fertilisation and 
Embryology Authorities Code of Practice. 
Section Legal Requirement 
3 8 No gametes shall be kept in storage for longer than the statutory storage period. Statutory 
storage period in respect of gametes is such period not exceeding ten years. A person’s gametes 
must not be kept in storage unless there is an effective consent by that person to their storage 
and they are stored in accordance with the consent 
T50 
 
 
T50 
Prior to the processing of patient gametes or embryos, intended for use in treatment or storage, 
the centre must carry out the following biological tests to assess the risk of cross contamination:  
HIV 1 and 2, Anti HIV 1 and 2, Hepatitis B, HBsAg / Anti-HBc, Hepatitis C, Anti-HCV-Ab and where 
relevant; Rh D, Malaria, CMV, T.cruzi, HLTV 1. 
Devise a system of storage which clearly separates: quarantined / unscreened gametes and 
embryos, gametes and embryos which have tested negative, and gametes and embryos which 
have tested positive. 
T75 Centres must ensure that all storage processes are carried out under controlled conditions. 
17.4 The centre’s documented procedures should also ensure that: gametes and embryos are stored 
under controlled conditions that are validated and monitored and gametes and embryos are 
packaged for storage in a way that: prevents any adverse effects on the material and minimises 
the risk of contamination. 
17.9 Centres should:(a) assess the risks of cross-contamination during the quarantine period (b) put 
procedures in place to minimise these risks, and (c) document the rationale for the chosen 
quarantine procedures. 
17.7 A centre storing gametes and/or embryos for patients whose future fertility may be impaired by a 
medical condition or procedure should divide individual patients’ samples into separate storage 
vessels, in case of dewar failure. 
17.12 If there is an intention to store gametes or embryos, or where this possibility arises during 
treatment, in addition to relevant information about treatment and donation, the centre should 
give those providing the gametes or embryos relevant information about:  
(a) the possible deterioration or loss of viability of gametes or embryos as a result of 
storage, and the potential risk of cross-contamination between samples. 
(b) regulations for statutory storage periods for gametes and embryos, and regulations for 
extending storage periods. 
(c) the likelihood of a live birth resulting from previously cryopreserved embryos or 
gametes. 
(d) screening tests to be done, the cost of these, the reason for them and the implications 
of the tests for the gamete providers. 
17.13 The centre should provide specific information tailored to the needs and circumstances of 
oncology patients and other patients requiring long-term storage. 
T32 The centre must put in place a quality management system and implement this system to 
continually improve the quality and effectiveness of the service. 
23.7 Provide a service that meets its users’ needs and requirements. 
HIV=Human Immunodeficiency Virus, Anti=Antibodody, HBsAg=Hepatitis B surface antigen, Anti-HBc= 
Hepatitis B core antibody, Anti-HCV-Ab=Hepatitis C Virus antibody, Rh D= Rh blood group, D antigen, CMV= 
Cytomegalovirus, T.cruzi=Trypanosoma cruzi, HLTV=Human T cell Lymphotropic Virus. 
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1.2.4 Cryopreservation Related Spermatozoa Injury 
 
Mazur’s “two-factor hypothesis” (Mazur et al., 1972) first described the 
fundamentals of how freeze-thaw damage occurs and further research has built 
upon this theory. Cryopreservation injury to sperm is multifactorial, largely 
mediated through osmotic and oxidative stress (for reviews see (Watson, 1995, 
Holt, 2000a, Holt, 2000b, Watson, 2000, Tatone et al., 2010, Di Santo et al., 
2011)). 
 
Although sperm compared with other cells have relatively low water content 
(~50%), major stress during cryopreservation is induced by osmotic mediated cell 
volume changes. In response to Cryo-Protectant Agent (CPA) addition, which 
creates an  extracellular hyper-osmotic condition, cells shrink as water flows out of 
the cell to maintain equilibrium (Mazur, 1984). This is then followed by subsequent 
swelling, as water and CPA (if a permeating CPA is used) flow into the cell. 
Extracellular ice formation during freezing, results in hyper-osmolar concentrations 
of solutes causing further sperm cell water loss and shrinkage. The reverse 
process occurs with the hypotonic extracellular conditions that occur with thawing 
and CPA removal. Additional micro-architectural osmotic factors may complicate 
responses when sperm lie across channels of concentrated salts with 
simultaneous exposure to both high and low salt concentrations (Holt, 2000a).  
 
The risk of exposure to hyperosmolar conditions from slow freezing rates has to be 
balanced against the risks of intracellular ice occurring from rapid freezing rates. 
Cells that cool too rapidly cannot lose water fast enough to maintain osmotic 
equilibrium. This results in a relative accumulation of super-cooled intracellular 
water, and subsequent ice crystallization once nucleation temperature is reached. 
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Ice crystallisation and crystal growth may also occur upon warming (Watson, 
1995). The coupled flow of water and CPA (in the case of permeating CPA) in and 
out of the cell is a dynamic process. The final concentration of CPA inside the cell 
is critical to prevent intracellular ice formation before the final rapid cooling step 
that will vitrify the intracellular space. However, it should be noted that the theory 
of intracellular ice with rapid cooling is not universally accepted (Morris et al., 
2012). The ability of any cell to respond and tolerate osmotic volume changes 
during cooling and warming is determined by multiple factors; size and shape, 
membrane lipid composition, lipid phase transition temperatures, cytoskeletal 
elements, membrane permeability to CPA and water, and membrane  pump and 
ion channel activity (Holt, 2000a, Holt, 2000b, Watson, 2000, Meyers, 2005). 
Sperm motility appears particularly sensitive to osmotic insults during 
cryopreservation  (Gao et al., 1995). 
 
In addition to individual tolerance of osmotic mediated damage, evidence supports 
tolerance to oxidative injury is the other major factor that determines 
cryopreservation outcome. The plasma membrane of the sperm cell has high 
levels of polyunsaturated fatty acids, which are particularly sensitive to lipid 
peroxidation from free radical-mediated attacks. Cryopreservation causes 
excessive generation of Reactive Oxygen Species (ROS) and increased lipid 
peroxidation (for review see (Tatone et al., 2010)). Cryopreservation induced ROS 
is associated with an increase in DNA fragmentation (Tatone et al., 2010), though 
doubt concerning its occurrence and mechanism remain (Di Santo et al., 2011). 
Recent studies have established that many antioxidants can improve 
cryopreservation outcomes (for review see (Said & Agarwal, 2012)). 
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1.2.5 Assisted Conception with Cryopreserved Spermatozoa 
 
Cryopreservation of human semen has detrimental effects on several parameters 
that are associated with male fertility, this includes sperm motility, morphology and 
viability (Keel et al., 1987, O'Connell et al., 2002, Ozkavukcu et al., 2008). For 
mammalian species it is generally accepted that frozen / thawed semen has 
impaired fertility compared with fresh semen (Watson, 2000). This is most 
apparent in domesticated animals where some species require 20 fold increases 
in the insemination dose when cryopreserved semen is used (Holt et al., 2005). 
However, this is not similar to human ART dose requirements when using 
cryopreserved semen. A review on donor insemination with cryopreserved semen 
(Barratt et al., 1998) found the post-thaw inseminated Total Motile Count (TMC) to 
be the most critical factor for conception. Their reported minimum post-thaw 
inseminate TMC required for success (~0.5x106) is in accordance with a meta-
analysis on minimum TMC threshold requirements with fresh sperm (Vanweert et 
al., 2004). It is worth noting that even when post-thaw quality is adequate, 
fecundity with cryopreserved donor semen shows highly noticeable individual 
donor differences (Barratt et al., 1998). Although post-thaw motile counts may limit 
ART choice, evidence demonstrates that ART with frozen sperm can achieve 
comparable success to fresh sperm for Direct Insemination (DI), Intrauterine 
Insemination (IUI), In Vitro Fertilisation (IVF) and Intra Cytoplasmic Sperm 
Injection (ICSI) (Table 1-3).  
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Table 1-3 ART success with cryopreserved sperm 
Sperm 
Source 
Treatment (n)                              Finding Reference 
-------------------------------------------------------------Reported success rates------------------------------------------------- 
Sperm 
donors 
DI frozen (5953) 
IVF frozen (185) 
DI PR 13.7% per cycle, LB 87% 
IVF PR 33% per couple 
(Clarke et al., 1997) 
 
Cancer 
patients 
IUI frozen (55) 
ICSI frozen (82) 
IUI PR 14.8% per cycle, LB 75% 
ICSI PR 38.6% per cycle, LB 79% 
(Schmidt et al., 2004) 
Cancer 
patients 
IUI frozen (35) 
IVF frozen (22) 
ICSI frozen (22) 
IUI PR 31.4% per cycle 
IVF PR 27.2% per cycle 
ICSI PR 54.5% per cycle 
(Kelleher et al., 2001) 
Cancer 
patients 
IUI frozen (7) 
IVF frozen (32) 
ICSI frozen (53) 
IUI PR 14.3% per cycle 
IVF PR 25.0% per cycle 
ICSI PR 30.1% per cycle 
(Van Casteren et al., 2008) 
Cancer 
patients 
IUI frozen (42) 
IVF frozen (26) 
ICSI frozen (19) 
IUI PR 7% per cycle, LB 100% 
IVF PR 23% per cycle, LB 83% 
ICSI PR 37% per cycle, LB 57% 
(Agarwal et al., 2004) 
Cancer 
patients 
IUI frozen (40) 
IVF frozen (8) 
ICSI frozen (77) 
IUI PR 12.8% per cycle, LB 10.3*% 
IVF PR 28.6% per cycle, LB 28.6*% 
ICSI PR 32.4% per cycle, LB 23.2*% 
(Bizet et al., 2012) 
Cancer 
patients 
IUI frozen (22) 
IVF frozen (8) 
ICSI frozen (38) 
IUI PR 11.1% per cycle, LB 77% 
IVF PR 0% per cycle 
ICSI PR 37.4% per cycle, LB 68% 
(Botchan et al., 2013) 
-------------------------------------Direct comparisons between fresh and frozen cycles ------------------------------ 
Ejaculated 
IVF fresh (39) 
IVF frozen (74) 
No difference (Yavetz et al., 1991) 
Testicular 
ICS fresh (25) 
ICSI frozen (14) 
No difference (Fedder et al., 2013) 
Testicular 
ICS fresh (32) 
ICSI frozen (28) 
No difference (Ben et al., 2003) 
Testicular 
ICS fresh (14) 
ICSI frozen (8) 
No difference (Huang et al., 2000) 
Testicular ICS fresh (65) 
ICSI frozen (35) 
Fertilisation, implantation, and live-birth 
rates lower with frozen-thawed 
(De Croo et al., 1998) 
Epididymal 
ICS fresh (157) 
ICSI frozen (118) 
No difference (Tournaye et al., 1999) 
Epididymal 
ICS fresh (40) 
ICSI frozen (13) 
No difference (Sukcharoen et al., 2001) 
Epididymal 
ICS fresh (19) 
ICSI frozen (19) 
No difference (Cayan et al., 2001) 
Epididymal 
ICS fresh (5) 
ICSI frozen (13) 
differences in all parameters (Shibahara et al., 1999) 
Ejaculated 
ICS fresh (118) 
ICSI frozen (122) 
Higher rate of ongoing pregnancy with 
frozen 
(Kuczyński et al., 2001) 
Ejaculated 
ICS fresh (79) 
ICSI frozen (61) 
No difference (Borges Jr et al., 2007) 
ART=Assisted Reproductive Technologies, DI=Direct Insemination, IUI=Intrauterine Insemination, IVF=In Vitro 
Fertilisation, ICSI=Intra Cytoplasmic Sperm Injection, PR=Pregnancy Rate per cycle, LB=Live Birth Rate 
(cumulative) *LB is per cycle. 
 
Table lists reported success rates of ART using cryopreserved sperm and studies that directly compared fresh 
and frozen sperm ART cycles. 
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1.2.6 The Rise of ICSI 
 
Over the last 20 years HFEA data demonstrates a UK wide decline in IVF 
treatments and a corresponding rise in ICSI treatments (H.F.E.A., 2013a). 
Increasing ICSI treatment is also reported in Europe; from 40% of all ART in 1997 
to 59% in 2004. (Andersen et al., 2008), and in the United States; from 11% in 
1995 to 58% in 2004 (Jain & Gupta, 2007). Large heterogeneity in ICSI treatment 
selection between clinics is also reported from each of these regions (Jain & 
Gupta, 2007, Andersen et al., 2008, Jones et al., 2012, H.F.E.A., 2013a). While 
ICSI has undoubtedly benefited many couples who without its use would not have 
become parents, evidence does not support improved outcomes over IVF without 
severe male fertility impairment (Jain & Gupta, 2007, Andersen et al., 2008, Jones 
et al., 2012).  
 
ICSI carries additional theoretical risks over other ART as it eliminates gamete 
natural selection processes. Sperm with defects that would not normally be 
capable of reaching or binding with oocytes can be forced to fertilise. Conversely, 
poor quality oocytes that would normally have been bypassed by sperm can also 
be forced to fertilise. The technique also carries a theoretical risk of introducing 
foreign DNA or other potentially pathological matter at the injection site. 
Approximately 10% of all oocytes suffer observable structural damage at the 
injection site (De Vos, 2000), while higher miscarriage rates have been reported 
with ICSI created frozen embryos (Aytoz et al., 1999). 
 
Children born following ART have increased risk of birth defects compared with 
naturally conceived children (Hansen et al., 2005). There are several hypothesised 
reasons for the increased risk including; the ART treatments themselves, 
  
36 
 
hormonal treatments, defects associated with underlying parental infertility, or ART 
associated low birth weight / small for gestational age issues (for review see 
(Hansen et al., 2005, Pandey et al., 2012, Pinborg et al., 2013)). While further well 
designed studies are required to address aetiology, controversial evidence has 
suggested an increased risk of birth defects with ICSI compared with other ART 
(Zuppa et al., 2010, Davies et al., 2012, Yin et al., 2013). This may be particularly 
concerning for cancer patients as a paternal history of cancer is associated with an 
increased risk of major congenital malformations (Ståhl et al., 2011). Certainly the 
evidence that currently exists is sufficient to urge caution with ICSI treatment 
selection.  
 
The introduction of ICSI (Palermo et al., 1992) undoubtedly allowed sperm 
cryopreservation to become much more useful, as only a single viable 
spermatozoa is required. However, while on a population basis ICSI with frozen / 
thawed sperm appears to be safe, there may be health implications for offspring 
for those individuals whose samples are more sensitive to cryopreservation. 
Sperm cryopreservation is associated with increased DNA damage (Tatone et al., 
2010, Di Santo et al., 2011). Male germline DNA damage is associated with 
defective embryonic development, high miscarriage rates and morbidity in the 
offspring, including childhood cancer (for review see (Marchetti & Wyrobek, 2005, 
Aitken & De Iuliis, 2007, Paul & Robaire, 2013)). The current lack of major 
phenotypic abnormalities in ART offspring does not assure that DNA lesions are 
not present and will not emerge in later life or future generations (Aitken & De 
Iuliis, 2007). On the basis of risk reduction, greater caution should be applied to 
selecting ICSI treatments with cryopreserved sperm compared with fresh sperm.  
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In addition to the discussed factors, ICSI is more expensive and demands more 
expertise than conventional IVF (Andersen et al., 2008, Jones et al., 2012). 
Unfortunately because of the cost differential, some clinics may be inappropriately 
selecting ICSI to increase profit margins (Abu‐Hassan & Al‐Hasani, 2003). This 
would explain the continued rise in ICSI over other ART in many regions. While 
the relationship between sperm cryopreservation damage, cancer, ICSI and 
offspring health in humans remains open to conjecture, the theoretical risks should 
be concerning enough to limit the treatment to cases that clearly require ICSI. It 
cannot be considered ethical to provide a more invasive treatment when a less 
invasive treatment will work. From the available information, selecting the least 
invasive successful ART with frozen / thawed sperm must be viewed as best 
practice.  
 
1.2.7 Spermatozoa Cryopreservation Variance   
 
In spite of the success of sperm cryopreservation in providing paternity, it has 
proven highly variable between and within individuals. Post-thaw variability is 
significantly higher than pre-freeze variability for fertile donors, men with male 
factor infertility, and cancer patients (Centola et al., 1992, Agarwal, 2000, Nallella 
et al., 2004). Men with poor semen quality exhibit particularly large post-thaw 
variability (Oehninger et al., 2000, Nallella et al., 2004). Considering only 
approximately a third of cancer patients present with a normal semen profile (van 
Casteren et al., 2010, Dearing et al., 2014a), cancer patients are often limited for 
ART choice before cryopreservation. When this quality limitation is considered in 
context with the variability of cryopreservation, the combined effect can be 
particularly severe for some cancer patients (Woods et al., 2004).  
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Prediction of post-thaw quality has not been achieved with great certainty. From 
studies on human donor sperm samples, even the evaluation of a single straw 
after freezing, does not guarantee the homogeneity of all the straws (Castilla et al., 
2007). A large, single center, retrospective review spanning several years reported 
that semen pre-freeze TMC was the optimum predictor of TMC after 
cryopreservation (Hotaling et al., 2010). However, this does not agree with an 
earlier study that found that motile count after dilution with CPA media was more 
predictive (Centola et al., 1992). A recent and by far the largest study of its kind 
concluded from the analysis of 14190 donor ejaculates that sperm concentration, 
progressive motility and normal morphology positively correlated with post-thaw 
progressive motility recovery (Zhang et al., 2012). Computer Assisted Semen 
Analysis (CASA) subpopulation analysis (for review see (Martínez-Pastor et al., 
2011)) may also be predictive of cryopreservation outcomes (Davis et al., 1995). 
 
Prediction of post-thaw quality may be particularly difficult in the cancer patient; 
there is little agreement on the effect of specific cancers on sperm 
cryopreservation. Examples of this disparity have been noted in testicular cancer 
(Hallak et al., 1999, Degl'Innocenti et al., 2013, Hotaling et al., 2013) and 
Hodgkin's lymphoma patients  (Hallak et al., 2000, Hotaling et al., 2013). However, 
studies generally agree; those patient groups with poor recoveries are the same 
groups who present with the poorest pre-freeze semen quality (Degl'Innocenti et 
al., 2013, Hotaling et al., 2013). This is similar to the findings from donor sperm 
cryopreservation (Zhang et al., 2012). Studies finding differences in post-thaw 
quality associated with specific cancer diagnosis struggle to account for many 
factors; cancer stage at diagnosis, other associated pathologies / factors with 
fertility consequences, non-standardisation of cryopreservation and / or semen 
analysis method and differences in individual responses to cryopreservation. 
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Studies on animal sperm support the hypothesis that individual variability of sperm 
cryopreservation is caused by individual susceptibility to cryo-injury (Holt, 2000a, 
Thurston et al., 2002, Holt et al., 2005, Loomis & Graham, 2008). An example of 
this is demonstrated by standard procedures for stallion sperm cryopreservation 
where split-ejaculate test-freezes are performed to identify optimal freezing 
protocols for individual animals (Loomis & Graham, 2008). In the boar, genetic 
markers have been found that can distinguish between individuals classified as 
good and poor responders to sperm cryopreservation (Thurston et al., 2002). The 
phenotypic differences these genetic markers represent are unknown, however 
individual variation in sperm lipid composition has been suggested (Holt et al., 
2005).  
 
Sperm plasma membrane lipid composition is species specific with varying 
amounts of phospholipids, neutral lipids, and glycolipids (Flesch & Gadella, 2000). 
The membrane has been shown to alter in response to cooling with lipid / protein 
rearrangements and phase transitions from a liquid to a gel phase, which are only 
partially reversible (Watson, 1981, Holt & North, 1984). Phase transitions can 
cause leakage and irreversible injury over a range of temperatures which manifest 
during warming (Holt et al., 1992, Drobnis et al., 1993). Additionally, this process 
appears to involve ion channel proteins and loss of calcium regulation which 
results in further deleterious consequences (Watson, 2000). Sperm membranes of 
species that exhibit a greater sterol to phospholipid ratio show greater resistance 
to phase transition during cooling (Drobnis et al., 1993).  
 
Major variations are found between individuals in sperm neutral lipid membrane 
composition, particularly with regards to cholesterol content (Flesch & Gadella, 
2000). A recent study on the cryopreservation of four different mouse strains 
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showed differences between sperm membrane cholesterol to phospholipid ratios 
that were associated with sperm cryopreservation survival rates (Loomis & 
Graham, 2008). While an earlier study found no such relationship in humans 
(Meseguer et al., 2004), their cholesterol estimation depended upon sperm counts 
estimated from the unreliable Makler chamber (Mahmoud et al., 1997). 
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1.3     Semen Analysis 
 
1.3.1 Introduction 
 
Semen analysis is mandatory in the investigation of suspected infertility or 
subfertility in men (Jungwirth et al., 2012, N.I.C.E., 2013). In the UK, the National 
Institute for Clinical Excellence (NICE) recommends semen analysis for all male 
partners of couples who have been unsuccessful with natural conception for 
greater than 12 months (N.I.C.E., 2013). In addition to detecting male factor fertility 
problems, semen analysis may provide; (1) a rough estimate of the probability of 
natural conception (Bonde et al., 1998, Slama et al., 2002), (2) an aid for the 
selection of appropriate ART (Coetzee et al., 1998, Van Waart et al., 2001, 
Vanweert et al., 2004) and (3), a guide for the quantity of ejaculates stored and 
frozen aliquot volumes for sperm banking (Tomlinson, 2010). Semen analysis 
parameters vary depending on clinical requirements, available technology, 
expertise and afforded timeframes. The fundamental parameters are semen 
volume, sperm count, motility and morphology. Evidence for the relationship 
between these parameters and human fertility are outlined in Table 1-4. 
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Table 1-4 Semen analysis and fertility outcome measures. 
N Fertility measure Finding Reference 
792 
Probability of natural 
conception 
Sperm count and total motility are the sole predictors of fertility. (Krause, 1996) 
430 
Probability of natural 
conception 
Sperm concentrations influenced probability of conception  up to a 
maximum concentration of 40x10
6
/mL 
(Bonde et al., 
1998) 
210 
Probability of natural 
conception 
Percentage morphologically normal sperm by strict criteria and total 
number of sperm showing particularly strong associations. 
(Zinaman et al., 
2000) 
358 
Probability of natural 
conception 
Sperm count, sperm total number and percentage motile spermatozoa 
were the most significant predictors for fertility. 
(Larsen et al., 
2000) 
942 Time to pregnancy 
Sperm concentrations influenced time to pregnancy up to a maximum 
concentration of 55x10
6
/mL 
(Slama et al., 
2002) 
1426 
Probability of natural 
conception 
After adjusting for male and female age, parity, year of first visit, and 
duration of infertility, sperm motility and normal morphology were 
significantly associated with spontaneous pregnancy, whereas sperm 
density was not. 
(Sripada et al., 
2010) 
731 
Probability of IVF and 
ICSI success 
No clear relationship between sperm concentration, sperm motility and 
normal morphology with fertilization rates. 
(Kini et al., 2010) 
353 
Probability of IUI 
success 
TMC ≥ 5x106 spermatozoa is required for IUI success. 
(Merviel et al., 
2010) 
Meta 
Probability of IVF 
success 
From a meta-analysis of 10 studies thresholds of 5% normal sperm 
morphology using strict criteria was predictive of IVF outcomes. 
(Coetzee et al., 
1998) 
Meta 
Probability of IUI 
success 
From a meta-analysis of 8 studies, threshold of <4% normal sperm 
morphology is predictive of IUI outcome. 
(Van Waart et al., 
2001) 
Meta 
TMC as a predictor of 
IUI success 
From a meta-analysis of 16 studies a TMC of 0.8-5.0x10
6
 is a threshold for 
predicting IUI failure. 
(Vanweert et al., 
2004) 
Meta 
Probability of natural 
conception 
From a meta-analysis of 4 studies, thresholds of <5% normal sperm 
morphology, a concentration <15 × 106/mL, and a motility <30% should 
be used to identify the subfertile male. 
(van der Merwe 
et al., 2005) 
TMC=Total Motile Count, IUI=Intrauterine Insemination, IVF=In Vitro Fertilisation, ICSI=Intra Cytoplasmic 
Sperm Injection, Meta=Meta-analysis. 
Table summarises a selection of studies finding associations between various fertility outcome measures and 
semen analysis. 
 
In spite of the predictive potential of semen analysis, its clinical usefulness has 
been particularly hindered by high between-laboratory and within-laboratory 
variance (Cooper & Yeung, 2006, Pacey, 2006, Tomlinson, 2010). The World 
Health Organisation (WHO), with regular updated editions of its semen analysis 
manual, has attempted to address this through promoting standardisation. 
However, techniques of semen analysis continue to be associated with high 
variance and poor methodology in many, and perhaps even the majority of 
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laboratories worldwide (Keel et al., 2002, Riddell et al., 2005, Pacey, 2006, Baker, 
2010, Mallidis et al., 2012, Filimberti et al., 2013).  
 
A solution to the high variance associated with semen analysis is to replace the 
manual elements of the analysis with automation. Four decades of development of 
CASA, coupled with computer power doubling every two years (Moore, 1965), has 
resulted in systems that are capable of analysing vast numbers of sperm in short 
time frames (Agarwal & Sharma, 2007, Tomlinson et al., 2010, Dearing et al., 
2014b, Lammers et al., 2014). However, in spite of the enormous potential of such 
systems, they remain largely underutilised in clinical diagnostic laboratories. This 
is partially due to costs, a lack of validation from developers, unfamiliarity with the 
technology, resistance to change, and specific CASA errors (E.S.H.R.E., 1998, 
Mortimer, 2000, Pacey, 2010, Tomlinson et al., 2010, Dearing et al., 2014b, 
Lammers et al., 2014). The relationship between CASA and human fertility 
outcomes are outlined in Table 1-5. 
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Table 1-5 CASA and fertility outcome measures. 
CASA 
system 
Patients           Cycles/Follow up 
Treatment 
(Outcome) 
Significant (<0.05) 
Parameters 
Reference 
Cell Soft 69 123 cycles IVF (Fertilisation) 
VSL, 
Motile density 
(Check et 
al., 1990) 
THMA 108 
Mean of 7.5 oocytes 
inseminated per 
patient 
IVF 
(Fertilisation) 
LIN, 
VSL, 
% of sperm with 
 VAP > 10 μ/s 
(Liu et al., 
1991) 
HTMA 222 
Median follow up 13 
months 
In vivo 
(Pregnancy) 
VAP 
Ejaculate count 
(Barratt et 
al., 1993) 
HTMA 303 
Median follow up 15 
months 
In vivo 
(Pregnancy) 
Sperm count 
Motility 
Morphometry 
Sperm velocity 
(Irvine et 
al., 1994) 
SM-CMA 
 
234 Follow up 7-18 months 
In vivo 
(Pregnancy) 
Sperm count 
 Motility 
(Krause, 
1995) 
HT-IVOS 150 
Mean of 8.4 oocytes 
inseminated per 
patient. 
 
IVF 
(Fertilisation) 
(Pregnancy) 
 
Progressive Motility 
VAP 
VSL 
VCL 
LIN 
Normal Morphology 
Hyperactivation 
(Donnelly et 
al., 1998) 
CRISMAS 419 24 month follow up 
In vivo 
(Pregnancy) 
Sperm count 
Ejaculate count 
TMC 
Total Motility 
VCL 
VAP 
STR 
BCF 
(Larsen et 
al., 2000) 
SHARMAS 1191 12 cycles follow up 
In vivo 
(Pregnancy) 
Morphometry 
VSL 
(Garrett et 
al., 2003) 
HTMA 160 682 cycles 
IUI 
(Pregnancy) 
Progressive motility 
VAP 
VSL 
VCL 
(Shibahara 
et al., 2004) 
HT-IVOS 120 120 cycles 
IVF 
(Fertilisation) 
 
Morphometry 
(Blanchard 
et al., 2011) 
VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path Velocity, LIN=Linearity, 
STR=Straightness , BCF=Beat Cross Frequency, CRISMAS=Copenhagen Rigshospitalet Image house Sperm 
Motility Analysis System, HTMA= Hamilton Thorn Motility Analyzer, HT-IVOS=Hamilton Thorn Integrated 
Visual Optical System, SHAMAS= Sperm Head Automated Morphometric Analysis System, SM=Stroemberg-
Mika 
 
Table summarises a selection of studies finding associations between various fertility outcome measures and 
CASA parameters. 
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1.3.2 Spermatozoa Counting 
 
The two major quantifiable elements of an ejaculate are the total number of 
spermatozoa and the total volume of fluid. While sperm concentration itself is not a 
direct measure of testicular function, as final semen volume includes secretions 
from the seminal vesicles and prostate (Eliasson, 1975), the total ejaculate 
spermatozoa number is shown to be related to various fertility endpoints (Table 1-
4 and 1-5). Additionally, once this dilution effect and abstinence is accounted for, 
the total number of spermatozoa in the ejaculate correlates with testicular volume 
(Handelsman et al., 1984, W.H.O., 1987) and is indicative of the spermatozoa 
production capability of the testes (MacLeod & Wang, 1979). Thus, the sperm 
count is one of the most critical parameters in the semen analysis profile.  
 
Spermatozoa counts from 4500 recent fathers from 14 countries who’s partners 
achieved a pregnancy within 12 months exhibit a large range (Cooper et al., 
2010). The WHO use the 5th percentile from this data as a one sided reference 
range, though acknowledge that this is only a guide as semen characteristics are 
not exclusive determinants of a couple’s fertility. Men below the threshold will still 
exhibit fertility, and men above the threshold are not guaranteed fertility (W.H.O., 
2010a). In addition to natural conception, counting sperm in semen or in separated 
samples can offer predictive information for ART treatment outcomes (Table 1-4 
and 1-5). 
 
To count spermatozoa the WHO recommends (W.H.O., 2010b) that a minimum of 
200 sperm should be counted in replicate, and if the replicates are not close new 
dilutions should be made and the process repeated. One of the reasons for the 
minimum of 200 sperm can be observed with simple standard error calculations on 
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Poisson distributions; the WHO utilise the simplified formula (N ± (2 × √N) 
(W.H.O., 2010c)). For example, If a laboratory was utilising a standard dilution of 
1/20 on all samples and counted only 20 sperm on a given sample, the 95% 
confidence interval is between 11 and 30x106. Because this result covers such a 
large range it offers reduced clinical information. In addition to poorly implemented 
techniques, it has been suggested that those performing the analysis fail to 
understand the implications of smaller sample sizes on confidence intervals 
(Pacey, 2006). What proportion of UK semen analysis laboratories are actually 
counting a minimum of 200 sperm twice is unknown, but because semen analysis 
is time consuming and because of ever present cost pressures, laboratories often 
admit to adopting methods that allow smaller numbers to be analysed (KS 
Lindsay, personal communication, May 2012). External Quality Assurance (EQA) 
data would suggest that the WHO sperm number recommendations are not 
universally followed (Pacey, 2006, Baker, 2010, Mallidis et al., 2012, Filimberti et 
al., 2013). 
 
To count spermatozoa, the WHO recommend counting diluted fixed sperm using a 
100µm deep haemocytometer chamber and give particular reference to the 
Improved Neubauer chamber (W.H.O., 2010d). The additional recommendations 
(W.H.O., 2010b) are lengthy, and are designed to minimise analytical error. Like 
the difficulties associated with sample numbers, with what stringency UK 
laboratories follow the recommendations are unknown. The WHO recognise that 
disposable chambers for sperm counting are also available (Seaman et al., 1996, 
Mahmoud et al., 1997, Brazil et al., 2004), but warn that they may generate 
significantly different results from the Improved Neubauer (W.H.O., 2010d).  
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The WHO recommend that if disposable chambers are to be used, they need to be 
extensively validated with the following threefold approach; (1) checking the new 
chambers dimension measurements, (2) comparing results against the Improved 
Neubauer and (3), obtaining satisfactory performance with EQA. The majority of 
disposable chambers are shallower than haemocytometers, and fill by capillary 
action. Uneven sperm distribution has been noted with disposable chambers 
(Douglas-Hamilton et al., 2005) and although correction factors for this effect are 
available (Douglas-Hamilton et al., 2005), they are not universally accepted as 
adequate (Björndahl & Barratt, 2005). In contrast to uneven sperm distribution, 
greater precision has been shown in some 20µm deep chambers when compared 
with the Improved Neubauer (Mahmoud et al., 1997). 
 
An obvious solution to the uncertainly associated with inadequate sampling 
numbers is the use of CASA. CASA concentration and motility data are shown to 
relate to both natural conception and ART outcomes (Table1-5). Although barriers 
to routine diagnostic application have been well documented (E.S.H.R.E., 1998), 
modern CASA systems have been shown to perform well in comparison to manual 
semen analysis (Agarwal & Sharma, 2007, Tomlinson et al., 2010, Dearing et al., 
2014b, Lammers et al., 2014). The WHO now recognise that CASA offers 
improved precision over manual methods and can be applied to routine analyses 
such as sperm counts, provided both adequate quality control procedures and 
high measurement standards are followed  (W.H.O., 2010e).  
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1.3.3  Motility 
 
Very few post-coital sperm reach the site of fertilisation; from the median fertile 
man’s ejaculate of 255 million sperm (Cooper et al., 2010), a few thousand reach 
the fallopian tubes and only tens will reach the oocyte (Suarez & Pacey, 2006, 
Kirkman-Brown & Smith, 2011). This can be explained by examining the difficulty 
of the journey sperm are required to make. A 50 µm sperm needs to swim over 20 
cm through a highly complex three dimensional maze of opposed surfaces coated 
with mucous of different viscosities (Kirkman-Brown & Smith, 2011). To put that 
into perspective, this is comparable to a human swimming approximately 7.0 Km.  
The few sperm that do reach the site of fertilisation do so by means of a motile 
flagella; swimming or crawling their way through the female reproductive tract 
(Suarez & Pacey, 2006). Because of this, it is generally accepted that a high 
proportion of sperm that are immotile or exhibiting poor motility will adversely 
affect male fertility (Turner, 2005). Several sperm motility parameters are found to 
relate to various fertility outcomes (Table 1-4 and 1-5). In addition, sperm motility 
is a functional test of mitochondrial activity (Pacey, 2006). Sperm motility is thus 
an essential parameter of semen analysis. 
 
While sperm maturation in the epididymis may have less of an impact on fertility in 
humans than other mammals, epididymal sperm exhibit several maturation 
characteristics compared with testicular sperm, including the capacity for motility 
(Cooper, 2007). After ejaculation sperm display two distinct types of physiological 
motility; activated motility consisting of symmetrical flagellar beating and 
hyperactivated motility consisting of asymmetrical flagellar beating (for reviews see 
(Kay & Robertson, 1998, Turner, 2005). Hyperactivated motility is most commonly 
seen when sperm undergo capacitation, a series of biochemical and physiological 
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processes that ready the sperm for fertilisation (for review see (Aitken & Nixon, 
2013). Evidence supports that hyperactivated motility enables enhanced 
swimming through oviductal mucus, penetration of the cumulus matrix and zona 
pellucida (Kay & Robertson, 1998, Turner, 2005, Aitken & Nixon, 2013). It should 
be noted that recent research has clarified that the movement of hyperactivated 
sperm is remarkably different in low viscosity, compared with physiological 
viscosities (Kirkman-Brown & Smith, 2011). 
 
The sperm tail consists of two main parts, the principal piece and the end piece. 
The principal piece constitutes most of the tail length and consists of the central 
core or axoneme made up of axial filaments with a classic 9+2 microtubule doublet 
arrangement. Motion is generated by ATP, which via protein motors called dynein 
arms, cause adjacent microtubule doublets to slide relative to one another 
producing axonemal bending, flagella beating and thus forward propulsion (for 
review see (Turner, 2005)). ATP is generated from glycolysis along the length of 
the tail, but also by mitochondrial oxidative phosphorylation in the midpiece 
(Turner, 2005, Piomboni et al., 2012). It is still unclear what exact proportions of 
ATP are provided by which metabolic pathways (Piomboni et al., 2012).  
 
The WHO recommend that sperm motility is assessed by phase contrast 
microscopy, within 30 minutes of production and immediately after liquefaction, 
though allow that this can be extended to within one hour after production if 
necessary (W.H.O., 2010f). These timeframes are designed to limit the motility 
damaging effects of changes in hydration, pH and temperature (Chomsrimek et 
al., 2008). Historically, sperm were graded into four grades of motility: Grade A; 
sperm with rapid forward progressive motility, Grade B; sperm also moving 
forward but sluggishly in comparison to Grade A, Grade C; sperm with non-
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progressive motility and, Grade D; immotile sperm. However, in 2010 the WHO 
amalgamated A and B class motility (W.H.O., 2010g) in response to the difficulties 
of accurate A and B classification (Cooper & Yeung, 2006). Thus, currently only 
three grades are recommended by the WHO; progressive (A and B amalgamated), 
non-progressive and immotile. This reclassification has not been adopted 
universally in the UK (A.B.A., 2012). As for sperm counting; the assessment of two 
replicates of a minimum of 200 sperm are recommend, with further replicates if the 
two results are significantly different (W.H.O., 2010f).  
 
Studies have highlighted the difficulties in standardising categorical assessment of 
sperm progression (Brazil et al., 2004, Cooper & Yeung, 2006), and the 
unreliability of the manual method due its subjective nature (Cooper & Yeung, 
2006, Huang & Lu, 2007, Tomlinson et al., 2010). Thus, the introduction of CASA 
has been favoured by several authors (Cooper et al., 2002, Agarwal & Sharma, 
2007, Huang & Lu, 2007, Tomlinson et al., 2010, Lammers et al., 2014). In 
addition to decreased subjectivity, CASA also allows kinematic motility variables to 
be obtained, which can identify hyperactivated sperm motility. Hyperactivated 
motility CASA parameters include: decreased Linearity (LIN), Straight Line 
Velocity (VSL) and Average Path Velocity (VAP), increased Curvilinear Velocity 
(VCL) and increased Amplitude of Lateral Head Displacement (ALH) (for review 
see (Kay & Robertson, 1998)). However, some disagreement between studies is 
evident and hyperactivation is multiphasic in nature and may be poorly described 
from “snapshot” CASA motility systems (Pacey et al., 1997, Kay & Robertson, 
1998, Mortimer, 2000).  
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1.3.4 Morphology 
 
Spermatozoa are the smallest and most polarised cells in the body. They require 
great specialisation to propel a highly condensed haploid genome to the egg, bind 
with it and achieve fertilisation. The process of becoming so specialised, where a 
visibly typical cell with a central nucleus loses the majority of its cytoplasm and 
transforms into a tiny motile highly condensed DNA package, may be remarkably 
inefficient (Auger, 2010); the vast majority of human sperm are morphologically 
irregular. While the structure at the distal end of the tail, the “endpiece” is not 
easily visible under the light microscope, detail of the head, the midpiece and 
principal piece (the tail), can be easily seen. These three major structures form the 
basis of WHO morphological classification (W.H.O., 2010h), into one of two 
possible categories; “normal” or “abnormal”.  A summary table of the current 
requirements for a single sperm to be categorised as normal can be seen in Table 
1-6. 
 
Table 1-6 WHO guidelines for grading sperm as “Normal” 
Structure Observation Normal 
Head 
Acrosomal size 40-70% of head area 
Acrosomal vacuoles No large vacuoles 
Acrosomal vacuoles Two or less small 
Post acrosomal vacuoles None 
Form 
 
Smooth, regular, oval 
Midpiece 
Length Same as sperm head 
Width Slender and regular 
Form Regular 
Alignment With head axis 
Residual cytoplasm 
 
Up to a third of head size 
Tail 
Length 10x the head (45um) 
Width Thinner than midpiece 
Form Uniform over entire length 
Alignment No sharp angles, loop is fine 
WHO 2010 guidelines for normal sperm are based on recommendations (Menkveld et al., 2001, Mortimer & 
Menkveld, 2001, W.H.O., 2010h). 
 
The concept of the “normal” sperm has been arrived at by studying sperm sub-
populations from postcoital endocervical mucus (Fredricsson & Björk, 1977, 
Menkveld et al., 1990) and from the zona pellucida surface (Menkveld et al., 1991, 
  
52 
 
Liu & Baker, 1992). If criteria determined from these subpopulations are applied to 
sperm in semen, the number of morphologically “normal” sperm can be predictors 
of fertility (Coetzee et al., 1998, Menkveld et al., 2001, Van Waart et al., 2001, van 
der Merwe et al., 2005). In addition to fertility measures, sperm morphology is 
associated with other semen analysis parameters, spermatogenesis disorders, 
aneuploidy, chromosomal abnormality, chromatin maturation level and DNA 
fragmentation (for review see (Auger, 2010, Menkveld et al., 2011)). While the 
main conceptual focus of WHO morphology is clearly on normality rather than 
abnormality, indices of multiple sperm defects (WHO optional procedures (W.H.O., 
2010j)) also appear to have prognostic potential (Table 1-7).  
 
Table 1-7 Indices of sperm abnormality and prognostic potential. 
Index Calculation Evidence 
Multiple Anomalies 
Index 
(MAI) 
Mean number of all head, midpiece and tail 
anomalies per abnormal spermatozoon using 
David classification system (David et al., 1975, 
Auger et al., 2000a). 
 
394 men attending a fertility clinic followed up 
over three years. Best prognostic indicator of 
natural fertility was the percentage of motile 
sperm and the MAI, particularly in patients 
with primary infertility .(Jouannet et al., 1988). 
 
Teratozoospermia 
Index 
(TZI) 
Mean number (maximum of 4) head, midpiece 
and tail anomalies per abnormal 
spermatozoon using strict classification 
system (Menkveld et al., 2001, Mortimer & 
Menkveld, 2001). 
 
 
ROC analysis on 107 men of partners who had 
a spontaneous pregnancy within one year of 
unprotected intercourse and 103 men 
attending a fertility clinic with counts <20x10
6
  
(Menkveld & Kruger, 1996, Menkveld et al., 
2001). 
 
Sperm Deformity 
Index 
(SDI) 
Number of defects divided by the total 
number of spermatozoa using strict 
classification system (Menkveld et al., 2001, 
Mortimer & Menkveld, 2001). 
 
 
The sperm deformity index had a greater 
sensitivity (96%), specificity (72%), positive 
predictive value (90%), and negative predictive 
value (86%) than the proportion of normal 
sperm morphology on 158 Patients undergoing 
IVF (Aziz et al., 1996). 
 
ROC=Receiver Operator Characteristic.  
Table lists the three indices of abnormal sperm morphology, how they are calculated and the evidence for 
their use. 
 
Although sperm morphology can predict fertility and is associated with many 
fertility associated parameters, there are several problems specific to the analysis. 
The threshold values for predicting infertility are 3-5% for ART (Coetzee et al., 
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1998, Van Waart et al., 2001) and for natural conception (van der Merwe et al., 
2005, Cooper et al., 2010). These low threshold values appear to have reduced 
predictive ability compared with the previously higher threshold values (Morbeck et 
al., 2011). The David morphology classification system (Jouannet et al., 1988, 
Auger et al., 2000a) contrasts sharply with that recommended by the WHO as 
being less strict as borderline forms are considered normal rather than abnormal. 
A comparison of Davids criteria and strict criteria on 1000 men from four European 
cities demonstrated high correlation between criteria (Slama et al., 2002). One 
recent interpretation of this work concludes that the interpretation of borderline 
forms as normal rather than abnormal results in a superior prognostic tool (Auger, 
2010). 
 
Similar to count and motility estimations, the WHO recommend reporting the mean 
percentage of normal sperm from two replicate measurements of 200 sperm, and 
further replicates if these two results are not within defined limits (W.H.O., 2010h). 
However, a sample size of 400 has 80% power to detect a median difference of 
only 10 with a significance level of 0.05 (two tailed) (Pezzullo, 2009). Thus, the 
recommended numbers are not high enough to statistically provide the power 
required to differentiate morphology results either side of the threshold values 
(Menkveld, 2010). Even the WHO table of acceptable morphology differences 
(W.H.O., 2010i) gives a span across the diagnostic threshold when the mean of 
the two replicates is between 5-7%. For example, an average of 6% (5.5% 
rounded to the nearest even number) can be accepted under these 
recommendations from one replicate of 3% and another replicate of 8%. One 
result is clearly below the threshold and one is clearly above and yet the result is 
reported as 6%.   
 
  
54 
 
The problem of statistical power is further compounded by the fact that many 
routine laboratories appear to estimate morphology with poor methodology or with 
lower numbers than are recommended (Keel, 2004, Riddell et al., 2005, Baker, 
2010, Mallidis et al., 2012, Filimberti et al., 2013, Walczak-Jedrzejowska et al., 
2013). Accurately assessing sperm morphology is also hindered by the lack of a 
definitive staining method (W.H.O., 2010h). Significant differences between sperm 
head measurements according to stain type and technique have been 
documented (Maree et al., 2010). While staining is recommended by the WHO 
(W.H.O., 2010h). A 2005 UK survey (Riddell, 2005), found many laboratories 
analyse morphology using non-recommended simple wet preparations at lower 
magnifications. This same survey found that only two of 37 UK semen analysis 
laboratories were fully compliant with WHO morphology recommendations. 
 
CASA morphology systems have been found to be acceptable for routine 
diagnostic use (Barroso et al., 1999, Agarwal & Sharma, 2007, Lammers et al., 
2014), though some authors disagree (Steigerwald & Krause, 1998, Akashi et al., 
2005). The major benefits of using CASA morphology over manual techniques 
appears to be improved standardisation and precision (Barroso et al., 1999, 
Agarwal & Sharma, 2007, Huang & Lu, 2007, Lammers et al., 2014). The major 
disadvantage of CASA for morphology is that systems are unable to deal with 
atypical samples including those with unusual or rare morphological abnormalities 
(Agarwal & Sharma, 2007, Lammers et al., 2014). However, some CASA systems 
may be particularly complementary to derived indices (Auger, 2010), one recent 
study concluding CASA morphology results using strict criteria were superior to 
David criteria (Blanchard et al., 2011). Because CASA morphology systems 
generate large quantities of precise data they are theoretically very suited to 
calculating abnormality indices. 
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1.3.5 Reference Limits 
 
All clinical measurements require comparison with reference values to facilitate 
patient management and to guide treatment or further investigations. With regards 
to semen analysis parameters, one-sided lower limit thresholds are shown to be 
more suitable for predicting both natural fertility (Cooper et al., 2010) and assisted 
conception outcomes (Coetzee et al., 1998, Vanweert et al., 2004). However, 
differences between the fertility of specific geographic populations and high 
between-laboratory analytical variance, have lead the WHO to recommend that 
individual laboratories consider utilising reference ranges from local populations 
(W.H.O., 2010a). The recommended (W.H.O., 1999) population on which to base 
semen reference ranges are healthy men who have achieved a pregnancy with 
their partner within 12 months of halting contraception. The most recent edition of 
the WHO manual (W.H.O., 2010a) utilises reference limits (Cooper et al., 2010) 
that focused on direct, retrospective selection of these men.  
 
While the WHO threshold limits undoubtedly offer a vast improvement over the 
previous reference limits, there are several unavoidable limitations that illustrate 
some of the weaknesses with fertility reference ranges. These limitations include; 
(1) a large proportion of fertility problems have a female or unexplained origin and 
thus many men above the threshold will still experience infertility; (2) men who 
have recently conceived with their partner may not accurately represent other 
healthy men; (3) as the 5th percentile is used as a threshold limit, a proportion of 
men below the threshold will experience no infertility; (4) semen parameters are 
highly variable within men and multiple samples are required in conjunction with 
clinical details to fully investigate male fertility; (5) regional population differences 
in semen parameters are possible confounders (W.H.O., 2010a). 
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In regards to local reference limits, studying the WHO recommended population 
has proved to be extremely difficult for fertility clinics (Lewis, 2007). Additionally, 
this reference range would not be optimal to aid selection of appropriate ART 
treatments, which require threshold values estimated from populations of patients 
who undergo ART. The threshold limits used to select ART treatments using 
cryopreserved sperm from cancer patients ideally should be determined from that 
same population. Unfortunately, the numbers of these men are insufficient to 
formulate such a reference range. The closest achievable reference limits to 
compare with post-thaw semen are therefore, threshold values based on local 
men who undergo ART. 
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1.4 Variance 
 
1.4.1 Introduction 
 
Infertility affects 1 in 7 couples worldwide (Boivin et al., 2007) and the single most 
common cause has been identified as sperm dysfunction (Barratt et al., 2011). 
Thus, it is paradoxical that so many authors have questioned the clinical value of 
semen analysis (Alvarez et al., 2003, Jequier, 2005, Lefièvre et al., 2007, Lewis, 
2007, Jequier, 2010, Kini et al., 2010, Barratt et al., 2011). The concerns that 
authors have with semen analysis are many. Aside from the confounders in 
comparing results with reference values (see 1.2.5 Reference Limits), current 
semen analysis parameters are limited in that they are only able to estimate the 
probability that enough functional sperm will be available to achieve fertilisation 
(Holt, 2005, Pacey, 2006). Of the many requirements that sperm need to meet to 
achieve fertilisation (and healthy development) we are only able to estimate a few 
(Holt, 2009, Barratt et al., 2011). Add to this a lack of method standardisation, high 
analytical and biological variability (Pacey, 2006, Brazil, 2010, Barratt et al., 2011), 
and the limitations facing the clinical value of semen analysis become clearer. 
However, if some or any of these factors can be minimised then the clinical value 
of semen analysis should increase. 
 
1.4.2 Measurement Uncertainty 
 
All clinical diagnostic laboratories have the core requirement of the production of 
reliable test results on which the clinician can base health care decisions. Clinical 
laboratories use robust internal Quality Control (QC) and EQA systems to produce 
and maintain such reliability. However, no clinical result is exact and each reported 
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value has an associated level of doubt surrounding it. This doubt level or 
“uncertainty” is essential information to determine how much clinical weighting 
should be given to any particular test value. Measurement Uncertainty (MU) is an 
emergent UK clinical laboratory regulatory requirement as Clinical Pathology 
Accreditation (CPA) standards v2.0 (C.P.A., 2012) are replaced by ISO 15189. 
This international standard will require each laboratory to determine its own MU for 
every procedure that generates quantity based results. Additionally, accredited 
laboratories will have to demonstrate regular review estimates of MU and have 
evidence that uncertainty remains within defined performance limits. Laboratory 
analytical variance, as the major measurable factor for MU, is thus of increased 
importance for UK clinical laboratories for improving quality, assisting clinical 
decision making and maintaining or gaining accreditation. A robust method of 
establishing ongoing and threshold MU is required for our laboratory. 
 
Two fundamentally different methodologies are available that may be used to 
calculate the uncertainty of a measurement. The first is the “GUM” approach (Bell, 
2001, ISO, 2008) which may be described as a “bottom up” methodology. This 
approach identifies all factors that contribute to the uncertainty, characterises the 
variance of each and then combines them to arrive at an overall figure. An 
example of factors this approach could include for semen analysis is presented in 
Table 1-8.  
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Table 1-8 Bottom up MU calculation for semen analysis clinical laboratories 
Source Semen analysis example 
The measuring instrument 
 
Bias or imprecision from ageing counting chambers or drift in an individual operator’s 
interpretation of sperm motility. 
 
The item being measured 
 
The decrease in sperm motility with time. 
The measurement process The operator results are less precise because of time demands on a busy day as less 
sperm are included in the analysis. 
 
‘Imported’ uncertainties 
 
Recalibrating a balance to measure semen weight to estimate volume or a toxic 
affect from a sample pot. 
 
Operator skill 
 
An unexperienced technician exhibiting higher variance between results compared 
with an experienced technician. 
 
Sampling issues 
 
A single aliquant from a poorly mixed ejaculate. 
The environment A poorly heated laboratory in winter affecting sperm motility estimations. 
MU=Measurement Uncertainty. Based on guidance (Huang et al., 2000). 
 
Table lists potential sources of MU that could be included in a “bottom up” MU calculation for semen analysis 
laboratories. 
 
In contrast to “bottom up” methodology, “top down” methodology estimates 
variation directly from experimental or QC data (Westgard, 2010, Westgard, 2012). 
The “top down” methodology is simpler and generally considered more suitable for 
clinical laboratories (Westgard, 2012). This approach depends on combining MU 
from imprecision and bias estimates and is outlined in Table 1-9.  
 
Table 1-9 Top down MU calculation for clinical laboratories 
Source Time frame Reflecting variance in 
---------------------------------------------------------------Imprecision MU--------------------------------------------------------------- 
Long term QC data 3-6 months Different lots of reagents / consumables 
Calibrations 
Pipetting 
Temperature stability 
Different operators 
Different operating conditions 
------------------------------------------------------------------Bias MU------------------------------------------------------------------ 
EQA data Ongoing Bias between laboratories 
------------------------------------------------------------------Total MU----------------------------------------------------------------- 
 
(𝑀𝑈𝑖𝑚𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛2 + 𝑀𝑈𝑏𝑖𝑎𝑠2)1/2 = 𝑀𝑈  
MU=Measurement Uncertainty. Based on guidance from (White, 2008, Westgard, 2012). 
Table demonstrates “top down” MU calculation for semen analysis laboratories. 
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1.4.3 Semen Analysis Variance 
 
MU calculation may be particularly difficult and potentially even unwelcome for the 
semen analysis laboratory; the concept may reveal large inadequacies with many 
laboratories’ current methodologies. Unfortunately, laboratories performing semen 
analysis have been comparatively slow in QC and EQA uptake (Pacey, 2010). 
Even the WHO did not include QC and EQA in its guidance until the fourth edition 
was published (W.H.O., 1999). This and the lack of agreement on the need for 
quality assurance in semen analysis (Holt, 2005, Jequier, 2005, Pacey, 2006), 
may have resulted in diminished drivers to improve quality and standardisation. 
The evidence for non-standardised semen analysis with poor methodology is 
compelling (Table 1-10).  
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Table 1-10 Evidence for poor semen analysis methodology 
Location 
Type 
(time) 
Results Conclusion Reference 
Germany 
EQA study on 
10 laboratories 
Count CV = 23-73% 
Motility CV = 21% 
Morphology CV = 25-87% 
Highest variability for low 
concentrations. 
(Neuwinger et al., 
1990) 
Italy 
EQA study on 
20 laboratories 
Count CV = 30-52% 
Motility CV = 39-72% 
Morphology CV = 17-26% 
- 
(Gandini et al., 
2000) 
 
United 
States 
Compliance 
survey (2002) 
Significant lack of 
standardization in the 
performance and reporting of 
semen analyses 
Supports the urgent plea for 
standardization 
of semen analysis 
methodologies. 
(Keel et al., 2002) 
Spain EQA (5 years) 
Count CV = 20-34% 
Motility CV = 24-70% 
Morphology CV = 54-72% 
Urgent need for 
improvement. 
(Alvarez et al., 
2005) 
UK 
Compliance 
survey (2005) 
5% of laboratories WHO 
compliant with morphology 
Urgent need for education 
and training. 
(Riddell et al., 
2005) 
United 
States 
Compliance 
surveys (2008) 
2% of laboratories WHO 
compliant with morphology 
- (Brazil, 2010) 
China 
Compliance 
survey (2010) 
0% of laboratories WHO 
compliant 
Urgent need for 
standardisation and QC. 
(Lu et al., 2010) 
Germany EQA (10 years) 
<8% of laboratories WHO 
compliant 
Majority of laboratories 
using methods expressly 
opposed by the WHO. 
(Mallidis et al., 
2012) 
Italy 
EQA (initial 3 
returns) 
Count CV = 46-75% 
Motility CV = 20-80% 
Morphology CV = 89-106% 
A need for EQA, training and 
WHO compliance. 
(Filimberti et al., 
2013) 
Poland 
Compliance 
survey (2013) 
<6% of laboratories WHO 
compliant 
Need for standardisation and 
continuous unified training. 
(Walczak-
Jedrzejowska et 
al., 2013) 
CV=Coefficient of Variation, EQA=External Quality Control, QC=Quality Control, WHO=World Health 
Organisation 
 
Table lists evidence demonstrating high between-laboratory variance and / or poor standardisation of semen 
analysis. 
 
Even more concerning is that the high between-laboratory variance recorded by 
EQA schemes may be significant underestimates. EQA schemes generally rely on 
the presumption that the EQA samples are treated in the same manner as routine 
samples. In practice this may not occur as systems to ensure that EQA samples 
are treated similarly are left up to the individual laboratory. For example in the UK, 
since EQA is a regulatory requirement and poor performance letters are written to 
individual laboratories who submit results significantly far from consensus values, 
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there is pressure on laboratories to “pass” EQA. Moreover, considering that 
biological, collection and toxicity sources of variance are not estimated by EQA 
schemes (Tomlinson, 2013), true between-laboratory variance is likely to be 
considerably larger. Between-laboratory variance is the major factor that limits the 
usefulness of WHO threshold values.  
 
Even manual semen analysis of the very highest quality relies on estimations 
made from only a limited number of sperm from a fluid that exhibits extreme 
heterogeneity. The most recent WHO guidance (W.H.O., 2010k) attempts to 
account for this in two ways; firstly the assessment of enough sperm per replicate 
and secondly the assessment of at least two replicates with further replicates if the 
initial two results are significantly different (see Semen Analysis 1.2 for details). 
Considering the many reports of high between-laboratory variance (Table 1-10), it 
is noteworthy that the new guidance vigorously highlights sampling errors  
(W.H.O., 2010b, W.H.O., 2010c, W.H.O., 2010f, W.H.O., 2010h, W.H.O., 2010i). 
Only time will tell if the new guidance will result in improved quality and correct the 
lack of motivation towards standardisation (Brazil, 2010).  
 
One source of variance that contributes to between-laboratory variance is 
between-operator variance. Between-operator variance has been estimated from 
multiple sources; QC of routine clinical laboratory practice, studies specifically 
designed to measure the variance, training workshops attempting to improve 
standardisation, and from multicentre comparisons who use a central location 
(Table 1-11). Depending on study design, time frames examined, operator 
expertise, semen analysis methodology and data analysis, the variance can range 
from insignificant to a magnitude that will have clinical impacts (Table 1-11). It 
should be noted that between-operator variance is not limited to manual semen 
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analysis; large between-operator differences have also been reported with CASA 
systems (Holt et al., 1994).  
 
Table 1-11 Between-operator variance in semen analysis 
Compared 
CV % mean or range 
Notes Reference 
Count Motility Morphology 
IQC study - 8-23 3-85 
Recommends that technicians should 
be recruited who have natural ability 
as observers. 
(Dunphy et 
al., 1989) 
IQC data from EQA study 10 8 8 
Unclear if data reflects within or 
between-operator variance. 
(Neuwinger 
et al., 1990) 
IQC study 6 6 6 
Low values excluded from CV % 
calculation. 
(Cooper et 
al., 1992) 
IQC motility only study - 0-76 - 
Used CASA to blindly examine 
subjectivity of 5 trained technicians 
motility grading. 
(Yeung et al., 
1997) 
 
Comparison of 4 
technicians from 4 
different laboratories at 
central location 
71-77 22-60 12-18 
Each operator used their own 
laboratory methods (3 different 
counting chambers). 
(Jørgensen et 
al., 1997) 
Comparison of 13 
technicians from 10 
different laboratories at 
central location 
23 22 - 
Each operator used their own 
laboratory methods (4 different 
counting chambers). Large difference 
between expert and novice 
operators. 
(Auger et al., 
2000b) 
IQC data from EQA study 11 7-20 9-24 
Between-technician variation (data 
from three to five technicians 
assessing one sample monthly for 33 
months. 
(Cooper et 
al., 2002) 
IQC from multicenter study 
of semen quality focusing 
on standardisation 
4-26 3-84 - 
Could not standardise  the 
categorical assessment of individual 
sperm progression. 
(Brazil et al., 
2004) 
3 Workshops on count and 
motility 
8-28 11-17 - 
A significant reduction in CV of 
counts was achieved after 3 
workshops. 
(Toft et al., 
2005) 
IQC motility only study - 43-65 - 
Used CASA to blindly examine 
subjectivity of 3-5 trained technicians 
motility grading over 43 months. 
(Cooper & 
Yeung, 2006) 
CV=Coefficient of Variation, EQA=External Quality Control, IQC=Internal Quality Control. 
 
Table summaries evidence demonstrating magnitudes of between-operator variance.  
 
Estimates of between-operator variance may struggle to reflect fluctuating time 
pressures that may adversely influence quality during day to day operation of a 
busy semen analysis laboratory; it is not possible to completely reproduce the real 
“bench” experience. The ideal semen analysis QC has been described as 
consisting of “blinded samples, unrecognized as QC by the technician, analysed at 
the normal pace and intensity of the daily routine and representative of the range 
of specimens normally processed by the laboratory” (Brazil, 2010). Unfortunately, 
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similar to the problems described with EQA, between-operator variance may be 
significantly underestimated as the risk of special treatment by the operator cannot 
be removed. As shown by MU calculations, total uncertainty is a product of 
individual uncertainties. If between-operator variance can be minimised, between-
laboratory variance will decrease and semen analysis may become clinically more 
useful. 
 
1.4.4 Biological Variance, Lifestyle and Environmental Factors 
 
There is large biological variation seen in semen quality (Alvarez et al., 2003, Keel, 
2006). Each ejaculate is a mix of varying concentrations of sperm and secretatory 
fluid from both epididymides, which is in turn mixed with secretatory fluid from the 
prostate, seminal vesicles and bulbourethral glands (W.H.O., 1999). The ejaculate 
is produced in several boluses with smooth muscle contractions from orgasm that 
differ in strength between and within individuals (Bohlen et al., 1980). Known 
sources of variation of semen quality include collection method (Zavos & 
Goodpasture, 1989), arousal time (Pound et al., 2002), sample completeness 
(Björndahl & Kvist, 2003), accessory sex gland activity (Amann, 2009), length of 
sexual abstinence (Cooper et al., 1993), degree of epididymidal emptying (Cooper 
et al., 1993), and  testicular size (Handelsman et al., 1984, W.H.O., 1987, 
Andersen et al., 2000).  
 
In addition to biological variance, a host of environmental and lifestyle factors have 
more recently been implicated in semen quality (for review see (Giwercman & 
Giwercman, 2011)). In the UK, men with a history of testicular surgery, being in 
manual work, not working, not wearing loose underwear and of black ethnicity 
were recently found to have a higher risk of low motile sperm counts (Povey et al., 
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2012). Some indication of the sensitivity of the male reproductive system to 
lifestyle and environmental influences is the finding that semen quality may be the 
optimum marker of adverse environmental exposures (Nordkap et al., 2012). 
Additionally, a life expectancy cohort study of 43,277 men found that semen 
quality is a fundamental biomarker of overall male health (Jensen et al., 2009). 
Such findings reinforce the need for semen analysis with low analytical 
uncertainty.  
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Chapter 2 Trends in a London NHS Sperm Bank for Men with Cancer 
 
2.1 Introduction 
 
Sperm cryopreservation is currently the only method offering men insurance 
against sterilising iatrogenic clinical interventions, most notably benefiting men 
with cancer (Pacey, 2007). As such, current United Kingdom (UK) guidelines 
(R.C.P., 2007, N.I.C.E., 2013) agree that sperm banking should be universally 
available and fully funded on the National Health Service (NHS). UK clinics that 
bank sperm have a legal responsibility to continually improve the quality and 
effectiveness of the service to meet its users’ needs and requirements. However 
there is a general lack of data on the patients who are referred to our sperm bank.  
 
The primary aims of this study are to; (1) identify trends in referral for cancer 
patients referred to our sperm bank, (2) identify the diagnoses leading to sperm 
cryopreservation, (3) examine the diagnosis relationship with semen quality before 
cryopreservation and (4), determine the proportion and demographic 
characteristics of men who use their stored sample in assisted conception. To 
meet these aims, two audits were performed. Audit one focused on all the men 
who banked sperm following a cancer diagnosis between 1976 and 2013. To 
account for lag times between storage and sample use, a smaller secondary audit 
was undertaken. This included all the men who banked following a cancer 
diagnosis between 1976 and 2009. The results of both audits were then examined 
to identify any trends occurring over time. The results will be used to characterise 
the population of cancer patients requiring the cryopreservation service for this 
research thesis, explore any novel findings and to improve services at our centre. 
 
  
67 
 
2.2 Methods 
 
Local Policy  
Our centre operates a “walk in” weekday and emergency out of hours service for 
iatrogenic sperm banking. We utilise a glycerol based multi-step slow freezing 
method and recommend each patient store a minimum of three ejaculates before 
treatment and more if quality is severely compromised. Stored samples are 
reviewed biannually at which time, electronic and paper records are matched with 
a physical audit of samples in storage. Samples continue in storage or are 
disposed within a six month period after review or after obtaining consent for 
disposal. Each patient’s medical requirements for extended storage are reviewed 
before 10 years from the initial storage date or last review date.  
 
Audit One: Cancer Patient Referral Numbers and Ages 
All cancer patients’ records from 1976 until 2013 from the sperm bank database 
were downloaded into Microsoft Excel 2010 (Microsoft Excel v 14.0, Microsoft, 
Berkshire, UK). The number of new patients being referred was examined over 
time. Age at referral was compared over time. A summary of the latest available 
cancer statistics was made from Cancer Statistics Registrations, England (Series 
MB1), No. 42, 2011, released 26 June 2013 from the UK Office of National 
Statistics (Glare et al., 2008). The age ranges of all cancer patients seen at the 
sperm bank were compared with the cancer profiles and age ranges for men in 
England in 2010. 
 
Audit Two: Usage, Diagnosis and Semen Quality 
The number of men using their stored samples in Assisted Reproductive 
Technology (ART) procedures and the ratio of patients using their samples to new 
  
68 
 
patient referral was examined for the years 1976 to 2009.  The sperm count of 
patients storing sperm was also collated to examine whether the quality of 
samples being stored changed over time. Median age at referral was compared for 
men who use their samples in ART procedures, men who do not use their samples 
and men who are azoospermic. 
 
Patients with a clearly identified referral cancer diagnosis were matched with pre-
freeze semen analysis results from the first ejaculate stored. Patients without a 
specific cancer diagnosis but who had cancer, chemotherapy or radiotherapy 
recorded in their notes were grouped into an unknown cancer group. Semen 
parameters were ranked and compared with the 2010 WHO reference range for 
fertile men (Cooper et al., 2010). Identified cancer diagnoses (testicular cancers, 
Hodgkin’s lymphomas, non-Hodgkin’s lymphomas, leukaemia’s, melanomas & 
myelomas, brain cancers, prostate cancers) were compared for sperm count, 
semen volume, total motility, whole ejaculate count and Total Motile Count (TMC). 
In addition, rates of cryptozoospermia (sperm only seen in centrifuged pellet and / 
or Leja 100 chamber (Cooper et al., 2006), and oligozoospermia (sperm count less 
than 15x106) were compared by cancer diagnosis. 
 
Data were analysed from all cancer patients who stored and used their samples in 
ART procedures between 1976 and 2009. These men transferred their sperm 
samples out of the bank for fertility treatments at other clinics. Clinics and patients 
were telephoned to determine what fertility treatments were being selected with 
cryopreserved sperm and to determine live birth rates from those treatments. All 
patients had provided written consent to disclosure prior to storing their sperm. 
The semen profiles of the men who received fertility treatment with cryopreserved 
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sperm were compared by each treatment type, for volume, count, total motility, 
and TMC. 
 
Statistics 
Semen analysis parameters percentiles were calculated for each cancer 
diagnoses and medians compared with Kruskal-Wallis testing. Semen analysis 
parameters percentiles were calculated for each ART. Significant differences were 
tested for with Mann Whitney U test. Differences in proportions of patients were 
tested with Fisher’s exact test. Linear regression was used to examine the yearly 
increase in the number of new referrals, the number of men using their samples 
and the ratio of use to referral. The data were analysed using Prism version 4.0 
(GraphPad Version 4.01,San Diego, USA, www.graphpad.com) on a Samsung 
personal computer (Samsung NC10 Samsung Electronics, Samsung.com). 
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2.3 Results 
 
Audit One: Cancer Patient Referral Numbers and Ages 
From 1976 until the end of 2013, the sperm bank at Hammersmith Hospital has 
frozen or stored after transfer a total of 4362 men’s semen samples for fertility 
preservation before commencing cancer treatment. During the first 13 years 
(1976-1989) sperm were banked for only 129 men. From 1990 until the end of 
2013 the number of new patients increased linearly year on year (r2=0.96, 
p<0.0001) (Figure 1A). The magnitude of the increase may be highlighted by 
examining the number of new cases at the start of each decade: 45 new cases in 
1990, 144 new cases in 2000 and 310 new cases in 2010. The rate of increase for 
new referrals to our bank is higher than that for cancer diagnosis in England 
(Figure 2-1 A).  
 
Also increasing linearly per year was the 25th percentile age (r2=0.46, p=0.0001), 
median age (r2=0.60, p<0.0001) and 90th percentile age (r2=0.47, p=0.0001) of 
men storing, while a non-significant decrease in the minimum age is also apparent 
(Figure 2-1 B). The median age for patients storing before 1990 was 26 which rose 
significantly (p<0.0001) to a median age of 32 from 2005 onwards. The oldest 
patient storing sperm at the bank was 73 years old while several 13 year olds 
represent the youngest patients to have banked. 782 teenage cancer patients 
(ages 13 to 19) have banked sperm at the centre. 
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Figure 2-1 New referrals, cancer incidence and patient ages. 
 A. The number of new referrals for sperm cryopreservation are plotted by year with the number of new cancer 
diagnosis for England.  B. The range, 25
th
, 50
th
 and 75
th
 percentiles of patients ages at referral are displayed 
by year 
 
The cost of storing sperm increases yearly which influences the cost of storing 
samples that will never be used. As the number of new patients increases each 
year, the proportional cost of storing samples that are not used becomes a greater 
financial burden (Table 2-1).  
 
Table 2-1 Past, current and projected cost of storing sperm based on numbers of new patients and the cost of 
storage in line with an inflation measure (4%).     
Year 
Number of new 
Patients per year 
Number of new 
patients who 
wont use* 
-----------------------------------Costs £-------------------------------------- 
per 
patient 
per year
1* 
 
All new 
patients per 
year 
All new 
patients over 
10 
years 
10 year cost of 
storing patients 
who don’t use 
2002 173 159 210 36,345 363,451 334375 
2003 169 155 219 36,984 369,841 340254 
2004 251 231 228 57,218 572,177 526403 
2005 228 210 238 54,140 541,403 498091 
2006 228 210 247 56,396 563,961 518,844 
2007 235 216 258 60,550 605,496 557,056 
2008 288 265 268 77,297 772,973 711,135 
2009 305 281 280 85,271 852,709 784,492 
2010 310 285 291 90,280 902,799 830,575 
2011 292 269 303 88,581 885,811 814,946 
2012 324 298 316 102,384 1,023,840 941,933 
2013 331 305 329 108,875 1,088,751 1,001,651 
2014 344 316 342 117,424 1,174,239 1,080,300 
2015 356 327 355 126,482 1,264,823 1,163,637 
2016 368 339 370 136,077 1,360,775 1,251,913 
2017 380 350 384 146,238 1,462,379 1,345,389 
2018 393 361 400 156,993 1,569,935 1,444,340 
2019 405 373 416 168,376 1,683,755 1,549,055 
2020 417 384 432 180,417 1,804,169 1,659,836 
*The number of patients per year who won’t use their sample based on current use rates.  
1
* Cost increases 4% per year.  
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Since 2004 the bank has stored samples from patients referred with known 
positive virus serology; 38 patients are Hepatitis B positive, 27 patients are Human 
Immunodeficiency Virus (HIV) positive, 23 patients are Hepatitis C positive and 
five patients are positive for more than one virus.  
 
Audit Two: Usage, Diagnosis and Semen Quality 
From 1976 until the end of 2009, 3062 cancer patients’ stored samples and 183 
used their samples in ART, which represents 6.0% of this total. Cancer patients 
who stored and later disposed of their samples are included in these figures.  
Excluded from these figures were; unrecorded storage reason (171), non-cancer 
fertility or pre-vasectomy storage (126), biopsy cases including vasectomy reversal 
(27), retrograde ejaculation (6), sickle cell disease (4), hypergonadotropic 
hypogonadism (2), nephrotic syndrome (1) and ulcerative colitis (1). Usage figures 
varied considerably depending upon the time frame examined. A usage rate of 
12.4% occurred from the cohort who stored from 1976 until the beginning of 1990. 
In contrast between 2006 and 2009, 992 men stored and by the end of this period 
only 32 had used their sample, a usage rate of only 3.2%. Examining the lag time 
between storage and use, demonstrated that the majority of patients who used 
their stored samples did so within a five year period (Figure 2-2 A). However, while 
the cumulative probability of use curve flattened after 5 years, a significant 
proportion (20%) of patients still used their samples after this period (Figure 2-2B). 
The longest time frame between storage and use was 17 years; the donation from 
a 24 year old man in 1986.  
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Figure 2-2 Frozen sample usage rates. 
A. The number of cancer patients using their sample in ART are plotted by the number of years between 
storage and use. B. The cumulative probability of use by year as a percentage of all patients who use their 
sample. 
 
Year on year, the number of ART procedures linearly increased (r2= 0.95, 
p=0.005) though the ratio of ART procedures to new referrals did not. Men who 
had stored and used their samples in assisted conception were older (p<0.0001) 
at referral (median age 34) than all men who stored (median age 31). Men 
presenting with azoospermia (10% of all men) were younger (p<0.0001) at referral 
(median age of 27) than men who stored and used their samples in assisted 
conception (p<0.0001) and all men who stored (p=0.0143).  
 
The most common diagnoses associated with sperm banking are those which 
affect men of reproductive age (Table 2-2). Of the 3062 cancer patients, 45% did 
not have a specific cancer diagnosis recorded. These 1364 patients could be 
identified from their notes as having cancer or receiving chemotherapy / 
radiotherapy but a specific cancer diagnosis had not been recorded. This is 
unfortunately a major weakness with this dataset as the assumption cannot be 
made that missing diagnoses is a random event across oncology disciplines.  
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Table 2-2 Median semen analysis parameter values of first ejaculates of men with cancer (n=3062) compared 
by specific cancer diagnosis. 
Diagnosis N 
Crypt. 
(%) 
Oligo. 
(%) 
Count 
(x10
6
) 
Motility 
(%) 
Volume 
(mL) 
Ejac. Ct 
(x10
6
) 
TMC 
(x10
6
) 
Unknown  Cancer 1364 3.5 25.4 37 37 2.5 93 34 
Lymphoma 301 2.0 22.3 42 35 2.5 105 36 
Testicular 617 9.4 40.4 20 36 3.0 60 21 
Leukaemia 352 11.1 33.2 34 30 2.5 85 25 
Mel. & Myeloma 69 2.9 29.0 38 30 3.5 133 39 
Hodgkin’s 240 8.3 27.5 36 40 2.5 90 36 
Brain 68 0.0 17.6 54 40 2.5 135 54 
Prostate 51 0.0 23.5 69 38 1.5 104 39 
Kruskal-Wallis p  
K-W Statistic 
   
<0.0001 
96.7 
<0.0001 
35.9 
<0.0001 
39.6 
<0.0001 
61.6 
<0.0001 
34.6 
Crypt.=Cryptozoospermia (sperm only seen in centrifuged pellet and / or Leja 100 chamber), 
Oligo.=Oligozoospermia (sperm count less than 15x10
6
), Ejac =Ejaculate, Mel.=Melanoma. Unknown cancer 
category not included in Kruskal-Wallis analysis. 
 
The remaining 1698 patients with an identifiable cancer referral diagnosis showed 
that the greatest single referral diagnosis was testicular malignancies. The total 
3062 patients’ semen analysis results demonstrate that cancer has a large 
detrimental effect on male fertility parameters including decreased semen volume, 
count and motility (Table 2-3).  
 
Table 2-3 Semen analysis parameter percentiles for men with cancer (n=3062) compared with the WHO 2010 
reference values. 
 
Semen 
Volume (mL) 
Sperm 
Count (x10
6
) 
Ejaculate 
Count (x10
6
) 
Total 
Motility (%) 
Percentiles Cancer WHO Cancer WHO Cancer WHO Cancer WHO 
5 1.0 1.5 <1 15 <1 39 <1 40 
10 1.0 2.0 2 22 2.6 69 1 45 
25 1.5 2.7 11 41 21 142 17 53 
50 2.5 3.7 32 73 79 255 34 61 
75 3.5 4.8 73 116 202 455 47 69 
90 5.0 6.0 135 169 396 622 55 75 
95 6.0 6.8 174 213 574 802 60 78 
WHO=World Health Organisation 2010 reference values for fertile men (Cooper et al., 2010) 
 
183 patients who stored between 1976 and 2009 before beginning cancer 
treatment used their samples for assisted conception in 40 fertility clinics. 90% of 
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clinics and 60% of patients contacted were able to provide assisted treatment 
data. 109 patients received Intra Cytoplasmic Sperm Injection (ICSI) resulting in 
59 live births, 18 received In Vitro Fertilisation (IVF) with 7 live births, while 23 
patients received Intrauterine Insemination (IUI) with 9 live births. By far the largest 
group of patients receiving ICSI over other assisted conception treatments were 
those with testicular cancer (96%). After 2004, ICSI also appeared to be 
increasingly the treatment of choice with cryopreserved sperm (Figure 2-3).  
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Figure 2-3 ART treatment selected with cryopreserved sperm 1994-2009.  
 
A proportion of this increase can be explained by the fact that poor quality samples 
were not stored as often as they are today; evident as a negative correlation 
between sperm count and storage year (r2 = -0.09, p=0.02). It must also be noted 
that it was not possible to control for the historical availability of ICSI at UK clinics, 
ICSI only being a treatment option from 1992 (Palermo et al., 1992).  Although the 
majority of patients who received ICSI exhibited poorer semen quality with lower 
median sperm counts and motility than patients selected for IUI or IVF, a 
significant number of patients with a normal semen profile before cryopreservation 
also received ICSI (Table 2-4). 
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Table 2-4 Percentiles of pre-freeze semen characteristics from men with cancer (n=183) are compared by 
ART selection with frozen / thawed sperm. 
Percentiles Volume (mL) Count (x10
6
) Tot. Motility (%) Total Motile Count (x10
6
) 
IUI IVF ICSI IUI IVF ICSI IUI IVF ICSI IUI IVF ICSI 
 
5 1.0 1.0 1.0 2 3 0.01 3 <1 <1 0.36 <0.01 <0.01 
10 1.0 1.0 1.5 8 11 0.4 5 5 1 2.25 1.93 0.01 
25 2.0 2.0 2.0 36 34 1 29 27 1 21.90 17.64 0.06 
50 3.0 2.5 3.0 52 81 18 40 40 20 58.80 72.00 7.20 
75 4.0 4.0 4.0 89 112 50 50 55 39 109.26 163.50 35.61 
90 5.0 5.3 5.0 150 219 96 60 61 50 167.40 230.55 86.20 
95 5.7 6.0 6.0 241 364 134 65 63 53 227.08 340.28 196.40 
IUI=Intrauterine Insemination, IVF=In Vitro Fertilisation, ICSI=Intra Cytoplasmic Sperm Injection  
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2.4 Discussion 
 
The major aim of this study was to identify trends in referral for cancer patients 
referred to our sperm bank and to determine the proportion and demographic 
characteristics of men who use their stored sample. From 1976 until the end of 
2013 over four thousand cancer patients have successfully stored semen samples 
at the Hammersmith Hospital sperm bank. This bank is thus one of the largest of 
its kind, with a wide age range (13-73) of men storing and sample usage rates 
(6.0%) similar to those reported from other centres (Ragni et al., 2003, Pacey & 
Eiser, 2011, Bizet et al., 2012, Freour et al., 2012, Rives et al., 2012). Several 
local trends over time are identified: (1) both the total number of men referred for 
sperm banking and the number using their samples is increasing year on year; (2) 
The ages of men storing are increasing over time which is beginning to influence 
the cancer profiles of patients who store; (3) A large increase in ICSI preference 
over other ART for frozen / thawed sperm is occurring.  
 
There are likely to be multiple factors responsible for the large patient referral 
increases seen at the bank. Previous studies have found that the predicted 
numbers of sperm banking patients from population statistics and the incidence of 
cancer in reproductive aged men (O.N.S., 2013) are always greater than the 
number of patients actually referred for sperm banking (Gilbert et al., 2010, Pacey 
& Eiser, 2011). Largely implicated has been under-referral due to a lack of 
information being given to patients, with 30-50% of patients not adequately 
informed about sperm storage services generally (Schover, 2002, Edge et al., 
2006). Recent criticism of the lack of referral and rising risk of patient litigation 
(Lawford-Davies, 2009, Gilbert et al., 2010, Pacey & Eiser, 2011) may now be 
resulting in greater oncologist referral. Increases may also be indicative of 
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improvements in cancer survival rates (Dohle, 2010), since with increased survival 
patients become more concerned about quality-of-life issues such as fertility 
preservation (Agarwal & Allamaneni, 2005). Thus, a greater number of men may 
be seeking the service as part of a generally improved positive outlook for life after 
cancer (Pacey et al., 2013). Increased referral rates may also partially be a 
product of the annual increase of cancer diagnosis in reproductive aged men 
(Steliarova-Foucher et al., 2004). For example, testicular cancer cases in Europe 
have roughly doubled in a decade and a half (Bray et al., 2006).  While identifying 
which proportion of the observed increase in referral can be attributed to any 
individual factor is difficult to establish, it is certain that year on year a greater 
number of men access, and thus benefit, from the service. One of the reasons for 
this may be changing attitudes to age and reproduction. 
 
At the bank, 82% of patients consent to store their samples for 10 years or longer. 
All patients are reviewed every 10 years and storage extended if fertility proves to 
be compromised (H.F.E.A., 2013b). The samples are destroyed at the end of this 
period if the named individual on the consent form does not require further storage 
for a medical reason. The bank uses a current non-profit sperm storage cost of 
£316 per patient per year which accounts for liquid nitrogen, labour, continuous 
temperature monitoring, regulatory audit and administrative costs. The cost for a 
full 10 years of storage is £3160 per patient. In 2012, 324 new patients banked 
sperm, at current use rates, 298 of these patients will never use their samples and 
for a 10 year storage period will cost £941,933. In 2020 this non-use figure will rise 
to 384 patients with a 10 year cost of £1,659,836. Factoring in these patients who 
don’t use their samples, in 2012 the 10 year cost of the bank for each patient who 
does use their sample is £39,378; by 2020 this figure will increase to £54,671.  
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Further cost complications are encountered with the growing number of patients 
with positive viral serology. The cost of storage per patient for viral positive 
patients is greater because of the need to store small numbers of samples in 
separate tanks to avoid cross viral contamination which has been shown possible 
in liquid nitrogen (Tedder et al., 1995). Patients positive for multiple viruses are 
particularly problematic. Whether these costs represent good value for the NHS, 
whether the initial 10 year consent period is adequate or whether sperm banks can 
continue to operate as a service to all patients in these financially challenging 
times have to be considered as relevant questions.  
 
The number of men with cancer who store at the bank and then go on to use their 
samples in ART procedures is increasing. Encouragingly, three quarters of cancer 
patients are now long-term survivors (Dohle, 2010). With a greater number of men 
surviving cancer a greater proportion of those who initially store wish to become 
fathers. Usage rates are also limited by the time frames examined and the ages of 
the patient storing. For example, a 13 year old who stored sperm in the year 2000 
will only reach the average age of first-time UK fathers (32 (O.N.S., 2014)) in 
2019. The significance of this cannot be overstated: 782 of the cancer patients 
storing were teenagers at storage. Historical usage rates are thus unlikely to be 
comparable with current and future demands, particularly as cancer survival rates 
are likely to continue to improve. 
 
Unfortunately the 1976-2009 audit could only identify a specific cancer diagnosis 
on 55% of patients, thus a risk of bias cannot be removed. The patients surveyed 
revealed that by far the greatest single referral was testicular malignancies, 
followed by leukaemia, non-Hodgkin’s lymphomas and Hodgkin’s lymphomas: 
data which are similar to previous reports (Dohle, 2010).  These cancers represent 
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only a small fraction of all male UK diagnosed cancers, but are those most 
associated with reproductive age (O.N.S., 2013). However, this cancer profile is 
now being influenced by increasing (p<0.0001) median age at referral. This is 
demonstrated with a greater (p=0.0230) proportion of men referred with a 
diagnosis of prostate cancer post 2008 compared with pre 2000. Also contributing 
is the improved diagnosis and increased prevalence of prostate cancer in young 
men (O.N.S., 2013). These figures may also in part, be due to social change, with 
a greater number of older men having younger female partners who themselves 
wish to have children and thus influence their partner’s decision on whether or not 
to bank sperm. Partners’ views have previously been shown to be important for 
influencing sperm banking decisions (Eiser et al., 2011). 
 
This current audit is in agreement with previous estimates, in that only about a 
third of men with cancer (Van Casteren et al., 2008, Dohle, 2010) have a semen 
profile above the WHO threshold values (Cooper et al., 2010). Specific cancers 
are associated with specific semen parameter defects which may be of interest to 
sperm banks for cryopreservation method selection. Particularly low semen 
volumes were noted for prostate cancer sufferers and particularly low counts for 
testicular malignancies for example. The prevalence of oligozoospermia was 
highest for testicular cancer patients (40%), followed by leukemia patients (33%) 
then other cancers (18-29%). This is a hierarchy similar to that reported previously 
though the actual prevalence rates differ markedly (Chung et al., 2004, Trottmann 
et al., 2007). Semen parameter characteristics between studies were also not 
directly comparable: median sperm counts from 240 patients with Hodgkin’s 
lymphoma was notably higher (36x106) than those reported (22.7 x106) in a 
previous audit on 202 patients (Sieniawski et al., 2008). Differences between the 
prevalence of oligozoospermia or semen parameters may be due to differences 
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between fertility affecting cancer symptoms or cancer stages. For testicular cancer 
patients, spermatogenesis defects are higher in tissue in close proximity to the 
tumour (Ho et al., 1992). Patients with larger or more invasive tumours will have 
higher levels of spermatogenesis defects and a higher prevalence of 
oligozoospermia. Differences in inclusion criteria, changes in WHO reference 
values and between-laboratory differences are also likely confounders. 
 
For men who store samples with few or even a single sperm, ICSI is the only 
realistic chance for fathering their own genetic offspring. In this regard ICSI has 
revolutionised the value of sperm cryopreservation and enabled many men to 
become fathers who otherwise would not. However, while the results of this audit 
do highlight marked decreased semen parameters for men with cancer, not all 
men with cancer suffer poor semen quality. 73% of all patients received ICSI and 
yet the median semen parameters were a volume of 2.5 mL, count of 32 x 106 and 
TMC of 27 x 106. These values are almost double the WHO threshold limits for 
natural conception (Cooper et al., 2010). Since only relatively recent advances in 
ART have enabled paternity with very poor quality semen, such samples have not 
historically been stored as often as they are today. Thus, an increase in ICSI 
treatments is somewhat an expected result. However, even taking this into 
account and considering the well documented negative effects of cryopreservation 
(Keel et al., 1987), ICSI treatment selection appears to be occurring for some 
patients irrespective of sample quality. Limitations in the quantity of material being 
stored for cancer patients may be a factor. The criteria employed to select patients 
for ICSI has previously been shown to be heterogeneous in the UK (Jones et al., 
2012). It is concerning that ICSI may be being overused in this particular patient 
group.  
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10% of cancer patients seen at the bank are azoospermic; a figure similar to 
previous reports (Dohle, 2010). These men were younger at referral (p=0.0143, 
median 27) than all those who stored (median 31) and than those who used their 
samples in ART procedures (p<0.0001, median 34). Unfortunately scenarios like 
azoospermia or non-sample production appear to increase the emotional distress 
for some young men dramatically. However, it is not currently possible to predict 
who is azoospermic or will fail to produce a sample. Neither is it possible to predict 
for an individual which cancers or treatment will result in permanent damage to the 
gonad (Bahadur et al., 2005). Additionally, If men after cancer treatment find they 
are infertile and sperm cryopreservation is not offered, litigation may be a real 
possibility (Tomlinson & Pacey, 2003, Lawford-Davies, 2009, Pacey & Eiser, 
2011). Sperm banking therefore has to be offered to all men at any risk of 
infertility.  
 
Encouragingly, although sperm banking for cancer has historically been 
underutilised, our local referral rates for sperm cryopreservation are rising sharply. 
Similarly, the numbers of local men who store and then go on to use their samples 
with ART is also correspondingly increasing. Historical use rates of frozen sperm 
are therefore likely to be significant underestimations of future use. Older men are 
seeking the service which is beginning to influence the cancer profiles of men 
storing samples; a greater proportion of men are storing with a diagnosis of 
prostate cancer. ICSI is overwhelmingly becoming the assisted conception 
treatment of choice with cryopreserved sperm. Establishing an evidence base for 
ART procedure selection following sperm cryopreservation and attempting to 
develop more patient individualised approaches to sperm cryopreservation may be 
useful areas to improve future services. 
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Chapter 3 Measurement Uncertainty in Semen Analysis 
 
3.1 Introduction 
 
All laboratories have the fundamental requirement to produce reliable test results. 
However, no result is exact and each reported value has an associated level of 
“uncertainty”. Measurement Uncertainty (MU) is an emergent UK clinical 
laboratory regulatory requirement as Clinical Pathology Accreditation (CPA) 
standards (C.P.A., 2012) are replaced by ISO 15189. This international standard 
will require each laboratory to determine its own MU for every procedure that 
generates quantity based results. The estimation of laboratory analytical variance, 
as the major measurable factor for MU, is thus of increased importance for UK 
clinical laboratories for improving quality, assisting clinical decision making and 
maintaining or gaining accreditation. A robust method of establishing ongoing and 
threshold uncertainty is required for our laboratory. 
 
The objective of this study is to establish which factors contribute to measurement 
uncertainty for our laboratory. This will be achieved by introducing a novel Quality 
Control (QC) tool. The results will be used to improve understanding of the 
uncertainty of semen analysis, which is the outcome measure used to gauge 
sperm cryopreservation response for this thesis. The quality tool if found useful will 
be used to calculate and review MU for our laboratory and will be introduced as 
part of our Internal Quality Control (IQC) procedures. 
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3.2 Methods 
 
Internal Quality Control Tool  
Andrology trained Biomedical Scientist (BMS) staff working in a busy diagnostic 
semen analysis laboratory (Andrology Laboratory, Hammersmith Hospital, Imperial 
College, London, UK) were shown how to use a novel QC computer programme. 
The PC programme, Internal Quality Control Tool (IQCT), was developed by Chey 
Dearing, Mark Smorifit and Kevin Lindsay to provide IQC for diagnostic semen 
analysis. After further development the programme may be available from Item 
Tracker (Item Tracker, http://www.itemtracker.com). IQCT was developed to allow 
individual operators to perform QC rapidly with two aims, (1) to provide an 
accurate measure of within-laboratory variance and (2), to examine whether 
regular daily graphical representation of operator bias and imprecision could 
improve quality within our laboratory.  
 
IQCT Data Collection 
Each operator was given a specific password to access IQCT and was instructed 
to use it daily. Prior to beginning semen analysis each operator logged into the 
programme and selected a motility assessment. The programme plays a randomly 
selected video of motile sperm which the operator then analyses using World 
Health Organisation (WHO) criteria (W.H.O., 1999). The operator enters the 
results into the programme and is presented with two graphs. The first plots the 
entered current results against the mean and Standard Deviation (SD) of previous 
results for that operator for that specific video. The second graph plots the current 
results against the mean and SD of previous results for all operators’ for that 
specific video. The first graph thus acts as a graphical representation of that 
operator’s own precision, while the second shows operator bias against the mean 
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values of all operators’ for that video. All BMS were instructed to perform this QC 
before beginning semen analysis and after each sixth sample. 
 
At the end of the semen analysis session, each operator logged back into the 
programme and entered all D class motility and sperm count results from patient 
semen analysed by that specific operator for that day. Only numerical results were 
recorded. IQCT generates box and whisker plots from the entered data 
representing the range, 25th percentile, median and 75th percentile. The graphs 
show the operator’s most recent results against their previous results and against 
all operators’. The number of results to include in each box is flexible but pre-
determined from the programme settings by an operator with administrator 
privileges. IQCT also automatically performs a Man-Whitney U test to check for 
significant differences for each comparison. These graphs and tests of significance 
were designed to show an individual operator any drift and bias that was occurring 
in their own results and allow them to improve over time. 
 
IQCT allows a user with administrator privileges to download all results entered. 
One year (2011) of patients’ results for count and D motility were downloaded and 
analysed. To compare any improvements in quality by the use of IQCT, historical 
patient results from two years (2009 and 2010) prior to IQCT were compared with 
one year’s results from the IQCT. Both pre and post IQCT data sets were 
examined for differences between and within operators for count and D motility.  
 
WHO Motility Categorisation 
Because of large significant differences in the central measures and distributions 
from individual operators for D motility grading, a subsequent analysis of full 
motility grading (W.H.O., 1999) was carried out. Motility results generated by the 
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four most experienced staff from 2000 patients analysed after IQCT introduction 
(500 results from each operator) were collated and analysed.  
 
Imprecision Estimations 
Within-laboratory precision was estimated for motility by data collected from 10 
videos from the IQCT. Four operators completed a minimum of 10 attempts at 
each video over a period of three months. Correlation Variation (CV) was 
calculated from a minimum of 10 results for each precision analysis. Within-
laboratory precision was estimated for count and morphology by repeat 
measurements on 28 UK EQA samples by individual operator staff blinded to other 
results. Between-laboratory motility, count and morphology precision was 
estimated from data collected from 96 EQA samples from 24 EQA reports (07 Feb 
2005 to 12 Sep 2011). 
 
External Quality Assurance Samples 
EQA samples are provided by the UK National External Quality Assessment 
Service (NEQAS). NEQAS samples used for this project are pooled semen fixed in 
10% formalin prepared by the NEQAS Reproductive Science Scheme 
(Reproductive Medicine, Andrology Laboratories, Saint Mary’s Hospital, 
Manchester, UK). Four samples are sent to every laboratory in the scheme each 
distribution. Four distributions are sent each year on a quarterly cycle for a total of 
16 samples per year. NEQAS samples only use consensus values grouped by 
counting method and are not related to a true reference standard. 
 
Laboratory Methods for Count, Motility and Morphology 
All laboratory methods were performed by Health and Care Professions Council 
(HCPC) registered BMS staff using WHO methods (Chapter Four, Methods).  
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Statistics 
The difference between pre and post IQCT results were tested by Mann-Whitney 
U test. Kruskal-Wallis with Dunn's Multiple Comparison Test as a post hoc test 
was used for the following: differences between and within groups; testing for drift 
within operators on consecutive results grouped as months, batches of 200 and 
batches of 400; differences within WHO classes of motility data. Bias was tested 
by graphing the percentiles from operators on QQ Plots. The data were analysed 
using Prism version 4.0 (GraphPad Software, San Diego, CA, USA, 
www.graphpad.com) on a Samsung personal computer (Samsung Electronics, 
Samsung.com). 
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3.3 Results 
 
IQCT 
IQCT was found to be a useful tool for rapid QC in as close to as possible 
conditions as those used for semen analysis (Figure 3-1 A-F). 
 
 
 
 
A 
B 
C 
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Figure 3-1 Photos of IQCT 
Photo (A) shows the IQCT log in screen. Photo (B) shows the control centre for selecting which QC to 
perform. Photo (C) shows a motility assessment graph for comparing an individual’s current result from 
historical results from uploaded motility videos. Photo (D) shows a median and quartile operator drift 
assessment box plot for comparing medians between variable numbers of results. Photo (E) shows a median 
and quartile operator bias assessment box plot for comparing medians between all operators ’. Photo (F) 
shows a Mann Whitney U test table for comparing statistically relevant bias between-operators. 
 
 
 
 
F 
D 
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Bias and Drift 
Between-operator and within-operator differences for sperm count and D motility 
before and after the introduction of IQCT are summarised (Table 3-1).  For sperm 
counts, significant (p<0.001) between-operator differences occurred between all 
operators’ prior to IQCT introduction and between all but two operators (operator 2 
and 7) after introduction (Appendices 9.1, Tables 9-1, 9-2). For D motility, 
significant (p<0.001) between-operator differences occurred between all operators’ 
both before and after IQCT introduction (Appendices 9.1, Figure 9-1). 
 
The all operator D motility median significantly (p<0.001) decreased (38 to 35) 
after the IQCT introduction. Individual operator median D motility results (of the 
four that contributed to both pre and post IQC data) moved closer to the group 
median after IQCT introduction; operator 1, 2 and 3 (p<0.001). Operator 4 
significantly (p<0.001) reduced their positive bias, but as the IQCT median also 
shifted, operator 4 was actually further away from the combined median post IQCT 
(Appendices 9.1, Figure 9-1). Viewing QQ plots of D motility percentiles for 
individual operators established that D motility bias patterns are operator specific 
pre and post IQCT (Appendices 9.1, Figure 9-2). 
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Table 3-1 Sperm count and D class WHO motility drift within operators and bias between-operators compared 
before and after IQCT introduction. 
 Sperm Count Pre IQCT  Sperm Count Post IQCT 
Operator N Median 
Drift  
p 
Drift 
KW 
Bias p 
 
N Median 
Drift  
p 
Drift 
KW 
Bias p 
1 2661 37 0.004 43.45 
p<0.001 
KW=55.76 
 1694 39 0.007 37.14 
p<0.001 
KW=24.01 
2 1712 42 <0.001 59.70  343 43 0.860 3.26 
3 1558 39 0.368 22.75  676 34 0.243 11.50 
4 1913 40 0.818 16.82  622 37 0.412 10.34 
5 986 29 0.604 10.14  - - - - 
6 361 40 0.678 2.31  - - - - 
7 - - - -  1105 42 0.250 0.05 
 D Class Motility Pre IQCT   D Class Motility Post IQCT 
Operator N Median 
Drift 
 p 
Drift  
KW 
Bias 
 
N Median 
Drift 
 p 
Drift 
KW 
Bias 
1 2461 34 <0.001 406.2 
p<0.001 
KW=1015 
 1429 33 <0.001 54.66 
p<0.001 
KW=263 
2 1598 43 <0.001 62.34  246 38 <0.001 50.17 
3 1417 37 <0.001 54.34  639 35 0.298 9.55 
4 1747 44 0.029 37.52  629 42 <0.001 38.07 
5 903 31 0.120 17.94  - - - - 
6 350 36 0.131 7.13  - - - - 
7 - - - -  1073 37 <0.001 182.7 
IQCT=Internal Quality Control Tool, KW=Kruskal-Wallis Statistic. 
 
Drift=Within-operator drift tested from KW p value and KW Statistic from serial batched results for each 
operator. Bias=Between-operator bias calculated from KW p value and KW Statistic from entire operator data 
set. Differences between pre and post IQCT operator numbers are due to staff changes over time. 
 
 
Drift was visibly apparent from box and whisker plots of both monthly (Figure 3-2) 
and consecutively batched results of 200 (Figure 3-3). Drift appeared to be 
reduced after IQCT introduction (Figure 3-4). Regrouping into batches in 400 also 
showed drift (p<0.001) before and after IQCT introduction.  
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Figure 3-2 D motility patient results from a single BMS plotted by month over two years prior to IQCT.  
The Box and Whisker plots represent the range, 25
th
 percentile, median and 75h percentile of D motility 
results from patients analysed by one BMS for a single month, X axis values are the number of patients in the 
given month.  
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Figure 3-3 D Motility results generated by one BMS plotted in consecutive batches of 200. 
Each Box and Whisker plot represents the range, 25
th
 percentile, median and 75
th
 percentile of immotile 
fraction results from one batch of 200 patients. Results before the introduction of the IQC tool are compared 
with results after the introduction.  
 
The difference between each operator’s combined median and the median from 
consecutively batched results of 200, demonstrated that drift is reduced with the 
use of IQCT (Figure3-4). 
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Figure 3-4 Pre and post IQCT compared for D motility. 
The difference between each BMS total median D motility and their consecutive 200 batch median D motility 
are plotted to compare pre and post IQCT 
 
Post IQCT, the motility results from 500 patients estimated by each operator (500 
patients result for each of four operators) demonstrate that post IQCT, operator 
motility grading variation remains a large and significant source of error in our 
laboratory (Table 3-2 and Figure 3-5). 
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Table 3-2 WHO motility classes median results from 500 patients for each of four operators post IQCT. 
Operator A Class 
Median 
B Class 
Median 
A+B Class 
Median 
C Class 
Median 
D Class 
Median 
1 48 12 61 5 33 
3 52 8 61 4 35 
4 40 11 51 4 44 
7 35 15 52 9 35 
Kruskal-Wallis p <0.001 <0.001 <0.001 <0.001 <0.001 
Kruskal-Wallis Statistic 308.1 431.3 193.9 284.8 188.2 
IQCT=Internal Quality Control Tool, WHO=World Health Organisation 
 
Expanding these results into QQ plots (Figure 3-5) demonstrates that manual 
motility results do not follow a normal distribution and that large differences occur 
between how individual operators view and grade sperm motility.  
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Figure 3-5 The distributions of WHO grades of sperm motility for four Andrology BMS staff are compared. 
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Motility and Count Precision 
The imprecision of all WHO classes of sperm motility measurements displayed a 
heteroscedastic precision profile with better precision at higher values for within-
laboratory (Figure 3-6) and between-laboratory estimations (Figure 3-7). 
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Figure 3-6 Within-laboratory precision profile for WHO motility. 
Generated from data from all BMS staff from the data set for the IQC Tool motility videos.  
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Figure 3-7 Between-laboratory variance recorded from 24 NEQAS reports. 
 
The imprecision of sperm count measurements displayed a heteroscedastic 
precision profile with better precision at higher values for between-operator and 
between-laboratory measurements (Figure 3-8). 
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Figure 3-8 Precision profile of between BMS sperm counts. 
A was generated from the results of BMS staff that analysed the same NEQAS samples. B between-
laboratory sperm counts generated from the reports of 25 NEQAS distributions. 
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Morphology Precision 
Blind morphology results demonstrated large differences between-operators 
(Figure 3-9). 
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Figure 3-9 Precision profile for morphology. 
A between BMS morphology was generated from the results of BMS staff that analysed the same NEQAS 
samples. B between-laboratory morphology generated from the reports of 25 NEQAS distributions. 
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3.4 Discussion 
 
The major aim of this study was to introduce a novel QC tool to establish which 
factors contribute to MU for our laboratory. IQCT was a well-received tool for rapid 
QC of semen analysis, which allowed daily estimation of operator precision, bias 
and drift. The programme was found to be a flexible addition to the internal QC 
scheme. IQCT motility videos were used to record imprecision in as close to as 
possible conditions as those used for semen analysis. The use of count and D 
motility median patient results allowed realistic recording of operator bias and drift. 
Compliance was high and non-compliance easily recorded. The programme was 
found to be user friendly and after the initial training sessions no major problems 
were reported by any operator. IQCT allowed in depth analysis of QC data by 
users with administrator privileges on a level that has not been previously possible 
within the time frames afforded by our busy diagnostic semen analysis laboratory. 
MU for manual semen analysis is complex and may require specific uncertainty 
calculations for each individual operator. 
 
The latest edition of the WHO manual for semen analysis (W.H.O., 2010m) states 
the aim of semen analysis QC is “is to monitor the extent of both random and 
systematic errors and reduce where possible”. Monthly mean style calculations are 
recognised by the WHO as useful QC tools (W.H.O., 2010m) and have previously 
been used to test for laboratory bias or drift (Knuth et al., 1989, Cooper et al., 
1992). The major requirements for using monthly means is that control limits 
should be determined from a minimum of 6 months observations, they should 
include an absolute minimum of 20 results for each central tendency result and 
that they should be reviewed often (W.H.O., 2010m). The major advantage of 
using monthly mean or medians from real patient data over other techniques of 
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bias calculation is that operators are blind when the results are generated. In 
addition to blinding, the entire data set of actual patients results can be examined 
which reduces the observed analytical variance discrepancies shown to be related 
to both the material used for quality purposes and semen quality itself (Alvarez et 
al., 2003). Also, by graphing percentiles of large numbers of individual operator 
generated patient results on Q-Q plots, the focus is entirely on bias as imprecision 
“noise” is removed. However, it should be noted that significant changes in this QC 
can occur from a multitude of factors including; changes in patient populations, 
equipment, consumables and testing environments (W.H.O., 2010m). 
 
The results show substantial operator bias for sperm counting and larger operator 
bias for motility and morphology estimations. Motility compared with sperm 
counting has previously been shown to be more subjective (Jørgensen et al., 
1997, Auger et al., 2000b) and easily overestimated (Cooper & Yeung, 2006, 
Tomlinson et al., 2010, Tomlinson, 2013). For the human eye, onset movement in 
particular has been shown to capture attention (Abrams & Christ, 2003). This 
would be consistent with motile sperm entering the field of view, being erroneously 
included in the analysis resulting in an overestimation of the motile fraction. The 
results from this work show that sperm motility grading bias is complex and 
specific for individual operators. Each operator viewed motility in an individual and 
repeatable pattern. Between-operator bias was reduced for some operators with 
the introduction of IQCT, though the bias appears inherent with manual motility 
grading and further strategies to reduce this error are required. Between-operator 
bias for motility results should be considered a possible source of error in motility 
results from laboratories that use manual methods without QC strategies that 
specifically demonstrate its absence. 
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Because bias from individuals can be so specific, the combined result on total 
laboratory bias may be difficult to predict and may exclude the use of average bias 
figures for uncertainty calculations for manual methods. For example, in this 
current work two operators displayed a negative D motility bias that proportionally 
decreased with increasing D motility. This individual proportional bias also 
becomes apparent as a total laboratory bias if the results from all staff are 
combined, manifesting as a sudden decrease in negative laboratory bias at 70% D 
motility. For our laboratory an average figure of operator bias would greatly 
overestimate negative bias at 70% D motility. Thus average figures of operator 
bias are unlikely to be accurate for manually derived semen parameters as bias 
can fluctuate substantially with range. Robust and accurate uncertainty 
calculations for manual semen analysis methods may require specific uncertainty 
calculations for each individual operator. 
 
Within-operator drift for both count and D motility results were shown to occur for 
some trained staff, with D motility appearing to be particularly inclined to drift over 
time. While seasonal effects on semen parameters have been reported (Centola & 
Eberly, 1999), the combined central tendency measures for our laboratory did not 
deviate with season. Nor were there changes in equipment or consumables. Thus, 
the recorded drift is likely to be changes within interpretation over time.  
Previously, feeding QC results back to operators has been shown to improve 
quality (Cooper et al., 1999). The regular viewing of IQCT box and whisker plots of 
an operators own results decreases the incidence and magnitude of the drift, 
though does not completely remove it. Drift can only be picked up retrospectively 
by examining large serial batches of patient data, but is significant enough to 
warrant being included as part of uncertainty calculations for manual semen 
analysis. 
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Because relative to the IQCT count results, D motility results demonstrated greater 
operator bias and drift, a subsequent examination of the differences between-
operator motility for all grading categories was performed. The data from 2000 
patient results (500 from each of four operators) demonstrated significant 
differences in both median values and in distributions from every operator. All four 
staff that contributed to this dataset viewed sperm motility considerably differently 
from one another, implying that the manual grading of sperm motility using our 
methods may be too subjective to achieve interchangeable results between-
operators. There is some evidence from this work that the WHO amalgamation of 
A and B class motility (W.H.O., 2010g), in response to the difficulties of accurate A 
and B classification (Cooper & Yeung, 2006), is warranted. Although individual 
operator differences were still apparent, the results between staff and the 
distributions are undeniably closer than separate A or B class motility. The motility 
distribution data also raises concerns about the accurate calculation of uncertainty 
measurements around reference range limits. The WHO fifth percentile lower 
reference limit for progressive (A+B class motility) and total motility (A+B+C class 
motility) are 32% and 40% respectively (Cooper et al., 2010). The A+B and D 
motility distribution graphs clearly show that these lower limits coincide with the 
largest differences between individual operator distributions for the parameters in 
question. Thus, the greatest between-operator distribution biases unfortunately 
occur where the greatest certainty is required. 
 
The results from this work found that both between-laboratory and between-
operator imprecision in all three semen analysis parameters are heteroscedastic in 
profile. Only D class motility at the very upper limit approached CV’s of 10%, with 
mean CV for A, B, C and D class motility of 23%, 37%, 38% and 12% respectively. 
The mean count CV was 20% and the mean morphology CV was 64%. This is 
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comparable  (Auger et al., 2000b, Cooper & Yeung, 2006) or somewhat higher 
(Dunphy et al., 1989, Cooper et al., 1992, Cooper et al., 2002, Brazil et al., 2004) 
than previously measured between-operator variances for semen analysis 
parameters. However, the method used to calculate the imprecision, unlike the 
majority of earlier work, was designed to replicate a normal laboratory procedure 
under significant time demands. Operators were required to perform QC in 
between-patient samples in a busy laboratory over several months. The results of 
this study are an accurate reflection of imprecision in a busy semen analysis 
laboratory using current methods. 
 
Variance between-operators can be reduced with regular continuous systematic 
quality control and intensive training (Cooper et al., 1999, Franken et al., 2000, 
Toft et al., 2005). However, IQCT alone does not appear to reduce this variance. 
Imprecision measurements proved to be remarkably similar for within-laboratory 
and between-laboratory estimations for count and morphology. This raises the 
question as to what proportion of between-laboratory imprecision can be attributed 
to differences between individuals. While our laboratory has not been a poor 
performer in the UK EQA scheme, it would appear that our current methods 
contain sufficient magnitudes of bias and imprecision that questions whether they 
are fit for purpose. Unfortunately, the cost pressures on UK laboratories and the 
current EQA scheme do not currently appear to be facilitating the improvement in 
quality that is required to make semen analysis more meaningful. 
 
Previous work has highlighted the difficulties in standardising categorical 
assessment of individual sperm progression (Brazil et al., 2004, Cooper & Yeung, 
2006), and the unreliability of the analysis of sperm motility by manual methods 
due its subjective nature (Cooper et al., 1999, Cooper & Yeung, 2006, Huang & 
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Lu, 2007). The data from this study support those views with the demonstration of 
sizable imprecision, bias and drift. Motility reference ranges should reflect these 
uncertainties. As a solution to the subjective nature of motility analysis the 
introduction of CASA has previously been suggested (Cooper et al., 2002, Cooper 
& Yeung, 2006, Huang & Lu, 2007). Although achieving quality results with CASA 
may have its own problems (Dearing et al., 2014b, Lammers et al., 2014) the large 
irregular bias, drift and imprecision with manual motility measurements certainly 
strengthen the arguments for its inclusion.  
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Chapter 4 CASA: A Solution to High Measurement Uncertainty 
 
4.1 Introduction 
 
Sperm count, motility and morphology are fundamental parameters of semen 
analysis which is recommended for all male partners of couples who have been 
unsuccessful with natural conception for 12 months or longer (N.I.C.E., 2013). An 
accurate semen analysis is also a useful guide for clinical decision making for 
Assisted Reproductive Technology (ART) treatments (Coetzee et al., 1998, Van 
Waart et al., 2001, Vanweert et al., 2004, Merviel et al., 2010).  
 
The World Health Organisation (WHO) provides concise recommendations for 
manual semen analysis but also recognises that Computer Assisted Semen 
Analaysis (CASA) systems can be used if validated for use (W.H.O., 2010e). 
Manual methods are time consuming and cannot approach the numbers of cells 
counted or precision possible with advanced CASA systems. The objective of this 
study was to gather the evidence to validate or reject the innovative Sperm Class 
Analyser (SCA) CASA system for use as a tool for routine diagnostic and research 
semen analysis. The methods if accepted will be used to estimate semen analysis 
parameters in this research project and will be adopted as the main diagnostic 
methods by the Andrology Laboratory, Hammersmith Hospital, Imperial College 
NHS Trust, London UK.  
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4.2 Methods 
 
4.2.1 General Methods and statistics 
 
Computer Assisted Semen Analysis 
The CASA system used for all experiments is the Sperm Class Analyser (SCA 
version 4.1, Microptic, S.L. Viladomat, Barcelona, Spain). The software is run on a 
Dell Optiplex GX620 PC (Dell Solutions (UK), Glasgow, Scotland, UK). The 
microscope used with CASA is an Olympus BH-2 (Olympus, Southend-on-Sea, 
UK). For count and motility all experiments were performed at 100x magnification 
under positive phase contrast. CASA acquisition parameters are 25 images 
acquired at an acquisition rate of 25 images per second. The chambers used with 
CASA are Leja 20µm chambers (20µm Leja slides, Leja; Gynotec Malden, Nieuw 
Vennep, The Netherlands). For morphology all experiments were performed at 
1000x magnification under oil immersion. 
 
Sperm Count and Motility Population and Sample Selection 
A total of 688 patients attending the Andrology Laboratory (Andrology Laboratory, 
Hammersmith Hospital, Imperial College NHS Trust, London, UK) for semen 
analysis had their sample tested by the manual method and CASA. Of these, 352 
patient samples were compared for sperm count, 336 patients samples were 
compared for motility. Patients were referred from clinicians querying subfertility, 
or seeking guidance on the male partner’s suitability for ART treatments; In Vitro 
Fertilisation (IVF), Intra Cytoplasmic Sperm Injection (ICSI) or Intrauterine 
Insemination (IUI). All patient samples with sperm were directly compared with the 
CASA system. Azoospermic samples and post vasectomy samples without sperm 
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and high concentrations of Nucleated Cells Other than Sperm (NCOS) and / or 
debris were used for blank and recovery experiments. 
 
All patients were informed that samples ideally should be collected between three 
to seven days of sexual abstinence. All samples were self-collected in private 
collection rooms near the Andrology laboratory by masturbation into a clean wide-
mouthed labelled plastic container (125BM/50, Sterilin, Newport, UK) at (23 0C ± 3 
0C). These containers were from a batch that had been checked and shown to 
have no toxic effects on sperm. All samples were left standing to liquefy for a 
maximum of one hour before testing. 
 
External Quality Assurance Samples 
EQA samples are provided by the National External Quality Assessment Service 
(NEQAS) (Chapter Three, Methods). 
 
Statistics 
Correlations were performed by Spearman’s rank correlation and regression lines 
calculated using Deming’s regression. Linear regression was used for linearity 
experiments. Bland-Altman plots were constructed to test for bias. Coefficient of 
Variation (CV%) was calculated as mean divided by standard deviation multiplied 
by 100 from a minimum of 10 replicates for each category.  
 
Differences between counts from nine specific areas of the Leja 20µm chamber 
were tested for by repeated measures ANOVA with Tukeys honest significant 
difference test as the post hoc test. Significant differences between proximal, 
central and distal areas of the chamber were tested by unpaired t test.  
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For motility comparisons, the Wilcoxon matched pairs test was used to compare 
CASA and WHO categories (A,B,C and D. For the phantom motility experiments 
each WHO motility category (A,B,C and D) for each sample type was correlated 
(Pearson’s correlation) against sperm count. 
 
Quantile-Quantile (Q-Q) plots were constructed to demonstrate the bias and range 
of measurement differences between Scanning Electron Microscope (SEM) and 
CASA sperm morphology. Scatter plots were constructed to tests for systematic 
measurement errors between SEM and SCA categories for individual patients.  
 
All data were analysed using Prism version 4.0 (GraphPad Version 4.01,San 
Diego, CA, USA, www.graphpad.com). 
 
4.2.2 Methods Part A: CASA Count 
 
Accuracy of CASA Count against Latex Beads 
Leja 20µm chambers were prepared with two levels of accubead Quality Control 
(QC) material (Hamilton Thorne Biosciences, Beverly, USA). 20 Chambers were 
completely filled with a well-mixed aliquot of accubead QC material (10 chambers 
for each concentration) and left to stand for five minutes. Each chamber was 
analysed using three, then five fields of analysis, including a minimum of one 
proximal field in each analysis.  
 
Improved Neubauer Chamber Count 
Sperm count was estimated by the WHO Improved Neubauer method (W.H.O., 
1999). A 1:19 dilution of sample into 1% formal saline was made using 100µl of 
semen with a positive displacement pipette. The dilution was mixed on a vortex 
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mixer and transferred with a glass capillary into an Improved Neubauer 
haemocytometer (Figure 4-1). After five minutes to allow cells to settle, sperm cells 
were counted by phase contrast light microscopy at 200x magnification. 
 
 
The formula below was used to calculate sperm density.             
              
CSPERM = Sperm/mm
3              
C 
C  = number of cells counted CSPERM =            A x H x D  
A = area counted (mm
2
) 
H = height (depth) of counting chamber (0.1mm) 
D = dilution (20) 
 
CSPERM will be multiplied by 1000 to obtain the number of Sperm/cm
3 
(cells/ml). 
 
 
Figure 4-1 Improved Neubauer for sperm counting.  
 
NEQAS samples 
16 NEQAS samples were analysed by CASA and compared with the Improved 
Neubauer manual count results of five trained operators.  
 
The Neubauer haemocytometer for sperm counting
Grid -  
Square 5c. 
subdivided  
into 16 
smaller 
squares.
Improve d 
Newbauer
Depth 0.1mm
1   1  mm 
16 400
2
Channels
Coverslip No. 3 or 4
Complete grid - 9 x 1mm squares
Ruled area
1.0mm
1.0mm
1.0mm
2
3 4
1
5
{
5
1
.0
m
m
0
.2
m
m
0
.0
1
m
m
5a 5b
5e
5c 5d
The cells will be 
counted in five squares 
(5a-5e), cells touching 
the top and left hand 
lines will be included 
and cell touching the 
bottom and right hand 
side lines will not be 
counted to comply with 
the recommendations 
of the WHO  
 
  
109 
 
Manual Leja 20µm Chamber Count 
Samples were transferred with a glass capillary to a Leja 20µm chamber. After five 
minutes to allow cells to settle, sperm cells were counted by phase contrast light 
microscopy using an eyepiece graticule (Figure 4-2). 
 
 1 2 3 4 5 6 7 8 9 10  
A           A minimum of 200 sperm should be counted and a 
tally of the number of boxes made.  
 
Concentration = 1000000 (µl per mL) 
                            20 µm x 14.9 x 49.8 
                        (chamber depth x box area) 
 
Concentration = 20.16 
B           
C           
D           
E           
F           
G           
H           
I           
J           
 
Sperm concentration = No. Sperm counted x 20.16 
                                              Number of boxes 
 
 
Figure 4-2 Leja 20µm chamber for sperm counting. 
 
CASA for sperm count 
CASA counts were preformed both uncorrected and corrected. Uncorrected 
counts were achieved by simply recording the CASA count given by the system 
irrespective of observed counting errors. Corrected CASA counts were obtained 
by continuously repeating a one second CASA generated video of a random single 
field of view from the leja 20µm slide. All the sperm visible on that single field are 
counted manually; dividing this result by a factor of six converts the result to 
106/ml. CASA counts were compared with the Neubauer and Leja manual 
counting methods. 
 
 
 
  
110 
 
Precision Experiments 
The same single field was analysed 10 times by CASA to generate a single field 
CV% for two levels of accubead QC material, immotile sperm in semen, motile 
sperm in semen and motile sperm in media. Each sample class received a 
minimum of 10 separate single field CV% calculations on a minimum of 10 
separate chambers. The number of single field CV% estimations, mean CV%, 
confidence intervals, minimum and maximum CV% were calculated for each 
sample class. Single field precision was also calculated for varying numbers of 
sperm (estimated as the mean number of sperm per field). Each Leja 20µm 
chamber with motile sperm was sealed with DPX and reanalysed for single field 
CV% when sperm had ceased being motile.  
 
10 separate fields were analysed per chamber with CASA to generate a multiple 
field CV% for two levels of accubead QC material, immotile sperm in semen, 
motile sperm in semen and motile sperm in media. Each sample class received a 
minimum of 10 separate multiple field CV% calculations on a minimum of 10 
separate chambers. The number of multiple field CV% estimations, mean CV%, 
confidence intervals, minimum and maximum CV% were calculated for each 
sample class. Multiple field precision was also calculated for varying numbers of 
sperm (estimated as the mean number of sperm per field). Precision profiles were 
generated for three and five fields of analysis for motile sperm. 
 
Linearity Experiments 
Linearity was estimated on both sperm in semen and swim migrated (SWT) sperm 
in media. A single pool of semen was made as stock solution from the samples of 
10 men with high (>80x106/ml) sperm counts. This pooled sample was 
concentrated by centrifugation at 3000g for 15 minutes, the supernatant discarded 
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and the pellet re-suspended in pooled seminal plasma. This concentrated sample 
was serially diluted with pooled sperm free seminal plasma. Neat and diluted 
samples were analysed by the CASA system using 5 fields of analysis. Pooled 
swim sperm from 10 men was centrifuged at 500g for 10 minutes, the supernatant 
decanted, and the pellet re-suspended in 1 mL of flushing media (Origio 1084 
1076 Origio a/s Knardrupvej 2 DK-2760 Måløv Denmark). The concentrated 
sample was then serial diluted with flushing media. Neat and diluted samples were 
analysed by the CASA system using five fields of analysis. The linearity samples 
were also used to generate a single field CV% by repeating the single field 
analysis 10 times. Sperm number for these experiments was calculated as the 
mean number of sperm per field. Each Leja 20µm chamber was sealed with DPX 
and reanalysed for single field CV% when sperm had ceased being motile.  
 
Chamber Bias, Dimensions and Segre-Silberberg effects 
Nine specific areas (Figure 4-3) were counted on 10 Leja 20µm chambers for two 
levels of accubead QC material. Area one was counted first and repeated after all 
nine areas had been counted to control for dehydration effects that may have 
occurred during the experiment. The high concentration accubead QC material 
slides had 10 single field analysis made on each area to examine if single field 
precision was different between area, while the low concentration accubead QC 
had a single field analysis per area. A further test of the Segre-Silberberg (SS) 
effect was performed with 16 semen samples of immotile sperm measured for the 
same nine areas. 
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Figure 4-3 Areas counted on the Leja 20µm chamber.  
The same nine areas were counted on 10 Leja 20µm chambers for both levels of accubead QC 
material. Area 1 was counted first and repeated at the end to test for dehydration effects that 
occurred during the experiment. The chamber was also analysed by general areas: distal area 
(areas 3,4 and 9), central (areas 2,5 and 8) and proximal (area 1,6 and 7). 
 
Recovery Experiments 
10 separate CASA count estimations were made on concentrated pooled semen 
spiked into cell free pooled seminal plasma and cell free seminal plasma with a 
high concentration of NCOS and debris. Recovery was calculated and plotted on a 
box plot for each category.  
 
Clinical Decision Tables 
Agreement between both the Improved Neubauer and the Leja 20µm manual 
method with uncorrected and corrected CASA counts for three clinically important 
ranges (1-5 x 106, 6-15 x 106, and > 15 x 106) were made. The number of 
comparisons, correlation within the given range and the percentage agreement of 
results within the range were calculated for each separate range. 
 
Audit on BMS compliance with WHO standards 
A blind audit of manual sperm counting technique was undertaken at our 
laboratory. A single observer who was working as an assistant to trained 
Biomedical Scientist (BMS) staff performing Improved Neubauer counts observed 
the techniques of three trained BMS staff over a single week and compared 
9 
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observations to the WHO recommendations (W.H.O., 2010b). The BMS staff were 
blind to the assessment. 
 
4.2.3 Methods Part B: CASA Motility 
 
Manual Count and Motility 
Samples were mixed well on a vortex mixer and were transferred with a positive 
displacement pipette to either a Leja 20µm chamber or to a glass slide 
(J2800AMNZ, Gerhard Menzel GmbH, Braunschweig, Germany) with a No. 1.5 
coverslip (BB022022A1, Gerhard Menzel GmbH, Braunschweig, Germany). After 
five minutes to allow cells to settle, 200 sperm cells for each sample were 
categorised into the four WHO categories (W.H.O., 1999) of sperm motility (A,B,C 
and D) under phase contrast at 200x magnification using a Celltrac counter (KPG 
Products Ltd, Hove, East Sussex, UK). 
 
CASA Sperm Motility Analysis 
CASA categorises sperm into the four WHO categories (W.H.O., 1999) of sperm 
motility (A,B,C and D) based upon sperm velocity. The CASA operator has the 
choice of using Curvilinear Velocity (VLC) or Straight Line Velocity (VSL) as the 
basis to make the categorisation. The operator can also change the classification 
cut off values to classify more or less sperm into preferred categories. The 
experiments carried out on CASA were using “as sold” classification values and on 
derived values calibrated with local operator results. In addition to the (A, B, C and 
D) classification, CASA measures more descriptive motility parameters (Figure 4-
4) and. allows the raw data from each analysis to be downloaded into excel 
(Microsoft Excel v 14.0, Microsoft, Berkshire, UK).  
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Figure 4-4 CASA motility parameters. 
Curvilinear Velocity (VLC), average velocity (μm/s). of a sperm head along its actual (curvilinear) path. 
Straight Line Velocity (VSL), average velocity (μm/s) of a sperm head along a straight line between the first 
and last recorded position. Average Path Velocity (VAP), average velocity (μm/s) of a sperm head along an 
average path calculated by a smoothing algorithm. Amplitude of Lateral Head Displacement (ALH), magnitude 
of lateral sperm head displacement (μm) calculated by algorithm along an average path. Linearity (LIN), 
calculated by VSL/VCL. Wobble (WOB), oscillation calculated by VAP/VCL. Straightness (STR), calculated by 
VSL/VAP. Beat Cross Frequency (BCF), average rate (Hz) of the curvilinear path crossing the average path. 
 
Initial Motility Comparisons 
225 patient’s samples were measured by manual sperm motility analysis by five 
BMS staff and one BMS using CASA motility (settings for VLC were as sold 
10/15/35). Separate aliquots were used for traditional sperm motility analysis and 
CASA analysis. Glass slides with No. 1.5 cover slips were used by BMS staff for 
manual sperm motility analysis and Leja 20µm chambers were used for the CASA 
analysis. 
 
Internal Quality Control Tool Motility Video Comparisons 
The novel andrology specific QC computer programme, Internal Quality Control 
Tool (IQCT) (Chapter Three, Methods) was used to compare the precision of 
manually analysed motility with CASA analysed motility. One second digital videos 
from 10 fields from one pooled semen sample were made using CASA. Each one 
second video was copied and spliced into a two minute video showing 120 one 
second repeats of each CASA generated video. 10 videos were made, one from 
each of the 10 one second CASA videos. The transformed videos were uploaded 
to IQCT and incorporated into the QC procedures for the laboratory. 
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Prior to beginning semen analysis each BMS logged into the IQCT programme 
and selected a motility assessment. The programme plays a randomly selected 
video (one of the 10 expanded CASA videos) of motile sperm which the BMS was 
asked to categorise into the four 1999 WHO (A, B, C, D) categories (W.H.O., 
1999). The BMS entered the motility results into the programme and the results 
were recorded on IQCT. All BMS staff were instructed to perform this QC before 
beginning semen analysis and after each sixth sample.  
 
400 BMS generated results (each of four BMS staff completed a minimum of 10 
repeats for each of the 10 expanded videos) were compared with 400 CASA 
generated results (40 repeat analysis of each of the ten original one second 
videos). CASA VCL motility settings were 15/18/30 which were derived from the 
initial correlations. Each expanded video was also given a consensus motility 
result. This was achieved during group sessions were every individual sperm track 
was repeatedly viewed until all four BMS staff agreed on a classification. 
 
Secondary Motility Comparisons 
100 patient’s samples were estimated for motility by one BMS using manual 
analysis and one BMS using CASA (settings for VLC were derived from the initial 
comparisons 15/18/30). The same Leja 20µm chamber was used for both 
analyses.  
 
Precision Profiles for (A, B, C, D) categories 
Precision profiles were generated for manual sperm motility analysis from the 
results from four BMS staff from 20 videos used in the IQCT. Precision profiles 
were generated for CASA motility by a minimum of 10 repeats on 20 patient 
samples. The precision profiles for CASA motility by number of fields was 
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generated from a minimum of 10 repeat measures on 25 patients. The precision 
profile for CASA motility by sperm count was generated from four repeats for 80 
patients. 
 
Precision Tables for Kinematic CASA Motility Parameters 
Precision of CASA kinematic parameters (VLC, VSL, VAP, LIN, STR, WOB, ALH, 
BCF) were estimated for within-sperm, within-chamber and between-chamber. 
Within-sperm precision was estimated from 10 repeat analysis of a one second 
CASA generated video containing approximately 100 sperm. Within-chamber 
precision was estimated for N number of 50, 100, 200, 400, 1000 and 2000 sperm 
from repeat measures from 10 samples in 10 Leja 20µm chambers. Between-
chamber precision was estimated for 50, 100, 200, 400, 1000 and 2000 sperm 
from repeat measures from 10 samples in 20 Leja 20µm chambers.  
 
Phantom Motility 
Phantom motility (CASA motility signals recorded from stationary objects) was 
examined by performing CASA motility analysis on latex bead preparations and on 
heat immobilised sperm. Leja 20µm chambers were prepared with two levels of 
accubead QC material. 20 Leja 20µm chambers were completely filled with a well-
mixed aliquot of accubead QC material (10 chambers for each concentration) and 
left to stand for five minutes. 16 patients samples were prepared in Leja 20µm 
chambers and heat immobilised by placing on a hot plate at 60 0C. Each chamber 
was analysed using five repeats at 100x magnification. A total of 100 
measurements were made on the low accubead concentration, 500 
measurements on the high accubead concentration and 160 measurements on 
patient’s samples. 
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4.2.4 Methods Part C: CASA Morphology 
 
Scanning Electron Microscopy (SEM) 
10 patients’ SWT sperm from 0.5 mL of semen were fixed with a gluteraldehyde 
solution (G5882, Sigma-Aldrich, Dorset, UK) and sent to Charing Cross Hospital 
Electron Microscopy Unit for Scanning Electron Microscopy (SEM) processing. 
The measurements for this study were made by Dr Tim Ryder and Mrs Margeret 
Mobberley. The sperm are prepared for SEM by air-drying then gold coating on a 
Al stub. SEM was performed using a S360 Scanning Electron Microscope with the 
following SEM parameters: 
 
Accelerating voltage : 10kV 
Probe size : 75Å 
Working distance : 10mm 
Magnification : 5000 
Specimen tilt : 0° 
 
Head and midpiece measurements were taken from 100 sperm from each 
separated sample using a Kontron Computer incorporating Videoplan Image 
Analyser software with digitising tablet and stylus. Moving the stylus on the 
digitising tablet causes a superimposed spotlight over the sperm image on the 
screen. The sperm head perimeter and area are estimated simultaneously by 
tracing the outline of a sperm head with the spotlight using the stylus. Head length, 
width and midpiece width and length are made by touching the spotlight to the 
range of the feature to be measured. The data were presented in excel format to 
the researcher. 
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CASA Morphology 
The same 10 samples analysed for SEM morphology were analysed for CASA 
morphology.  SWT sperm from 0.5 mL of semen were fixed with Cytofix (Cellpath 
Ltd, Newtown, Powys, UK), air dried and stained by Papanicolaou on a Leica 
Autostainer XL (Leica Microsystems, Milton Keynes, Bucks, UK) Using the staining 
times and chemicals listed in table 4-1 and 4-2. 
 
Table 4-1 steps, chemicals and timings used for Papanicolaou stain steps 
Station Solution Time 
1 95% Alcohol 1:30 
2 70% Alcohol 1:30 
3 Haematoxylin 4:45 
4 Acid water 0:05 
Wash 1 Water Wash 
Wash 2 Water Wash 
Wash 3 Water Wash 
Wash 4 Water Wash 
5 70% Alcohol 2:00 
6 95% Alcohol 1:00 
7 OG6 2:00 
8 95% Alcohol 0:10 
9 95% Alcohol 0:10 
10 EA50 6:00 
11 95% Alcohol 0:15 
12 95% Alcohol 0:15 
13 Abs. Alcohol 1:00 
14 Abs. Alcohol 1:00 
15 Abs. Alcohol 1:00 
16 Xylene 3:00 
17 Xylene 2:00 
Exit Xylene 1:00 
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Table 4-2 Chemicals for Papanicolaou stain. 
Chemicals Product number/Company 
Alcohol 99 %IMS 1110436/IMS 
Haematoxylin 4213-00A/Cell path 
Hydrochloric acid Analar 190685/VWR 
OG6 4211-00A/Cellpath 
EA50 4212-00A/Cellpath 
Xylene XYL250/Genta Medical 
 
100 sperm for each separated sample were analysed by CASA morphology under 
oil at 1000x magnification.   
 
Comparison with EQA 
One year of Andrology NEQAS samples (n=16) were analysed for morphology by 
CASA. A minimum of 100 sperm from each sample was analysed and the 
proportion of sperm defined as normal compared against the NEQAS consensus 
values for strict criteria. Three “Normal” definitions were tested; (1) a local CASA 
morphology fertile reference range, (2) the 1999 WHO normal sperm 
measurements, (3) a novel modified Teratozoospermia Index (TZI) like derived 
calculation (Menkveld & Kruger, 1996, Menkveld et al., 2001): based upon the 
1999 WHO reference range for normality TZIWHO HEAD. 
 
TZIWHO HEAD =  WNHL +WNHW + WNHWR 
          Number of Sperm Analysed x 3 
 
WNHL = the percentage of sperm with a WHO Normal Head Length (4.0-5.0 µm) 
NHW = the percentage of sperm with a Normal Head Width (2.5-3.5 µm) 
NHWR = The percentage of sperm with a Normal Head / Width Ratio (1.41-1.69) 
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Blind Manual Morphology 
10 patient samples had manual morphology estimated by four blinded andrology 
trained BMS staff. 100 unstained sperm fixed in 1% formal saline were graded as 
normal or abnormal at 400X magnification under phase contrast for each sample. 
 
Precision 
Single sperm CASA morphology measurement precision was estimated by CV% 
calculated from 10 repeat measures of 100 random PAP stained sperm over 10 
slides. Within-slide morphology precision was estimated from mean 
measurements over a range of N numbers of sperm from 10 slides. CV% for this 
estimation was made on a minimum of two values for each estimation. 15 patients 
had duplicate slides made which were used to estimate CASA precision between 
slide. CV% for this estimation was made on a minimum of four values for each 
estimation. 
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4.3 Results  
 
4.3.1 Part A: CASA Count 
 
Accuracy against Latex Beads 
Accuracy of CASA counts on two concentrations of latex beads was excellent 
when means of three fields of analysis were used and improved when five fields 
were used (Figure 4-5). 
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Figure 4-5 Accuracy of latex beads counts using CASA using three and five fields of analysis. 
 
Correlations against Improved Neubauer and Leja 20µm  
The sperm count results of trained BMS staff (combined results of four operators 
and both Improved Neubauer and Leja 20µm manual counting methods) showed a 
strong correlation with CASA (r2 = 0.95) without correcting for counting errors 
(Figure 4-6). A strong correlation with CASA was also evident when the two 
manual counting methods were separated, Neubauer (r2 = 0.94) and Leja (r2 = 
0.92) (Appendices 9.2, Figure 9-4, 9-5). However overestimation of low (<15x106) 
sperm counts was noted and resulted in poor correlations at those concentrations: 
counts ≤5x106 Neubauer (r2=0.66) and Leja (r2=0.56), counts 5-15x106 Neubauer 
(r2=0.64) and Leja (r2=0.74).  
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Figure 4-6 Correlation of manual counting methods with CASA for 352 patient’s samples. 
 
Bias Estimations 
Overestimation was demonstrated on Bland-Altman plots as a moderate positive 
bias at low counts compared with the Improved Neubauer chamber (Figure 4-7) 
and a large positive proportional bias compared with the Leja 20µm chamber 
(Figure 4-8). The positive bias was increased at results <30x106 and reduced at 
≥30x106 (Figure 4-9). 
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Figure 4-7 Bland-Altman of CASA count and the Neubauer Chamber. 
 
25 50 75 100 125 150 175 200 225 250 275 300-100
-50
0
50
100
Average Manual +SCA
              2
D
if
fe
re
n
c
e
S
C
A
-M
a
n
u
a
l
 
Figure 4-8 Bland-Altman of CASA count and the Leja 20µm Chamber.  
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Figure 4-9 Bland-Altman of CASA counts <40x10
6
 and Neubauer.  
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Corrected CASA Count Correlation and Bias 
Further tests on samples with sperm counts < 30x106 demonstrated that capturing 
a one second video from CASA and manually counting all the sperm on the screen 
correlated highly (r2 = 0.99) with the manual Leja 20µm method (Figure 4-10). 
Using this method of performing manual Leja counts from the CASA screen for 
results < 30x106 combined with uncorrected CASA counts for results ≥ 30x106 
resulted in excellent overall correlation against the Improved Neubauer method (r2 
= 0.98). There was no bias observed using corrected counts (Figure 4-11). 
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Figure 4-10 Correlation of counts < 30x10
6
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Figure 4-11 Bland-Altman of counts < 30x10
6
 between manually counting from the CASA screen 
and the Leja 20µm chamber. 
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Precision 
Single field precision was excellent with mean CV% of < 1% on latex beads and a 
mean CV% of 2.4% on immotile sperm (Table 4-3). Unsurprisingly, analysis of 
motile sperm resulted in higher single field CV% (mean of 3.6% for semen, mean 
of 4.5% for swim sperm). Both motile and immotile sperm in semen and swim 
sperm in media displayed a heteroscedastic precision profile with optimal precision 
at approximately 200 sperm per field (Table 4-4). 
  
Table 4-3 Precision of CASA single field analysis. 
CV=Coefficient of Variation.  
 
A minimum of 10 separate single field CV% calculations were made on a minimum of 10 separate chambers 
per category. 
 
Table 4-4 Effect of sperm motility on single field CV% 
CV=Coefficient of Variation. 
 
The same single field was analysed 10 times by CASA to generate a single field CV%. Sperm number is 
calculated as the mean number of sperm per motile sperm field. Each Leja 20µm chamber was sealed with 
DPX and reanalysed for single field CV% when sperm had ceased being motile. Each chamber received a 
single CV% calculation. Significant clumping was observed on the immotile sperm.   
 
 Multiple field precision was predictably higher than single field precision, though 
optimal multiple field precision was also approximately 200 sperm per field (Tables 
4-5 & 4-6).  Precision decreased markedly below 100 sperm per field.  
Category N Mean CV% 95%CI Min Max 
Accubeads High Concentration 100 0.8 0.8-0.9 0.3 1.9 
Accubeads Low Concentration 10 0.9 0.7-1.1 0.5 1.3 
Immotile Sperm 16 2.4 1.9-2.9 1.2 2.9 
Motile Sperm in Semen 10 3.6 2.0-5.2 1.6 6.7 
Motile Sperm in Media 10 4.5 2.6-6.4 3.1 8.9 
Sperm number in Semen CV% 
Motile 
CV% 
Immotile 
603 2.29 2.14 
313 1.59 3.58 
166 2.36 2.97 
82 6.68 12.78 
30 4.50 7.06 
23 5.67 9.18 
Sperm number in Media CV% 
Motile 
CV% 
Immotile 
580 3.67 1.02 
354 3.48 1.77 
225 3.11 1.60 
120 3.34 1.29 
48 5.26 2.81 
20 20.58 2.72 
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Table 4-5 CV% summary from CASA multiple field analysis 
CV=Coefficient of Variation  
 
10 separate fields were analysed per chamber by CASA to generate a multiple field CV%. Each sample class 
received a minimum of 10 separate multiple field CV% calculations on a minimum of 10 separate chambers. 
The number of multiple field CV% estimations, mean CV%, confidence intervals, minimum and maximum 
CV% are shown for each sample class.  
 
Table 4-6 Sperm motility and multiple field CV% 
CV=Coefficient of Variation  
 
10 separate fields were analysed per chamber by CASA to generate a multiple field CV%. Sperm number is 
calculated as the mean number of sperm per motile sperm field .Each Leja 20µm chamber was sealed with 
DPX and reanalysed for multiple field CV% when sperm had ceased being motile. Each chamber received a 
single CV% calculation. 
 
Precision improves for each increase in field number included in the final analysis, 
though each increase yields a smaller improvement (Table 4-7). Precision profiles 
were created using three fields (Figure 4-12) and five fields (Figure 4-13) of 
analysis.    
 
Table 4-7 Effects of field number on CV% using one, three and five fields of analysis 
Category Number of Fields Analysed 
 1 3 5 
Accubeads High 14.0 (13.4-14.5) 6.8 (5.9-7.7) 4.0 (3.5-4.5) 
Accubeads Low 17.9 (15.8-20.0) 6.9 (3.3-10.4) 6.3 (2.9-9.7) 
Immotile Sperm 18.4 (14.0-23.0) 7.6 (6.1-9.2) 5.7 (4.4-7.0) 
Motile Sperm in Semen 17.2 (7.9-26.5) 7.2 (0.3-14.2) 3.0 (0.5-5.6) 
Motile Sperm in Media 15.7 (8.5-22.9) 8.2 (0.5-16.0) 6.3 (1.1-11.4) 
CV=Coefficient of Variation 
 
Category Mean CV% 95%CI Min  Max 
Accubeads High Concentration 13.5 12.9-14.0 9.8 18.2 
Accubeads Low Concentration 17.9 15.8-20.0 13.0 13.2 
Immotile Sperm 18.4 14.1-22.7 14.1 22.7 
Motile Sperm in Semen 20.3 10.6-29.9 7.4 36.2 
Motile Sperm in Media 26.5 16.6-36.4 15.4 43.5 
Sperm number in Semen CV% 
Motile 
CV% 
Immotile 
557 7.58 11.50 
299 7.10 25.58 
166 9.84 17.32 
107 15.74 20.95 
60 25.83 23.83 
21 33.67 54.55 
Sperm number in Media CV% 
Motile 
CV% 
Immotile 
660 16.30  15.37 
385 9.72 27.09 
215 6.43 21.14 
106 7.17 24.09 
50 12.32 27.78 
27 31.64 43.47 
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Figure 4-12 Motile sperm precision profile with three fields of analysis.  
Three random fields (One proximal, one central and one distal, Figure 4-3) were analysed for each 
Leja 20µm chamber by CASA. Repeat measurements were made on the same chamber. Mean 
counts were generated for each three field analysis and CV% of those means are plotted against 
the mean number of sperm per field for the chamber.  
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Figure 4-13 Motile sperm precision profile with five fields of analysis.  
Five random fields (at least one proximal field, Figure 4-3) were analysed for each Leja 20µm 
chamber by CASA. Repeat measurements were made on the same chamber. Mean counts were 
generated for each three field analysis and CV% of those means are plotted against the mean 
number of sperm per field for the chamber.  
 
Linearity 
Concentrated pooled semen serially diluted with pooled sperm free seminal 
plasma and analysed by the CASA system (Figure 4-14) demonstrated excellent 
linearity (r2=0.99). Pooled swim sperm centrifuged to pellet and re-suspended in 
flushing media then serial diluted with flushing media (Figure 4-15) also 
demonstrated excellent linearity (r2=0.99). Leja 20µm chambers sealed with DPX 
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and left for two days and then reanalysed (Figure 4-16) demonstrated excellent 
linearity (r2=0.95), though significant clumping was observed. 
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Figure 4-14 Linearity of CASA counts of motile sperm in semen.  
Pooled semen and serial diluted semen was analysed by the CASA system using 5 fields on 
analysis. The expected concentration is plotted against the CASA measured concentration with the 
linear regression line and 95% confidence intervals. 
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Figure 4-15 Linearity of CASA counts of motile sperm in media.  
Pooled SWT sperm and serial diluted samples were analysed by the CASA system using 5 fields 
on analysis. The expected concentration is plotted against the CASA measured concentration with 
the linear regression line and 95% confidence intervals. 
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Figure 4-16 Linearity of CASA counts of immotile sperm in media.  
Leja 20µm chambers were filled with motile swim sperm, sealed with DPX and analysed when 
motility had ceased.  
 
CASA and BMS against UK NEQAS 
CASA achieved the second highest correlation (r2 =0.97) against one year of 
NEQAS samples when compared with five trained BMS staff (r2 =0.98, 0.93, 0.92, 
0.92 and 0.72) (Figure 4-17). While bias compared with NEQAS consensus values 
for the Improved Neubauer was observed in two of the BMS staff on Bland-Altman 
plots, no bias was detected on CASA results (Figure 4-17). 
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Figure 4-17 CASA compared with BMS and NEQAS. 
16 NEQAS count samples representing one year of EQA were analysed by five trained 
experienced operators and CASA. The correlations on the right correspond to the Bland-Altman’s 
on the left. Bland-Altman Y axis are difference (NEQAS-Operator), X axis are average 
(NEQAS+Operator/2). Correlations Y axis are operator, X axis are NEQAS. 
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Segre-Silberberg effects 
In a series of experiments testing the Segre-Silberberg (SS) effect the same nine 
areas were counted on 10 Leja 20µm chambers for both levels of accubead QC 
material (Figure 4-3) The leja 20µm chamber distal end (areas 3, 4 and 9) had 
significantly (p<0.001) higher latex bead counts than the central (areas 2, 5 and 8) 
and proximal areas (areas 1, 6 and 7). This effect became insignificant once three 
fields of analysis including one proximal, central and distal field were included for 
each count. There was no measurable effect from dehydration.  
 
Table 4-8 Segre-Silberberg effects on Leja 20µm Chambers area bias.   
The same 9 areas were counted on 10 Leja 20µm chambers for both levels of accubead quality control 
material. The distal end of the chamber (areas 3,4 and 9) had significantly (p<0.001) higher counts than the 
central (areas 2,5 and 8) and proximal (area 1,6 and 7). 
 
A further test of the SS effect was performed with 16 semen samples of immotile 
sperm measured for the same nine areas as described (Table 4-8 and figure 4-3). 
Areas 1 and 3 and areas 3 and 7 were different from each other (Table 4-9). 
 
 
 
 
 
 
 
 
 
 
 
Category    N    1 2 3 4 5 6 7 8 9 Proximal Central Distal 
High 1000 188 206 242 240 205 217 204 199 242 203 203 241 
Low 100 94 93 118 124 89 94 94 104 124 94 95 122 
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Table 4-9 ANOVA of Leja 20µm chambers area bias on immotile sperm. 
Tukey's Multiple 
Comparison Test 
Mean Diff. q P value 
1 vs 2 48.00 3.474 NS 
1 vs 3 62.00 4.487 P < 0.05 
1 vs 4 43.94 3.180 NS 
1 vs 5 30.25 2.189 NS 
1 vs 6 8.250 0.597 NS 
1 vs 7 -1.188 0.085 NS 
1 vs 8 34.44 2.492 NS 
1 vs 9 45.13 3.266 NS 
2 vs 3 14.00 1.013 NS 
2 vs 4 -4.063 0.294 NS 
2 vs 5 -17.75 1.285 NS 
2 vs 6 -39.75 2.877 NS 
2 vs 7 -49.19 3.560 NS 
2 vs 8 -13.56 0.981 NS 
2 vs 9 -2.875 0.208 NS 
3 vs 4 -18.06 1.307 NS 
3 vs 5 -31.75 2.298 NS 
3 vs 6 -53.75 3.890 NS 
3 vs 7 -63.19 4.573 P < 0.05 
3 vs 8 -27.56 1.995 NS 
3 vs 9 -16.88 1.221 NS 
4 vs 5 -13.69 0.990 NS 
4 vs 6 -35.69 2.583 NS 
4 vs 7 -45.13 3.266 NS 
4 vs 8 -9.500 0.687 NS 
4 vs 9 1.188 0.085 NS 
5 vs 6 -22.00 1.592 NS 
5 vs 7 -31.44 2.275 NS 
5 vs 8 4.188 0.303 NS 
5 vs 9 14.88 1.076 NS 
6 vs 7 -9.438 0.683 NS 
6 vs 8 26.19 1.895 NS 
6 vs 9 36.88 2.669 NS 
7 vs 8 35.63 2.578 NS 
7 vs 9 46.31 3.351 NS 
8 vs 9 10.69 0.773 NS 
16 semen samples with immotile sperm were measured for the 9 areas of the Leja 20µm chamber (Table 3.06 
and figure 3.01). Two significant results were generated from ANOVA: areas 1 and 3 and areas 3 and 7 were 
both significantly different from each other. 
 
Recovery 
10 separate CASA count estimations from sperm spiked into cell free pooled 
seminal plasma and cell free seminal plasma with a high concentration of NCOS 
and debris demonstrated a large increase in counts in samples containing a high 
concentration of NCOS and debris (Figure 4-18).  
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Figure 4-18 Increased mean recovery with a high concentration of NCOS and debris.  
 
Clinical Decision Considerations 
Using the CASA with no correction results in overestimations of count at 
concentrations below 15x106. Approximately 80% of Neubauer and 33% of Leja 
20µm count results between 1 and 5x106 were reclassified by the CASA system 
as being significantly higher (Tables 4-10 & 4-11). The CASA system cannot be 
used without the addition of a corrective step at low concentrations.  
 
Table 4-10 CASA comparison with Neubauer for clinical decisions.   
Neubauer 
Result 
(x106/mL) 
 
N 
 
r² 
 
p 
CASA Range Agreement (x106/mL) 
1-5 6-15 >15 
1-5 10 0.66 0.062 20% 40% 40% 
6-15 15 0.64 <0.001 0% 27% 73% 
>15 162 0.93 <0.001 0% 0.5% 99.5% 
The table compares the agreement between the Improved Neubauer and uncorrected CASA counts for three 
clinically important ranges (1-5 x 10
6
, 6-15 x 10
6
, and > 15 x 10
6
) The number of comparisons, the correlation 
within the given range, p value and the percentage agreement of results within the range are given.  
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Table 4-11 CASA comparison with Leja 20µm for clinical decisions.  
Leja 
Result 
(x106/mL) 
 
N 
 
r² 
 
p 
CASA Range Agreement (x106/mL) 
1-5 6-15 >15 
1-5 52 0.56 <0.001 67% 33% 0% 
6-15 51 0.72 <0.001 2% 69% 29% 
>15 41 0.95 <0.001 0% 0% 100% 
The table compares the agreement between the Leja 20µm and uncorrected CASA counts for three clinically 
important ranges (1-5 x 10
6
, 6-15 x 10
6
, and > 15 x 10
6
) The number of comparisons, the correlation of results 
within the given range, p value and the percentage agreement of results within the range are given.  
 
In contrast to the uncorrected CASA counts, the corrected CASA counts at 
concentrations below 15x106 displayed far greater agreement with the manual 
Leja 20µm method (Table 4-12). 
 
Table 4-12 Corrected count CASA method comparison with Leja 20µm for clinical decisions.     
Leja 
Result 
(x106/mL) 
 
N 
 
r² 
 
p 
CASA Classification (x106/mL) 
1-5 6-15 >15 
1-5 50 0.85 <0.001 98% 2% 0% 
6-15 37 0.91 <0.001 5% 95% 0% 
>15 28 0.96 <0.001 0% 0% 100% 
The table compares the agreement between the Leja 20µm and corrected CASA counts for three clinically 
important ranges (1-5 x 10
6
, 6-15 x 10
6
, and > 15 x 10
6
). The number of comparisons, the correlation of results 
within the given range, p value and the percentage agreement of results within the range are given. 
 
Using the manual CASA corrected count to calculate sperm concentrations ≤ 
30x106 and the automatic (uncorrected) CASA count for sperm concentrations > 
30x106 results in high correlations (r2 = 0.98, p = <0.0001) with the manual Leja 
20µm method (Figure 4-21). 
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Figure 4-19 Comparison with Leja 20µm using dual CASA methods.  
The graph represents the comparison between the Leja 20µm manual method and a combination 
of two CASA methods: CASA corrected counts for sperm concentrations ≤ 30x10
6
 and the 
automatic (uncorrected) CASA count for sperm concentrations > 30x10
6 
 
A blind audit of Andrology BMS staff performing Improved Neubauer counts found 
marked differences between the actual procedures being followed and the WHO 
recommendations (Table 4-13). 
 
Table 4-13 Audit of compliance to WHO guidelines for sperm counting.  
Recommendation Audit Finding 
Dilution factor calculation from wet prep examination at 400x magnification. No
1 
Dilutions made with a minimum 50 µm well mixed semen. Yes 
Use of positive displacement pipettes. Yes 
Pipette tip wiping before semen transfer to the fixative. No
2 
Pipette tip fixative rinsing by aspirating and expressing the fixative. No
3 
Minimum ten seconds maximum speed vortexing of fixative semen dilutions. No
4 
No. 4 coverslip used. No
5 
Minimum of four minutes in a humid chamber before analysis. No
6 
A minimum of 200 sperm counted twice. No
7 
The counting of only whole sperm. Yes 
Rigorous sperm head/tail position rules for counting sperm in relation to chamber grid lines. Yes 
Third counts on large differences between repeats No
8 
1. All samples receive a 1/20 dilution. 2. Pipette tips are not wiped. 3. Pipette tips are not rinsed. 4. An 
average of 2 seconds is used. 5. No. 3 coverslip is used. 6. No humid chamber is used and minimum times 
are not followed. 7. An average of 60 sperm counted once. 8. Duplicate counts are made on the same 
chamber but repeats are not made because of significant differences. 
Based on WHO (W.H.O., 2010b). 
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4.3.2 Results Part B: CASA Motility 
 
Initial comparisons between CASA motility and five BMS staff showed that CASA 
recorded lower A class (CASA median = 12, BMS median = 43, p<0.0001), higher 
B class (CASA median = 11, BMS median = 9, p<0.0001), higher C class (CASA 
median = 12, BMS median = 5, p<0.0001) and higher D class motility (CASA 
median = 64, BMS median = 41, p<0.0001).  Only A and B class motility 
correlated, B class and C class were not significant (Figure 4-20). Bland Altman 
plots demonstrated large proportional bias. CASA displayed a negative 
proportional bias for increasing A and C values, and a positive proportional bias for 
increasing B value. CASA D motility was negatively biased at low D values, 
positively biased at mid D values and appeared to be approaching negative bias 
again at the upper range of D motility (Figure 4-21). 
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Figure 4-20 Correlations of manual WHO motility and CASA 
Correlation of 225 patient results measured by the current manual method by five trained BMS staff and CASA 
motility results. CASA motility settings for VLC were as sold (10/15/35). 
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Figure 4-21 Bland-Altman of manual WHO motility and CASA.  
Bland-Altman of 225 patient results measured by the current manual method by five trained BMS 
staff and CASA motility. CASA motility settings for VLC were as sold (10/15/35). 
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IQCT QC videos clearly demonstrated large variance within BMS staff results. 
When these results are compared with consensus values a BMS overestimation of 
A class motility becomes apparent (Figures 4-22 to 4-25). 
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Figure 4-22 A class motility, manual method, consensus and CASA compared. 
40 A class motility results (10 results for each of four BMS) are compared with 40 CASA results and the 
consensus values for each of 10 videos. CASA motility settings for VLC were experimentally derived 
(15/18/30). 
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Figure 4-23 B class motility, manual method, consensus and CASA compared. 
40 B class motility results (10 results for each of four BMS) are compared with 40 CASA results 
and the consensus values for each of 10 videos. CASA motility settings for VLC were 
experimentally derived (15/18/30). 
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Figure 4-24 C class motility, manual method, consensus and CASA compared.  
40 C class motility results (10 results for each of four BMS) are compared with 40 CASA results 
and the consensus values for each of 10 videos. CASA motility settings for VLC were 
experimentally derived (15/18/30). 
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Figure 4-25 D class motility, manual method, consensus and CASA compared.  
40 D class motility results (10 results for each of four BMS) are compared with 40 CASA results 
and the consensus values for each of 10 videos. CASA motility settings for VLC were 
experimentally derived (15/18/30). 
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Calibrating CASA motility to achieve results as close as possible to mean BMS 
manual motility and making comparisons against only one BMS resulted in greater 
correlations than those achieved in the initial comparisons (Figure 4-26). CASA 
recorded similar A + B class motility (CASA median = 27, BMS median = 27, 
p=0.921), higher C class motility (CASA median = 7, BMS median = 5, p=0.003) 
and non-significant lower D class motility (CASA median = 63, BMS median = 65, 
p=0.052).   
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Figure 4-26 Correlations of manual WHO motility and CASA.  
Correlation of 100 patient results measured by the current manual method by one trained BMS and 
CASA motility results. CASA motility settings for VLC were experimentally derived (15/18/30). 
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Calibrated CASA motility compared with a single BMS resulted in less bias than 
the initial comparisons (Figure 4-27). 
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Figure 4-27 Bland-Altman of manual WHO motility and CASA.  
Correlation of 100 patient results measured by the current manual method by one trained BMS and 
CASA motility. CASA motility settings for VLC were experimentally derived (15/18/30). 
 
CASA motility exhibited greater precision than BMS staff. The increased precision 
was evident across the entire range of results for A, B and C class motility. CASA 
D class motility offered greater precision than BMS staff at low D values but the 
precision was similar at higher D values (Figure 4-28). 
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Figure 4-28 Precision profiles for manual WHO motility and CASA.  
A separate precision profile plotting CV% and mean motility is presented for each of four WHO 
classes of motility. CASA motility settings for VLC were experimentally derived (15/18/30). 
 
Precision by field number was similar for means of three and five fields. Using a 
single field offered less precision for sperm counts > 30x106 though for counts 
greater than this there appeared to be little benefit in increasing the field number 
(Figure 4-29). 
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Figure 4-29 Precision profiles for SCA by field number.  
A precision profile plotting CV% and mean motility is presented for single field, mean of three fields 
and mean of five fields. CASA motility settings for VLC were experimentally derived (15/18/30). 
  
143 
 
Precision of WHO motility classes demonstrated that C class precision is more 
greatly compromised than other WHO classes at lower numbers of sperm per 
field. D class motility precision appeared remarkably stable across the range 
(Figure 4-30). 
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Figure 4-30 Precision profiles for CASA WHO motility categories by sperm count.  
A precision profile plotting single field CV% and sperm count is presented. CASA motility settings 
for VLC were experimentally derived (15/18/30). 
 
Precision experiments on repeats of one second videos (Videos generated by 
CASA) for kinematic parameters demonstrated no variance (Table 4-14). 
 
Table 4-14 CV% on Single Sperm Motility using CASA. 
Statistic VLC VSL VAP LIN STR WOB ALH BCF 
 
N 
 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 CV% Mean 0 0 0 0 0 0 0 0 
         
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency 
 
A one second video measuring 100 sperm for each category was repeatedly analysed (10 repeats) using 
CASA to generate the Mean CV%. 
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Within-slide precision experiments for kinematic parameters demonstrated 
precision improvements for every increase in N number. At 200 sperm tracks 
imprecision was reduced with CV% below 10% for every category (Table 4-15). 
 
Table 4-15 Single Slide CV% on Sperm CASA Motility using CASA. 
N VLC VSL VAP LIN STR WOB ALH BCF 
50 15.39 25.49 18.51 13.18 7.87 5.83 16.48 15.04 
100 12.88 17.08 12.82 10.43 6.68 4.40 14.52 8.99 
200 9.80 8.24 8.83 6.69 3.69 2.79 9,63 6.16 
400 3.58 5.78 2.80 5.21 2.54 2.72 4.77 4.44 
1000 1.76 3.31 0.61 3.34 1.85 1.43 3.73 3.92 
2000 0.67 2.89 0.66 2.68 1.76 0.90 2.66 2.55 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency. 
 
Motile sperm from each of 10 slides were measured. The Mean CV% and 95% CI are shown for varying 
means of N categories. 
 
Between-slide precision experiments for kinematic parameters demonstrated 
precision improvements for every increase in N number. At 200 sperm tracks 
imprecision was reduced with CV% below 10% for every category (Table 4-16). 
 
Table 4-16 Between-slide CV% on Sperm Motility using CASA. 
N VLC VSL VAP LIN STR WOB ALH BCF 
50 13.39 15.26 11.74 8.397 6.561 2.700 8.567 14.01 
100 11.46 12.98 10.55 7.04 5.00 2.89 6.98 11.45 
200 8.406 9.88 8.11 5.67 3.46 2.01 4.35 7.98 
400 4.258 5.12 4.14 3.52 2.35 1.20 2.76 3.45 
1000 1.43 1.70 2.85 2.94 0.95 1.61 0.99 1.24 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency. 
 
10 samples had matched Leja 20 chambers prepared and analysed using CASA. The Mean CV% and 95% CI 
are shown for varying N categories.  
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CASA was observed during experiments to occasionally record motility in areas of 
the field of view where there was no motility. To measure this “phantom” motility 
experiments involving latex quality control beads and immobilised sperm were 
carried out to estimate the size of the error. The high latex bead quality control 
experiment produced a significant correlation with count (p=0.02, r2=0.12) 
suggesting that the error is proportional (Table 4-17).  
 
 
Table 4-17 Phantom Motility with CASA 
 
 
Category 
 
 
 
N 
Mean Motility 
(95%Confindence Interval) 
D motility / 
Count Correlation 
 
A 
 
B 
 
C 
 
D 
Pearsons 
R
2
 
Pearsons 
p 
Accubeads High conc. 500 0 0.1 
(0.0-0.1) 
0.8 
(0.71-.08) 
99.5 
(99.3-99.7) 
-0.12 0.02 
Accubeads Low conc. 100 0 0.05 
(0.0-0.1) 
0.4 
(0.0-0.6) 
99.5 
(99.3-99.8) 
-.010 0.47 
Immotile Sperm 160 0.03 
(0.0-0.7) 
1.3 
(1.1-1.5) 
3.1 
(2.7-3.5) 
95.4 
(94.9-96.0) 
-0.08 0.40 
CASA motility results and correlations of d motility with sperm count are presented for two concentrations of 
quality control latex beads and on immotile sperm. 
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4.3.3 Results Part C: CASA Morphology 
 
The SEM images (Figures 4-31, 4-32) offered far greater clarity than those 
produced by the light microscope based CASA system (Figure 4-33). Some SEM 
images can be difficult to measure due to debris or other cells (Figure 4-32). 
 
 
 
Figure 4-31 SEM Images A. The resolving power of SEM allows great clarity. 
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Figure 4-32 SEM Images B. Some sperm are difficult to measure due to debris or other cells 
 
The CASA system is fitted with an automated stage with an autofocus which can 
produce well focused images, providing samples are without significant debris, 
clumping or overlapping. The autofocus settings can be adjusted but irrespective 
of the settings the majority of images are out of focus (Figure 4-33).  
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Figure 4-33 Images from CASA morphology.  
A selection of PAP stained sperm generated from 1000x magnification under immersion oil display 
reduced clarity compared with SEM. 
 
CASA morphology demonstrated large variance with both measurement and 
classification with changes in focus (Figure 4-34). Unfortunately the great majority 
of sperm analysed by this method had to be discarded and human judgement was 
required to determine if an accurate measurement had been made on every image 
captured. This makes the process long and laborious. 
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Figure 4-34 Dependency of focus on CASA morphology measurement.  
The focus of the sperm being analysed can have a profound effect on CASA measurements. A,B,C 
and D are SCA measurements on the same sperm with varying focus; acrosomal area and 
midpiece measurements can be observed to change significantly. E,F,G and H are SCA 
measurements on the same sperm with varying focus; acrosomal area and midpiece 
measurements can be observed to change significantly with focus and E and H have the midpiece 
position reversed. 
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Q-Q plots demonstrated significant (p<0.001) proportional negative bias for head 
length, head width, head area and head perimeter with CASA compared with 
SEM. Head acrosome area measurements were also significantly (p<0.001) lower 
for SCA, though the bias was proportional greater at the lower measurements 
contrasting with other head measurements (Figure 4-35). 
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Figure 4-35 Q-Q plots of CASA head measurements compared against SEM. 
1000 measurements for each category (100 sperm head measurements for each of 10 patients) 
are displayed as Q-Q plots. Sperm head length (A), width (B), area (C), perimeter (D) and 
acrosome % (E) values generated by SCA are compared with SEM.  
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CASA midpiece width showed a mixed positive bias compared with SEM with the 
greatest bias occurring in the middle of the range and decreasing at each end 
(Figure 4-36). CASA midpiece area showed an unusual bias pattern: SCA 
midpiece area is a result calculated by the CASA system while SEM area values 
are manually calculated by multiplying midpiece width by length (Figure 4-36). 
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Figure 4-36 Q-Q plots of CASA midpiece measurements compared with SEM. 
1000 measurements for each category (100 sperm head measurements for each of 10 patients) 
are displayed as Q-Q plots. Sperm midpiece width (A) and area (B) values generated by SCA are 
compared with SEM. SEM area values are calculated by multiplying midpiece width by length. 
 
Difference values, calculated by sorting each 100 measurements largest to 
smallest for both SEM and SCA and calculating the differences between equally 
ranged results, demonstrates subpopulations of head measurements for some 
patients (Figure 4-37). 
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Figure 4-37 Scatter plots of CASA and SEM difference for individual patients. 
Each individual patient’s results are displayed by difference (SEM-SCA). Difference values were 
achieved by sorting each 100 measurements largest to smallest for both SEM and SCA and 
calculating the differences between equally ranged results. Graph A is head length, B head width, 
C head area, D head perimeter and E Acrosome %. 
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Median values from 100 measurements from SCA and SEM correlated for head 
length, head width, head area and head perimeter (Figure 4-38). Acrosome and 
midpiece measurements did not correlate. 
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Figure 4-38 Correlations of CASA against SEM for individual patients.  
Median values from 100 measurements for each category for both SCA and SEM are compared. 
Graphs represent: (A) Head length, (B) Head width, (C) Head Area, and (D) Head Perimeter. 
Acrosome and midpiece measurements did not significantly correlate. 
 
Analytical variance for repeat measures on the same sperm was excellent for 
head measurements (~1%) with the exception of acrosome area (33%). The 
corresponding midpiece measurement imprecision was very high (> 60%) for all 
categories (Table 4-18). 
 
Table 4-18 CV% on single sperm morphology using CASA. 
 Sperm Head Sperm Mid-piece 
 Length Width Area Perimeter Acrosome Width Area Dist Angle 
N 
 
100 100 100 100 100 100 100 100 100 
 CV% Mean 1.2 1.1 1.2 0.9 32.8 63.1 66.0 94.0 86.0 
95% CI L 
 
0.8 0.9 0.7 0.6 4.7 29.0 31.8 59.6 54.8 
95% CI H 1.4 1.3 1.6 1.2 60.1 97.1 99.2 128.9 117.1 
CV=Coefficient of Variation, CI=Confidence Interval 
 
100 random PAP stained sperm from 10 slides were each measured 10 times.  Mean CV% and 95% CI are 
displayed. 
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Using mean values, CV% decreased proportionally to increases in the number of 
sperm used to calculate the mean value. Using means values from 25 sperm, 
repeat mean head measurements were acceptable (≤ 5%) for all measurements 
with the exception of the acrosome area (~10%) (Table 4-19). 
 
Table 4-19 Single slide CV% on head morphology using CASA. 
N 
 
Length Width Area Perimeter Acrosome 
10 
 
4.6 (3.6-5.6) 5.8 (5.1-6.4) 8.4 (6.9-9.8) 4.2 (3.4-5.1) 12.1 (9.2-14.9) 
25 
 
3.1 (2.0-4.1) 4.2 (3.4-5.0) 5.5 (4.0-7.1) 2.7 (2.0-3.5) 9.6 (5.8-13.5) 
50 
 
2.8 (1.6-4.0) 3.5 (2.6-4.4) 4.6 (3.2-6.1) 2.5 (1.8-3.2) 9.3 (6.1-12.5) 
75 
 
1.9 (1.1-2.6) 2.9 (1.9-3.9) 4.0 (2.8-5.2) 1.8 (1.2-2.5) 7.2 (3.4-11.0) 
100 
 
1.0 (0.7-1.4) 2.2 (1.1-3.2) 2.7 (1.2-4.1) 1.2 (0.7-1.7) 7.2 (3.0-11.3) 
150 
 
0.6 (0.2-0.9) 1.5 (1.0-2.0) 1.5 (0.8-2.3) 0.6 (0.1-1.0) 4.2 (1.5-6.8) 
200 0.9 (0.2-1.7) 1.7 (0.9-2.6) 2.1 (0.7-3.6) 1.1 (0.3-1.8) 5.7 (0.3-11.2) 
CV=Coefficient of Variation  
 
400 random PAP stained sperm from 10 slides were each measured. The Mean CV% and 95% CI are shown 
for varying means of N categories.  
 
Between-slide CV% varied between-patients though mean results were between 
2-8% for all measures (Table 4-20). 
 
Table 4-20 Between-slide CV% on sperm morphology using CASA. 
 50 Sperm / Slide  100 Sperm / Slide 
Sample Length Width Area Perim Acro%  Length Width Area Perim Acro% 
1 3.95 2.32 5.11 4.33 5.63  3.25 3.12 6.11 3.33 3.63 
2 2.99 3.01 5.71 2.72 1.89  1.77 2.22 3.71 1.83 4.04 
3 1.96 6.92 8.75 3.75 9.22  2.52 1.79 4.02 2.46 0.13 
4 3.40 3.04 5.80 3.62 5.77  2.13 5.20 7.45 3.35 7.58 
5 3.92 0.23 4.28 2.66 6.64  1.38 1.69 3.43 1.76 11.74 
6 1.46 0.38 1.82 0.83 12.17  0.37 1.21 0.29 0.13 17.80 
7 2.34 2.59 4.71 3.23 4.60  2.33 1.33 3.70 2.36 1.21 
8 0.59 2.85 3.59 1.55 1.14  1.19 0.81 0.24 0.13 1.67 
9 1.76 2.10 3.04 1.80 3.33  0.69 1.54 1.31 0.26 6.10 
10 0.16 1.30 0.44 0.32 11.83  0.69 0.97 0.77 0.76 8.77 
11 5.64 1.18 4.81 3.87 5.56  2.31 2.40 3.83 2.17 9.68 
12 4.40 3.37 7.88 4.75 20.92  4.09 5.09 8.90 4.57 16.16 
13 1.29 5.09 6.93 2.51 10.25  0.87 3.70 4.73 2.06 7.38 
14 1.58 5.78 7.60 3.14 7.33  1.22 3.87 4.86 2.14 4.76 
15 1.40 4.29 6.40 2.63 14.36  3.07 4.51 7.64 3.93 11.57 
Mean 2.456 2.963 5.125 2.781 8.043  1.859 2.630 4.066 2.083 7.481 
95% L 1.603 1.902 3.859 2.088 5.148  1.260 1.794 2.579 1.330 4.572 
95% H 3.309 4.025 6.390 3.473 10.94  2.457 3.466 5.553 2.835 10.39 
CV=Coefficient of Variation, L=Low, H=High 
 
15 random samples had matched slides prepared, PAP stained and analysed using CASA. The effect on 
between-slide CV% was examined using 50 and 100 sperm per slide. 
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One year of Andrology NEQAS samples (n=16) were analysed for morphology by 
CASA and correlated against the UK consensus values for strict criteria. Sperm 
head length for the WHO 1999 values (r2=0.33, p=0.02) correlated against strict 
criteria consensus values (Figure 4-39). 
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Figure 4-39 UK NEQAS results using SCA.  
16 NEQAS morphology samples were analysed by SCA and the current manual method. Results 
were compared against NEQAS strict criteria consensus values. A1 and A2 are 16 NEQAS results 
submitted by our laboratory, B1 and B2 are the same 16 samples analysed by SCA Head Length% 
Normal. SCA results are divided by 9.5 as a correction factor. 
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10 patient’s samples analysed blindly for sperm morphology by four trained BMS 
staff demonstrated large variance between individual BMS with a mean CV% of 
78% (95%CI 55-102). All four BMS staff agreed on abnormality on four samples 
that were scored by all BMS staff as 3% or below (Figure 4-40). 
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Figure 4-40 Blind morphology results from four trained BMS 
10 patient’s samples were analysed for sperm morphology by 4 andrology trained BMS staff. 
Actual results and 95% CI are displayed for each sample.  
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4.4 Discussion  
 
4.4.1 Part A: CASA Count 
 
The aim of this study was to validate or reject SCA CASA for sperm counting in an 
accredited UK semen analysis laboratory. CASA was compared with the Improved 
Neubauer chamber and performed well with the exception of low counts. A further 
method of counting low sperm numbers directly from the CASA screen was 
developed which performed well against the Leja 20µm chamber. There are pros 
and cons of using Leja style 20µm chambers with CASA compared with manual 
haemocytometers when the WHO recommendations (W.H.O., 2010b) are 
considered. The CASA system is not advanced enough to count only whole 
sperm, thus all cells of a similar size to sperm, including sperm without tails are 
counted. Also 20µm chambers are affected by uneven flow rates and may show 
uneven distribution of sperm (Douglas-Hamilton et al., 2005). However, several 
haemocytometer specific errors are also avoided. The rigorous sperm head and 
tail position rules for counting sperm in relation to haemocytometer chamber grid 
lines are unnecessary. The problems associated with coverslips such as correct 
thickness, poor fit, and whether or not use clamps are removed. Moreover, dilution 
errors and positive displacement pipette errors are completely eliminated. In 
addition, CASA offers automated data collection which compared with manual 
counting methods is more rapid with less risk of transcription error, an important 
consideration for the clinical laboratory.  
 
Manual semen analysis is a time consuming process that needs to be performed 
to a high standard with trained individuals in laboratories with robust quality 
assurance in order to produce clinically relevant results (Tomlinson et al., 1999, 
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Björndahl et al., 2004, Pacey, 2006). However, the current cost pressures on 
laboratories are counterproductive to environments that produce such quality, and 
unfortunately this is unlikely to change. Validated CASA systems remove some 
sources of analytical error, dramatically increase the number of sperm analysed 
and thus decrease measurement uncertainty. As all operators use the same 
automated system, operator bias is minimised. The training is less intense than 
manual methods and with automation individuals are less inclined or able to drift 
from the method. With time, decreased measurement uncertainty should yield 
more clinically relevant results and may remove some of the concerns about the 
clinical use of semen analysis. 
 
Previous work has demonstrated advanced CASA systems can accurately count 
sperm (Agarwal & Sharma, 2007, Tomlinson et al., 2010, Lammers et al., 2014). 
This current study (Dearing et al., 2014b) agrees with that evidence. CASA was 
very accurate with latex bead quality control and correlated against one year of 
EQA at least as well as trained BMS staff without observable bias; CASA would 
appear to improve EQA returns for our laboratory.  
 
Uncorrected CASA counts correlated highly with both Improved Neubauer and 
Leja 20µm methods. However, correlation at low sperm concentrations (<30x106) 
was poor due to CASA count overestimation. Overestimation was caused by 
erroneous counting of random small NCOS, cell debris and tailless sperm heads. 
This overestimation with CASA due to misclassification has been previously 
recognised as a CASA specific problem (E.S.H.R.E., 1998, Tomlinson et al., 
2010). For SCA, the positive bias was increased at results <30x106 and reduced at 
≥30x106. The error still occurs at higher concentrations but because of a 
proportional effect it appears reduced in relation to the count. Overestimations at 
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low count range has clinical implications, thus uncorrected CASA counts cannot 
be used to replace current counting methods for low sperm counts. However, 
capturing a one second video and manually counting sperm from the CASA 
screen eliminates this error and results in excellent correlation with no bias. Using 
this combined approach of reporting uncorrected counts ≥30x106 and counting 
from the CASA screen for results <30x106, bias appeared to be minimal at critical 
values for clinical reporting. 
 
Precision of CASA was generally excellent with optimal precision at approximately 
200 sperm per field. This was true for both single and multiple field precision tests. 
Large increases in imprecision were observed at descending concentrations below 
100 sperm per field, though mean results from three fields of analysis give 
acceptable precision for all categories tested. While increasing the field number 
beyond three does decrease imprecision the gain is not large and because of the 
corresponding time increase may not be warranted for routine diagnostic work. 
 
In addition to the count overestimation errors, several other specific types of error 
were observed from the CASA system when used with the Leja 20µm chambers. 
Infrequent counting errors occurred when CASA analysed phantom motile sperm 
(see motility discussion for details). An additional infrequent error related to poor 
focus / contrast was the counting of immotile sperm twice. Both of these gross 
errors are easily identified and removed by re-achieving Kholler illumination / 
phase contrast and cleaning and optimising the microscope. Also, sperm were 
occasionally not detected, however this was infrequent and while the CASA 
operator does have the option of adding the sperm back in manually, at 100x 
magnification each sperm added only increases the count by 0.2x106 for that 
particular field. Unless many sperm have been missed the error may be 
  
160 
 
considered too small to warrant the time to correct. Another source of error 
previously described (Douglas-Hamilton et al., 2005) for 20µm chambers using 
motile sperm relates to uneven flow into the chamber known as the Segre-
Silberberg (SS) effect. This current work found that by including one 100x 
magnification field from each area (distal, central and proximal) in the overall 
count, the SS effect is not significant.  
 
While the overestimation due to miscounting has the potential to be a large and 
clinically relevant error, trained operators should have little difficulty recognising 
when the error has occurred and either correcting the result or counting that 
particular sample with a different method. Other described errors occur 
infrequently and are also easily identified and corrected. It must be noted that even 
occasional counts >30x106 were significantly affected due to other cells and 
debris. It cannot be understated that significant error due to misidentification is 
possible at all concentrations using this technology. Errors will occur and 
individuals using the system will need specific training on how to identify and 
correct these errors. Providing errors are corrected, SCA CASA will produce rapid, 
accurate, linear, precise results with less analytical variance than manual methods 
that correlate well against the Improved Neubauer chamber. 
 
4.4.2 Discussion Part B: CASA Motility 
 
The aim of this study was to validate or reject SCA CASA for sperm motility 
estimation in an accredited UK semen analysis laboratory. The initial comparisons 
between trained BMS staff and CASA were poor, with large differences between 
medians, weak correlations and bias. However, the difficulty for technical staff in 
distinguishing between A and B class motility (Brazil et al., 2004, Cooper & Yeung, 
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2006) and complex motility distribution patterns between individual BMS (Chapter, 
Three) were likely confounders. The results from the expanded one second 
motility videos demonstrated large variance between and within BMS staff motility 
results, which further supports this theory. To account for these confounders the 
comparison was made again with A and B class motility combined, with one BMS 
staff member to remove between-operator bias, and with CASA calibrated to 
provide WHO results closer to manual analysis. This secondary comparison 
resulted in much closer agreement, improved correlations and bias elimination. 
The results from this work highlight some the problems encountered in comparing 
methods for subjective results where more than one operator is involved in the 
comparison.  
 
CASA motility results using the mean values from three fields of analysis proved to 
offer greater precision than manual analysis. The exception to this occurred at 
approximately 70% D class motility where both CASA and manual motility 
achieved similar precision. Increasing the fields of analysis from three to five fields 
offered little improvement in precision. In contrast, single field analysis exhibited 
larger proportional imprecision at lower motility values. CASA C class motility 
exhibited higher imprecision than other motility classes when the number of sperm 
was less than 300 sperm per field, which is likely due to a proportionally lower 
number of C class sperm than other classes and the effects of low sperm numbers 
of precision. This is also the likely reason that CASA D class motility offered 
superior precision than any other WHO class across the entire range.  
 
Precision for kinematic motility parameters (VLC, VSL, VAP, LIN, STR, WOB, 
ALH, BCF) of single sperm tracks was perfect with CASA producing the exact 
same figures for each repeated one second video. Although SCA does have the 
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option of re-analysing fields, the results from these precision experiments 
demonstrated that the system simply reproduces the first recorded result. The 
experiments for within-slide and between-slide precision demonstrate that if a 
minimum 200 sperm tracks are measured, precision for all kinematic motility 
parameters is below 10%. This is in agreement with the WHO recommendations 
on using CASA systems (W.H.O., 2010l). Increasing the number of sperm tracks 
to 400 improves CV to 5% or less, while using less than 200 sperm tracks results 
in a proportional decrease in precision with decreasing N number.  
 
CASA was observed to register motility occasionally where no motility or 
observable drift was present, which has been reported in other CASA systems 
(Tomlinson et al., 2010). There appears to be several scenarios that result in this 
“phantom motility”. Infrequent gross errors occur when SCA records phantom 
motile sperm in large concentration, predominately graded as WHO class B 
motility. The second scenario occurs when a motile sperm touches or passes 
close enough to disturb an immotile sperm or other immotile object that is then 
recorded as independent motility. The third scenario appears to be an algorithmic 
generated background “noise” when there is no or little motility in the field of view. 
The background noise motility weakly correlates (p=0.02, r2=-0.12) with count for 
latex beads suggesting that the error is proportional. For the great majority of 
instances the later two classes of phantom motility are unlikely to lead to 
significant errors; however the first is a gross error and would certainly adversely 
affect results. Staff using CASA will have to be trained to recognise and correct for 
this error. 
 
A commonly reported finding when manual motility is compared with CASA is 
higher D class motility with CASA (E.S.H.R.E., 1998, Tomlinson et al., 2010, 
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W.H.O., 2010l). The difference can be accounted for as a combination of 
particulate debris and / or NCOS being counted by CASA in error (E.S.H.R.E., 
1998) and probable overestimation of motility by technical staff (Tomlinson et al., 
2010). While CASA displayed significantly higher D class motility from the initial 
comparisons, using adjusted CASA WHO motility categorisation and comparing 
values against one BMS displayed little difference. Although CASA does exclude 
particles outside an user adjustable measurement range, overestimation of D 
motility was occasionally observed to occur with samples containing debris or 
other bodies such as small NCOS. Additionally, while individual trajectories at high 
(>100 x 106) sperm counts were often accurate, above 60x106 there appears to be 
a higher probability of trajectory error. This is likely to be related to how individual 
frames are reconstructed when sperm are within each other’s centroid zone of 
probability (Mortimer, 2000). Operators using the system have to make a case by 
case decision on whether to accept or reject any given analysis, or whether to 
adjust the analysis by removing errors or adding missed sperm in. CASA motility 
cannot be used without operator analysis of each field analysed and operators will 
require specific training, both in semen analysis and in the use of CASA to achieve 
quality results. 
 
The theory that manual motility results are prone to overestimation (Agarwal & 
Sharma, 2007, Tomlinson et al., 2010), and subsequently D motility is 
underestimated, because the human eye is invariably drawn to onset movement 
(Abrams & Christ, 2003), is supported by this current work. The results from every 
video tested, demonstrated higher manual A class motility than either CASA 
results or the consensus values. When BMS staff were forced to slow down and 
reach consensus for every individual sperm on any video, their results were closer 
to the lower CASA values than the manual analysis medians. SCA CASA motility 
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provides a faster, more accurate analysis with increased precision compared with 
our current manual method. 
 
4.4.3 Discussion Part C: CASA Morphology 
 
A major aim of the evaluation of SCA CASA morphology was to gather evidence to 
support or reject the CASA system based upon its comparison with results 
generated by SEM. SEM has been shown to be a useful tool in assessing sperm 
morphology (Mundy et al., 1995) though due to cost pressures it is not commonly 
used in routine diagnostic semen analysis. The electron microscope offers 
unparalleled clarity and has to be considered the definitive method for any fine 
detail analysis of cell structure. To our knowledge Imperial College Healthcare 
NHS Trust was the only UK centre offering a scanning electron sperm morphology 
service for diagnosis. However, as electron microscope work is costly in materials, 
time and personal, the service has unfortunately been withdrawn. As no other 
technique has been introduced to replace the loss, the Trust has diminished ability 
to accurate diagnose some conditions (KS Lindsay, personal communication, July 
2012). Thus CASA was examined as a potential replacement for the lost SEM 
service. 
 
Both CASA and SEM were limited to a random 100 sperm from each patient, thus 
measures of direct bias estimation such as Bland-Altman could not be utilised. Q-
Q plots on equally ranged results demonstrated proportional negative bias for all 
SCA morphology head measurements and a mixed positive bias for midpiece 
width. Midpiece area demonstrated a highly unusual bias pattern that is likely to be 
either a mathematical phenomenon, or a systematic error within the CASA system. 
SCA midpiece area measurements are estimated by the programme while the 
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corresponding SEM measures are manually calculated from the midpiece length 
and width. Unfortunately SCA does not measure the midpiece length separately 
from midpiece area which makes direct comparisons impossible for this 
parameter. The systematic bias for head length measurements demonstrate the 
need for independent reference ranges for each specific CASA system. From the 
bias data, CASA midpiece measurements did not compare well with SEM. 
Midpiece measurements made by SCA CASA should be interpreted with caution.  
 
Scatter plots of result differences (SEM-SCA) were generated by sorting 100 
measurements largest to smallest for both SEM and SCA and calculating the 
differences between equally ranged results. These plots, initially designed to test 
for measurement bias within individual patients, clearly demonstrate 
subpopulations for some patients. Whether these subpopulations are an analytical 
or biological phenomenon is unknown, but an analytical source is suspected. A 
subsequent examination of individual SEM and SCA data did not demonstrate the 
same subpopulation spread of results.  
 
Median patient values for SCA and SEM correlated with the exception of the 
acrosome and midpiece parameters. This evidence supports SCA as a possible 
replacement for SEM for some parameters. Although SEM offers unparalleled 
clarity of image in comparison to SCA, it is by far the more laborious of the two 
techniques. SEM also must carry a risk of significant operator measurement 
variance as sperm are measured by manually tracing the outlines or ranges 
measured. Although CASA morphology offers less clarity, it is cheaper and faster, 
can be automated and is thus more easily adapted to measuring higher sperm 
numbers. However, the CASA automatic focus is not accurate enough to precisely 
focus on a large number of sperm. Poorly focused images resulted in striking 
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errors in measurement. SCA CASA requires human input to accept or reject every 
analysed image. 
 
The non-correlation between SCA and SEM acrosome and midpiece parameters 
is unsurprising when the precision data for CASA Morphology is examined. The 
mean CV% on repeat measurement on a single sperm was 33% for acrosome 
area, 63% for midpiece width and 66% for midpiece area. The same measures on 
head length, width, area and perimeter were 1.2%, 1.1%, 1.2% and 0.9% 
respectively. Any use of CASA morphology requiring precision should have all the 
midpiece measurements removed and possibly the acrosome measurements also. 
Because CASA morphology does not measure tails, and midpiece measurements 
display high imprecision, the technique cannot realistically be used as a direct 
replacement for traditional WHO morphology analysis. 
 
To further compare CASA morphology, one year of EQA samples were analysed 
by both CASA and by trained BMS staff using the laboratory manual method. The 
manual method showed a negative bias compared with the EQA strict criteria 
consensus values, an unsurprising result considering the laboratory in question 
has a documented history of negative bias for morphology. (KS Lindsay, personal 
communication, July 2012). However, the manual method results also did not 
correlate with the strict criteria consensus values. This is a possible example of the 
effect of the high variance associated with the manual analysis of only 100 sperm. 
Sperm head length CASA measurements did correlate with the strict criteria 
consensus values and the % of sperm from within the 1999 WHO reference range 
(p=0.02).  
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When proposed (Coetzee et al., 1998, Van Waart et al., 2001, van der Merwe et 
al., 2005) morphology diagnostic thresholds are taken in context with power 
calculations (Pezzullo, 2009), the usefulness of the current manual sperm 
morphology analysis becomes questionable. In this current work, the blind 
assessment between four trained BMS staff demonstrated large between-operator 
variance. While not a like for like assessment, CASA has the potential to 
dramatically reduce this variance, a conclusion in agreement with previous work 
(Barroso et al., 1999, Agarwal & Sharma, 2007, Garrett et al., 2007, Huang & Lu, 
2007). Unfortunately, SCA CASA morphology cannot replace manual analysis as 
not all aspects of sperm morphology can yet be examined. However, CASA 
systems are undoubtedly the future for morphology analysis. While such systems 
still cannot make all the necessary measurements nor measure enough sperm 
independently of human input to satisfy the demands of power calculations, surely 
it is simply a matter of time. 
 
4.4.4 CASA Validation Conclusion 
 
This study provided the process validation required to adopt the SCA CASA 
system as the main method for sperm counting, motility and morphology in a busy 
diagnostic andrology laboratory and for this research project. The count and 
motility technology was generally well received by laboratory staff, though some 
initial mistrust was evident. After process validation was completed, CASA has 
provided the laboratory with; (1) a rapid precise sperm counting method that 
counts far greater numbers than manual methods allow, (2) rapid WHO sperm 
motility grading that is comparable to BMS staff results with improved precision 
compared with manual methods and (3), an automated morphology method that 
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can offer precise sperm head measurements but cannot fully replace the manual 
method. 
 
It must be emphasised that the system does require operators to understand and 
recognise likely CASA sources of error, and to employ effective strategies to 
correct or minimise their occurrence. While CASA may improve clinical 
information, the technology will not remove the requirements to standardise 
analysis time following production and temperature to limit the motility damaging 
effects of changes in hydration, pH and temperature. CASA will also not remove 
the need for robust quality control, adequate staff training, routine competency 
assessment and supervision.  
 
CASA technology is not a stand-alone “black box” but rather a tool for trained 
andrology staff that allow rapid analysis of higher numbers of sperm than are 
possible with manual methods. Both CASA count and motility offer improved 
precision over manual estimations with less subjectivity and are easily adapted to 
the diagnostic laboratory. While SCA CASA morphology might not yet fully replace 
a full WHO morphology analysis, it could conceivably be used to accurately 
differentiate between morphologically normal and abnormal head structures. 
CASA automation of semen analysis has the potential to provide more meaningful 
diagnostic results though current data are lacking with regard to reproductive 
outcomes.  
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Chapter 5 Uncertainty of Threshold Values for Assisted Conception 
 
5.1 Introduction 
 
All clinical measurements require comparison with reference values in order to 
facilitate patient management, further investigations and / or treatment. While the 
majority of clinical reference ranges are two-sided with upper and lower limits, 
one-sided lower limit thresholds are shown to be more suitable for predicting both 
natural fertility (van der Merwe et al., 2005, Cooper et al., 2010) and assisted 
conception outcomes (Coetzee et al., 1998, Vanweert et al., 2004). However, 
regional differences between the fertility of geographic populations and high 
between-laboratory analytical variance, have led the World Health Organisation 
(WHO) to recommend that individual laboratories consider utilising reference 
ranges from local populations (W.H.O., 2010a). 
 
The objective of this research was to compare both well described and novel 
threshold limits to predict infertility with Assisted Reproductive Technologies (ART) 
from local populations. The ART treatments examined were Intrauterine 
Insemination (IUI), In Vitro Fertilisation (IVF) and Intra Cytoplasmic Sperm 
Injection (ICSI). The reference threshold limits can be introduced as local 
reference ranges for ART assessments for patients attending the clinic and can be 
used to estimate the fertility of men following cryopreservation for this research 
project. The secondary objective was to compare the validated Computer Assisted 
Semen Analysis (CASA) system with manual semen analysis for predicting fertility 
outcomes. 
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5.2 Methods 
 
IUI Population and Ejaculate Selection 
A total of 1014 semen analysis and inseminate results from 571 patients attending 
the Andrology Laboratory (Andrology Laboratory, Hammersmith Hospital, Imperial 
College NHS Trust, London, United Kingdom (UK)) for IUI preparation were 
collated. All the IUI preparations at the clinic between February 2008 and May 
2012 (824 ejaculates from 450 patients) received manual semen analysis (Chapter 
Four, Methods). An additional 190 results from 121 patients, representing all 
patients who received IUI treatment between May 2012 and January 2013, 
received CASA semen analysis (Chapter Four, Methods). All IUI cycles were 
stimulated and all female patients were free of tubal pathology as diagnosed with 
laparoscopy. All semen analysis results were matched with IUI outcomes provided 
by the IUI treatment centre (Obstetrics and Gynaecology Department, West 
Middlesex University Hospital (WMUH), Middlesex, UK). 
 
IVF / ICSI Population and Ejaculate selection 
A total of 1158 semen analysis results from patients who attended the Andrology 
Laboratory and produced a single ejaculate for fertility workup prior to their female 
partners IVF or ICSI treatment were collated. This pre-treatment fertility workup 
ejaculate is used to aid ART selection. 889 patients representing all the fertility 
work up for the year 2011 received manual semen analysis. 269 patients who 
attended between May 2012 and September 2012 received CASA semen 
analysis. All collated semen analysis results were matched with female partners. 
IVF / ICSI outcomes from female partners were provided by the IVF / ICSI 
treatment centre (IVF Hammersmith, Hammersmith Hospital, London, UK). 
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Pregnancy Definition 
The pregnancy definition for this study was a biochemical pregnancy tested at 2 
weeks. For the IUI cohort pregnancy results were determined two weeks post 
treatment by urinary dipstick (NADAL hCG Early Test 10mIU/mL Test Cassette, 
142000, nal-vonminden GmbH, Moers, Germany) at West Middlesex University 
Hospital. For the IVF / ICSI cohort pregnancy was determined 14-16 days after 
egg collection by urinary dipstick (Alere hCG Easy 25mIU/mL, Stockport, 
Cheshire, UK) at Hammersmith Hospital.  
 
Parameters Examined 
The following semen analysis, whole ejaculate and inseminate parameters were 
collated and compared for ART outcomes; semen volume, sperm count, 
progressive motility, total motility, ejaculate count, ejaculate Total Motile Count 
(TMC), ejaculate Progressive Motile Count (PMC), viscosity, Nucleated Cells 
Other than Sperm (NCOS), Mixed Agglutination Reaction (MAR), abstinence 
period, time between production and analysis, Swim Migration Test (SWT) and / or 
Density Gradient (DG) test. The validated (Dearing et al., 2014b) CASA system 
(SCA V 4.0, MICROPTIC S.L. Viladomat, Barcelona, Spain) was used to generate 
CASA results (Chapter Four, Methods). Manual semen analysis was performed as 
described in Chapter Four, Methods.  
 
Semen volume was determined by weight (W.H.O., 2010m). All samples were 
collected into pre-weighted sample pots (125BM/50, Sterilin Limited, Newport, UK) 
and this weight was subtracted from the post-collection weight to determine 
sample volume. This was based on the assumption that 1 g of semen equates to 1 
mL (W.H.O., 2010n).  Viscosity was determined after liquefaction. An aliquant of 
well mixed sample was gently aspirated into a 3.0 mL plastic disposable pipette 
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(3.0 mL Liquipette, Elkay Laboratory Products, Basingstoke, UK) and allowed to 
drop by gravity. Samples leaving the pipette in small discrete drops were graded 
as normal, samples forming threads longer than 2 cm were graded as abnormal. 
NCOS were counted with the Improved Neubaeur or directly from the CASA 
screen (Chapter Four Methods). MAR testing was performed by pipetting 10 µL 
IgG sensitised red blood cells (ORIr, NBS Reagents, NHSBT Colindale, London, 
UK), 10 µL IgG AntiSerum (OSAS15, Siemens, Camberley, Surrey, UK) and 10 µL 
well mixed semen onto a clean glass slide (J2800AMNZ, Gerhard Menzel GmbH, 
Braunschweig, Germany). This combination was well mixed and covered with a 22 
x 22 mm coverslip (BB022022A1, Gerhard Menzel GmbH, Braunschweig, 
Germany). After three minutes the slide was graded as follows; <10 % sperm 
bound = Negative, ~10 % sperm bound = “+ MAR”, 10-90 % sperm bound = “++ 
MAR” and > 90% sperm bound = “+++ MAR”. A MAR negative control (RBC 
agglutination) was included with each test.  
 
SWT tests were performed by injecting 0.5 mL of well mixed liquefied semen 
below 2.0 mL flushing media (Origio a/s Knardrupvej 2 DK-2760 Måløv Denmark) 
in a sterile non-toxic plastic tube (Falcon, (35)2003 12x75 mm tube B.D., Oxford, 
UK). The injection was gentle to minimise the disturbance at the interface when 
removing the pipette. The tube was then placed at 37 0C and Incubated for 120 
minutes. After incubation the top 0.5 mL was removed to a sterile non-toxic fresh 
tube. An aliquot was then immediately taken for sperm count and motility using the 
Improved Neubauer chamber (Chapter Four, Methods). Low recovery SWT counts 
(<0.5 X 106) had DG testing performed as a reflex test.  
 
DG tests were performed by making a single tube of a two layer gradient (80% as 
the bottom layer and 50% as the top layer) of readymade Suprasperm density 
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gradient (Origio a/s Knardrupvej 2 DK-2760 Måløv Denmark). Each layer was 
aliquotted slowly into a sterile non-toxic 5.0 mL tube to form a clear separation 
between the two gradients.  1.0 mL of semen was layered over the gradient which 
was then centrifuged at 600 x g for 15 minutes to reach the isopycnic point. Layers 
were removed down to and including the interface above the lower gradient layer 
leaving the pellet. Pellets were then re-suspended to 1.0 mL with flushing media 
and mixed well. An aliquot was then immediately taken for sperm count and 
motility with the Improved Neubauer chamber. 
 
IUI Data Analysis 
Comparisons between pregnancy and non-pregnancy were made using the 
couple, the cycle and the first cycle only as separate units of analysis. Improved 
Neubauer results were compared with CASA results for predicting non-pregnancy 
from sperm count, total ejaculate count and IUI inseminate (DG) count. The 
potential for semen parameters predicting miscarriage was examined. The 
optimum threshold TMC was calculated by including and excluding miscarriage, 
focusing on first cycle data only and adjusting for female age. The semen 
characteristics of men successful with IUI was compared against the 2010 WHO 
reference range (Cooper et al., 2010) by tabulating percentiles. 
 
Cluster analysis using VAP and LIN CASA data was attempted after consideration 
of a number of available techniques (Rokach & Maimon, 2005, Martínez-Pastor et 
al., 2011). Kinematic data from 1000 sperm tracks from each of 20 patients’ 
samples that resulted in a pregnancy were combined. These combined data of 
20000 sperm tracks were analysed for VAP / LIN clusters (Rokach & Maimon, 
2005, Martínez-Pastor et al., 2011). Both hierarchical and k means clustering were 
attempted. For k means clustering, which requires the number of clusters to be 
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identified before the analysis, eight separate attempts at analysis was performed 
using three to 10 clusters. Each of these analyses were then plotted and 
graphically compared, with eight clusters appearing optimal. Every patients 
sample was then re-analysed using the eight identified clusters areas and the 
proportion of sperm within each cluster area recorded. This analysis was repeated 
for both the prepared inseminate and for neat semen. Proportions were compared 
using ROC analysis (pregnant vs. non-pregnant) for each of the 8 clusters 
individually and also in combination with other clusters. In addition, CASA 
kinematic motility variables, uncurving velocity (UCV), percentile variance, 
percentile sum, percentile kurtosis and percentile skewness (Chapter Four, 
Methods) were compared for patients that achieved a pregnancy with patients that 
did not achieve a pregnancy.  
 
CASA Morphology 
102 couples undergoing IUI had CASA morphology performed after Papanicolaou 
(PAP) staining on the IUI preparation before insemination. In addition, 16 National 
External Quality Assurance Scheme (NEQAS) semen analysis samples (Chapter 
Three, Methods) were analysed for morphology by CASA.  A minimum of 100 
sperm from each ejaculate or NEQAS sample was analysed. The CASA 
morphology results from 3590 sperm from 12 ejaculates that resulted in a 
pregnancy were used to generate a local reference range for CASA morphology. A 
novel modified Teratozoospermia Index (TZI) like derived calculation (Menkveld & 
Kruger, 1996, Menkveld et al., 2001, W.H.O., 2010j) was made based upon the 
local reference range, TZI Fertile Head. 
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TZI Fertile Head =
𝑁𝐻𝐿+𝑁𝐻𝑊+𝑁𝐻𝐴+𝑁𝐴𝐴+𝑁𝐻𝑊𝑅
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑝𝑒𝑟𝑚  𝑎𝑛𝑎𝑦𝑠𝑒𝑑 𝑥 5
 
NHL = the % of sperm with a Normal Head Length (3.47-4.17* µm) 
NHW = the % of sperm with a Normal Head Width (2.02-2.60* µm) 
NHA = the % of sperm with a Normal Head Area (5.99-8.52* µm
2
) 
NHP = The % of sperm with a Normal Head Perimeter (9.74-11.48* µm) 
NAA = The % of sperm with a Normal Acrosome Area (31.66-52.76* %) 
NHWR = The % of sperm with a Normal Head / Width Ratio (1.41-1.89*) 
*All values were calculated from 3590 sperm from 12 men who achieved an IUI pregnancy. 
 
The proportion of sperm designated as normal from TZI Fertile Head was tested for 
correlations against the NEQAS consensus values for strict criteria. Receiver 
Operator Characteristic (ROC) analysis to predict pregnancy was performed using; 
(1)  The proportion of sperm designated as normal based on the local reference 
range for head length, width, area, perimeter, acrosome area and length/width 
ratio; (2) The proportion of sperm designated as normal based on the 1999 WHO 
figures for normal head size (W.H.O., 1999) for head length, width and 
length/width ratio; (3) The proportion of sperm designated as normal based on TZI 
fertile head and TZI using the WHO 1999 values; (4) The median measurements for 
head length, width, area, perimeter, and acrosome area; (5) Kolmogorov-Smirnov 
distance as a normal distribution measure for head length, width, area, perimeter, 
and acrosome area; (6) Coefficient of Variation (CV) (Standard deviation / mean x 
100)  as a heterogeneity measure for head length, width, area, perimeter, and 
acrosome area. 
 
IVF / ICSI Data Analysis 
Comparisons were only made using the couple as the unit of analysis as the data 
provided by IVF Hammersmith precluded any other analysis. For IVF patients the 
same clusters identified from IUI were used with ROC analysis to examine 
predictive potential. IVF outcomes were also examined using a 40% fertilisation 
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rate of mature eggs. Egg collections of less than 5 eggs were excluded from this 
analysis. 
 
IUI Preparation 
After ejaculate production and liquefaction, 0.1 mL of ejaculate was taken for 
semen analysis. The remaining ejaculate was then prepared for IUI with the same 
DG kit and method as used for DG testing. Multiple tubes were prepared for each 
ejaculate so that the entire ejaculate volume was separated. Re-suspended pellets 
were then transferred to a single tube which was then centrifuged at 600 x g. The 
supernatant was then removed and the pellet again re-suspended with 1.0 mL 
flushing media. A third and final 600 x g centrifugation was followed with the 
supernatant being discarded and the pellet being re-suspended in 1.0 mL flushing 
media. This final preparation tube was then sealed in a receptacle (30 mL Western 
Polystyrene Container, Consumables Solutions, Portsmouth, UK) to protect 
against temperature fluctuations. This was then transported to the clinic by the 
male partner where the female partner was readied for insemination. An aliquant 
(approximately 0.05 mL) of this final preparation was taken and analysed for 
sperm count and motility before transport. 
 
Statistics 
For both IUI and IVF / ICSI datasets, patients that achieved a pregnancy were 
compared with patients that did not achieve a pregnancy at a range (2.5th, 5th, 10th, 
25th, 50th, 75th, 90th, 95th and 97.5th) of percentiles for semen analysis, ejaculate, 
SWT, DG and IUI inseminate parameters. ROC curves were generated to 
compare the predictive potentials of each parameter. Odds ratios of treatment 
failure and pregnancy were calculated with logistic regression. Correlations 
between parameters were assessed using Spearman correlation. Significant 
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differences between pregnant and non-pregnant groups were assessed with 
Mann-Whitney U testing. Logistic regression adjusted odds ratios, ROC, 
percentiles, percentile variance, percentile sum, percentile kurtosis, percentile 
skewness and k means clusters were generated with IBM SPSS Statistics 
(Version 20, IBM Corp, www.ibm.com). All other graphs and statistical 
comparisons were made with Prism version 4.0 (Version 4.01, Graph Pad, San 
Diego, CA, USA, www.graphpad.com). 
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5.3 Results IUI Threshold Values 
 
The characteristics of the ejaculates of men who achieved an IUI pregnancy (with 
that or subsequent ejaculates) compared with the ejaculates from men who failed 
to achieve a pregnancy with IUI displayed large differences at low percentiles 
values for semen parameters (Table 5-1), whole ejaculate parameters (Table 5-2) 
and IUI inseminate parameters (Table 5-3).  
 
Table 5-1 Semen ejaculate (n=191) characteristics from men (n=102) who achieved a pregnancy with their 
partner from IUI are compared with ejaculates (n=823) from men (n=469) who failed to achieve a pregnancy. 
Percentiles 
Semen Volume 
(mL) 
Sperm Count 
(x10
6
) 
Progressive Motility 
(%) 
Total Motility 
(%) 
P NP P NP P NP P NP 
2.5 0.50 0.60 4.72 1.80 10.80 1.00 26.00 5.00 
5 0.76 0.90 6.00 3.64 15.00 6.00 39.60 26.00 
10 1.02 1.10 8.44 7.88 25.20 17.00 46.00 38.00 
25 1.80 1.60 18.70 14.70 36.00 31.00 55.00 51.00 
50 2.50 2.40 33.70 31.00 47.00 44.00 64.00 62.00 
75 3.90 3.30 57.00 59.00 54.00 53.00 70.00 69.00 
90 5.30 4.50 89.00 97.00 62.00 60.00 74.00 74.00 
95 6.68 5.20 104.40 120.32 64.80 65.00 76.40 77.00 
97.5 7.56 6.04 121.12 153.40 67.60 70.00 83.40 80.00 
IUI=Intrauterine Insemination, P=Pregnant, NP=Non-Pregnant 
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Table 5-2 Percentiles of whole ejaculate (n=191) characteristics from men (n=102) who achieved a pregnancy 
with their partner from IUI are compared with ejaculates (n=823) from men (n=469) who failed to achieve a 
pregnancy. 
Percentiles 
Total Ejaculate Count 
(x10
6
) 
Total Ejaculate PMC 
(x10
6
) 
Total Ejaculate TMC 
(x10
6
) 
P NP P NP P NP 
2.5 6.32 3.16 2.28 0.15 4.67 0.73 
5 10.87 6.69 3.75 0.91 6.74 2.48 
10 23.09 13.24 7.29 2.78 11.62 6.09 
25 41.42 32.20 14.56 10.50 23.66 16.95 
50 78.40 70.60 32.82 30.53 48.31 42.76 
75 148.40 138.00 68.11 67.32 95.63 85.80 
90 273.20 265.79 124.15 116.40 155.63 160.64 
95 345.79 395.90 154.04 191.46 206.64 253.76 
97.5 423.48 537.44 233.93 266.55 265.02 329.21 
IUI=Intrauterine Insemination, P=Pregnant, NP=Non-Pregnant, PMC=Progressive Motile Count, TMC=Total 
Motile Count 
 
Table 5-3 Percentile IUI inseminate (n=191) characteristics from men (102) who achieved a pregnancy with 
their partner from IUI are compared with inseminates (n=823) from men (n=469) who failed to achieve a 
pregnancy. 
Percentiles 
IUI Count 
(x10
6
) 
Prog. Motility (%) Total Motility (%) 
PMC 
(x10
6
) 
TMC 
(x10
6
) 
P NP P NP P NP P NP P NP 
2.5 0.80 0.30 20.00 1.00 40.00 5.00 0.52 0.01 0.64 0.05 
5 1.86 0.80 38.00 15.00 50.00 30.00 0.86 0.22 1.23 0.30 
10 3.50 1.82 50.00 30.00 60.00 50.00 1.94 0.78 2.18 0.99 
25 6.50 4.50 60.00 50.00 75.00 70.00 4.69 2.52 5.25 3.15 
50 13.00 10.50 70.00 70.00 85.00 85.00 9.43 7.20 10.85 8.17 
75 22.13 19.45 85.00 80.00 90.00 90.00 17.04 14.68 19.48 16.60 
90 40.00 39.79 90.00 90.00 95.00 95.00 29.94 27.45 33.74 29.27 
95 41.57 40.00 90.00 90.00 95.00 95.00 36.00 35.74 38.17 38.00 
97.5 59.42 50.45 91.00 95.00 95.80 99.00 52.14 38.49 57.52 45.95 
IUI=Intrauterine Insemination, P=Pregnant, NP=Non-Pregnant, PMC=Progressive Motile Count, TMC=Total 
Motile Count 
 
ROC analysis of semen, ejaculate and inseminate parameters using the cycle, the 
couple and first cycles only as separate units of analysis, demonstrated that first 
cycles only is the optimal unit of analysis to predict IUI failure (Table 5-4). 
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Table 5-4 ROC analysis results for IUI failure comparing the cycle (n=191 pregnant, 823 non-pregnant), the 
couple (n=101 pregnant, 469 non-pregnant) and first cycles only (n=55 pregnant, 516 non-pregnant). 
Unit of Analysis Parameter ROC Area 
ROC 95
th
 CI 
Lower Upper 
The Cycle 
Semen Volume 0.53 0.47 0.6 
Semen Count 0.53 0.47 0.58 
Semen Progressive Motility 0.54 0.48 0.59 
Semen Total Motility 0.55 0.49 0.6 
Elaculate Count 0.54 0.48 0.6 
PMC 0.55 0.49 0.6 
TMC 0.55 0.49 0.6 
DG (inseminate) count 0.58 0.52 0.63 
DG (inseminate) PMC 0.59 0.53 0.64 
DG (inseminate) TMC 0.58 0.53 0.64 
The Couple 
Semen Volume 0.54 0.49 0.58 
Semen Count 0.52 0.48 0.56 
Semen Progressive Motility 0.55 0.5 0.59 
Semen Total Motility 0.54 0.49 0.58 
Elaculate Count 0.54 0.49 0.58 
PMC 0.55 0.51 0.59 
TMC 0.54 0.50 0.58 
DG (inseminate) count 0.57 0.52 0.61 
DG (inseminate) PMC 0.57 0.53 0.61 
DG (inseminate) TMC 0.57 0.53 0.61 
First Cycles Only 
Semen Volume 0.55 0.50 0.58 
Semen Count 0.55 0.50 0.57 
Semen Progressive Motility 0.56 0.51 0.6 
Semen Total Motility 0.55 0.50 0.6 
Elaculate Count 0.55 0.5 0.6 
PMC 0.58 0.53 0.64 
TMC 0.59 0.53 0.64 
DG (inseminate) count 0.62 0.55 0.69 
DG (inseminate) PMC 0.64 0.58 0.71 
DG (inseminate) TMC 0.63 0.56 0.7 
Significant ROC (Receiver Operator Characteristic) areas in bold. PMC=Progressive Motile Count, TMC=Total 
Motile Count 
 
Men from partners who experienced a miscarriage had lower sperm counts 
(p=0.041), whole ejaculate counts (p=0.034), inseminate counts (p=0.012), 
inseminate PMC (p<0.001), and inseminate TMC (p<0.001). ROC analysis to 
discriminate between miscarriage and pregnancy from semen analysis parameters 
were sperm count (0.63, 95% CI 0.44-0.82), whole ejaculate count (0.65, 95% CI 
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0.48-0.83), inseminate PMC (0.69, 95% CI 0.50-0.89), sperm count (0.69, 95% CI 
0.49-0.88). CASA counts demonstrated that compared with Neubauer counts, 
CASA offered superior prediction using ROC analysis. (Figure 5-1). 
 
 
 
 
Figure 5-1 ROC analysis of sperm count, ejaculate count and inseminate count parameters by cycle. 
 (A) 86 inseminates from men who achieved a pregnancy with their partner with IUI from that cycle are 
compared with 738 ejaculates from men who failed to conceive with that cycle. All count data were generated 
from Neubauer. ROC areas were; count (0.50, 95% CI 0.44-0.56), whole ejaculate count (0.52, 95% CI 0.46-
0.58), inseminate count (0.56, 95% CI 0.50-0.62). (B) 16 inseminates from men who achieved a pregnancy 
with their partner with IUI from that cycle are compared with 174 ejaculates from men who failed to conceive 
with that cycle. All count data were generated from CASA. ROC areas were; sperm count (0.69, 95% CI 0.57-
0.81), whole ejaculate count (0.68, 95% CI 0.56-0.81) and inseminate count (0.68, 95% CI 0.54-0.83). 
 
The probability of pregnancy by cycle, demonstrated a clear decrease in 
probability with increasing cycle number. Odds of pregnancy from cycle one 0.12 
(95% CI 0.02-0.84), cycle two 0.11 (95% CI 0.02-0.80), cycle three 0.10 (95% CI 
0.01-0.78), cycle four 0.09 (95% CI 0.01-0.79) (Figure 5-2). Logistic regression of 
female age adjusting for cycle number and TMC provided an odds ratio for IUI 
failure of 4.09 (95% CI 1.26-13.30) for woman over 42, 3.34 (95% CI 1.77-6.32) for 
woman over 40 and 1.21 (95% CI 0.87-1.68) for woman over 36 (Figure 5-2). 
From ROC analysis the optimal cut off for predicting non pregnancy with IUI from 
A B 
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the TMC was 1.37 x 106. This figure excluded miscarriage, used only first cycle 
data and adjusted for female age. Patients below the TMC cut off (1.37 x 106) gave 
a treatment failure adjusted odds ratio of 8.82 (95% CI 1.20-65.10) with a 
specificity of 97.92% (95% CI 88.93-99.95) and a sensitivity of 15.61 (95% CI 
12.35-19.34) (Figure 5-2). 
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Figure 5-2 Cycle number, female age and TMC.  
(A) The cumulative percentage of patients achieving a pregnancy is plotted against cycle number. (B) Odds 
ratios of pregnancy are calculated for female age. (C) TMC of men from pregnant and non-pregnant couples 
from first cycle data.   
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Correlations between semen parameters (Appendices 9.3, Table 9-3) and whole 
ejaculate parameters (Appendices 9.3, Table 9-4) established that the majority of 
these parameters significantly correlate with IUI PMC and TMC.  Poorer semen 
quality was observed in men from couples who are successful with IUI than the 
WHO 2010 reference values (Table 5-5). A range of cut off values are possible 
with each measure depending upon the diagnostic sensitivity and specificity 
desired (Table 5-6).   
 
Table 5-5 Percentile semen (n=191) characteristics of men (n=102) who were successful with IUI are 
compared with the WHO 2010 reference values (Cooper et al., 2010). 
Percentiles 
Semen  
Volume (mL) 
Sperm 
Count (x10
6
) 
Ejaculate 
Count (x10
6
) 
Progressive 
Motility (%) 
Total 
Motility (%) 
IUI WHO IUI WHO IUI WHO IUI WHO IUI WHO 
2.5 0.3 1.2 6 9 16 23 11 28 37 34 
5 0.5 1.5 8 15 16 39 22 32 39 40 
10 1.0 2.0 9 22 24 69 27 39 48 45 
25 1.8 2.7 21 41 42 142 38 47 59 53 
50 2.6 3.7 39 73 86 255 48 55 67 61 
75 4.5 4.8 52 116 146 455 54 62 70 69 
90 5.4 6.0 92 169 198 622 63 69 72 75 
95 6.2 6.8 104 213 402 928 71 72 74 78 
IUI=Intrauterine Insemination, WHO=World Health Organisation  
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Table 5-6 Cut off values, sensitivity,  specificity and Likelihood ratio of treatment failure for four parameters 
calculated from 55 first cycle ejaculates from men who achieved a pregnancy and 516 first cycle ejaculates 
from men who failed to conceive with IUI. 
Parameter Percentile Cut Off Value 
Specificity % 
(95% CI) 
Sensitivity % 
(95% CI) 
Likelihood 
Ratio 
(95% CI) 
Total Ejaculate 
PMC 
(x10
6
) 
 
5
th
 
 
3.75 96.08 
(90.26-98.92) 
11.22 
(9.24-13.45) 
2.74 
(1.35-5.56) 
10
th
 
 
7.29 90.05 
(84.90-93.90) 
18.97 
(16.21-21.83) 
2.25 
(1.35-3.74) 
25
th
 
 
14.56 75.39 
(68.66-81.32) 
30.79 
(27.63-34.09) 
1.40 
(0.97-2.01) 
Total Ejaculate 
TMC 
(x10
6
) 
5
th
 
 
6.74 95.29 
(91.24-97.82) 
10.40 
(8.40-12.70) 
2.51 
(1.23-5.12) 
10
th
 
 
11.62 90.05 
(84.90-93.90) 
16.13 
(13.78-18.98) 
1.89 
(1.11-3.09) 
25
th
 
 
23.66 75.39 
(68.66) 
31.53 
(28.34-34.85) 
1.42 
(0.98-2.04) 
Inseminate 
PMC 
(x10
6
) 
5
th
 
 
0.86 95.29 
(91.24-97.82) 
10.71 
(8.78-13.05) 
2.66 
(1.31-5.41) 
10
th
 
 
1.94 90.05 
(84.90-93.90) 
19.21 
(16.56-22.09) 
2.32 
(1.39-3.85) 
25
th
 
 
4.69 75.39 
(68.66-81.32) 
38.05 
(34.70-41.49) 
1.94 
(1.35-2.78) 
Inseminate 
TMC 
(x10
6
) 
5
th
 
 
1.23 95.76 
(90.58-97.46) 
11.82 
(9.68-14.24) 
2.87 
(1.42-5.82) 
10
th
 
 
2.18 90.58 
(85.52-94.32) 
17.49 
(14.93-20.28) 
2.02 
(1.21-3.37) 
25
th
 
 
5.25 75.92 
(69.21-81.80) 
36.45 
(33.14-39.87) 
1.77 
(1.24-2.54) 
IUI=Intrauterine Insemination, PMC=Progressive Motile Count, TMC=Total Motile Count 
 
VAP was plotted against LIN for all available sperm tracks from semen and from 
IUI preparations from men who were successful with IUI. The results were 
analysed using k mean clusters with 8 clusters appearing optimal (Figure 5-3). 
Separate cluster centres for IUI preparations (Appendices 9.3, Table 9-5) and 
semen (Appendices 9.3, Table 9-6) were determined.  
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Figure 5-3 CASA VAP / LIN clusters from a Fertile Population.    
The graphs represent the CASA VAP plotted against LIN of; (A) 24500 sperm from 20 IUI preparations that 
resulted in a pregnancy, (B) 19800 sperm from 16 men’s semen ejaculates that resulted in a pregnancy with 
IUI, (C) VAP/LIN k mean clusters from group A, (D) VAP/LIN k mean clusters from group B. 
 
Median percentage clusters from IUI preparations were compared for pregnancy 
and non-pregnancy with IUI (Appendices 9.3, Table 9-7). Combining clusters 5 
and 8 identified from IUI preparations (DG clusters) achieved the highest 
significant difference (p<0.001) between successful and unsuccessful patients. A 
DG 5 + DG 8 cluster size cut-off of ≥ 23% proved highly sensitive and correctly 
identified 94% of patients who achieved a pregnancy, however the specificity 
(32%) was poor as many non-pregnant patients also had high proportions of 
sperm within this cluster area. While this test is very limited for predicting 
pregnancy with IUI it is an effective test for predicting non-pregnancy with a 
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negative predictive value of 97%. ROC analysis of all significant and close to 
significant predictors using cluster analysis can be seen in Table 5-7. 
 
Table 5-7 Significant or close to significance ROC analysis results using individual and combined clusters to 
predict pregnancy with IUI 
Cluster Group Area Significance 
95% Confidence Interval 
Lower Upper 
DG 5 0.69 0.011 0.56 0.82 
DG  8 0.64 0.067 0.49 0.79 
SEM  1 0.34 0.031 0.20 0.47 
SEM  2 0.65 0.049 0.51 0.79 
SEM  3 0.35 0.042 0.21 0.49 
SEM  5 0.36 0.060 0.23 0.49 
SEM  8 0.68 0.019 0.55 0.81 
DG  5 + DG 8 0.79 <0.001 0.66 0.91 
ROC=Receiver Operator Characteristic, DG=Density gradient cluster, SEM=Semen Cluster, IUI=Intrauterine 
Insemination 
 
ROC analysis on CASA kinematic motility percentiles between pregnant and non-
pregnant groups demonstrated no difference for VSL, VAP, LIN and STR. Several 
predictors of non-pregnancy were demonstrated for; VLC (Appendices 9.3, Table 
9-8), WOB (Appendices 9.3, Table 9-9), ALH (Appendices 9.3, Table 9-10), BCF 
(Appendices 9.3, Table 9-11) and UCV (Appendices 9.3, Table 9-12). The most 
predictive ROC analyses are summarised in Table 5-8. 
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Table 5-8 CASA motility variables with the largest significant ROC areas with cut off values and corresponding 
specificity and sensitivity. 
 
CASA 
Variable 
ROC Cut-Off Values 
Optimum 
Measure 
Cut-Off 
Value 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
VCL 90
th
 Percentile 98.37 
83.33 
(73.19-90.82) 
30.00 
(11.89-54.28) 
WOB Skewness -0.38 
79.52 
(69.24-87.59) 
25.00 
(8.657-49.10) 
ALH 90
th
 Percentile 3.05 
91.67 
(83.58-96.58) 
25.00 
(8.657-49.10) 
BCF 5
th
 Percentile 1.00 
81.25 
(70.97-89.11) 
35.00 
(15.39-59.22) 
UCV 50
th
 Percentile 38.60 
82.50 
(72.38-90.09) 
40.00 
(19.12-63.95) 
ROC=Receiver Operator Characteristic, VLC=Curvilinear Velocity, WOB=Wobble, ALH=Amplitude of Lateral 
Head Displacement, BCF=Beat Cross Frequency, UCV=Uncurving Velocity 
 
A reference range was created for PAP stained sperm head measurements from 
3590 sperm from 12 IUI preparations that resulted in a pregnancy (Appendices 
9.3, Table 9-13). TZI Fertile Head (a modified TZI using the fertile reference range 
values) correlated (r2=0.27, p=0.04) against strict criteria consensus values from 
one year of Andrology NEQAS samples (n=16). ROC analysis of possible 
morphology measurements for a fertile reference range revealed only KS distance 
for acrosome was a discriminator (Table 5-9). 
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Table 5-9 ROC analysis results of sperm head dimension measurements and associated distribution 
measurements for predicting pregnancy.   
Test Area Significance 
95% Confidence Interval 
Lower Upper 
% of sperm within the local fertile reference range 
Length 0.47 0.776 0.26 0.69 
Width 0.56 0.532 0.38 0.74 
Area 0.57 0.434 0.38 0.76 
Perimeter 0.54 0.658 0.37 0.72 
Acrosome 0.57 0.472 0.38 0.76 
Length / Width Ratio 0.44 0.531 0.26 0.63 
Combined 0.67 0.073 0.51 0.83 
Combined excluding Acrosome 0.67 0.071 0.52 0.82 
% of sperm within the 1999 WHO reference range 
WHO Length 0.45 0.627 0.28 0.63 
WHO Width 0.53 0.714 0.36 0.71 
WHO Length / Width Ratio 0.61 0.229 0.43 0.80 
Combined 0.64 0.139 0.49 0.78 
TZI based Head Measurements 
Fertile TZI 0.54 0.654 0.34 0.75 
WHO TZI 0.63 0.161 0.45 0.82 
Median Sperm Head Measurements 
Median Length 0.45 0.610 0.28 0.63 
Median Width 0.52 0.845 0.34 0.70 
Median Area 0.44 0.534 0.26 0.62 
Median Perimeter 0.40 0.288 0.23 0.57 
Median Acrosome 0.35 0.093 0.17 0.52 
Kolmogorov-Smirnov (KS) Distance as a Normal Distribution Measure 
KS Distance Length 0.42 0.364 0.28 0.56 
KS Distance Width 0.40 0.273 0.25 0.55 
KS Distance Area 0.40 0.291 0.25 0.56 
KS Distance Perimeter 0.49 0.910 0.34 0.64 
KS Distance Acrosome 0.31 0.042 0.18 0.44 
CV% as a Heterogeneity Measure 
CV Length 0.46 0.689 0.26 0.67 
CV Width 0.38 0.215 0.21 0.56 
CV Area 0.43 0.452 0.23 0.63 
CV Perimeter 0.43 0.484 0.24 0.63 
CV Acrosome 0.52 0.855 0.31 0.72 
ROC=Receiver Operator Characteristic, TZI=Teratozoospermia Index, CV=Coefficient of Variation, 
WHO=World Health Organisation, KS= Kolmogorov-Smirnov Test 
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5.4 Results IVF / ICSI Threshold Values 
 
In 2011 1330 woman underwent IVF or ICSI treatment at Hammersmith Hospital 
IVF department. A corresponding male partner semen analysis performed at 
Hammersmith Hospital Andrology laboratory prior to IVF or ICSI treatment could 
be identified for 889 of these women. From this 889 cohort, 450 pregnancies in 
total were achieved representing 51% of the total. It must be noted that because 
IVF or ICSI treatments were selected partially on the results of these semen 
analysis results, an unavoidable bias is inherent with this dataset. For IVF / ICSI 
treatments combined, there was no differences between pregnant and non-
pregnant semen analysis parameters for any of the semen, swim or density 
gradient parameters analysed. Age was found to be the greatest single factor in 
determining either treatment success (Figure 5-4).  
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Figure 5-4 Female Age and IVF and ICSI Treatment Success. 
Figure shows the odds ratio of treatment failure for IVF and ICSI by female age. 
 
443 women underwent IVF with 238 conceiving (54%). Of these 443 IVF couples, 
274 (62%) of the male partners presented with a normal semen profile. Neither 
WHO designated normal semen profiles, or local reference ranges for SWT or DG 
were associated with successful treatments. The characteristics of fertility workup 
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ejaculates from men who went on to provide ejaculates resulting in successful IVF 
treatments are given in Table 5-10 and 5-11. 
 
Table 5-10 Percentile parameters from fertility work up semen ejaculates (n=238) from men who achieved a 
pregnancy with IVF from subsequent ejaculates. 
Percentiles 
Volume 
(mL) 
Count 
(x10
6
) 
Progressive 
Motility 
(%) 
Total 
Motility 
(%) 
Ejaculate 
Count 
(x10
6
) 
PMC 
(x10
6
) 
TMC 
(x10
6
) 
2.5 1.00 5.85 6.85 27.43 16.97 3.22 8.19 
5 1.20 10.00 16.00 38.95 28.57 11.46 19.45 
10 1.79 19.80 28.90 48.00 50.19 18.10 27.60 
25 2.18 34.75 39.00 58.00 98.53 39.61 57.33 
50 2.90 58.50 49.00 64.00 170.30 87.19 115.83 
75 3.90 102.50 56.00 72.00 304.25 142.21 191.82 
90 5.01 154.10 61.00 75.00 440.02 205.16 286.11 
95 6.02 210.25 64.00 77.05 621.19 313.01 404.66 
97.5 7.12 268.08 67.03 80.00 793.00 402.56 560.77 
IVF=In Vitro Fertilisation, PMC=Progressive Motile Count, TMC=Total Motile Count 
 
Table 5-11 Percentile parameters from swim up (n=232) and density gradients (n=44) from fertility work up 
semen ejaculates from men who achieved a pregnancy with IVF from subsequent ejaculates. 
 Swim Up  Parameters Density Gradient Parameters 
Percentiles 
Count 
(x10
6
) 
Progressive Motility 
(%) 
Total Motility 
(%) 
Count 
(x10
6
) 
Progressive Motility 
(%) 
Total Motility 
(%) 
2.5 .01 1.00 5.00 0.83 10.00 20.63 
5 .05 1.00 5.00 1.08 15.00 27.50 
10 .20 43.00 55.00 1.56 30.00 40.00 
25 .60 80.00 90.00 2.58 50.00 60.00 
50 1.40 90.00 95.00 3.75 60.00 80.00 
75 2.75 90.00 95.00 6.22 80.00 90.00 
90 4.30 95.00 99.00 10.50 87.50 95.00 
95 4.87 95.00 99.00 11.90 90.00 95.00 
97.5 6.05 95.00 99.00 15.09 94.38 98.50 
IVF=In Vitro Fertilisation 
 
Logistic regression of female age provided an odds ratio for IVF infertility of 2.81 
(95% CI 1.50-5.28, p=0.001) for woman over 40 years of age. The odds ratio for 
infertility proportionally decreased for yearly decreases in age but remained 
significant until the age of 35. Removal of woman over the age of 40 from the 
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analysis resulted in a significant ROC analysis for sperm count (p=0.013) and 
NCOS count (p=0.012). No other parameters were predictive (Table 5-12).  
 
Table 5-12 Area under the curve for ROC analysis of IVF pregnancy (n=152 pregnant, 222 not pregnant) with 
95% confidence intervals and significance for semen analysis and ejaculate parameters predicting IVF 
success in woman (≤ 40). 
Variable Area Significance 
95% Confidence Interval 
Lower Bound Upper Bound 
Semen Analysis Parameters 
Volume 0.49 0.779 0.43 0.55 
Count 0.58 0.013 0.52 0.63 
Progressive Motility 0.52 0.475 0.46 0.58 
Total Motility 0.50 0.883 0.44 0.55 
Viscosity 0.51 0.786 0.45 0.57 
NCOS 0.58 0.012 0.52 0.64 
MAR Test 0.49 0.831 0.43 0.55 
Whole Ejaculate Parameters 
Ejaculate Count 0.56 0.053 0.50 0.62 
Progressive Motile Count 0.55 0.082 0.50 0.61 
Total Motile Count 0.55 0.076 0.50 0.61 
ROC=Receiver Operator Characteristic, IVF=In Vitro Fertilisation, NCOS=Nucleated Cells Other than Sperm, 
MAR=Mixed Agglutination Reaction 
 
For woman ≤40 undergoing IVF the presence of NCOS was higher (p=0.011, chi-
square, df 6.524) in the non-pregnant group (39%) compared with the pregnant 
group (27%). This was not evident with IVF and ICSI combined or with ICSI alone. 
There was no difference between the NCOS count values in either group. A 
NCOS count of ≥1 x 106 gave a IVF failure odds ratio of 1.9 (p=0.007, 95%CI 1.2-
3.0) while a NCOS count of ≥5.0 x 106 gave a IVF failure odds ratio of 2.0 
(p=0.015, 95%CI 1.1-3.4).  
 
CASA motility proved to be a greater discriminator of IVF success than manual 
motility when used to generate TMC (Figure 5-5). 
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Figure 5-5 ROC curves for CASA motility vs manual motility for IVF success.  
Graph compares the ROC analysis curves for CASA and manual motility generated TMC to predict pregnancy 
from IVF. 27 pregnant, 29 non pregnant, woman >40 excluded CASA produced a ROC area of 0.66 (95%CI 
0.51-0.80), p=0.041. Manual motility produced a ROC area of 0.51 (95%CI 0.36-0.66), p=0.893. 
 
442 women underwent ICSI with 213 conceiving (48%). Of the 442 ICSI couples, 
65 (15%) of the male partners presented with a normal semen and swim test 
profile. The characteristics of the male fertility workups from men who went on to 
provide ejaculates resulting in successful ICSI treatments are given in Table 5-13 
and 5-14. None of the parameters examined were different between pregnant 
and non-pregnant groups or were predictive of outcome. 
 
Table 5-13 Percentile parameters from fertility work up semen ejaculates (n=212) from men who achieved a 
pregnancy with ICSI from subsequent ejaculates. 
Percentiles 
Volume 
(mL) 
Count 
(x10
6
) 
Progressive 
Motility 
(%) 
Total 
Motility 
(%) 
Ejaculate 
Count 
(x10
6
) 
PMC 
(x10
6
) 
TMC 
(x10
6
) 
2.5 0.53 <0.01 <0.01 0.00 <0.01 <0.01 <0.01 
5 0.93 0.01 <0.01 0.65 0.02 <0.01 <0.01 
10 1.30 0.01 1.00 5.00 0.04 <0.01 <0.01 
25 2.00 3.00 15.00 37.00 9.07 1.72 3.98 
50 3.00 13.00 34.50 55.00 39.75 11.46 20.41 
75 4.30 34.75 46.00 66.00 98.22 37.89 56.70 
90 5.97 70.70 54.00 72.00 232.80 107.53 139.17 
95 7.00 103.70 61.00 76.00 368.11 176.11 238.95 
97.5 8.27 127.43 64.35 79.67 529.75 229.81 356.83 
ICSI=Intra Cytoplasmic Sperm Injection, PMC=Progressive Motile Count, TMC=Total Motile Count 
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Table 5-14 Percentile parameters of swim up (n=189) and density gradients (n=119) from fertility work up 
semen ejaculates from men who achieved a pregnancy with ICSI from subsequent ejaculates. 
 Swim Parameters Density Gradient Parameters 
Percentiles 
Count 
(x10
6
) 
Progressive 
Motility 
(%) 
Total 
Motility 
(%) 
Count 
(x10
6
) 
Progressive 
Motility  
(%) 
Total 
Motility 
(%) 
2.5 <0.01 <0.01 <0.01 0.01 1.00 5.00 
5 <0.01 <0.01 <0.01 0.01 1.00 5.00 
10 <0.01 <0.01 <0.01 0.01 1.00 5.00 
25 0.01 1.00 5.00 0.50 10.00 20.00 
50 0.01 1.00 5.00 1.50 35.00 50.00 
75 0.40 70.00 83.75 3.80 60.00 80.00 
90 1.10 90.00 95.00 7.50 80.00 90.00 
95 2.35 90.00 95.00 10.00 80.00 90.00 
97.5 3.28 91.38 96.10 14.00 85.00 90.00 
ICSI=Intra Cytoplasmic Sperm Injection 
 
The cluster centres identified from IUI patients showed potential as predictors of 
IVF outcomes, however the significant clusters were different from those identified 
for IUI success (Table 5-15). 
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Table 5-15 ROC analysis results of cluster analysis for IVF success (n=33 pregnant, 35 non pregnant) with 
female  >40 excluded. 
   95% Confidence Interval 
Cluster Area Significance Lower Upper 
DG Identified Clusters 
DG 1 0.46 0.591 0.32 0.60 
DG 2 0.40 0.139 0.26 0.53 
DG 3 0.63 0.060 0.50 0.77 
DG 4 0.67 0.023 0.54 0.79 
DG 5 0.60 0.162 0.46 0.74 
DG 6 0.39 0.129 0.26 0.53 
DG 7 0.67 0.018 0.54 0.80 
DG 8 0.45 0.464 0.31 0.59 
Semen Identified Clusters 
SEM 1 0.50 1.000 0.36 0.64 
SEM 2 0.49 0.857 0.35 0.63 
SEM 3 0.54 0.606 0.40 0.68 
SEM 4 0.68 0.013 0.55 0.81 
SEM 5 0.48 0.750 0.34 0.62 
SEM 6 0.66 0.033 0.53 0.79 
SEM 7 0.38 0.090 0.24 0.51 
SEM 8 0.50 0.954 0.36 0.64 
ROC=Receiver Operator Characteristic, IVF=In Vitro Fertilisation, DG=Density gradient cluster, SEM=Semen 
Cluster 
 
Using a mature oocyte fertilisation rate of 40% (minimum local policy fertilisation 
requirement of IVF Hammersmith) as the fertility outcome instead of pregnancy 
demonstrated that the progressive motile count was the best predictor of 
fertilisation for IVF (Table 5-16). If miscarriage, patients with NCOS count >1.0 x 
106 and patients with < 5 eggs collected were removed greater significance was 
found.  Several options for cut off values are available (Table 5-17). IUI 
preparation cluster 8 (p=0.012) and semen cluster 5 (p=0.045) were also 
predictive of fertilisation rate. 
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Table 5-16 ROC analysis results from semen parameters in predicting ≥ 40% fertilisation of mature eggs 
collected. 
Semen Parameter Area Significance 
95% Confidence Interval 
Lower Upper 
Count 0.68 0.007 0.56 0.81 
Ejaculate Count 0.67 0.012 0.56 0.78 
Progressive Motile Count 0.71 0.002 0.59 0.82 
Total Motile Count 0.69 0.006 0.57 0.80 
SWT Count 0.69 0.005 0.57 0.81 
SWT Progressive Motility 0.55 0.507 0.40 0.69 
SWT Total Motility 0.55 0.443 0.41 0.69 
ROC=Receiver Operator Characteristic, SWT=Swim Test, Patients with < 5 eggs collected excluded, Patients 
with NCOS > 1.0 excluded, Miscarriage excluded. 
 
 
Table 5-17 Percentile value cut off values with ROC sensitivity, specificity for ejaculate total progressive motile 
count to achieve ≥ 40% fertilisation with mature eggs. 
Parameter Percentile Cut Off Value 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
 
 
Total Ejaculate PMC 
(x10
6
) 
2.5
th
 
 
8.0 97.44 
(93.57 to 99.30) 
0.0 
(0.0 to 16.11) 
5
th
 
 
14.7 96.15 
(91.82 to 98.58) 
14.29 
(3.05 to 36.34) 
10
th
 
 
18.1 92.31 
(86.95 to 95.96) 
28.57 
(11.28 to 52.18) 
25
th
 
 
42.6 78.21 
(70.90 to 84.41) 
47.62 
(25.71 to 70.22) 
ROC=Receiver Operator Characteristic, PMC=Progressive Motile Count. Patients with < 5 eggs collected 
excluded, Patients with NCOS > 1.0 excluded, Miscarriage excluded.  
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5.5 Discussion 
 
The aim of this study was to compare both well described and novel threshold 
limits to predict infertility with Assisted Reproductive Technology (ART) treatment 
from local populations. Minimum threshold values for successful IUI, IVF and ICSI 
can be established. However, optimum threshold values for IVF and ICSI 
treatment selection remain elusive. For the populations examined, total and 
progressive motile counts are the optimum semen parameters for predicting IUI 
failure, while sperm count and the presence of NCOS are predictive of IVF failure. 
CASA motility cluster analysis and CASA percentile distribution measures have 
potential as novel reference ranges for both IUI and IVF outcome prediction. 
Methodological issues common to fertility research and high analytical parameter 
variance at threshold values are the major limiting factors preventing accurate 
threshold identification for IVF or ICSI selection.  
 
Research examining the relationships between semen characteristics and fertility 
is often weakened by inadequate information on female pathology with fertility 
consequences (Tomlinson et al., 2013). This current work has attempted to control 
for female age, stimulation and tubal pathology where possible, however other 
female factors could not be taken into account because of an unavoidable lack of 
available data.  Additionally, the data did not allow the length of sub-fertility for 
each couple to be established. Between-laboratory variance was eliminated as all 
analysis was performed at the same laboratory. Within-laboratory variance was 
minimised by use of CASA for a portion of the dataset. No information on the 
effects of clinical variance could be obtained as all fertility treatments were 
performed at other centres. Two common sources of bias in fertility studies are 
selection bias (bias when not all patients presenting with the relevant condition are 
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included in the study) and verification bias (bias from a decision for a couple to 
undergo ART influenced by a previous test result). These sources of bias were 
minimised for the IUI dataset as the study clinic only offers IUI and all patients’ 
results within a specified timeframe were included. For the IVF / ICSI dataset, 
selection bias was minimised by including all patients within a specified timeframe. 
However verification bias is unavoidable for this dataset as ART selection was 
partially facilitated by these same semen analysis results.  
 
The IUI dataset may be viewed as preferential in comparison to the IVF / ICSI 
dataset because of the likelihood that the ejaculate assessed is the same 
ejaculate giving rise to the pregnancy. Also, there is less female variance with the 
IUI dataset as all cycles were stimulated and all females with tubal pathology were 
excluded. Stimulation and fertility pathology details were not available with the IVF 
/ ICSI dataset. Moreover, as WMUH only offers IUI, scenarios where patients are 
treated with a more invasive fertility treatment than that required (Tomlinson et al., 
2013) could not occur. However, neither dataset could exclude the confounders 
that occur when patients receive a less invasive treatment because of cost, risk or 
personal preference. This confounder is in fact likely for a proportion of patients 
from the IUI dataset. Patients with parameters below IUI threshold limits still 
receive IUI at WMUH as no other ART is available. This scenario of access to 
treatment is a well described occurrence in the UK, commonly referred to as the 
“postcode lottery” (Cannell, 2008). Biochemical, ongoing pregnancy and live birth 
were not analysed separately because the distinction could be made with certainly 
from the available data and follow up time frame.  
 
Ejaculate and inseminate parameters for men achieving an IUI pregnancy 
compared with men not achieving an IUI pregnancy demonstrates that differences 
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between the groups only occur at the lower (≤25th) percentiles. This is in 
agreement with a large meta-analysis on post wash IUI data (Vanweert et al., 
2004), finding that high specificity in predicating a failure to achieve pregnancy can 
be achieved but only limited sensitivity in predicating the ability to become 
pregnant. This is also similar to the approach taken in the generation of the latest 
WHO reference ranges (Cooper et al., 2010). Highlighting that it is the cut-offs 
applied to populations with suspected infertility or sub-fertility that offers the best 
discriminating potential of fertility data. 
 
The differences between the pregnant and non-pregnant groups for IUI, clearly 
demonstrates that WMUH are selecting a proportion of patients who have 
decreased chances of pregnancy with IUI. This may be particularly relevant 
considering the latest NICE recommendations to severely limit the use of IUI 
based on their finding that the treatment offers no improvement over natural timed 
conception (N.I.C.E., 2013). However, there are no well-designed randomised 
control trials to support the NICE finding.  Moreover, there may be a significant 
flaw in the design of studies comparing timed intercourse with IUI as patient 
selection criteria from individual clinics are unlikely to be directly comparable. For 
many clinics, including the clinic in this current work, IUI is the only fertility 
treatment available. At these clinics couples best suited to IVF or ICSI undergo IUI 
with decreased chance of success because the alternative is no treatment at all. 
Certainly the clinic from this study would have improved their IUI pregnancy rates 
with a more rigorous patient selection process. 
 
Semen quality is a factor for predicting IUI outcomes, particularly the total number 
of motile sperm (for reviews see (Ombelet et al., 2003, Tomlinson et al., 2013). 
From this current work, the whole ejaculate progressive motile count and the 
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whole ejaculate total motile count were the best non-inseminate predicators of IUI 
outcome. Unsurprisingly since IUI is a treatment used for mild male factor 
infertility, the group that achieved a pregnancy from this study displayed 
significantly poorer semen quality than the natural conception group used to 
generate the current WHO reference range (Cooper et al., 2010). IUI can thus 
achieve acceptable pregnancy rates with poor quality semen, lending further 
evidence that the treatment may be more useful than the updated N.I.C.E 
guidelines suggest. 
 
The negative association between advanced female age and fertility is well 
established (Wainer et al., 2004, Merviel et al., 2010, H.F.E.A., 2013a, Tomlinson 
et al., 2013). In this current work, after adjusting for semen quality, a sharply 
increasing odds ratio for IUI treatment was demonstrated for every additional year 
after a female age of 36. However, female age was not found to be a greater 
determinant of outcome than decreased TMC. A low TMC (<1.37x106) had odds 
for treatment failure 9 times that of a TMC above this threshold. 
 
A common limitation encountered with IUI data is the sole use of the cycle as the 
unit of analysis which carries the risk of overrepresentation of the infertile couple 
who undergo multiple unsuccessful cycles (Vanweert et al., 2004). In addition, 
cumulative pregnancy rates by cycle number demonstrate a decreasing probability 
of success with increasing cycle number. To account for these confounders by 
limiting the data to first cycles only, a more accurate measure of IUI success may 
be established. Excluding couples with a female age of greater than 36 and / or a 
TMC of <3.0x106 a pregnancy rate of 14.1% was achieved from a single IUI cycle 
per couple. Comparing the semen characteristics of these men with the WHO 
reference range for fertile men (Cooper et al., 2010) again clearly demonstrates 
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that pregnancy is achieved from a group with markedly poor semen quality 
compared with those men who contributed to the WHO reference range.  
 
Sperm morphology has previously been shown to be predicative of IUI outcomes 
(Van Waart et al., 2001, Spiessens et al., 2003), and may partially explain poor 
pregnancy rates with a high TMC (Spiessens et al., 2003, Wainer et al., 2004). 
However, other authors have found no such relationship (Karabinus & Gelety, 
1997, Check et al., 2002).  Using the validated CASA system for morphology 
demonstrated promising potential using a local fertile reference range. These 
values were close to significance but unfortunately the sample size precluded 
opportunities to remove those patients with a diminished TMC, which may have 
increased statistical significance (Spiessens et al., 2003, Wainer et al., 2004). 
Between-patient variance and the number of sperm that are required to be 
analysed per patient to reach statistical significance are also likely confounders. 
An unexpected finding was that Kolmogorov-Smirnov (KS) distance for acrosome 
area was the best morphology parameter for predicting fertility with IUI. 
Unfortunately morphology is not a parameter routinely tested for IVF fertility work 
up patients at Hammersmith and so no assessment of CASA morphology and IVF 
outcomes was made. Future work using CASA and local fertile reference range 
and distribution measures has been identified. 
 
Determining sperm threshold limits for IVF and / or ICSI success is unquestionably 
more difficult than determining such limits for IUI because of the greater number of 
potential confounders and the diminished numbers of sperm required for success. 
In addition, not only are the factors already discussed for IUI also relevant for the 
more invasive treatments, they also appear to have greater proportional effects on 
outcomes (Tomlinson et al., 2013). Embryological factors play a large part in IVF 
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and ICSI outcomes and include media and culture conditions, embryo grading 
criteria, operator competence, staging and assisted hatching. Controlling these 
embryo conditions for each cycle would be desirable in any clinical trial examining 
semen or sperm parameters and ART success. Unfortunately, similar to the 
evidence for IUI, a general lack of randomised controlled trials examining non 
clinical issues like male factor infertility  limits robust conclusions (Tomlinson et al., 
2013).   
 
Female age was found to be the largest single factor influencing IVF and ICSI 
outcomes. Similar to the effects of female age on IUI outcomes, a female age of 
36 and each additional year of age was associated with a higher IVF and ICSI 
failure rate. This finding is supported by UK Human Fertility Embryonic Agency 
(HFEA) data with a live birth rate per IVF cycle of 33% in woman under 35 and 
only 12% in woman aged 40 to 42 (H.F.E.A., 2013a). Once the influence of female 
age was accounted for, semen analysis parameters became better predictors of 
IVF pregnancy with both sperm counts and the presence of NCOS generating 
significant ROC curves. None of the examined semen parameters were significant 
for ICSI outcomes. 
 
NCOS are either of spermatogenic origin or of non-spermatogenetic origin and 
while both types are considered normal in low concentrations, there is much about 
their aetiology that is unknown. White blood cells, mainly neutrophils, are found in 
most semen ejaculates (Tomlinson et al., 1993) and their presence may negatively 
affect spermatozoa function (Wolff, 1995, Henkel et al., 2005). Tomlinson et al. 
(1993) found that in patients undergoing in IVF for unexplained infertility, seminal 
white blood cells have little if any influence on the fertilising capacity of the 
spermatozoa, whereas large numbers of germinal elements is associated with 
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decreased success of IVF. This current work found less chance of success with 
IVF when NCOS were ≥1 x 106, which is the WHO threshold value for NCOS 
(W.H.O., 2010d). Further work on accurate differentiation of NCOS could be of 
real clinical value in IVF and ICSI treatment selection. 
 
A major limitation against the use of semen analysis to select appropriate ART 
treatments, is that the final sperm population for ART is often a poor 
representation of the original heterogeneous ejaculate (Tomlinson et al., 2013). 
Large improvements in morphology and DNA fragmentation quality can be 
produced with DG separation for example (Tomlinson et al., 2001). It is 
unsurprising therefore that semen parameters were not associated with ICSI 
outcomes, which require the selection of only a single sperm. Additionally, IVF 
sperm are not required to travel the same distances or interact with the female 
reproductive tract as for IUI success. This partially explains the decreased 
significance in the motile count ROC area curves for IVF compared with IUI. 
Although a minimum number of motile sperm are still required for IVF, because the 
concentration is lower than that required for IUI there is greater analytical 
uncertainly. These limitations are highlighted in other studies finding a general lack 
of predictive potential from the WHO reference limits for IVF outcomes (Chen et 
al., 2009, Kini et al., 2010). However in spite of the limitations, this current study 
established that CASA can improve predictive potential and generate significant 
ROC curves for IUI and IVF. 
 
Sperm motility is highly heterogeneous and subpopulations within the motility 
spectrum may be potential discriminators for predicting ART outcomes. Motility 
subpopulation cluster analysis has been attempted in several species (Martínez-
Pastor et al., 2011) with studies identifying between four (Martínez-Pastor et al., 
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2011) and 11 (Núñez‐Martínez et al., 2006) separate clusters. Both k means and a 
hierarchical method were attempted with the current dataset, though the 
hierarchical method could not compute the clusters due to the large number of 
sperm tracks. Using k means with eight clusters offered significant ROC areas 
discriminating between-ejaculates achieving and not achieving a pregnancy for 
both IUI and IVF.  
 
Cluster analysis for IUI success revealed four inseminate clusters (DG cluster 
4,5,7 and 8) and 4 semen clusters (SEM cluster 1,2,3 and 6) with significant ROC 
analysis areas. Combining DG clusters 5 and 8 achieved the highest ROC 
analysis area for successful IUI prediction (0.78, 95%CI 0.66-0.91, p<0.001). 
Cluster analysis for IVF success with the same clusters identified from IUI 
demonstrated significant differences between every cluster when all patients were 
included in the analysis. This result was highly unexpected given the number of 
factors known to influence IVF outcome and has to be treated with caution. Once 
woman over the age of 40 were excluded from this data set the significance 
dropped to three clusters groups only. DG cluster 4, and 7 were both significantly 
(p=0.002 and p=0.015 respectively) higher in ejaculates achieving a pregnancy 
with IVF. Combining these two adjacent clusters generated optimum ROC analysis 
results (area 0.78 (95%CI 0.67-0.89), p<0.001).  
 
The cluster groups identified from DG preparations and neat semen proved to 
show significance in the same graph areas. In addition for both IUI and IVF, the 
clusters areas offering the greatest predictive potential showed remarkable 
similarity. DG identified cluster 4 which represents high speed sperm with low 
linearity, and DG identified cluster 7 representing high speed sperm with medium 
linearity where both significantly higher in ejaculates achieving a pregnancy with 
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either ART. In contrast, DG cluster 8 representing low speed high linearity sperm 
and DG cluster 5 representing high speed high linearity sperm was significantly 
higher for IUI alone. This may indicate that higher sperm linearity is advantageous 
for IUI in comparison to IVF.  
 
Percentiles were calculated for CASA motility variables to examine optimum 
threshold percentiles and distribution measures for significant differences between 
pregnant and non-pregnant IUI patients. Where an optimum threshold could be 
identified, these percentiles tended towards the tail of a distribution, the 90th 
percentile for VLC and ALH measurements and the 5th percentile for BCF. Other 
notable findings were a significantly higher percentile variance for ALH (p<0.001) 
and lower percentile variance for BCF in ejaculates unsuccessful for IUI. 
Additionally, percentile skewness for WOB and UCV and percentile sum for VLC 
were shown to be predictive of IUI outcome. Further work examining the 
relationship between distribution variance and fertility is warranted.  
 
Although some semen parameters may be used to produce threshold limits below 
which fertility becomes less probable, many parameters simply do not appear to 
have this power. As low parameter values exhibit particularly high variance, using 
semen quality threshold testing to determine whether a couple should receive IVF 
or ICSI is not possible with great certainty. CASA has the potential to improve this 
certainty and is preferable over manual semen analysis. Minimum threshold 
values for successful ART were established for this research project, though 
optimum threshold values for IVF and ICSI selection cannot be recommended. 
Further work such as a multicentre trial, with each centre using the same validated 
CASA system is recommended as the best strategy to provide the robustness of 
data required to achieve this aim. 
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Chapter 6 Egg Yolk and the CoolCell  
 
6.1 Introduction 
 
Sperm cryopreservation is an essential service for men who require iatrogenic 
treatments, though large variance between and within patients is a limiting factor. 
Homemade egg yolk sperm cryopreservation media may have displayed superior 
freeze / thaw results, but was withdrawn with a United Kingdom (UK) regulatory 
shift towards Conformité Européenne (CE) marked products. Our Andrology 
laboratory freezes over 1000 ejaculates per year from men requiring insurance 
against iatrogenic treatments.  After many years of process validation, our 
preferred cryopreservation method is to use Sperm Freezing Media (SFM) (Origio, 
Denmark) with an adapted method. The single adaption we make to the 
manufacturers recommended method simply involves achieving a slightly slower 
initial freezing curve, cooling for the first 30 minutes in a -20 0C freezer, rather than 
in nitrogen vapour.  
 
The objective of this study was to evaluate a newly available CE marked egg yolk 
Cryo-Protectant Agent (CPA) media, Test Yolk Buffer (TYB) (Irvine Scientific, 
USA), by comparing it with our current sperm cryopreservation method. A second 
objective was to examine the CoolCell as a novel freezing receptacle to reduce 
variance and improve sperm cryopreservation. 
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6.2 Methods 
 
Samples 
All patients were informed that samples ideally should be collected between three 
to seven days of sexual abstinence. All samples were self-collected in private 
collection rooms near the Andrology laboratory by masturbation into a clean wide-
mouthed labelled plastic container (125BM/50, Sterilin, Newport, UK)  at (23 0C ± 3 
0C). These containers were from a batch that had been checked and shown to 
have no toxic effects on sperm. All semen samples received full semen analysis 
(W.H.O., 1999, A.B.A., 2012).  
 
Because individuals often exhibit varying sensitivity to cryopreservation, 
experiments using pooled semen were included to minimise individual patient 
variance. A minimum of 10 men’s samples were pooled for each experiment. All 
samples contributing to each pool were produced within 120 minutes of each other 
and kept in the original collection pot with the lid firmly screwed down and at room 
temperature (23 0C ± 3 0C) until pooled. Only samples with counts > 15.0 x 106 
and > 50 % motile sperm were used for each pool.  
 
Test Yolk Buffer 
TYB (Irvine Scientific, Newtown, Co. Wicklow, Ireland) was used with the 
manufacturers recommended method. 1.0 mL ampoules (5000-0012, Nalgene, 
Thermo Fisher Scientific, Rochester, NY 14625, U.S.A.) were prepared with a 1:1 
dilution with CPA media and semen. Ampoules were placed into a 1 L beaker of 
water at 37 0C. The beaker with floating ampoules was then placed in a fridge at 4 
0C which initiates a slow cooling curve. After 90 minutes ampoules were plunged 
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into Liquid Nitrogen (LN2) and frozen. Ampoules were thawed by plunging into 37 
0C water after a minimum storage of 24 hours at -196 0C. 
 
Sperm Freezing Medium  
SFM (Origio a/s Knardrupvej 2 DK-2760 Måløv Denmark) was used with a method 
adapted from the manufacturers recommended method. 1.0 mL ampoules were 
prepared with a 1:1 dilution with media and semen and left to equilibrate for 10 
minutes. Ampoules were placed into a freezer at -20 0C for 30 minutes and then 
placed over LN2 vapour for a further 30 minutes before being plunged into LN2. 
Ampoules were thawed by plunging into 37 0C water after a minimum storage of 
24 hours at -196 0C. 
 
Comparison of freeze media 
A total of 10 separate experiments on pooled semen were carried out to examine 
any differences between TYB and SFM. Well mixed matched 1.5 mL aliquots from 
each pool were added to clean plastic containers (the same type and batch used 
for sample collection) at room temperature (23 0C ± 3 0C). Each container had 
either 1.5 mL SFM or TYB added to it over 90 seconds and was then frozen. Both 
sets of media were added to semen at as close to the same time as possible to 
minimise any environmental differences. 1.0 mL aliquots for each type of media 
were frozen in duplicate cryopreservation ampoules and stored for a minimum of 
24 hours at -196 0C. All ampoules from each pool were thawed in batches of four 
(two ampoules of each media for each pool) by plunging into 37 0C water. After 
incubation at 37 0C for 30 minutes, ampoules were randomly selected, mixed well 
and an aliquot analysed.  
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All aliquots were measured for Total Motile Count (TMC), Progressive Motile 
Count (PMC), A, B, C and D motility, Curvilinear Velocity (VCL), Straight Line 
Velocity (VSL), Average Path Velocity (VAP), Linearity (LIN) Amplitude of Lateral 
Head Displacement (ALH) and Beat Cross Frequency (BCF) using a minimum of 
200 sperm tracks for each measurement. A and B class WHO motility was 
separated as the CASA system (Chapter Four, Methods) is able to distinguish 
between these categories with acceptable precision (< 10 %CV). TMC recovery 
and PMC recovery were calculated as the percentage of the neat semen motile 
count that could be recovered post-thaw.  
 
In addition to the direct comparison of freeze methods, three experiments with 
pooled semen and CPA media (1.5 mL pooled semen and 1.5 mL CPA media) 
were performed to determine changes in motility immediately following CPA media 
addition to neat pooled semen. 1000 sperm tracks for each CPA from each pool 
were analysed 
 
CoolCell 
A series of experiments on freezing sperm in CoolCells (BCS-136, BioCision, Mill 
Valley, CA 94941, USA) were performed to determine if CoolCells could be used 
in clinical practice. Pooled sample experiments were performed by placing 
matched ampoules of semen mixed with each freeze media into CoolCells and 
removing an ampoule every 15 minutes after placing the CoolCell into a -80 0C 
freezer, and every 30 minutes after placing in a -120C freezer. Ice nucleation 
temperature was estimated by detection of phase transition latent heat by 
incorporating data logger temperature probes (DNL910, Fortec, Barrington, RI 
02806, USA) into 1.0 mL aliquots of semen mixed 1:1 with TYB in 
cryopreservation ampoules. These ampoules were frozen in pre-chilled racks in a -
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12 0C freezer.  Repeat experiments with temperature probes in 1.0 mL aliquots of 
semen mixed 1:1 with TYB in cryopreservation ampoules were performed to 
estimate freezing curve variability. After cooling matched paired ampoules of 
pooled semen in CoolCells in a -120C freezer for 90 minutes, the central space of 
each CoolCell was completely filled with LN2. A second fill was made at either 
2,5,15, or 20 minutes after the first. Ampoules were thawed and compared after 24 
hours storage. 
 
Repeat experiments on matched pair ampoules were conducted to determine the 
suitability of the CoolCell in comparison with the manufacturers recommended 
method. In addition, 80 patients had matched pair aliquots of their samples frozen 
by our currently used SFM method and the CoolCell TYB method. Both sets of 
media were added to semen at as close to the same time as possible to minimise 
environmental differences. Outcome measures were the same as for the 
comparison of freeze media. 
 
TYB Pre-Process Storage, Addition Speed and Audit Validation 
A series of experiments were carried out to examine any effects of time delays on 
processing clinical samples. In addition, effects of sample volume and pre-process 
storage condition was also examined in relation with time delay.  Pools were split 
into matched 1.5, 1.0 or 0.5 mL aliquots in plastic containers (the same type and 
batch used for sample collection) at room temperature (23 0C ± 3 0C). These 
containers were then stored at room temperature or at 37 0C from production until 
analysis. All aliquots were measured for CASA motility parameters at 0, 60, 120, 
180, 240 and 300 minutes. A minimum of 1000 sperm tracks were recorded at 
each interval. 
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A series of experiments were carried out to examine the effect of CPA media 
addition speed on sperm motility. 1.5 mL TYB was added to 1.5 mL aliquots of 
pooled semen at a range of addition speeds (10, 20, 30, 40, 50, 60, 70, 80, 90 and 
100 seconds). All aliquots were measured for CASA A, B, C and D motility, a 
minimum of 1000 sperm tracks were used to estimate motility at each addition 
speed. Addition was performed at room temperature (23 0C ± 3 0C) with room 
temperature TYB. 
 
A series of experiments on pooled semen frozen with TYB were performed to 
estimate ambient temperature risk from audit and sample transfer activities. 
Duplicate freezing ampoules with temperature probes placed inside the ampoules 
were cryopreserved under optimal conditions. The ampoule was then (1) left on a 
laboratory bench at room temperature, (2) Placed in a storage tray 5cm above LN2  
and (3) left in a pre-cooled to LN2 temperature storage tray at room temperature. 
Internal cryopreservation ampoule temperature change was recorded over time. 
 
Statistics 
All variables were tested for Gaussian distributions with D'Agostino-Pearson 
normality omnibus K2 test to determine parametric statistic suitability. Differences 
were tested with the Wilcoxon matched paired test for non-Gaussian parameters 
and the paired t-test for Gaussian parameters. Variability of freeze curves and ice 
nucleation temperature were estimated by Coefficient of Variation (CV%). 
Proportions were tested with Fisher’s exact test. The data were analysed and 
graphs constructed using Prism (Prism, Version 4.0 GraphPad Software,San 
Diego, CA, USA, www.graphpad.com) on a Samsung personal computer 
(Samsung Electronics, Samsung.com). 
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6.3 Results 
 
SFM / TYB Comparison 
Comparing our current SFM method and the TYB manufacturer’s method on 10 
repeat experiments with pooled semen revealed improved post-thaw total motility 
and linearity with TYB (Table 6-1). 
 
Table 6-1 Median post-thaw results from 10 repeat experiments with pooled semen comparing our current in 
use SFM process validated method and the TYB manufacturers recommended method.  
Parameter Pre-Freeze SFM TYB p 
TMC (x 10
6
) 136.4 44.6 51.1 NS 
PMC (x 10
6
) 98.4 23.7 29.4 NS 
TMC Recovery (%) - 34.3 36.3 NS 
PMC Recovery (%) - 24.2 26.7 NS 
Progressive Motility (%) 
1*
 49 15.8 19.6 NS 
Total Motility (%) 
1*
 71 29.7 34.1 0.031 
WHO A Class 
1*
 36 8.9 10.8 NS 
WHO B Class 
1*
 25 7.1 8.8 NS 
WHO C Class 9 13.9 14.5 NS 
WHO D Class 
1*
 30 70.3 65.9 NS 
VLC (µm/s) 33.2 27.2 28.5 NS 
VSL (µm/s) 13.1 10.9 11.7 NS 
2*
 
VAP (µm/s) 20.7 16.8 18.4 NS 
2*
 
ALH (µm) 1.6 1.5 1.4 NS 
BCF (Hz) 4 4 4 NS 
LIN (%) 52 42.5 45.9 0.009 
 TMC=Total Motile Count, PMC=Progressive Motile Count, WHO=World Health Organisation, NS=Not 
Significant, SFM=Sperm Freeze Media, TYB=Test Yolk Buffer. 1* Variables were from Gaussian 
distributions thus mean and paired t test results are presented. 2* VSL was close to significance (p=0.072), 
VAP was close to significance (p=0.089). A minimum of 200 sperm tracks were analysed for each pool. 
 
Analysing this data with VAP / LIN cluster analysis revealed further differences 
between the two CPA media (Figure 6-1). SEM cluster area 1 (Chapter 5) 
contained a lower (p=0.041) proportion of post-thaw sperm when TYB was used 
compared with SFM (36.9% vs. 41.3%). SEM cluster area 8 (Chapter 5) contained 
a higher (p=0.038) proportion of post-thaw sperm when TYB was used compared 
with SFM (31.2% vs. 27.4%).  
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Figure 6-1 VAP vs LIN of sperm tracks from 10 pooled semen experiments comparing SFM and TYB. 
Proportions of sperm within each graph area were compared with Fisher’s exact test. NS=Not Significant. 
 
Immediately after CPA Addition 
Comparing these two methods immediately after CPA addition to pooled semen 
revealed results comparable to post-thaw results. This  analysis of 3000 sperm 
tracks from each media type over three pooled semen experiments found a 
greater number of WHO A class sperm (p=0.028, mean 19.1 ± 3.9 vs. 16.0 ± 2.9) 
and progressively motile sperm (p=0.041, mean 33.6 ± 6.7 vs. 30.2 ± 5.2) with 
TYB. CASA parameters revealed lower LIN (p<0.001), and VSL (p=0.024) and 
higher ALH (p<0.001) with SFM. VLC was not different. 
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CoolCell Method Process Validation 
The CoolCell (Figure 6-2) was found to be a highly regulatory complaint by 
allowing individual patients samples to be isolated from one another during 
cryopreservation. Additionally samples encounter fewer exposures to ambient 
temperature insults.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 The CoolCell. 
Designed with a highly thermo-conductive core to ensure uniform cooling profiles to all ampoules being 
cryopreserved (Images supplied courtesy of Biocision http://biocision.com). 
 
 
Experiments with pooled semen in the CoolCell at -80 0C demonstrated that SFM 
media preserved greater motility than TYB with rapid cooling rates, and TYB 
preserved greater motility than SFM with slow cooling rates (Table 6-2). Both 
methods produced results comparable to the control ampoules frozen with the 
manufactures recommended method. 
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Table 6-2 Matched paired aliquots of pooled semen frozen with SFM and TYB in CoolCells at -80 
0
C 
Variable Media Control Time in minutes 
0 15 30 45 60 75 90 
Progressive 
Motility 
SFM 13.2 12.4 10.9 9.7 8.9 7.6 5.7 6.6 
TYB 13.5 9.3 8.9 12.7 11.8 12.4 10 10.2 
D Class 
Motility 
SFM 70.0 72.6 80.1 75.3 77.4 77.2 86.3 80.4 
TYB 68.4 80.9 78.4 70.6 72.8 77.7 80.1 79.3 
SFM=Sperm Freeze Media, TYB=Test Yolk Buffer.  
 
Ampoules were removed from the CoolCell at 0, 15, 30, 45, 60, 75 and 90 minutes and plunged into LN2, 
stored for 24 hours, thawed and analysed. One ampoule for each method was frozen as per manufacturers 
recommendation as a control.  
 
A series of experiments to demonstrate ice nucleation temperature with semen 
mixed 1:1 with TYB demonstrated variability with both freezing temperature and 
time (Figure 6-2 A). The maximum latent heat temperature for 1.0 mL ampoules 
was –8.0 0C. Semen mixed 1:1 with TYB and frozen in the CoolCell demonstrated 
decreased variability in cooling curves (Figure 6-2 B). Ampoules after 90 minutes 
in the cool cell at -12 0C had a mean temperature of -7.6 0C (95% CI 6.9-8.3) with 
a CV% of 7.7. 
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Figure 6-3 Ice nucleation temperature and the CoolCell. 
Pooled semen was mixed 1:1 with TYB and cooled in 1.0 mL aliquots with temperature probes incorporated 
into the ampoules. Ampoules were placed in a -12 
0
C Freezer in either a metal rack (A) or a CoolCell (B).   
 
 
TYB with pooled semen in the CoolCell at -12 0C demonstrated broad response 
curves with 90 minutes in the -12 0C freezer preserving the greatest total motility 
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and VLC. Additions of LN2 to the central space of the CoolCell demonstrated that 
a range of cooling rates and final temperature is possible by timing the additions of 
LN2 (Figure 6-3). However, increased variance in cooling rate was noted with 
increased LN2 additions. The greatest TMC recovery was achieved by adding two 
additions of LN2 to the central space of the CoolCell after samples had been in the 
CoolCell for 90 minutes at -12 0C. This however, was not different than direct 
immersion into LN2 after 90 minutes at -12 
0C. 
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Figure 6-4 Additions of LN2 to the central space of the CoolCell.  
A single addition of LN2 to the central space of a pre-cooled (-7.5 
0
C) CoolCell was made and the temperature 
curve recorded (A). Repeat experiments were performed with a second LN2 addition at 2 (B), 5 (C), 15 (D) 
and 20 (E) minutes after the first. 
 
The optimal timing of the second addition of LN2 was 5 minutes with a greater 
number of WHO A class sperm than a 2 minute addition (p<0.001) or a 20 minute 
addition (p=0.023). VLC was higher at 5 minutes than 2 minutes (P<0.001) and 20 
minutes (P<0.001), there was no difference between 5 and 15 minutes. Optimal 
results using the CoolCell with 1:1 TYB:Semen were achieved by placing room 
temperature ampoules in a room temperature CoolCell for 90 minutes in a -12 0C 
freezer followed by two additions of LN2 to the central space of the CollCell five 
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minutes apart. This is followed with long term LN2 temperature storage after a 
further 30 minutes.  
 
A straight comparison between the process validated CoolCell method and the 
TYB manufacturers own method using pooled semen displayed greater 
progressive motility for the CoolCell samples on 6 of the 7 experiments, but the 
differences were small and not significant. However, combining the data from all 7 
experiments (12,000 sperm tracks) demonstrated that SCA CASA motility 
variables were increased (p<0.001) for all CASA motility categories with the 
exception of ALH. The post-thaw results of matched paired aliquots from the 
ejaculates of 80 patients comparing our SFM method with the TYB CoolCell 
method are summarised in Table 6-3. 
 
Table 6-3 Median thaw parameters are presented from patients samples (n=80) split and frozen using the 
SFM method and the TYB CoolCell method. 
Parameter Pre Freeze SFM TYB CoolCell p 
TMC (x 10
6
) 96.8 36.2 36.8 NS 
1* 
PMC ( x 10
6
) 80.1 13.1 14.1 NS 
TMC Recovery (%) - 37.4 38.2 NS 
PMC Recovery (%) - 18.8 20.8 NS 
Progressive Motility (%) 41.3 7.6 9.0 NS 
Total Motility (%) 53.8 16.6 17.8 NS 
WHO A Class (%) 21.9 3.9 4.4 NS 
WHO B Class (%) 11.4 3.7 4.6 NS 
WHO C Class (%) 8.1 9.0 8.8 0.044 
WHO D Class (%) 53.6 83.3 82.2 NS 
1*
 
VLC (µm/s) 29.9 23.4 24.0 NS 
VSL (µm/s) 12.2 9.1 10.0 0.039 
VAP (µm/s) 19.7 16.7 17.6 NS 
ALH (µm) 1.45 1.41 1.36 0.034 
BCF (Hz) 4.1 3.00 2.38 NS 
LIN (%) 44.1 37.9 41.4 <0.001 
TMC=Total Motile Count, PMC=Progressive Motile Count, WHO=World Health Organisation. 1* TMC was 
close to significance (p=0.11), WHO D Class was close to significance (p=0.11). NS=Not Significant, 
VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path Velocity, LIN=Linearity, 
STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, BCF=Beat Cross 
Frequency 
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Analysing each of the 80 patients 10th, 25th, 50th 75th and 90th percentile VAP and 
LIN measurements using cluster analysis revealed further differences between the 
two methods (Figure 6-4). Non-linear regression curves and subpopulation 
proportions clearly demonstrate that the TYB CoolCell method results in greater 
proportions of high linearity sperm (Figure 6-4). 
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Figure 6-5 Non-linear regression lines of VAP vs LIN percentiles (10
th
,25
th
,50
th
,75
th
,90
th
) from 80 patients 
comparing SFM and TYB CoolCell methods. 
Proportion of sperm within each box was compared with Fisher’s exact test. 
 
TYB Pre-Process Storage, Addition Speed and Audit Validation 
A series of experiments on optimum semen storage temperature on a range of 
semen volumes before cryopreservation demonstrated that semen motility is best 
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preserved by storing samples at room temperature. This is true for the range of 
semen volumes examined. However, for samples with low (0.5 mL) volumes 
semen motility is compromised at faster rates than observed in higher volume 
samples irrespective of storage temperature (Figure 6-5). The toxic effects on 
sperm from the addition of cryopreservation media containing glycerol were shown 
to be diminished at addition speeds of 60 seconds or greater (Figure 6-6). 
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Figure 6-6 Pre-processing storage temperature and time effects on CASA motility. 
Linear Regression lines of SCA CASA motility parameters from pooled semen split into matched aliquots and 
stored at 20 
0
C (blue) and at 37 
0
C (red) temperatures. For each data point a minimum of 1000 sperm tracks 
were analysed at 0, 60, 120, 180, 240 and 300 minutes. Lines in descending order are VLC, VAP, VSL, LIN, 
STR, WOB, ALH, and BCF.  Separate experiments for 1.5 mL, 1.0 mL and 0.5 mL aliquots were performed. 
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Figure 6-7 Sperm motility and CPA addition speed. 
TYB was added to 1.5 mL aliquots of pooled semen at a range of addition speeds between 0 and 100 
seconds. A minimum of 1000 sperm were analysed by SCA CASA for each interval and category. 
 
Experiments designed to examine ambient temperature risks to ampoules from 
transfer and audit activities demonstrated that ampoules stored at -198 0C could 
reach the glass transition temperature (-132 0C) in as little as 90 seconds (Figure 
6-7).  During audit activities samples placed in LN2 trays remain below the glass 
transition temperature only provided they remain in direct contact with LN2. 
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Figure 6-8 Ambient temperature risk to frozen semen during audit activities. 
Temperature probes were placed into freezing ampoules with TYB and cryopreserved under optimal 
conditions. The ampoule was then (A) left on a laboratory bench at room temperature, (B) Placed in a storage 
tray 5cm above LN2  and (C) left in a pre-cooled to LN2 temperature storage tray at room temperature. 
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6.4 Discussion 
 
The aim of this study was to gather the evidence to validate or reject an available 
CE marked egg yolk CPA media and the CoolCell for sperm cryopreservation by 
comparing it with our currently used method. The combined results of pooled 
semen experiments are consistent with those from the matched paired aliquots 
from the samples of 80 patients. TYB offers small but measurable sperm motility 
improvements over our in use SFM based method. The cluster analysis results 
suggest that TYB compared with SFM may confer an increased probability of IUI 
conception, though further work would be required to establish this. Egg yolk 
based medias have previously been found to be superior to non-egg yolk CPA 
media (Duru et al., 2001, Hammadeh et al., 2001, Paras et al., 2008). This current 
work is in accordance with those findings. Why egg yolk confers such 
improvements is unknown, though several plausible explanations have been 
suggested (Holt, 2000b). Egg yolk has been found to be cryoprotective on its own 
(Sherman, 1990) and both phospholipid and protein isolated from the low-density 
lipoprotein fraction of egg yolk are active constituents (Watson, 1981). 
 
The series of experiments on storage temperature prior to cryopreservation 
demonstrate that irrespective of sample volume, CASA sperm motility parameters 
are better preserved if samples are stored at room temperature (23 0C ± 3 0C),  
rather than at 37 0C. Several factors may be attributed to decreased motility over 
time in semen including dehydration, fluctuating pH or temperature, Reactive 
Oxygen Species (ROS) production, bacterial overgrowth and metabolic nutrient 
depletion  (Chomsrimek et al., 2008, W.H.O., 2010f). Cryopreservation induced 
ROS membrane phospholipid damage may lead to mitochondrial ATP depletion 
and subsequent motility loss (for review see (Tatone et al., 2010)). As post 
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cryopreservation processing can also take significant time, decreases in motility 
should be avoided at every stage so as to not limit ART choice with freeze thawed 
sperm. It is thus recommended that semen samples waiting processing be stored 
at laboratory room temperature. 
 
Further recommendations can be made for low volume samples (~0.5 mL); these 
should be processed immediately or have media added to preserve motility as 
rapid drops in motility occur irrespective of storage temperature. Low semen 
volume prevalence and epidemiology are not well described in the literature 
(Roberts & Jarvi, 2009). Samples with low volumes have greater sensitivity to 
external pressures. The experiments replicating ambient temperature exposure 
and those replicating variation in CPA media addition speed, both demonstrate 
significant time exposure risks. It is thus recommended that these activities 
become timed activities with strict limits to ensure post-thaw quality is maximised.  
 
Mammalian sperm in the female reproductive tract undergoes capacitation, a 
series of biochemical and physiological processes that ready the sperm for 
fertilisation. One of these processes involves a change in motility from symmetrical 
flagellar beating with high linearity or “activated” motility to asymmetrical flagellar 
beating and non-linearity (even swimming in circles) known as “hyperactivated” 
motility. Evidence supports that hyperactivated motility enables enhanced 
swimming through oviductal mucus, penetration of the cumulus matrix and zona 
pellucida (for review see (Kay & Robertson, 1998). While capacitation and 
hyperactivation are necessary for fertilisation, a specific type of cryopreservation 
damage appears to result in an incomplete capacitation or "cryocapacitation" 
(Watson, 1995, Watson, 2000). Cryocapacitation is not an equivalent process to 
capacitation (Green & Watson, 2001) and has been suggested to reduce the 
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fertilising potential of cryopreserved sperm (Watson, 2000). Increased numbers of 
sperm displaying hyperactivated motility may thus indicate a poorer response 
following freeze / thaw.  
 
The use of CASA for sperm cryopreservation process validation, allows much 
larger numbers of sperm to be analysed with less subjectivity than is possible with 
manual analysis, though specific CASA errors must be avoided (E.S.H.R.E., 1998, 
Tomlinson et al., 2010, Dearing et al., 2014b). CASA also allows kinematic motility 
variables to be obtained, which can identify hyperactivated sperm. Hyperactivated 
motility CASA parameters include; decreased LIN, increased VCL and increased 
ALH, however some disagreement between studies are evident (Kay & Robertson, 
1998, Mortimer, 2000). In addition, hyperactivation is multiphasic in nature and 
thus may be poorly described from “snapshot” CASA motility systems (Pacey et 
al., 1997, Mortimer, 2000). The CASA descriptive motility changes observed in this 
study may be consistent with a decrease in hyperactivated sperm, which may 
indicate a protective effect of egg yolk against cryocapacitation. However, to fully 
investigate this; experiments establishing the specific hyperactivated motility 
parameters with the SCA CASA system would be required (E.S.H.R.E., 1998, 
Mortimer, 2000). Such experiments would also require deeper chambers than 
those used for this current study (E.S.H.R.E., 1998, Mortimer, 2000). 
 
The preliminary results from this work were presented as a poster at the British 
Andrology Society meeting (Liverpool, September 2013). This generated several 
enquires and discussion concerning the safety of CPA media containing egg yolk. 
While a safety assessment of egg yolk in sperm cryopreservation media is beyond 
the scope of this work, it is worth noting that TYB is produced from viral free laying 
stock, is heat inactivated, membrane filtered, contains Gentamycin and is CE 
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marked. The European Union (EU) Tissues and Cells Directive does not permit 
the use of animal products that carry a known risk of Transmitting Spongiform 
Encephalopathies (TSE). Specifically this relates to animal tissues and derivatives 
from species of the following mammals; cow, sheep, goat, deer, elk, mink and cat. 
Thus, egg yolk from chickens is not banned under the EU Tissue and Cells 
Directive. We have contacted the HFEA and requested a statement on the use of 
egg yolk in CPA media to provide clarity. We believe that TYB is safe and 
regulatory compliant for use in the UK and Europe. 
 
The second objective of this work was to evaluate the CoolCell as a novel sperm 
freezing receptacle. The CoolCell was found to be suitable for freezing sperm with 
reduced cooling curve variance. At the end of the process the CoolCell central 
space can be flooded with LN2, completing the freezing process and enabling the 
CoolCell to become a transporter of cryopreserved sperm that holds its internal 
temperature for over 30 minutes. As a transporting device, the CoolCell has the 
thermal insulation sufficient for the exterior to be handled without protection, 
reducing the risk of cold burns to staff. Moreover, the CoolCell reduces the risk of 
ambient temperatures adversely affecting the cryopreserved sperm. Ice 
recrystallization and ice crystal growth may occur at temperatures as low as -96 0C  
(Meryman, 2007). Once the ampoules have been placed in the CoolCell they 
remain inside free from ambient temperature insults for the entire freezing 
process. 
 
The CoolCell vessels were also found to be highly compliant with the current 
HFEA code of practice (H.F.E.A., 2013b). These regulations require that prior to 
the processing of patient gametes for storage; the centre must carry out biological 
testing for HIV 1 and 2, Hepatitis B and C to assess the risk of cross 
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contamination. Unfortunately, in practice it is not always possible to test patients 
before processing, as to do so can delay urgent clinical interventions. In order to 
prevent cross contamination, the HFEA require a system of storage which clearly 
separates unscreened samples from negative screen samples, and positive 
screen samples. The CoolCell is very suited to these regulations becoming a self-
contained freezing container that allows complete separation of each patient’s 
samples during the entire cryopreservation process. Individual pre-designated 
CoolCells can be used for screened, unscreened and viral positive patients as a 
best practice approach to sperm cryopreservation. 
 
A proportion of the total variation in cryopreservation response occurs from 
variability encountered within the cryopreservation method. The optimal rate of 
freezing is a balancing of two opposing risk factors encountered with slow and 
rapid freezing. Too slow freezing increases the time sperm are exposed to the 
ever increasing hyper-osmolal concentrations of solutes as water becomes 
extracellular ice. Subsequent osmotic induced intracellular water loss and 
shrinkage then causes reversible and irreversible damage. In contrast rapidly 
freezing sperm cells cannot maintain osmotic balance as they cannot lose water 
fast enough. This results in an accumulation of super-cooled intracellular water 
and subsequent lethal ice crystallization once nucleation temperature is reached. 
The CoolCell method ensures no large departures from the optimal freezing curve 
and thus reduces the likelihood of too rapid or too slow freezing damage. This will 
improve both the freezing responses for some patients and the quality of 
information on true biological responses for further research.  
 
Although the CoolCell is designed to be used at -80 0C and indeed can be used 
this way to freeze sperm with acceptable results, the best motile recovery was 
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found by using the CoolCell with TYB in a freezer set to -12 0C. The freezing curve 
at this temperature exhibits low variation and brings a 1.0 mL sample to a mean 90 
minute temperature of -7.6 0C (95% CI -6.9-8.3), just above the phase transition 
temperature. An addition of LN2 to the central space with a second LN2 addition 
after 5 minutes optimally freezes the sample which can then be placed into long 
term LN2 or vapour storage. Further experiments suggest that the CoolCell design 
for uniform cooling will allow great flexibility with regard to frozen aliquot volumes. 
Although further work is required to confirm this, volumes as low as 0.1 mL have 
been frozen in the CoolCell with good post-thaw recovery. This may benefit some 
patients by enabling a greater number of post-thaw fertility cycles from a single 
ejaculate. In comparison with the TYB manufacturers method the CoolCell TYB 
method resulted in higher (p<0.001) CASA motility for all parameters apart from 
ALH. The CoolCell is thus an economic, regulatory compliant and simple addition 
to a manual freezing method that freezes sperm with comparable or improved 
results with less variation.   
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Chapter 7 Cryopreservation Uncertainty and Prediction 
 
7.1 Introduction 
 
Intra Cytoplasmic Sperm Injection (ICSI), which requires few or even a single 
viable sperm, has recently been found to be increasingly selected for Assisted 
Reproductive Technology (ART) treatments with cryopreserved sperm (Dearing et 
al., 2014a). Overuse of ICSI treatment has concerned some authors (Hodes-Wertz 
et al., 2012, Jones et al., 2012). ICSI was originally intended (Palermo et al., 1992) 
to treat severe deficits in male factor infertility, and this “best use” of ICSI has 
recently been further endorsed by Cornell University (Cornell, 2013). Variance in 
post-thaw recovery and the quantity of sperm being stored may be factors limiting 
ART choice with cryopreserved sperm. 
 
The objectives of this chapter were, for patients seen at our clinic; (1) to estimate 
the variance in post-thaw semen quality within and between-patients, (2) to 
examine associations between cryopreservation variance and storage and 
demographic data, (3) to attempt to predict post-thaw semen quality using 
methods available to National Health Service (NHS) laboratories and (4), to 
calculate the number of ART cycles available to local patients from the quantity of 
ejaculates currently being stored at our centre. An additional aim was to further 
investigate preliminary results which suggested an unexpected relationship 
between mortality and sperm cryopreservation. These objectives will be achieved 
by examining 1000 frozen ampoules from cancer patients who have historically 
stored at our centre and performing cryopreservation outcome prediction research 
on a cohort of local patients without cancer. Predication will attempted using 
demographic, CASA and sperm membrane cholesterol data. 
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7.2 Methods 
 
Population for Cryopreservation 
A total of 1452 ampoules were thawed and examined from 747 ejaculates from 
443 patients attending the Andrology Laboratory (Andrology Laboratory, 
Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom 
(UK)). Of these, 217 men diagnosed with cancer who stored sperm at the clinic 
between 1976 and 2012 provided 1000 ampoules from 521 ejaculates. 226 
patients without cancer provided 452 ampoules from 226 ejaculates. All non-
cancer patients consented to cryopreservation experimentation. All cancer patients 
consented for sperm disposal and post-thaw quality was examined for quality 
assurance purposes as recommended by the Human Fertility Embryonic Agency 
(HFEA). 
 
Population for Estimation of Non-Cancer Between-ejaculate Variance. 
Semen analysis results were collated from 541 patients who produced more than 
one ejaculate for Intrauterine Insemination (IUI) preparation at the Andrology 
Laboratory. These patients received IUI ejaculate processing at our clinic between 
February 2008 and December 2013. 
 
Sperm Cryopreservation 
All non-cancer patients were frozen using Test Yolk Buffer (TYB) in the CoolCell 
(Chapter Six, Methods). Cancer patients freezing method and media were not able 
to be identified due to an unavoidable lack of available data. 
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Semen Analysis 
For cancer patients, pre-freeze semen analysis was performed by multiple BMS 
staff using manual methods (Chapter Four, Methods). The reliance on historical 
pre-freeze semen analysis results was an unavoidable limitation for this cohort of 
patients. For non-cancer patients, pre-freeze count and motility was performed 
using validated (Dearing et al., 2014b) Sperm Class Analyser (SCA) Computer 
Assisted Semen Analysis (CASA) methodology (Chapter Four, Methods). All post-
thaw count and motility analysis was performed using CASA.  
 
Deprivation 
The English Indices of Deprivation 2010 (ID, 2010) were matched with patient 
postcodes and examined for relationships with ejaculate pre-freeze and post-thaw 
semen quality. This analysis was repeated with cancer patients using first 
ejaculates only to remove the confounding effect from patients who store a large 
number of ejaculates. The relationship between deprivation and cryopreservation 
recovery, patient mortality, cancer diagnosis and semen cell cholesterol was also 
examined. 
 
ART Fertility and Cycle Number Estimations 
Post-thaw samples were analysed for the proportion of sperm within previously 
identified CASA Average Path Velocity / Linearity (VAP / LIN) cluster areas 
(Chapter Five, Results). Additionally, samples were examined for previously 
identified fertility threshold limits for Curvilinear Velocity (VLC), Wobble (WOB), 
Lateral Head Displacement (ALH), Beat Cross Frequency (BCF) and Uncurving 
Velocity (UCV) (Chapter Five, Results). The number of possible ART cycles from 
post-thaw quality per ejaculate and per patient was then calculated using motile 
count thresholds from a local population (Chapter Five, Results). 
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Non-Cancer Group Only 
Cryopreservation recovery for the non-cancer group was examined for 
associations with semen volume, count, progressive and total motility, the 
presence and count of Nucleated Cells Other than Sperm (NCOS) (Chapter Five, 
Methods), abstinence period, sperm antibodies (Chapter Five, Methods), sperm 
morphology (Chapter Four, Methods), VAP / LIN clusters, fertility threshold limits 
and deprivation indices. 
 
The effect of cooling and rewarming was examined by cooling a 5 µL aliquot of 
semen to 4 0C for 30 minutes then rapidly rewarming (30 seconds) to 37 0C and 
analysing using CASA. These CASA data were compared with pre-freeze CASA 
data for the prediction of post-thaw quality.  
 
Semen and seminal plasma were tested for cholesterol using an Abbott Architect 
c16000 (Abbott Laboratories Ltd, Maidenhead, UK). The cholesterol method is 
based on the method developed by Allain (Allain et al., 1974), modified by 
Roeschlau (Roeschlau et al., 1974). Cholesterol esters are hydrolysed by 
cholesterol esterase. All free cholesterol in the sample is then oxidized by 
cholesterol oxidase to cholest-4-ene-3-one and hydrogen peroxide. The 
concentration of hydrogen peroxide proportionally combines with hydroxybenzoic 
acid and 4-aminoantipyrine to form quinoneimine, the concentration of which is 
estimated by spectrophotometry at 500 nm. 
 
Semen cell cholesterol was calculated as the difference between the cholesterol 
result of neat well mixed ejaculate and the cholesterol result of cell free seminal 
plasma. Semen cell cholesterol was examined for associations with semen 
analysis parameters. The slope of the linear regression line of sperm count and 
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semen cell cholesterol was used to calculate the ratio of expected cholesterol to 
measured cholesterol. This ratio was then examined for associations with motility 
following cryopreservation. Cholesterol in semen, cholesterol in seminal plasma, 
semen cell cholesterol and the ratio of measured semen cell cholesterol to the 
predicted value was examined for associations with the indices of deprivation. 
Semen cell cholesterol precision was estimated by calculating Coefficient of 
Variation (CV%) from 10 repeats for three concentrations. Concentration linearity 
was calculated for sperm in semen and flushing media (Origio a/s Knardrupvej 2 
DK-2760 Måløv Denmark) by serially diluting a high concentration of sperm and 
measuring in duplicate and taking the mean value. A recovery experiment was 
conducted by spiking a high known concentration of cholesterol into semen and 
seminal plasma, each spike was measured in duplicate and mean recovery 
calculated. Logistic regression was used to predict recovery following 
cryopreservation from semen analysis parameters, VAP / LIN cluster profiles and 
semen cell cholesterol. 
 
Post-thaw Variance 
The following parameters were examined for variance; count, progressive motility, 
total motility, Progressive Motile Count (PMC) and Total Motile Count (TMC). For 
each parameter (where ejaculate number allowed) between-ampoule within-
ejaculate, between-ejaculate and between-patient pre-freeze and post-thaw CV% 
was calculated. Median CV% was calculated for each parameter, within each 
category of biological variance (Figure 7-1).  
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Figure 7-1 Predicted sources of variance 
 
Between-ampoule, between-ejaculate and between-patient variance were 
compared between parameters and within parameters for all classes of variance. 
Each level of post-thaw variance was examined for relationships with the indices 
of deprivation, semen analysis parameters, patient demographic data and sperm 
storage data.  
 
Cancer patients were compared with IUI patients for pre-freeze between-ejaculate 
variance for volume, count, progressive motility, total motility, TMC and PMC. The 
relationship between pre-freeze variance and post-thaw variance was examined. 
The effect of Cryo-Protective Agent (CPA) media on pre-freeze between-ampoule 
variance for non-cancer patients was examined as a control. 
 
The 95th percentile of TMC analytical variance was calculated over the TMC range 
from CASA validation data (Chapter Four, Results) and a line of best fit identified. 
The slope of the line of best fit was used to identify TMC variance for individual 
patients of a magnitude that could not be explained by analytical variance. The 
difference between the 95th percentile of expected analytical variance and 
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observed variance was examined for relationships with indices of deprivation, 
semen analysis parameters, and patient demographic data. 
 
Statistical Analysis 
Pre-freeze and post-thaw semen analysis parameters were collated and 
percentiles calculated by ranking. Post-thaw recovery was calculated as a 
percentage of pre-freeze values. The difference between patient groups was 
estimated with Mann-Whitney U test. The difference between pre-freeze and post-
thaw was estimated with Wilcoxon matched pair testing. Correlations were 
performed using non-parametric Spearman.  
 
Between-ampoule within-ejaculate, between-ejaculate and between-patient pre-
freeze and post-thaw parameter variance was estimated with CV% from two 
values only. CV% was calculated as standard deviation / mean x 100.  Median 
CV% was then calculated for each parameter. 
 
Logistic regression and Receiver Operator Characteristics (ROC) were used to 
predict post-thaw variance, mortality for cancer patients, and post-thaw recovery 
from the indices of deprivation, semen analysis parameters, semen cell 
cholesterol, patient demographic and sperm storage data. Logistic regression 
adjusted odds ratios, ROC, percentiles and k means clusters were generated with 
IBM SPSS Statistics (Version 20, IBM Corp, www.ibm.com). All other graphs and 
statistical comparisons were made with Prism version 4.0 (Version 4.01, Graph 
Pad, San Diego, CA, USA, www.graphpad.com). 
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7.3 Results 
 
Semen Quality and ART Following Sperm Cryopreservation 
Sperm motility was greatly decreased post-thaw with particularly large decreases 
in the proportion of fast swimming sperm. Median recovery as a percentage of 
WHO pre-freeze motility were; A class 17%, B class 21%, C class 39%, and D 
class 132%. These motility changes were also reflected in the median post-thaw 
PMC and TMC recoveries for cancer patients (TMC recovery 9.0%, PMC recovery 
4.4%) and non-cancer patients (TMC recovery 38%, PMC recovery 26%) (Table 7-
1). 
 
Table 7-1 Percentile distributions of TMC and PMC before and after cryopreservation for ejaculates from 
patients with cancer (n=822) and non-cancer (n=226). 
Population 
Parameter 
(x10
6
) 
Pre-freeze or  
Post-thaw 
Percentiles 
5 10 25 50 75 90 95 
Cancer 
TMC 
Pre-Freeze* 4.07 7.35 19.18 46.88 106.52 217.67 294.45 
Post-thaw 0.00 0.00 0.12 4.12 15.40 37.33 55.81 
PMC 
Pre-Freeze* 1.75 3.97 12.60 33.61 76.69 161.61 240.12 
Post-thaw 0.00 0.00 0.05 1.34 5.96 14.01 20.28 
Non-Cancer 
TMC 
Pre-Freeze 0.90 4.00 26.50 78.00 167.50 283.00 368.40 
Post- Freeze 0.00 2.00 11.50 28.00 56.00 99.80 144.50 
PMC 
Pre-Freeze 0.00 2.00 14.00 46.00 105.00 178.20 241.20 
Post- Freeze 0.00 0.00 3.00 13.00 23.50 42.60 60.40 
TMC=Total Motile Count, PMC=Progressive Motile Count. 
 
 *Pre-Freeze parameters for cancer patients were determined by multiple operators’ using manual semen 
analysis methods. 

 
Post-thaw recovery of pre-freeze motility correlated between WHO motility 
classes. A class recovery correlated with B class recovery (r2=0.61, p<0.001), C 
class recovery (r2=0.46, p<0.001) and D class recovery (r2=0.29, p<0.001). B class 
recovery correlated with C class recovery (r2=0.75, p<0.001). Large decreases 
(p<0.001) in velocity were noted but not in linearity. The post-thaw median velocity 
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and linearity values were not different between cancer and non-cancer groups 
(Table 7-2).  
 
Table 7-2 Median SCA CASA motility descriptors for cancer patients ejaculates (n=521) post-thaw and non-
cancer patient ejaculates (n=226) pre-freeze and post-thaw. 
non-cancer 
Pre-freeze / 
Post-thaw 
VCL 
 (µm/s) 
VSL 
 (µm/s) 
VAP 
 (µm/s) 
LIN 
 
STR 
 
WOB 
 
ALH 
(µm) 
BCF 
(HZ) 
UCV 
 
Pre-freeze 33.22 13.00 20.71 0.42 0.72 0.65 1.57 4.00 52.00 
Post-thaw 23.30 9.14 14.21 0.41 0.73 0.64 1.34 2.41 37.35 
Significance <0.001 <0.001 <0.001 NS NS NS <0.001 <0.001 <0.001 
cancer 
 VCL VSL VAP LIN STR WOB ALH BCF UCV 
Post-thaw 23.35 9.15 14.27 0.39 0.71 0.62 1.39 2.47 38.82 
VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path Velocity, LIN=Linearity, 
STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, BCF=Beat Cross 
Frequency, UCV=Uncurving Velocity. 
 
Only 13 ejaculates from cancer patients and 6 ejaculates from non-cancer patients 
exhibited post-thaw quality within CASA threshold limits for successful IUI 
treatment (Chapter Five, Results). Differences occurred in the proportions of 
cancer patients within threshold limits compared with non-cancer patients (Table 
7-3). 
 
Table 7-3 Percentage of cancer patients ejaculates (n=521) and non-cancer patient ejaculates (n=226) within 
local reference range CASA IUI cut-off values. 
 
VCL WOB ALH BCF UCV 
Patient 
Group 
90th Centile 
(98.37) 
Skewness 
(0.3816) 
90th Centile 
(3.046) 
5th Centile 
(1.003) 
50th Centile 
(38.6) 
non-cancer 2.7% 6.5% 72.2% 95.8% 68.9% 
cancer 1.3% 6.3% 87.0% 99.4% 70.3% 
Significance 0.013 NS 0.004 NS NS 
IUI=Intrauterine Insemination, VLC=Curvilinear Velocity, WOB=Wobble, ALH=Amplitude of Lateral Head 
Displacement, BCF=Beat Cross Frequency, UCV=Uncurving Velocity, NS=Not Significant. 
 
 
For non-cancer patients, where pre-freeze and post-thaw CASA parameters could 
be directly compared, post-thaw ejaculates displayed decreased velocity with 
unchanged linearity (Figure 7-2). The decreased velocity changed the proportions 
of sperm within previously identified cluster areas. Differences between the post-
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thaw proportions of sperm within cluster areas for cancer compared with non-
cancer patients were also evident for all cluster areas (Appendices 9.4, Figure 9-
14). 
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Figure 7-2 Changes in VAP/LIN clusters with cryopreservation.  
Graph plots VAP vs LIN for non-cancer patients (n=226) pre-freeze and post-thaw at the 5
th
, 50
th
 and 95
th
 
percentiles. 
 
The maximum number of possible ART cycles per ejaculate for cancer patients 
and non-cancer patients was calculated from post-thaw parameters. Calculations 
were derived using previously identified threshold parameters for IUI, In Vitro 
Fertilisation (IVF) and ICSI. For IUI this was the 5th percentile of successful IUI 
ejaculates (TMC of 6.74x106). For IVF this was the 5th percentile of successful IVF 
ejaculates (TMC of 19.45 x106). For ICSI this was the number of ampoules with 
motile sperm seen. The maximum number of ART cycles was plotted by patient 
percentile (Figure 7-3).  
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Figure 7-3 Maximum number of ART cycles per ejaculate for cancer and non-cancer patients post-thaw 
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For determining maximum number of IVF cycles, a comparison was made 
between the threshold cut-off for successful IVF ejaculates using the 5th percentile 
TMC and the IVF outcome measure of achieving a fertilisation rate of higher than 
40% (PMC of 14.7x106, Chapter Five, Results). The 40% fertilisation rate resulted 
in a lower number of maximum cycles (90th percentile 3.19 vs 1.65). Using 
minimum threshold values the number of ART cycles per ejaculate stored could be 
calculated (Table 7-4).  
 
Table 7-4 Maximum possible post-thaw fertility treatment cycles calculated by ejaculate number. 
Percentile 
of Cancer 
Patients 
1 Ejaculate 2 Ejaculates 3 Ejaculates 4 Ejaculates 5 Ejaculates 
IUI IVF ICSI IUI IVF ICSI IUI IVF ICSI IUI IVF ICSI IUI IVF ICSI 
10 <1 <1 2 <1 <1 4 <1 <1 6 <1 <1 8 <1 <1 10 
25 <1 <1 3 <1 <1 6 <1 <1 9 <1 <1 12 <1 <1 15 
50 1 <1 5 1 1 10 2 1 15 3 1 20 4 1 25 
75 4 1 7 8 3 14 12 4 22 16 5 29 19 7 36 
90 10 3 10 20 7 20 29 10 30 39 14 40 49 70 50 
IUI=Intrauterine insemination, IVF= In vitro fertilisation, ICSI= Intra Cytoplasmic sperm injection. 
 
Deprivation 
Deprivation indices (ID, 2010) could be identified for 217 cancer patients who 
produced 421 ejaculates and 221 non-cancer patients who each produced a single 
ejaculate. Cancer patients exhibited different indices of deprivation compared with 
non-cancer patients (Appendices 9.4, Figure 9-15). Deprivation was not compared 
for individual cancer diagnosis, because of the high proportion of patients with an 
unknown cancer diagnosis (59%). 
 
Various indices of deprivation weakly correlated with semen analysis parameters 
pre-freeze (Appendices 9.4, Table 9-16). Correlations while remaining weak, 
improved for some comparisons using post-thaw semen quality. Additionally, weak 
correlations were found between indices of deprivation and post-thaw motile count 
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recoveries (Appendices 9.4, Table 9-17). The most significant of these correlations 
occurred for cancer patients focusing on first ejaculates only (Table 7-5). 
Table 7-5 Correlations between deprivation indices and post-thaw semen analysis parameters and recovery 
for first ejaculates (n=217) from cancer patients. 
Parameter Stat IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
& 
Environment 
 
TMC 
r
2
 -0.10 -0.06 -0.08 -0.06 0.10 -0.10 -0.13 -0.16 
p NS NS NS NS NS NS 0.029 0.010 
 
PMC 
r
2
 -0.11 -0.07 -0.07 -0.08 0.07 -0.09 -0.15 -0.18 
p 0.048 NS NS NS NS NS 0.012 <0.001 
TMC 
Recovery 
r
2
 -0.13 -0.10 -0.11 -0.08 0.06 -0.16 -0.14 -0.14 
p 0.021 NS NS NS NS <0.001 0.011 0.008 
PMC 
Recovery 
r
2
 -0.12 -0.09 -0.09 -0.07 0.03 -0.16 -0.15 -0.13 
p 0.035 NS NS NS NS <0.001 0.009 0.018 
IMD= Index of Multiple Deprivation, NS=Not Significant, TMC=Total Motile Count, PMC=Progressive Motile 
Count. Negative correlations between deprivation and storage time were as follows; Income (r
2=-
0.17, 
p=0.004), employment (r
2
=-0.14, p=0.019), education (r
2
=-0.19, p=0.002) and crime (r
2
=-0.18, p=0.002).” 
 
Variance 
A large range of CV% were observed with post-thaw between-patient, between-
ejaculate and within-ejaculate (between-ampoule) categories (Figure 7-4). The 
hierarchy of variance is as predicted; between-ampoule CV% is lower followed by 
between-ejaculate CV% and between-patient CV%. Between ampoule variance 
was not different between cancer and non-cancer patients. 
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Figure 7-4 Median post-thaw variance within-ejaculate, between-ejaculate and between-patient.  
Box-plots represent the range, the 25
th
, 50
th
 and 75
th
 percentiles of CV% for each category. 
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Correlations were found between variance estimations for individual semen 
analysis parameters for within-ejaculate post-thaw variance (Appendices 9.4, 
Table 9-18), between-ejaculate post-thaw variance (Appendices 9.4, Table 9-19) 
and between-patient post-thaw variance (Appendices 9.4, Table 9-20). Pre-freeze 
between-ejaculate variance was shown to be larger for cancer patients than IUI 
patients (Appendices 9.4, Figure 9-5 and 9-6). Pre-freeze variance was shown to 
correlate with post-thaw variance for some semen analysis parameters for 
between-ejaculate (Appendices 9.4, Table 9-21) and between-patient (Appendices 
9.4, Table 9-22) measures. 
 
For cancer patients, two correlations were found between the indices of 
deprivation and post-thaw between-ejaculate variance (Table 7-6).  
 
Table 7-6 Correlations for between-ejaculate cancer post-thaw variance and deprivation indices (n=246). 
  CV% Semen Thaw 
Deprivation 
Measure 
Stat Count Prog. Mot. Total Mot. TMC PMC 
Crime and 
Disorder Score 
r
2
 -0.05 -0.17 -0.19 -0.13 -0.13 
p NS 0.005 <0.001 0.048 0.049 
Living 
Environment 
Score 
r
2
 0.01 -0.15 -0.10 -0.17 -0.18 
p NS 0.021 NS 0.039 <0.001 
Prog.=Progressive, Mot.=Motility, PMC=Progressive Motile Count, TMC=Total Motile Count, CV=Coefficient of 
Variation 
 
Other correlations with post-thaw variance were noted for storage time and patient 
age at storage (Table 7-7). 
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Table 7-7 Correlations between post-thaw variance in cancer patients and years of storage and patient age at 
storage (n=246). 
Measure 
Variance 
Measure 
Stat Count Prog. Mot. Total Mot. TMC PMC 
Years 
of 
Storage 
 
Between-
ampoule 
r
2
 0.23 NS NS 0.17 0.20 
p 0.001 NS NS 0.031 0.012 
Between-
ejaculate 
r
2
 NS -0.42 -0.41 -0.27 -0.33 
p NS <0.001 <0.001 0.002 <0.001 
Between-
patient 
r
2
 -0.55 -0.46 -0.49 -0.46 -0.46 
p <0.001 <0.001 <0.001 <0.001 <0.001 
Patient Age 
Between-
patient 
r
2
 NS -0.22 NS NS -0.21 
p NS 0.037 NS NS 0.040 
Prog.=Progressive, Mot.=Motility, NS=Not Significant. 
 
Age and storage time also correlated (r
2
 = -0.17, p = 0.001). 
 
 
Using a threshold cut-off from the 95th percentile of analytical variance determined 
from SCA CASA validation data (Chapter 4, Results), patients who exhibited TMC 
post-thaw variance of a magnitude that could not be wholly explained by analytical 
variance alone could be identified. The line of best fit was a nonlinear two phase 
exponential decay curve (Figure 7-5). 
 
𝑌 = 𝑆𝑝𝑎𝑛1 ∗ exp(−𝐾1 ∗ 𝑋) + 𝑆𝑝𝑎𝑛2 ∗ exp(−𝐾2 ∗ 𝑋) + 𝑃𝑙𝑎𝑡𝑒𝑎𝑢 
 
Best-fit values  
     SPAN1 10.99 
     K1 1.000e-007 
     SPAN2 36.21 
     K2 0.1028 
     PLATEAU -0.2066 
     Halflife_1 6.931e+006 
     Halflife_2 6.745 
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Figure 7-5 95th percentile of analytical variance in comparison with post-thaw variance measures. 
 
Separate logical regression analyses were conducted to predict between-ampoule 
within-ejaculate, between-ejaculate and between-patient variance in cancer 
patients. Tests of full models against constant only models were not significant.  
 
Mortality 
A logical regression analysis was conducted to predict mortality in cancer patients 
using the deprivation indices. A test of the full model against a constant only model 
was significant; indicating that the indices of deprivation improved prediction of 
mortality (chi square = 63.320, p<0.001 with df =7). Nagelkerke’s r2 of 0.188 
indicated only a weak relationship between indices of deprivation and mortality. 
Prediction success was 67.2% (78.1% for no mortality and 52.5% for mortality). 
The Wald criterion demonstrated that income score (p=0.044), barriers to housing 
and services score (p=0.003) and living environment score (p<0.001) were the 
only significant indices. 
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Using these three indices of deprivation, patient age, storage time, pre-freeze 
semen analysis parameters and post-thaw TMC recovery, achieved a superior 
model of prediction (chi square = 81.114, p<0.001 with df =11, Nagelkerke’s R2 of 
0.417). Prediction success was 71.8% (79.7% for no mortality and 59.8% for 
mortality). Repeating this analysis and removing patients with a post-thaw TMC or 
PMC < 1.0x106 decreased the number of cases to 160 though a superior model for 
the prediction of mortality was achieved (chi square = 91.839, p<0.001 with df =11, 
Nagelkerke’s R2 of 0.612). Prediction success was 85.0% (89.9% for no mortality 
and 74.5% for mortality). A TMC of < 20% as a binary predictor of mortality 
revealed an odds ratio for mortality of 6.5 (95% CI 1.4-29.5)  (Table 7-8).  
 
Table 7-8 Logistic regression results for mortality of cancer patients. 
Measure B S.E. Wald df p Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Barriers to Housing & 
Services 
.139 .035 15.820 1 <0.001 1.150 1.073 1.231 
Living & Environment -.200 .041 23.298 1 <0.001 .819 .755 .888 
Years of Storage -.245 .099 6.094 1 .014 .783 .644 .951 
TMC % Recovery <20 1.870 .772 5.858 1 .016 6.485 1.427 29.471 
TMC=Total Motile Count 
 
Between-ampoule within-ejaculate, between-ejaculate and between-patient 
variance data were used in separate logical regression analysis to predict mortality 
in cancer patients. For between-ampoule within-ejaculate variance the only 
significant odds ratios generated was CV% difference between post-thaw TMC 
variance and 95% percentile analytical variance prediction (Odds = 0.97, 95%CI 
0.94-0.99, p=0.008). However the test of the full model against the constant only 
model was not significant indicating that the between-ampoule variance does not 
improve prediction of mortality. No significant odds ratios were generated for 
between-ejaculate or between-patient variance measures. 
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Predicting Recovery Following Cryopreservation 
Pre-freeze semen quality, patient age at storage, storage time, between-ampoule 
variance, between-patient variance and indices of deprivation are associated with 
TMC and PMC post-thaw recovery (Table 7-9). 
 
Table 7-9 Correlations between percentage motile sperm count recoveries following sperm cryopreservation 
and patient data, variance and deprivation. 
Measure Statistic TMC Recovery PMC Recovery 
Pre-freeze TMC 
r
2
 0.21 0.27 
p <0.001 <0.001 
Pre-Freeze PMC 
r
2
 0.18 0.21 
p <0.001 <0.001 
Age at storage 
r
2
 0.10 0.10 
p 0.042 0.045 
Storage time 
r
2
 0.17 0.21 
p 0.003 0.002 
Post-thaw between-ampoule CV% 
r
2
 0.42 0.41 
p <0.001 <0.001 
Post-thaw between-patient CV% 
r
2
 -0.23 -0.23 
p <0.001 <0.001 
Employment 
r
2
 0.10 0.11 
p NS 0.037 
Education, Skills, Training 
r
2
 -0.12 -0.07 
p 0.024 NS 
Barriers to Housing & Services 
r
2
 0.10 0.11 
p 0.049 0.044 
Living & Environment 
r
2
 0.13 0.13 
p 0.013 0.012 
TMC=Total Motile Count, PMC=Progressive Motile Count, CV=Coefficient of Variation 
 
Variables found to have no associations with post-thaw recovery included semen 
volume, NCOS presence or count, abstinence period, and MAR result. Patients 
with morphology scores above the 5th percentile from the WHO manual (4% 
normal forms) had a poorer (p=0.020) TMC recovery (median recovery 33%) than 
patients with morphology scores below this threshold (median recovery 51%).  
 
Sperm count and WHO grade motility were predictive over a range of TMC and 
PMC recoveries (Appendices 9.4, Table 9-23). The best single predictor from this 
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data was pre-freeze CASA D class motility predicting a PMC recovery of < 30% 
(ROC area =0.77, p<0.001).  
 
The cluster profiles and SCA CASA variables identified in Chapter 5 also 
demonstrated predictive ability for TMC (Appendices 9.4, Table 9-24) and PMC 
recovery (Appendices 9.4, Table 9-25). The best single motile count recovery 
predictor from these data were cluster area SEM 6 predicting a TMC recovery of < 
40% (ROC area=0.67, p<0.001) and UCV predicting a PMC recovery of < 30% 
(ROC area=0.69, p<0.001). 
 
For semen analysis parameters, A class WHO motility from semen cooled to 4 0C 
for 30 minutes achieved a higher correlation (r2=0.74) with post-thaw A class 
motility than any other comparison made between WHO motility classes, cluster 
profiles and SCA CASA motility descriptors  (Appendices 9.4, Table 9-26). 
However once parameters were used to calculate TMC, there was little difference 
between the predictive potential of TMC from semen cooled to 4 0C for 30 minutes 
(r2=0.85) and semen not pre-cooled (r2=0.84). 
 
In spite of the improved correlations between motility variables from semen 
incubated at 4 0C and post-thaw motility compared with motility assessed within 60 
minutes of production, the best predictors of poor cryopreservation outcomes were 
CASA motility within 60 minutes of production (Appendices 9.4, Table 9-27). 
 
The IUI cluster analysis results (Chapter Five) demonstrated that density gradient 
cluster 5 and 8 combined provided the most significant cluster discriminator for 
successful IUI outcome. Although there was no difference in this combined cluster 
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after incubation at 4 0C for 30 minutes, the cluster size increased post-thaw from a 
median of 29% to 36% (p<0.001). 
 
Cholesterol 
Neat semen cholesterol did not correlate with seminal plasma cholesterol, nor did 
either of these correlate with any of the semen analysis or CASA parameters. 
However, semen cell cholesterol correlated with several parameters (Table 7-10). 
The best correlation with semen cell cholesterol was with sperm count. Using a 
linear regression line between semen cell cholesterol and sperm count allowed the 
identification of patients with low or high cholesterol relative to the count (Figure 7-
6). 
 
Table 7-10 Correlations between semen cell cholesterol and semen parameters. 
Semen Analysis Parameters 
Statistic Volume Count 
Ejaculate Motility 
Count A B AB C D 
r
2
 0.26 0.56 0.55 0.38 0.37 0.39 0.44 -0.44 
p NS <0.001 <0.001 <0.001 <0.001 0.002 <0.001 <0.001 
SWT Clusters 
 DG 1 DG 2 DG 3 DG 4 DG 5 DG 6 DG 7 DG 8 
r
2
 -0.07 0.12 0.21 0.43 0.26 0.06 0.33 -0.16 
p NS NS NS 0.001 NS NS 0.004 NS 
Semen Clusters 
 SEM 1 SEM 2 SEM 3 SEM 4 SEM 5 SEM 6 SEM 7 SEM 8 
r
2
 0.32 -0.37 0.31 0.32 0.38 0.35 -0.25 0.15 
p 0.005 <0.001 0.007 0.004 0.002 0.002 0.031 NS 
SCA CASA Parameters 
 VLC 90th WOB Skew. ALH 90th BCF 5th UCV 50th 
  
r
2
 0.39 0.24 0.33 0.27 0.27 
  
p 0.002 0.044 0.005 0.023 0.020 
  
DG=Density gradient cluster, SEM=Semen Cluster, VLC=Curvilinear Velocity, WOB=Wobble, ALH=Amplitude 
of Lateral Head Displacement, BCF=Beat Cross Frequency, UCV=Uncurving Velocity, Skew.=Skewness, 
th=th percentile 
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Figure 7-6 Linear regression line between sperm count and semen cell cholesterol (n=101).  
Group A are patients who exhibited higher than predicted semen cell cholesterol, group B are patients who 
exhibited lower than predicted semen cell cholesterol. 
 
The ratio between the measured semen cell cholesterol and that predicted using 
the sperm count semen cell cholesterol linear regression line (slope: 0.004037 ± 
0.0002102) has predicative potential. Patients with a ratio greater than 2.65 had 
an increased post-thaw total motility (p<0.001) and WHO A motility (p<0.001) 
compared with patients with a ratio of less than 1.33 (Figure 7-7). 
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Figure 7-7 Post-thaw motility by semen cell cholesterol ratio.  
Graph A, post-thaw change in total motility for patients based on semen cell cholesterol ratio. Graph B, post-
thaw change in A class motility for patients based on semen cell cholesterol ratio 
 
  
246 
 
Diagnostic test validation of semen cell cholesterol established excellent precision 
(CV% < 5%) and concentration linearity in semen (r2=0.99) and in flushing media 
(r2=0.99). A recovery experiment established a recovery from semen of 98% and a 
recovery from seminal plasma of 101%. Neither semen cell cholesterol nor the 
ratio of measured semen cell cholesterol to the count predicted value correlated 
with indices of deprivation. However, the concentration of cholesterol in semen 
and seminal plasma did correlate (Appendices 9.4, Table 9-28). 
 
A logistic regression analysis was conducted to predict > 30% TMC recovery in 
non-cancer patients using pre-freeze parameters. A test of the full model against a 
constant only model was significant; indicating that the parameters in the model 
improved prediction (chi square = 47.98, p<0.001 with df =6). Nagelkerke’s r2 of 
0.296 indicated the significance of the relationship. Prediction success was 73.2% 
(55.1% for < 30% TMC recovery and 85.3% for ≥ 30% TMC recovery). The Wald 
criterions demonstrated several significant predictors (Table 7-11). 
 
Table 7-11 Logistic regression of TMC recovery (≥ 30%) 
Parameter B S.E. Wald df p. Exp 
95% C.I. 
Lower Upper 
Count -0.002 0.004 0.285 1 0.593 0.998 0.99 1.006 
D mot < 45% 1.913 0.393 23.681 1 <0.001 6.771 3.134 14.629 
SEM_2 -0.089 0.024 14.016 1 <0.001 0.915 0.873 0.958 
SEM_5 -0.175 0.061 8.235 1 0.004 0.84 0.745 0.946 
SEM_7 -0.065 0.025 6.906 1 0.009 0.937 0.893 0.984 
SEM_8 -0.07 0.029 5.748 1 0.017 0.932 0.88 0.987 
Constant 5.599 1.856 9.103 1 0.003 270.198 
  
SEM=Semen Cluster 
 
Repeating the analysis and including semen cell cholesterol decreased the 
number of cases to only 80 patients. However a superior model was achieved for 
the prediction of > 30% TMC (chi square = 26.838, p<0.001 with df =7, 
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Nagelkerke’s r2 of 0.387). Prediction success was 78.8% (64.5% for < 30% TMC 
recovery and 87.8% for ≥ 30% TMC recovery). The Wald criterion demonstrated a 
D motility % of < 45% was the most significant predictor with a odds ratio 7.32 
(95% CI 2.05-26.11, p=0.001). 
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7.4 Discussion 
 
The aim of this study was to improve understanding of post-thaw variance, to 
predict post-thaw quality and to calculate the number of ART cycles available to 
local patients from the quantity of ejaculates currently being stored. This research 
confirms the well described decrease in total motility following cryopreservation 
(Keel et al., 1987, O'Connell et al., 2002). Post-thaw WHO motility class recovery 
clearly demonstrated sperm sensitivity to cryopreservation across the motility 
spectrum. However, faster moving sperm appeared more greatly affected than 
other motility classes, with lower recoveries noted for A class motility and PMC for 
both cancer and non-cancer patients. This is further demonstrated by CASA 
motility post-thaw with decreased velocity. These findings initially appear to be in 
conflict with previous work (Keel et al., 1987) which found that velocity is only 
marginally reduced post-thaw. While the Keel study was limited to 164 ejaculates 
on only 17 donors, used multiple exposure photography, and reported mean 
values not median values, their decreased velocity from 30 µm/s pre-freeze to 21 
µm/s is remarkably similar to this current research with a decrease from 33 µm/s to 
23 µm/s. While the decreases in post-thaw velocity when measured by central 
tendencies may not appear large, they do occur to the majority of sperm and are 
of sufficient magnitude to reclassify 80-90% of pre-freeze WHO A class sperm to a 
lower WHO grade. However, it should be noted that velocity estimations pre and 
post-thaw are not comparable between all studies (O'Connell et al., 2002). 
 
Pre-freeze / Post-thaw motility changes have implications for the selection of ART 
with post-thaw sperm. After thawing, less than 3% of all patients were inside the 
IUI VLC 90th percentile threshold and less than 7% inside the IUI WOB skewness 
threshold. Additionally, post-thaw TMC and PMC for most patients were low 
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enough to severely limit the number of ART cycles with IUI or IVF. Thus, ICSI 
would appear to be the evidence based ART choice for the majority of patients 
who store. However, not all patients require ICSI: 25% of patients who store at 
least three ejaculates present with TMC recoveries that would allow for a minimum 
of twelve IUI cycles. Additionally, the VAP / LIN cluster area most significantly 
associated with fertility for IUI patients paradoxically increased post-thaw. 
However, this cluster area may be associated with cryocapacitation rather than 
fertility (Watson, 1995, Watson, 2000). Cryocapaciation is thought to decrease 
length of time sperm can survive in the female reproductive tract  (Watson, 1995). 
Thus, minimum threshold parameters for ART success may be considerably 
different for fresh and frozen-thawed semen. 
 
English Indices of employment, income, health and living environment deprivation 
were found to negatively correlate with semen quality. The strongest semen 
quality correlations for men with cancer were high unemployment or low income. 
This result is similar with that reported from a recent multicentre study across 14 
UK fertility clinics which found men in manual work (odds ratio = 1.28, 95% CI: 
1.07, 1.53) or men not working (odds ratio = 1.78, 95% CI: 1.22, 2.59) have a 
higher risk of low-motile sperm concentrations (Povey et al., 2012). Correlations 
with health deprivation and living environment deprivation are not surprising 
considering the many well documented environmental and health associations 
with semen quality (for review see (Giwercman & Giwercman, 2011)). In addition, 
low socioeconomic status is associated with poor outcomes from cancer, 
attributed to later diagnosis (Woods et al., 2006). Thus, an advanced stage of 
disease may be influencing sperm quality in a cohort of these patients. Also, it 
must be stated that indices of deprivation are statistics calculated in 2010 and 
deprivation scores are likely to have been significantly different when individual 
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patients stored samples. Unfortunately, deprivation data does not allow the 
measurement of deprivation change over time. Additionally, the indices of 
deprivation apply to a small geographical area and not an individual.  
 
Correlations between the indices of deprivation and post-thaw quality were 
stronger than correlations with pre-freeze quality. Additionally, indices of 
deprivation correlated with post-freeze recovery. Sperm from men with cancer who 
live in geographical areas of higher living environment deprivation do not freeze as 
well as men who live in areas of lower living environment deprivation. Living 
environment deprivation is a composite of indoor living factors such as the quality 
of housing under the UK 1985 Housing Act and outdoor living factors including air 
quality. With respect to air quality, concentrations of four pollutants are measured; 
nitrogen dioxide, benzene, sulphur dioxide and particulates. All four pollutants are 
implicated in male reproductive toxicity (Giwercman & Giwercman, 2011, Zhou et 
al., 2014) 
 
Further evidence of the relationship between sperm cryopreservation and 
deprivation was observed with post-freeze between-ejaculate PMC variance and 
living environment deprivation (r2=-0.18, p<0.01). Additionally, while cancer 
patients’ between-ejaculate pre-freeze variance and post-thaw variance correlated 
for TMC and PMC, the correlation was principally led by count variance. Both total 
motility and progressive motility alone were not significant for this pre-freeze post-
thaw correlation. In contrast, the deprivation correlation with between-ejaculate 
variance was principally led by motility variance, while count variance did not 
correlate.  
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While correlation does not indicate causation, associations between post-thaw 
recoveries or variance following cryopreservation and socio economical 
geographical factors have not been previously reported. Cryo-injury to sperm is 
multi-factorial, mainly a combination of permanent and reversible osmotic and 
oxidative mediated damage (Watson, 1995, Holt, 2000a, Holt, 2000b, Watson, 
2000, Tatone et al., 2010, Di Santo et al., 2011)). There is a considerable body of 
evidence from the cryopreservation of animal sperm that demonstrates that 
individuals exhibit different susceptibilities to sperm cryo-injury (Holt, 2000a, 
Thurston et al., 2002, Holt et al., 2005, Loomis & Graham, 2008). This current 
research indicates that deprivation may influence individual susceptibility to sperm 
cryo-injury in humans. 
 
Variance between-ampoules within the same ejaculate was shown to be larger 
than can be explained from expected analytical variance, a finding supported by 
earlier research (Nallella et al., 2004). This variance may be partially attributed to 
poor adherence to cryopreservation protocols during processing, such as 
adequate mixing of the ejaculate. Correlations between-ampoule count variance 
and other semen parameter variance support this theory as counts, as predicted, 
do not decrease post-thaw. However, with respect to TMC variance, 39% was 
explained by count variance (p<0.001) and 67% by motility variance (p<0.001). 
These proportional effects of count and motility variance on TMC and PMC post-
thaw variance were also repeated for between-ejaculate and between-patient 
variance: Post-thaw TMC variance is therefore predominantly caused by changes 
in motility. 
 
Post-thaw variance may be partially explained from the population receiving sperm 
cryopreservation. Cancer patients exhibit significantly (<0.001) greater pre-freeze 
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between-ejaculate variance for volume, count, progressive motility, total motility, 
TMC and PMC than IUI patients. Further supporting this finding was higher 
(p<0.001) post-thaw between-patient variance in the cancer group than the non-
cancer group. These results with higher variance should not be unexpected 
considering the well-established semen quality effects from cancer for some but 
not all men (van Casteren et al., 2010, Dearing et al., 2014a). While post-thaw 
between-patient variance was higher in the cancer group, there was no difference 
between groups for between-ampoule within-ejaculate post-thaw variance. This 
similarity in variance between cancer patients and healthy men has been reported 
previously (Centola et al., 1992, Agarwal, 2000) and supports sample processing 
as a major source of this variance. 
 
Between-ampoule within-ejaculate variance correlated with storage time and was 
an unexpected result. Unfortunately records have not been kept for these patients 
that would allow a greater in depth exploration of this finding. Higher between-
ampoule variance in older ampoules may be related to exposure to ambient 
temperature as ice recrystallization and growth may occur at temperatures as low 
as -96 0C  (Meryman, 2007). Older samples are more likely to have been 
transferred between storage locations in response to changes in the HFEA code of 
practice. Splitting requirements, where a single patients sample has to be divided 
between more than one storage vessel to insure a patient will not lose all their 
frozen ampoules or straws in the unlikely event of a catastrophic tank failure 
became a requirement in 2004 for example (See H.F.E.A Chairs letters 
(Letters:2003-2006, 2014)). Many older samples have also been transferred from 
liquid nitrogen storage to vapour nitrogen storage to minimise risks of viral transfer 
been ampoules in liquid (Tedder et al., 1995).  In addition, older samples have 
been exposed during “storage review” a biennial HFEA requirement where 
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electronic records of storage are matched against a physical audit of sample 
location (H.F.E.A., 2013b). Thus, perhaps the HFEA requirements though well 
intended are inadvertently increasing between-ampoule variance and decreasing 
post-thaw recovery. Also the use of historical “homemade” media and / or 
improvements in commercial media over time may be implicated. Additionally, 
improvements in process validation methodology, protocol adherence and staff 
training may be factors. 
 
Several measures of between-ejaculate variance and between-patient variance 
strongly correlated with storage time. The greatest of these negative correlations 
were between-ejaculate progressive motility variance and storage time and 
between-patient count variance and storage time These are not unexpected 
findings as variance is higher in men with poor quality semen and men who have 
stored more recently are more likely to have stored with poor quality semen: 
sperm cryopreservation was not as routinely offered to men with poor quality 
semen before ICSI (which allows treatment with single sperm) became prevalent 
as an ART choice.  
 
While cryopreservation variance did not appear to be associated with mortality in 
cancer patients, both TMC recovery and PMC recovery following cryopreservation 
were predictive. A TMC recovery of < 20% has a mortality odds ratio of 6.49 
(p=0.016, 95% CI 1.43-29.47). These results support a relationship between 
cancer severity and sperm resistance to cryo-injury. Cancer is a systemic disease 
and a more invasive cancer is more likely to affect a greater number of biological 
processes, including spermatogenesis and / or sperm maturation. The living 
environment score from the indices of deprivation was the single most significant 
(p<0.001) predictive variable for cancer mortality.   
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In this research, patients with better pre-freeze semen quality exhibited better 
recoveries, which supports previous conclusions (Oehninger et al., 2000, Zhang et 
al., 2012); cryo-injury is more severe in ejaculates of poor quality. However, for all 
freeze / thaw cut-off TMC and PMC recoveries examined, percentage motility 
categories were superior predictors than count, ejaculate count, TMC and PMC. 
Sperm motility before freezing thus has a particularly large influence on motile 
count recoveries following cryopreservation. Patients with greater than 10% B 
class sperm gave a less than 30% TMC recovery odds ratio of 4.15 (95% CI 2.19-
7.86, p<0.001), while an immotile fraction of greater than 45% gave an less than 
30% TMC recovery odds ratio of 5.13 (95% CI 2.73-9.62, p<0.001). VAP / LIN 
clusters also proved predictive of outcomes and when included in logistic 
regression analysis improved the later odds ratio to 6.77 (95% CI 3.13-14.63, 
p<0.001).  
 
Semen cell cholesterol results were consistent with the concept that the 
cholesterol concentration within the sperm membrane is associated with freeze / 
thaw tolerance. Sperm plasma membrane lipid composition is species specific and 
cholesterol content in particular varies between species, between individuals and 
between-ejaculates (Flesch & Gadella, 2000). Species exhibiting higher sterol to 
phospholipid concentrations are more resistant to a specific type of cooling 
damage called “cold shock” which involves thermotropic phase transitions 
(Drobnis et al., 1993, Holt, 2000a). Recent research on cryopreservation 
responses of individual mouse strains support within species relationships 
between sperm cryopreservation tolerance and sperm membrane cholesterol 
(Loomis & Graham, 2008). While a previous study found no relationship between 
sperm membrane cholesterol and cryopreservation outcomes in humans 
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(Meseguer et al., 2004), their estimation relied on Mackler chambers, pelleted 
sperm concentrations and cholesterol extraction. This current research using a 
less invasive method demonstrates that sperm cholesterol variance within human 
sperm is associated with cryopreservation outcome. Cholesterol in both semen 
and seminal plasma cell correlated with several deprivation indices, perhaps 
supporting a relationship between deprivation and the lipid composition of the 
sperm membrane.  
 
This research demonstrates that prediction of sperm cryopreservation recovery is 
possible using both demographic data and techniques available to NHS 
laboratories. Techniques that provide detailed information about an individual’s 
sperm membrane composition, or defence mechanisms against reactive oxygen 
and / or nitrogen species or DNA fragmentation are unlikely to receive NHS 
funding. In contrast, CASA which is economically sound for the Andrology 
laboratory and simple / affordable additions using existing pathology platforms 
such as semen cell cholesterol have potential to reduce the uncertainty 
surrounding cryopreservation variability. This reduction in uncertainty can be used 
to guide both the number of ejaculates stored for individual patients and the 
selection of ART with thawed sperm with a greater evidence base than is currently 
employed. The relationship between sperm quality, cryopreservation and patient 
mortality deserves further exploration; any technique which may predict which 
patients warrant more aggressive anti-cancer treatments has the potential to 
improve outcomes for men with cancer.    
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Chapter 8 General Discussion  
 
8.1 Original Contribution to Knowledge 
 
The aim of this research was to characterise a population of men with cancer who 
require sperm cryopreservation, and to define and quantify the sources of 
uncertainty that limit their levels of fertility insurance. The contributions to 
knowledge from this research are diverse. These are; novel findings from the local 
cohort of cancer patients who require sperm cryopreservation (Dearing et al., 
2014a); the creation of an innovative quality tool to measure and reduce analytical 
uncertainty; an original approach to validation of Computer Assisted Semen 
Analysis (CASA) (Dearing et al., 2014b); the introduction of a novel receptacle for 
freezing human sperm (Dearing, 2014 in press) and several original contributions 
to the understanding of cryopreservation variance that are yet to be published. 
Sources of uncertainty in sperm cryopreservation for cancer patients are currently 
limiting fertility preservation. National Health Service (NHS) sperm banks are 
capable of decreasing this uncertainty for individual patients to provide improved 
guidance on the quantity of semen to be stored.  
 
Several novel sperm cryopreservation related findings were established from the 
local population of patients who require the service (Dearing et al., 2014a). The 
number of patients being referred is sharply increasing year on year, as is the 
number of patients who go on to use their sample in assisted conception. Thus, 
local reported use rates are likely underestimations of future use. While one in five 
cancer patients are teenagers at storage, both the age range and median age at 
storage has increased. Increased age at referral is influencing the cancer profile of 
men seen at the bank. This is highlighted by a disproportionate rise in the number 
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of men with prostate cancer. Specific cancers were shown to influence aspects of 
semen quality which have methodological implications for sperm banks. An 
increasing number of known viral positive men are being referred, requiring 
expensive safe storage solutions. The cost of storing samples from men who will 
never use their samples is becoming an increasing financial strain for public 
healthcare. 
 
In order to quantify within-laboratory measurement uncertainty, a novel quality 
control computer programme, Internal Quality Control Tool (IQCT), was designed 
and implemented into our daily semen analysis processes. IQCT was shown to be 
a flexible addition to the semen analysis laboratory, that can accurately record and 
even reduce Measurement Uncertainty (MU). IQCT demonstrated that operator 
bias in manual semen analysis is operator specific, complex, difficult to quantify 
and extremely difficult to control. Bias patterns for sperm motility are so operator 
specific that MU may need to be calculated for all individual operators within a 
laboratory. Unfortunately, cost pressures and the current External Quality 
Assurance (EQA) scheme do not appear to be facilitating the improvement in 
quality that is required to make manual semen analysis more meaningful. Manual 
semen analysis as it is currently performed may not be fit for purpose in the 
absence of unproved MU.  
 
The Sperm Class Analyser (SCA) CASA system received the first process 
validation of its kind to allow its use in an accredited UK semen analysis laboratory 
(Dearing et al., 2014b). For count and motility, SCA CASA compared with manual 
analysis is faster, more precise, requires less training and supervision. CASA also 
allows greater numbers of sperm to be analysed and should minimise individual 
operator bias and drift. However, several CASA specific errors require specialised 
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training to identify and to correct. Alternative methods of analysis are occasionally 
required. SCA CASA automated stage morphology also offers far greater precision 
and less operator bias than the manual equivalent. However, the CASA 
morphology system is slow, labour intensive, cannot estimate sperm tail 
morphology and generates imprecise mid-piece measurements that compare 
poorly with the scanning electron microscope. In spite of its deficiencies, SCA 
CASA sperm head morphometry may still offer clinically useful information. CASA 
technology is not a stand-alone “black box” but rather a tool for trained andrology 
staff. Research and clinical information generated from CASA systems that have 
not been robustly validated need to be interpreted with a high degree of caution. 
 
The CoolCell, was found to be a novel, flexible, economic, simple and highly 
regulatory compliant addition to a manual freezing method that freezes human 
sperm with reduced cooling curve variance (Dearing, 2014 in press). Optimum 
results were achieved with a CE marked egg yolk based media, which revealed 
superior fertility-associated motility profiles in comparison to a non-egg yolk based 
media. The improved motility may be due to a protective effect of egg yolk and 
may principally occur on media addition. Egg yolk may thus minimise glycerol 
sperm toxicity, although further work is required to confirm this.  
 
A major aim of the research was to estimate the Assisted Reproductive 
Technology (ART) treatment choices for men with cancer using their 
cryopreserved sperm. This required the identification of threshold values from local 
populations. Minimum threshold values for successful Intrauterine Insemination 
(IUI), In Vitro Fertilisation (IVF) and Intra Cytoplasmic Sperm Injection (ICSI) could 
be established. However, optimum threshold values for IVF and ICSI treatment 
selection remain elusive. Total and progressive motile counts are the optimum 
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semen parameters with which to predict IUI failure. Total ejaculate count and the 
presence of nucleated cells other than sperm (NCOS) offer predictive potential for 
IVF. CASA motility cluster analysis and CASA percentile distribution measures 
have potential as novel reference ranges for both IUI and IVF outcome prediction. 
CASA semen analysis significantly exceeds manual semen analysis for predicting 
both IUI and IVF outcomes. 
 
The threshold reference limits identified from local populations demonstrated that 
few cancer patients exhibited post-thaw quality that would indicate any ART other 
than ICSI. ICSI was also indicated for many patients simply based upon the 
quantity of sperm currently being stored. However, even those patients with 
semen quality that would allow for a less invasive ART are still receiving ICSI, a 
concerning non-evidence based treatment selection. Associations were found 
between post-thaw recovery for cancer patients and socio-economic factors which 
have not been previously reported. Post-thaw within-ejaculate variance is 
associated with storage time, which was an unexpected result with national policy 
implications. The semen cell cholesterol assay is a novel method that explains a 
portion of the individual variance in cryopreservation responses. A novel 
relationship was discovered between post-thaw quality and patient mortality, which 
may have implications for guiding cancer treatment. 
 
8.2 Implications for Practice and Policy 
 
MU is an emergent UK clinical laboratory regulatory requirement as Clinical 
Pathology Accreditation (CPA) standards v2.0 (C.P.A., 2012) are replaced by ISO 
15189. From October 2013, every accredited laboratory was required to determine 
its own MU for all quantity based results, and to demonstrate that MU remains 
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within defined performance limits. IQCT was shown to accurately record MU, can 
be used to calculate performance limits and to provide the ongoing evidence that 
uncertainty remains within those limits. Since its introduction, IQCT has proved 
invaluable as a training tool and has provided quality control evidence that has 
allowed our laboratory to maintain its CPA accreditation.  
 
CASA was shown to have many advantages over manual semen analysis 
including generating more clinically meaningful results for sperm count and 
motility. On the basis of this work SCA CASA was adopted to provide the main 
diagnostic methods for count and motility in our laboratory. While the results of this 
research strengthen the arguments for the introduction of CASA in routine semen 
analysis, the need for extensive process validation cannot be overemphasised. A 
recommendation for CPA inspection policy is thus to inspect for validation 
summaries from those laboratories utilising CASA. Conversely, between-operator 
bias, within-operator drift, and high imprecision should be considered as possible 
sources of error from laboratories using manual semen analysis methods. This will 
be particularly likely from those laboratories using less than recommended 
numbers of sperm in the analysis and without adequate quality control strategies 
that specifically demonstrate the absence of these uncertainties.  
 
There are several limiting factors preventing efficient sperm cryopreservation 
processing for NHS sperm banks, thus a significant length of time may be required 
between ejaculation and sample processing for cryopreservation. Samples 
awaiting processing at our centre have historically been stored at 37 0C as 
recommended by manufacturers of freeze media. However, this research found 
that this temperature hastens motility decline compared with room temperature 
storage. Low volume samples (~0.5 mL) displayed more dramatic rapid drops in 
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motility which occurs irrespective of storage temperature. This observation will be 
particularly relevant for prostate cancer sufferers who were identified as often 
presenting with decreased semen volume (Dearing et al., 2014a). Two 
recommendations for a change in practice are thus suggested; (1) pre-processing 
storage should be at room temperature and (2), low volume samples should be 
processed immediately to preserve motility. 
 
An essential quality requirement of the Human Fertilisation and Embryology 
Authority (HFEA) is “biannual review”, where electronic and / or paper records of 
storage are matched against a physical audit of sample location (H.F.E.A., 2013b). 
However, this audit may be counterproductive for cancer patients as within-
ejaculate post-freeze variance positively correlated with storage time. Additionally, 
experiments on pooled semen established that the internal temperature of frozen 
ampoules can reach glass transition temperature during our audit and sample 
transfer activities. Exposure to ambient temperatures may lead to ice 
recrystallization and growth, which may occur at temperatures even as low as -96 
0C  (Meryman, 2007).  Further audits from other sperm banks are required to 
confirm that these results are not an isolated finding before a change in biannual 
review HFEA policy can be recommended. However, a change in witnessing 
policy and practice can be recommended at this stage. Activities that expose 
frozen ampoules to ambient temperatures should become contemporaneous 
witnessed timed activities that are recorded in patient notes.  
 
The CoolCell was found to be highly compliant with the current HFEA policy 
(H.F.E.A., 2013b) for minimising the risk of pathogen cross contamination. 
Because one CoolCell is used per patient, samples are completely separated from 
one another during the entire cryopreservation process. Pre-designated CoolCells 
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can be used for screened, unscreened and viral positive patients as a best 
practice approach to sperm cryopreservation. Because the CoolCell has a highly 
thermally conductive core designed for uniform cooling, there was little change in 
freezing curves with lower volume aliquots. Similar recoveries of motile sperm at 
1.0 mL were made with as small volumes as 0.1 mL. On the basis of these results, 
the CoolCell and egg-yolk method was adopted as the method for freezing sperm 
by our laboratory. 
 
It was established that ICSI is being selected for the vast majority of fertility 
treatments requiring cryopreserved sperm. Since ICSI requires only a single viable 
sperm, the current policy of freezing in 1.0 mL aliquots results in many viable 
sperm being discarded after treatment. The CoolCell allows 0.1 mL aliquots to be 
stored, and freezing aliquots of this volume would dramatically increase the 
number of ICSI cycles available per ejaculate. There are several classes of patient 
that are likely to benefit from such a policy. Prostate cancer sufferers had median 
semen volumes which were at least 1.0 mL less than any other median volume for 
any other cancer diagnosis. These patients will therefore need to either store more 
ejaculates, or freeze in lower volumes in order to gain the same level of fertility 
insurance as other men. Similar considerations and solutions would be applicable 
to the low sperm counts seen with testicular cancer cases. For those patients who 
require urgent “next day” iatrogenic treatments, the availability of 0.1 mL freezing 
volumes may allow paternity of a complete family from even a single ejaculate. 
However, it should be noted that these ampoules would also be more sensitive to 
exposure to ambient temperature insults.  
 
Patients, who have adequate time frames in which to store multiple ejaculates, 
should be able to store sufficient qualities of semen to provide ART treatment 
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choice. The HFEA do not currently provide guidance on the quantity of semen to 
be stored, and the evidence from this research demonstrates that this is required.  
The work in this thesis also demonstrated that many factors are associated with 
post-thaw recovery. These include; cancer diagnosis, pre-freeze quality of the 
sample, cryopreservation technique, living and environment deprivation, semen 
cell cholesterol and storage time. Of these factors, clinically valuable prediction of 
post-thaw quality is possible from simple techniques that are available to NHS 
laboratories. This can be used to guide the number of ejaculates required for 
individual patients and to guide ART selection with frozen-thawed sperm. To allow 
ART choice and keep costs down, it is suggested that consent for storage be 
reduced to two years and be renewed biannually. Most patients who recover 
spermatogenesis should not need storage beyond this period. 
 
Percentile differences between semen parameters from the pregnant and non-
pregnant groups for IUI, clearly demonstrates selection bias. A significant 
proportion of patients from the IUI clinic with semen parameters under threshold 
limits still received IUI. This is because the only alternative in this cohort is no 
treatment at all. This observation is particularly relevant considering the recent 
NICE recommendations (N.I.C.E., 2013) to severely limit the use of IUI. The NICE 
recommendation is based on two low quality publications comparing stimulated IUI 
with expectant management. NICE’s own interpretation of the quality of the two 
studies is less than convincing; “The evidence quality was very low due to 
limitations in the study design and wide confidence intervals” (N.I.C.E., 2013). The 
IUI pregnant group in this current research achieved pregnancy with poor semen 
quality compared with the natural conception group used to generate the current 
WHO reference range (Cooper et al., 2010). This is not an isolated finding; 
acceptable IUI pregnancy rates from patient groups with semen parameters below 
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WHO threshold limits have been previously reported (Branigan et al., 1999, Dickey 
et al., 1999). The NICE policy on IUI treatment should be reconsidered. In 
addition, patients undergoing IVF with NCOS counts > 1.0x106 had twice the odds 
to experience treatment failure as other patients; this has policy implications for 
guiding IVF / ICSI treatment selection. 
 
8.3 Limitations 
 
An unavoidable limitation of this research is the limitation of semen analysis itself. 
To achieve fertilisation and healthy embryonic development, sperm need to be 
capable of many intracellular and extracellular functions that are not adequately 
described by current semen analysis methodology (Holt, 2009). The estimation of 
appropriate quantities of sperm that need to be stored for patients is thus based on 
semen minimum threshold values, not on the probability of conception. An 
additional limitation is that minimum threshold values are unlikely to be the same 
for each couple. Fecundity rates with cryopreserved semen are known to be 
specific for individuals in the human (Barratt et al., 1998) and in domesticated 
animals (Holt, 2000a). 
 
A major limitation of this research is unavoidable sources of bias. The results 
focussing on a definitive cancer diagnosis from patients storing between 1976 and 
2009 could only identify a specific legible cancer diagnosis on 55% of patients. It 
cannot be assumed that a missing diagnosis is even across all oncology 
disciplines. Several sources of bias were also evident from the fertility threshold 
data. As the IUI clinic only offers IUI, patients who would benefit from more 
invasive treatments receive IUI as no other ART is available. In contrast, the IVF 
clinic studied only offers IVF or ICSI, thus even patients with semen quality above 
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WHO threshold limits receive IVF. The limitation is that the percentile semen 
analysis profiles from men successful with IVF are higher than those from men 
successful with IUI, a paradoxical opposed hierarchy to that expected.  
 
Several limitations can be highlighted from CASA comparisons made between 
fluids of dissimilar compositions. For example, the cluster analysis average path 
velocity / linearity (VAP / LIN) areas identified from density gradient (DG) 
separation were applied to post-thaw semen that was not processed for DG 
separation. While the DG separation and post-thaw sperm populations are not a 
like-for-like comparison, both techniques do select a specific subpopulation of 
sperm from the original heterogeneous ejaculate. Recent advances in the 
understanding of viscosity and its relationship to sperm motility (Kirkman-Brown & 
Smith, 2011) questions the value of motility assessed in non-viscous fluids. 
Additionally, a non-linear decrease in median VLC has been established with 
increasing viscosity, though maximum velocity appears less effected (Hyun et al., 
2012).  However, while such viscosity effects cannot be entirely excluded from all 
experiments, the viscosities as evidenced as filling times of fixed coverslip 
chambers from matched paired experiments were not different. Also there was no 
difference between the VLC estimations from neat semen and semen diluted 1:1 
with TYB. 
 
8.4 Theoretical Implications and Future Work 
 
This current research demonstrated that CASA precision is improved by 
increasing the number of sperm in the analysis. For kinematic parameters this was 
true for increasing numbers up to 2000 sperm tracks. MU of sperm motility 
subpopulations will therefore primarily rely on the number of sperm in the 
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subpopulation, which will be directly proportional to the total number of sperm 
analysed. CASA systems that are capable of measuring unlimited numbers of 
sperm may offer greater potential for subpopulation identification. This current 
research experienced severely limiting CASA morphology focus problems on 
stained sperm at high (1000x) magnification. Motile Sperm Organelle Morphology 
Examination (MSOME) (Souza Setti et al., 2010) is a technology that may allow 
CASA morphology on motile unstained sperm, while also allowing higher sperm 
numbers within the analysis.  
 
CASA utilising MSOME or similar technology may also allow simultaneous count, 
motility, and morphological measurements on individual sperm which in turn would 
allow multidimensional cluster profiling. Such a CASA system continuously 
analysing vast numbers of sperm during challenge tests would have tremendous 
potential for characterising sperm populations. One such subpopulation of interest 
is sperm with hyperactivated motility, which is multiphasic and may be poorly 
described from “snapshot” CASA systems (Pacey et al., 1997, Kay & Robertson, 
1998, Mortimer, 2000). Changing sperm motility patterns, specifically head yaw, 
with increasing viscosity (Kirkman-Brown & Smith, 2011) demonstrate that deriving 
physiological implications from sperm motility is not straightforward. CASA 
analysis of sperm in physiological viscosity fluids may also yield new avenues of 
research.  
 
In this current research, the VAP / LIN cluster area most significantly associated 
with fertility for IUI patients increased post-thaw. In addition, acceptable IUI 
pregnancy rates were achieved with poor quality semen. While a post-thaw 
decrease in hemizona assay binding capacity has been previously reported in 
humans (Morshedi et al., 1995), that particular work focused only on fertile donors. 
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A recent study demonstrated that combining fresh and frozen thawed ejaculates 
can improve the pregnancy rate in oligozoospermic patients after IUI (Nie et al., 
2010). It is certainly possible that a subpopulation of sperm that is suitable for IUI 
may increase post-freeze for sub-fertile men. A multicentre randomised crossover 
control trial is suggested using a standardised fully validated CASA system. The 
first cohort could receive standard IUI with an inseminate prepared from fresh 
semen. The second cohort could receive IUI with an inseminate prepared from 
fresh semen combined with several thawed ejaculates, collected and frozen over 
several weeks. Both clinician and patient can be blinded to which sample type is 
being used. The female inclusion criteria and the IUI treatment should be 
rigorously standardised over all participating centres. Every semen analysis and 
inseminate should be analysed with fully validated CASA, using high numbers of 
sperm tracks to enable high precision cluster analysis. 
 
This research provided further evidence of the well described observation, that the 
motile count differences between successful and unsuccessful ART treatment 
groups occur at the lower percentiles of a distribution. Comparing central 
tendencies between these groups offers little useful discriminating information. 
The same concept can be applied to the distribution of sperm within an ejaculate. 
This research demonstrated optimal discriminating potentials for IUI outcomes at 
the 90th percentile of curvilinear velocity and lateral head displacement, the 5th 
percentile of beat cross frequency and the skewness of wobble. Similarly, the only 
significant discriminator for IUI using CASA morphology was Kolmogorov-Smirnov 
(KS) distance as a normal distribution measure. Novel methods of defining 
ejaculate heterogeneity are an identified area of future research. 
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Human sperm have comparatively high membrane cholesterol content and are 
thus generally more resistant than other species to membrane phase transitions 
that occur during cooling and freeze / thawing (Drobnis et al., 1993, Holt, 2000a). 
However, sperm membrane cholesterol content also varies between individuals 
and even between-ejaculates (Flesch & Gadella, 2000). This current research 
supports that cholesterol membrane variance within humans is associated with 
sperm cryosurvival. Cholesterol may be protecting against sperm membrane 
phase transitions during freeze / thaw, an hypothesis supported by recent 
research on cryopreservation responses of individual mouse strains (Loomis & 
Graham, 2008). Semen cell cholesterol is a simple, cost-effective, precise and 
readily available technique that may identify patients with low sperm membrane 
cholesterol content. Such identified patients may benefit from cholesterol 
cytodextrin loading which has been shown to improve cryopreservation response 
in some species.(Mocé et al., 2010). Additionally, further work is suggested on 
testing relationships between sperm membrane cholesterol and membrane 
integrity following freeze / thaw. 
 
Semen quality may be the most sensitive marker of adverse environmental 
exposures (Nordkap et al., 2012) and a fundamental biomarker of overall male 
health (Jensen et al., 2009). This current work found a novel relationship between 
post-thaw quality and mortality, and evidence that deprivation may influence 
individual susceptibility to cryo-injury in humans. Sperm cryopreservation therefore 
may have potential as a functional test of ejaculate and / or general health. 
Considering the limitations of deprivation data, which was estimated from a small 
geographical area in 2010, further work focussing on deprivation measures for 
individual patients at storage, is identified as an area of interest. Further research 
is suggested using the validated SCA CASA system and the cool cell to minimise 
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analytical and cooling curve variance. Cohorts worth investigation would include 
newly diagnosed cancer patients and newly diagnosed fertility patients. 
Prognostication is particularly important for those clinicians working with patients 
with advanced cancer (Glare et al., 2008), any technique that may predict which 
patients warrant more aggressive anti-cancer treatments has the potential to 
improve outcomes for men with cancer. 
 
8.5 Final Conclusion 
 
This research described a population of men with cancer requiring sperm 
cryopreservation and defined and quantified several sources of uncertainty that 
limit their levels of fertility insurance. Uncertainty of sperm cryopreservation for 
men with cancer is implicated in a non-evidence based rise in ICSI treatments with 
cryopreserved sperm (Dearing et al., 2014a). NHS sperm banks need to facilitate 
a service based on evidence. This evidence should include the prediction of post-
thaw outcomes to ensure adequate levels of fertility insurance to allow informed 
ART choices to be made without concerns regarding the quantity of semen stored. 
National guidelines on ICSI use need further clarification, specifically defining a 
severe deficit in semen quality. Additionally, an evidence base for ART selection 
with frozen thawed sperm is required and regulators need to ensure ICSI is not 
being inappropriately selected. Currently we are not storing enough sperm to meet 
the needs of most cancer patients who use their stored samples. Men with cancer 
who require sperm storage are not a fixed demographic but are individuals who 
require individual approaches to sperm cryopreservation. 
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Figure 9-1 Difference between-operator using manual semen analysis to estimate WHO D class motility. 
Each Box and Whisker plot represents the range, 25
th
 percentile, median and 75
th
 percentile of D motility 
patient’s results as measured by individual BMS staff. Graph A represents all BMS staff results for two years 
pre IQCT and graph B represents all BMS staff results one year post IQCT. 
 
 
Table 9-1 Dunns multiple comparison test results for sperm counts before IQCT.  
BMS One Two Three Four Five Six 
One - <0.001 <0.001 <0.001 <0.001 <0.001 
Two - - <0.001 <0.001 <0.001 <0.001 
Three - - - <0.001 <0.001 <0.001 
Four - - - - <0.001 <0.001 
Five - - - - - <0.001 
Six - - - - - - 
The non-parametric Kruskal-Wallis Test (p<0.0001, Kruskal-Wallis statistic 55.76) was used to test for 
significant differences between-operators for counts for patients from two years. Dunn’s Multiple Comparison 
Test was used as a post hoc test to examine for differences between specific individual operators. 
 
Table 9-2 Dunns multiple comparison test results for sperm counts post IQCT.  
BMS One Two Three Four Seven 
One - <0.001 <0.001 <0.001 <0.001 
Two - - <0.001 <0.001 >0.05 
Three - - - <0.001 <0.001 
Four - - - - <0.001 
Seven - - - - - 
The non-parametric Kruskal-Wallis Test (p<0.0001, Kruskal-Wallis statistic 24.01) was used to test for 
significant differences between individual operators for counts for patients one year post IQCT. Dunn’s 
Multiple Comparison Test was used as a post hoc test to examine for differences between specific individual 
operators. 
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Figure 9-2 Q-Q plots of the percentiles of D motility comparing pre and post IQCT. 
Results are for BMS staff 1-4 before (a) and after (b) IQCT. 
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9.2 Appendix B Chapter Four Supplementary Results 
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Figure 9-3 Correlation of Neubauer and CASA for 192 patient’s samples.  
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Figure 9-4 Correlation of Leja 20µm manual method with CASA for 160 patient’s samples.  
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9.3 Appendix C Chapter Five Supplementary Results 
 
Table 9-3 Spearman correlation coefficients and significance for semen parameters, IUI PMC and IUI TMC 
Parameter            Statistic 
Semen 
Volume 
Sperm 
Count 
Prog. 
Motility 
Total 
Motility 
IUI  
PMC 
IUI  
TMC 
Semen 
Volume 
Correlation 
Coefficient 
1.000 -.037 .019 -.002 .183
**
 .184
**
 
Sig. (2-tailed) . .244 .543 .938 .000 .000 
Sperm Count 
Correlation 
Coefficient 
-.037 1.000 .299
**
 .184
**
 .646
**
 .653
**
 
Sig. (2-tailed) .244 . .000 .000 .000 .000 
Prog. 
Motility 
Correlation 
Coefficient 
.019 .299
**
 1.000 .761
**
 .428
**
 .413
**
 
Sig. (2-tailed) .543 .000 . .000 .000 .000 
Total 
Motility 
Correlation 
Coefficient 
-.002 .184
**
 .761
**
 1.000 .334
**
 .319
**
 
Sig. (2-tailed) .938 .000 .000 . .000 .000 
IUI PMC 
Correlation 
Coefficient 
.183
**
 .646
**
 .428
**
 .334
**
 1.000 .994
**
 
Sig. (2-tailed) .000 .000 .000 .000 . .000 
IUI TMC 
Correlation 
Coefficient 
.184
**
 .653
**
 .413
**
 .319
**
 .994
**
 1.000 
Sig. (2-tailed) .000 .000 .000 .000 .000 . 
TMC=Total Motile Count, PMC=Progressive Motile Count, IUI=Intrauterine Insemination 
 
Table 9-4 Spearman correlation coefficients and significance for semen whole ejaculate parameters and IUI 
PMC and IUI TMC. 
Parameter Statistic 
Total 
Ejaculate 
Count 
Total 
Ejaculate 
PMC 
Total 
Ejaculate 
TMC 
IUI 
PMC 
IUI 
TMC 
Total Ejaculate 
Count 
Correlation Coefficient 1.000 .929
**
 .967
**
 .672
**
 .679
**
 
Sig. (2-tailed) . .000 .000 .000 .000 
Total Ejaculate 
PMC 
Correlation Coefficient .929
**
 1.000 .975
**
 .718
**
 .720
**
 
Sig. (2-tailed) .000 . .000 .000 .000 
Total Ejaculate 
TMC 
Correlation Coefficient .967
**
 .975
**
 1.000 .703
**
 .707
**
 
Sig. (2-tailed) .000 .000 . .000 .000 
IUI PMC 
Correlation Coefficient .672
**
 .718
**
 .703
**
 1.000 .994
**
 
Sig. (2-tailed) .000 .000 .000 . .000 
IUI TMC 
Correlation Coefficient .679
**
 .720
**
 .707
**
 .994
**
 1.000 
Sig. (2-tailed) .000 .000 .000 .000 . 
TMC=Total Motile Count, PMC=Progressive Motile Count, IUI=Intrauterine Insemination 
 
Table 9-5 Density gradient (DG) cluster centres for VAP/LIN k mean clusters from sperm tracks (n=24500) 
from IUI preparations (n=20) that resulted in a pregnancy. 
 
Centre 
Cluster 
DG 1 DG 2 DG 3 DG 4 DG 5 DG 6 DG 7 DG 8 
VAP 15.0872 40.5613 112.6072 75.1079 85.3522 57.5181 89.6278 20.2692 
LIN 25.5461 40.9138 90.3223 34.5172 89.8266 73.2404 64.2448 64.3193 
N 6964 3047 1574 1472 2675 3101 1567 3850 
DG=Density gradient cluster, VAP=Average Path Velocity, LIN=Linearity 
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Table 9-6 Semen (SEM) cluster centres for VAP/LIN K mean clusters from sperm tracks (n=19800) from 
semen samples (n=16) that resulted in an IUI pregnancy.  
 
CASA 
Cluster 
SEM 1 SEM 2 SEM 3 SEM 4 SEM 5 SEM 6 SEM 7 SEM 8 
VAP 41.28 35.41 13.55 96.64 50.38 71.88 21.96 67.21 
LIN 25.79 75.32 22.10 83.55 49.94 49.39 48.52 84.58 
N 3208 1722 6290 185 1887 921 4012 1575 
SEM=Semen cluster, VAP=Average Path Velocity, LIN=Linearity 
 
 
Table 9-7 IUI patients semen samples (n=110, pregnant=20, non-pregnant=90) were compared for the 
percentage of sperm within each cluster using previously identified cluster centres. 
Clusters Identified from IUI Preparations 
Statistic DG 1 DG 2 DG 3 DG 4 DG 5 DG 6 DG 7 DG 8 
Pregnancy Y N Y N Y N Y N Y N Y N Y N Y N 
Median 20 21 13 14 4 5 3 5 13 9 10 10 6 8 20 15 
Mean 24 23 15 15 6 8 5 8 13 9 11 10 6 10 20 16 
P Value 0.794 0.816 0.342 0.050 0.043 0.697 0.042 0.043 
Clusters Identified from Semen 
Cluster SEM 1 SEM 2 SEM 3 SEM 4 SEM 5 SEM 6 SEM 7 SEM 8 
Pregnancy Y N Y N Y N Y N Y N Y N Y N Y N 
Median 7 10 16 9 5 9 13 14 10 10 7 11 21 14 17 14 
Mean 7 10 15 11 6 10 14 16 9 11 8 12 22 17 17 14 
P Value 0.017 0.013 0.006 0.856 0.161 0.037 0.051 0.069 
DG=Density gradient cluster, SEM=Semen Cluster 
 
Table 9-8 Significant and close to significant ROC predictors of pregnancy from VLC distribution measures for 
IUI patients (n=100, pregnant=20, non-pregnant=80). 
Parameter Area Significance 
95% Confidence Interval 
Lower Upper  
Sum .647 .043 .527 .768 
Centile25th .643 .049 .516 .770 
Centile50th .637 .060 .512 .761 
Centile75th .635 .063 .518 .752 
Centile90th .648 .042 .528 .769 
Centile95th .636 .062 .521 .751 
ROC=Receiver Operator Characteristic, VLC=Curvilinear Velocity, IUI=Intrauterine Insemination 
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Table 9-9 Significant and close to significant ROC predictors of pregnancy from WOB distribution measures 
for IUI patients (n=100, pregnant=20, non-pregnant=80). 
Test Area Significance 
95% Confidence Interval 
Lower Upper 
Skewness .634 .049 .501 .769 
Centile50th .373 .080 .231 .515 
Centile75th .368 .070 .228 .508 
Centile90th .362 .057 .225 .499 
Centile95th .360 .054 .221 .499 
ROC=Receiver Operator Characteristic, WOB=Wobble, IUI=Intrauterine Insemination 
 
Table 9-10 Significant and close to significant ROC predictors of pregnancy from ALH distribution measures 
for IUI patients (n=100, pregnant=20, non-pregnant=80). 
Test Area Significance 
95% Confidence Interval 
Lower Upper 
Variance .655 .005 .615 .815 
Sum .688 .009 .570 .806 
Centile50th .671 .019 .554 .787 
Centile75th .713 .003 .599 .826 
Centile90th .729 .002 .614 .845 
Centile95th .697 .007 .571 .822 
ROC=Receiver Operator Characteristic, ALH=Amplitude of Lateral Head Displacement, IUI=Intrauterine 
Insemination 
 
Table 9-11 Significant and close to significant ROC predictors of pregnancy from BCF distribution measures 
for IUI patients (n=100, pregnant=20, non-pregnant=80). 
Test Area Significance 
95% Confidence Interval 
Lower Upper 
Variance .331 .020 .200 .463 
Centile5th .670 .019 .551 .789 
Centile10th .668 .021 .551 .784 
Centile25th .621 .095 .497 .745 
ROC=Receiver Operator Characteristic, BCF=Beat Cross Frequency, IUI=Intrauterine Insemination 
 
Table 9-12 Significant and close to significant ROC predictors of pregnancy from UCV distribution measures 
for IUI patients (n=100, pregnant=20, non-pregnant=80). 
Test Area Significance 
95% Confidence Interval 
Lower Upper 
Skewness .321 .014 .207 .435 
Sum .673 .017 .550 .795 
Centile5th .630 .073 .493 .767 
Centile10th .653 .035 .523 .783 
Centile25th .686 .010 .561 .810 
Centile50th .691 .009 .567 .814 
Centile75th .647 .043 .526 .767 
ROC=Receiver Operator Characteristic, UCV=Uncurving Velocity, IUI=Intrauterine Insemination 
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Table 9-13 SCA CASA morphology sperm head measurements (n=3590) from fertile men (n-12). 
Statistic 
Length 
(µm) 
Width 
(µm) 
Length/Width 
(Ratio) 
Area 
(µm
2
) 
Perimeter 
(µm) 
Acrosome 
(%) 
25
th
 Centile 3.47 2.02 1.41 5.987 9.74 31.66 
Median 3.81 2.33 1.61 7.327 10.62 43.70 
75
th
 Centile 4.17 2.60 1.89 8.518 11.48 52.76 
Mean 3.85 2.31 1.68 7.339 10.67 43.29 
Std. Dev. 0.56 0.41 0.37 1.123 1.352 18.00 
Low 95% CI 3.83 2.30 1.669 7.282 10.63 42.70 
High 95% CI 3.87 2.33 1.692 7.396 10.72 43.88 
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9.4 Appendix D Chapter Seven Supplementary Results 
 
Table 9-14 Median percentages of patient sperm within fertility clusters pre-freeze and post-freeze for non-
cancer patient ejaculates (n=226) and post-freeze for cancer patients ejaculates (n=521). 
Group DG 1 DG 2 DG 3 DG 4 DG 5 DG 6 DG 7 DG 8 
Non-Cancer  
Pre Freeze 
41.36 14.25 0.00 0.87 1.46 11.11 0.056 25.78 
Non-Cancer  
Post Freeze 
44.44 10.92 0.00 0.00 0.00 9.09 0.00 32.24 
Pre vs Post (p) <0.001 <0.001 <0.001 <0.001 <0.001 0.043 <0.001 <0.001 
Cancer  
Post Freeze 
45.33 11.06 0.00 0.00 0.00 8.89 0.00 32.75 
Cancer vs.Non-Cancer (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Group SEM 1 SEM 2 SEM 3 SEM 4 SEM 5 SEM 6 SEM 7 SEM 8 
Non-Cancer  
Pre Freeze 
9.75 19.82 7.30 0.08 9.40 2.46 32.89 11.86 
Non-Cancer 
 Post Freeze 
4.167 29.41 2.72 0.00 3.33 0.00 45.93 5.99 
Pre vs Post (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Cancer 
 Post Freeze 
5.155 29.04 3.57 0.00 4.17 0.00 47.02 5.71 
Cancer vs.Non-Cancer (p) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
DG=Density gradient cluster, SEM=Semen Cluster 
 
Table 9-15 Median deprivation indices for cancer patients (n=217) and non-cancer patients (n=221). 
Group IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
& 
Environment 
Cancer 13.82 0.12 0.065 -0.71 8.43 28.42 0.02 27.81 
Non-Cancer 22.55 0.15 0.074 -0.19 7.82 34.46 0.48 35.03 
p <0.001 <0.001 <0.001 <0.001 NS <0.001 <0.001 <0.001 
IMD= Index of Multiple Deprivation, NS=Not Significant. 
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Table 9-16 Correlations between deprivation indices and semen analysis parameters for all ejaculates 
(n=642) and cancer ejaculates (n=421). 
All Patients 
Parameter Stat IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
& 
Environment 
Semen 
Volume 
r
2
 0.08 -0.08 -0.06 -0.08 -0.02 0.00 -0.12 -0.08 
p 0.04 0.04 NS 0.04 NS NS 0.00 0.04 
Sperm 
Count 
r
2
 0.05 -0.05 -0.07 -0.06 -0.02 0.04 0.00 -0.09 
p NS NS 0.07 NS NS NS NS 0.02 
Progressive 
Motility 
r
2
 0.08 -0.08 -0.08 -0.07 -0.07 0.05 -0.02 -0.05 
p 0.05 0.05 0.05 NS NS NS NS NS 
Total 
Motility 
r
2
 0.03 -0.03 -0.04 -0.02 -0.01 0.05 0.04 -0.03 
p NS NS NS NS NS NS NS NS 
TMC 
r
2
 0.06 -0.06 -0.11 -0.12 0.00 -0.05 0.07 -0.10 
p NS NS 0.03 0.02 NS NS NS 0.05 
PMC 
r
2
 0.06 -0.06 -0.10 -0.12 -0.01 -0.04 0.07 -0.08 
p NS NS 0.03 0.01 NS NS NS NS 
Cancer Patients 
Parameter Stat IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
& 
Environment 
Semen 
Volume 
r
2
 -0.03 -0.01 -0.06 0.05 0.00 -0.07 -0.01 0.06 
p NS NS NS NS NS NS NS NS 
Sperm 
Count 
r
2
 -0.03 -0.09 -0.08 0.00 0.03 0.05 -0.09 -0.09 
p NS NS NS NS NS NS NS NS 
Progressive 
Motility 
r
2
 -0.07 -0.09 -0.08 -0.03 0.02 0.03 -0.07 -0.10 
p NS NS NS NS NS NS NS 0.05 
Total 
Motility 
r
2
 -0.04 -0.07 -0.04 0.02 0.04 0.04 -0.09 -0.10 
p NS NS NS NS NS NS NS 0.04 
TMC 
r
2
 -0.06 -0.11 -0.12 0.00 -0.05 0.07 -0.10 -0.05 
p NS 0.03 0.02 NS NS NS 0.05 NS 
PMC 
r
2
 -0.06 -0.10 -0.12 -0.01 -0.04 0.07 -0.08 -0.06 
p NS 0.03 0.01 NS NS NS NS NS 
IMD= Index of Multiple Deprivation, NS=Not Significant, TMC=Total Motile Count, PMC=Progressive Motile 
Count. 
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Table 9-17 Correlations between deprivation indices and post freeze parameters and recovery for all 
ejaculates (n=642), cancer ejaculates (n=421) and non-cancer ejaculates (221). 
Group 
& 
Parameter 
Stat IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
& 
Environment 
All 
TMC 
r
2
 -0.14 -0.13 -0.14 -0.13 0.08 -0.11 -0.13 -0.18 
p <0.01 <0.01 <0.01 <0.01 0.05 0.01 <0.01 <0.01 
Cancer 
TMC 
r
2
 -0.07 -0.09 -0.11 -0.07 0.08 -0.03 -0.03 -0.10 
p NS 0.07 0.02 NS NS NS NS 0.04 
Non-Cancer 
TMC 
r
2
 0.02 0.03 0.01 0.02 0.07 0.08 0.01 -0.07 
p NS NS NS NS NS NS NS NS 
All 
PMC 
r
2
 -0.14 -0.14 -0.14 -0.12 0.05 -0.10 -0.13 -0.18 
p <0.01 <0.01 <0.01 <0.01 0.19 0.01 <0.01 <0.01 
Cancer 
PMC 
r
2
 -0.07 -0.10 -0.12 -0.06 0.04 -0.03 -0.03 -0.11 
p NS 0.05 0.02 NS NS NS NS 0.03 
Non-Cancer 
PMC 
r
2
 -0.01 0.01 -0.01 -0.02 0.06 0.09 -0.06 -0.10 
p NS NS NS NS NS NS NS NS 
All TMC 
Recovery 
r
2
 -0.13 -0.11 -0.12 -0.11 0.08 -0.14 -0.06 -0.15 
p <0.01 0.01 <0.01 <0.01 NS <0.01 NS <0.01 
Cancer TMC 
Recovery 
r
2
 -0.06 -0.05 -0.08 -0.06 0.11 -0.08 0.05 -0.10 
p NS NS NS NS 0.03 NS NS 0.04 
Non-Cancer 
TMC 
Recovery 
r
2
 -0.10 -0.11 -0.13 -0.06 -0.01 -0.01 -0.14 -0.07 
p NS NS NS NS NS NS 0.05 NS 
All PMC 
Recovery 
r
2
 -0.13 -0.11 -0.11 -0.11 0.05 -0.14 -0.06 -0.15 
p <0.01 0.01 0.01 0.01 NS <0.01 NS <0.01 
Cancer PMC 
Recovery 
r
2
 -0.07 -0.07 -0.09 -0.06 0.06 -0.09 0.04 -0.10 
p NS NS NS NS NS NS NS 0.04 
Non-Cancer 
PMC 
Recovery 
r
2
 -0.08 -0.07 -0.08 -0.07 <0.01 -0.01 -0.16 -0.05 
p NS NS NS NS NS NS 0.02 NS 
IMD= Index of Multiple Deprivation, NS=Not Significant, TMC=Total Motile Count, PMC=Progressive Motile 
Count 
. 
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Table 9-18 Between-ampoule within-ejaculate parameter variance correlations for cancer ejaculates post 
freeze (n=325). 
Post-Freeze Between-ampoule 
 Variance 
 Post-Freeze Between-ampoule Variance 
Stat 
Progressive 
Motility 
CV% 
Total 
Motility 
CV% 
TMC 
CV% 
PMC 
CV% 
Count CV% 
r
2
 0.12 0.13 0.39 0.31 
p NS NS <0.001 <0.001 
Progressive Motility CV% 
r
2
 1.00 0.63 0.38 0.66 
p 
 
<0.001 <0.001 <0.001 
Total Motility CV% 
r
2
 0.63 1.00 0.67 0.48 
p <0.0001 
 
<0.001 <0.001 
TMC CV% 
r
2
 0.38 0.67 1.00 0.65 
p <0.001 <0.001 
 
<0.001 
PMC CV% 
r
2
 0.66 0.48 0.65 1.00 
p <0.001 <0.001 <0.001 
 
Ejaculates with TMC < 1.0x10
6
 not included in the analysis. TMC=Total Motile Count, PMC=Progressive 
Motile Count, CV=Coefficient of Variation 
 
Table 9-19 Between-ejaculate within patient semen parameter variance correlations post freeze (n=255) 
Post-Freeze 
 Between-ejaculate Variance 
 Post-Freeze Between-ejaculate Variance 
Stat 
Progressive 
Motility 
CV% 
Total 
Motility 
CV% 
TMC 
CV% 
PMC 
CV% 
Count CV% 
r
2
 0.52 0.53 0.36
*
 0.32 
p <0.001 <0.001 <0.001 <0.001 
Progressive Motility CV% 
r
2
 1.00 0.94 0.54 0.64 
p  <0.001 <0.001 <0.001 
Total Motility CV% 
r
2
 0.94 1.00 0.59 0.60 
p <0.001  <0.001 <0.001 
TMC CV% 
r
2
 0.54 0.59 1.00 0.91 
p <0.001 <0.001  <0.001 
PMC CV% 
r
2
 0.63 0.60 0.91 1.00 
p <0.001 <0.001 <0.001  
Ejaculates with TMC < 1.0x10
6
 not included in the analysis. TMC=Total Motile Count, PMC=Progressive 
Motile Count, CV=Coefficient of Variation 
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Table 9-20 Between-patient semen parameter variance correlations post-thaw (n=221). 
Post-Freeze Between-patient Variance 
 Post-Freeze Between-patient Variance 
Stat 
Progressive 
Motility 
CV% 
Total 
Motility 
CV% 
TMC 
CV% 
PMC 
CV% 
Count CV% 
r
2
 0.54 0.61 0.19 0.17 
p <0.001 <0.001 0.005 0.006 
Progressive Motility CV% 
r
2
 1 0.91 0.33 0.48 
p  <0.001 <0.001 <0.001 
Total Motility CV% 
r
2
 0.91 1 0.42 0.40 
p <0.001  <0.001 <0.001 
TMC CV% 
r
2
 0.33 0.42 1 0.88 
p <0.001 <0.001  <0.001 
PMC CV% 
r
2
 0.48 0.40 0.88 1 
p <0.001 <0.001 <0.001  
Ejaculates with TMC < 1.0x10
6
 not included in the analysis. TMC=Total Motile Count, PMC=Progressive 
Motile Count, CV=Coefficient of Variation 
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Figure 9-5 IUI and cancer patients between-ejaculate variance compared for semen volume and sperm count. 
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Figure 9-6 IUI and cancer patients between-ejaculate variance compared for progressive motility, total 
motility, TMC and PMC. 
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Table 9-21 Correlations between pre freeze semen and post freeze between-ejaculate variance in cancer 
patients (n=255). 
  
Between-ejaculate pre-freeze variance CV% 
Parameter Stat Count 
Progressive 
Motility 
Total 
Motility 
TMC PMC 
Between-
ejaculate 
Post Freeze 
Variance 
CV% 
Count 
r2 0.18 -0.01 0.00 0.07 0.08 
p 0.003 NS NS NS NS 
Progressive 
Motility 
r2 0.10 0.10 0.08 0.10 0.09 
p NS NS NS NS NS 
Total Motility 
r2 -0.01 -0.01 0.00 0.04 0.04 
p NS NS NS NS NS 
TMC 
r2 0.22 0.03 -0.01 0.07 0.07 
p <0.001 NS NS NS NS 
PMC 
r2 .26 0.12 0.07 0.10 0.12 
p <0.001 0.045 NS NS NS 
PMC=Progressive Motile Count, TMC=Total Motile Count, CV=Coefficient of Variation 
 
Table 9-22 Correlations between pre freeze semen variance and post freeze between-patient variance in 
cancer patients (n=221). 
  
Between-patient pre-freeze variance CV% 
Parameter Stat Count 
Progressive 
Motility 
Total 
Motility 
TMC PMC 
Between-
patient 
Post Freeze 
Variance 
CV% 
Count 
r2 0.45 0.22 0.27 0.40 0.36 
p <0.001 0.001 <0.001 <0.001 <0.001 
Progressive 
Motility 
r2 0.26 0.29 0.32 0.22 0.19 
p <0.001 <0.001 <0.001 0.001 0.004 
Total Motility 
r2 0.21
*
 0.20 0.23 0.15 0.13 
p 0.002 0.003 0.001 0.024 NS 
TMC 
r2 0.38
*
 0.22 0.26 0.39 0.36 
p <0.001 0.001 <0.001 <0.001 <0.001 
PMC 
r2 0.35 0.25
*
 0.29 0.41 0.37 
p <0.001 <0.001 <0.001 <0.001 <0.001 
PMC=Progressive Motile Count, TMC=Total Motile Count, CV=Coefficient of Variation 
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Table 9-23 ROC area under the graph and significance of sperm count and motility grading as predictors of 
post freeze TMC and PMC recovery. 
Parameter 
 
Area p Area p Area p Area p 
TMC<20% recovery TMC<30% recovery TMC<40% recovery TMC<50% recovery 
Count 0.48 NS 0.55 NS 0.59 0.018 0.59 0.030 
Ejaculate 
Count 
0.48 NS 0.56 NS 0.61 0.005 0.58 NS 
TMC 0.49 NS 0.58 0.039 0.64 0.001 0.60 0.021 
PMC 0.51 NS 0.57 NS 0.63 0.001 0.59 0.035 
A Class 0.60 0.040 0.65 <0.001 0.63 0.001 0.61 0.010 
B Class 0.62 0.015 0.69 <0.001 0.67 <0.001 0.66 <0.001 
A+B Class 0.62 0.013 0.68 <0.001 0.66 <0.001 0.64 0.001 
C Class 0.61 0.027 0.67 <0.001 0.67 <0.001 0.67 <0.001 
B+C Class 0.63 0.012 0.69 <0.001 0.68 <0.001 0.66 <0.001 
D Class 0.63 0.008 0.70 <0.001 0.67 <0.001 0.65 <0.001 
Parameter 
 
Area p Area p Area p Area p 
PMC<10% recovery PMC<20% recovery PMC<30% recovery PMC<40% recovery 
Count 0.521 0.705 0.59 0.028 0.60 0.011 0.62 0.005 
Ejaculate 
Count 
0.48 0.802 0.59 0.031 0.60 0.013 0.64 0.001 
TMC 0.52 0.669 0.63 0.002 0.64 <0.001 0.68 <0.001 
PMC 0.53 0.506 0.63 0.002 0.62 0.002 0.67 <0.001 
A Class 0.62 0.028 0.63 0.002 0.71 <0.001 0.69 <0.001 
B Class 0.64 0.009 0.69 <0.001 0.75 <0.001 0.73 <0.001 
A+B Class 0.65 0.006 0.68 <0.001 0.75 <0.001 0.72 <0.001 
C Class 0.61 0.043 0.69 <0.001 0.73 <0.001 0.73 <0.001 
B+C Class 0.65 0.006 0.70 <0.001 0.76 <0.001 0.74 <0.001 
D Class 0.67 0.002 0.70 <0.001 0.77 <0.001 0.74 <0.001 
PMC=Progressive Motile Count, TMC=Total Motile Count 
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Table 9-24 CASA clusters and motility descriptor variables as predictors of post freeze TMC recovery. 
 
Predicting <20% 
recovery of TMC 
Predicting <30% 
recovery of TMC 
Predicting <40% 
recovery of TMC 
Predicting <50% 
recovery of TMC 
Variable Area p Area p Area p Area p 
DG 1 0.51 NS 0.50 NS 0.46 NS 0.48 NS 
DG 2 0.47 NS 0.49 NS 0.54 NS 0.50 NS 
DG 3 0.55 NS 0.56 NS 0.57 0.082 0.57 NS 
DG 4 0.62 0.021 0.63 <0.001 0.66 <0.001 0.63 <0.001 
DG 5 0.53 NS 0.56 NS 0.59 0.026 0.61 0.010 
DG 6 0.43 NS 0.46 NS 0.51 NS 0.48 NS 
DG 7 0.58 NS 0.58 NS 0.59 0.03 0.58 NS 
DG 8 0.41 NS 0.42 0.049 0.36 0.005 0.40 0.021 
SEM 1 0.58 NS 0.61 0.017 0.63 <0.001 0.60 0.024 
SEM 2 0.37 0.014 0.35 0.004 0.32 0.003 0.33 <0.001 
SEM 3 0.59 NS 0.62 0.013 0.65 <0.001 0.61 0.012 
SEM 4 0.55 NS 0.56 NS 0.57 NS 0.58 NS 
SEM 5 0.54 NS 0.54 NS 0.63 <0.001 0.59 0.042 
SEM 6 0.61 0.047 0.63 0.001 0.67 <0.001 0.64 <0.001 
SEM 7 0.42 NS 0.42 NS 0.37 <0.001 0.41 0.032 
SEM 8 0.47 NS 0.49 NS 0.52 NS 0.53 NS 
VLC 90th 0.55 NS 0.60 0.029 0.58 NS 0.54 NS 
WOB 
Skew 
0.50 NS 0.50 NS 0.50 NS 0.50 NS 
ALH 90th 0.58 NS 0.60 0.026 0.57 NS 0.56 NS 
BCF 5th 0.54 NS 0.60 0.023 0.56 NS 0.55 NS 
UCV 50th 0.60 NS 0.64 <0.001 0.60 0.023 0.58 NS 
DG=Density gradient cluster, SEM=Semen Cluster, PMC=Progressive Motile Count, TMC=Total Motile Count, 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency, UCV=Uncurving Velocity, NS=Not Significant. 
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Table 9-25 CASA clusters and motility descriptor variables as predictors of thaw PMC recovery. 
 
Predicting <10% 
recovery of PMC 
Predicting <20% 
recovery of PMC 
Predicting <30% 
recovery of PMC 
Predicting <40% 
recovery of PMC 
Variable Area p Area p Area p Area p 
DG 1 0.51 NS 0.41 0.042 0.40 0.009 0.39 0.018 
DG 2 0.50 NS 0.56 NS 0.59 0.032 0.61 0.012 
DG 3 0.52 NS 0.57 NS 0.56 NS 0.55 NS 
DG 4 0.53 NS 0.62 <0.001 0.60 0.011 0.62 0.011 
DG 5 0.52 NS 0.58 0.049 0.59 0.031 0.59 0.043 
DG 6 0.49 NS 0.54 NS 0.56 NS 0.57 NS 
DG 7 0.53 NS 0.58 NS 0.53 NS 0.55 NS 
DG 8 0.44 NS 0.40 0.027 0.38 <0.001 0.37 0.002 
SEM 1 0.48 NS 0.57 NS 0.59 0.035 0.59 0.031 
SEM 2 0.49 NS 0.40 0.021 0.38 0.014 0.38 0.006 
SEM 3 0.48 NS 0.58 NS 0.60 0.021 0.61 0.012 
SEM 4 0.49 NS 0.54 NS 0.52 NS 0.54 NS 
SEM 5 0.49 NS 0.57 NS 0.61 0.014 0.63 <0.001 
SEM 6 0.53 NS 0.61 0.010 0.60 0.018 0.63 <0.001 
SEM 7 0.46 NS 0.37 <0.001 0.36 0.004 0.35 0.003 
SEM 8 0.49 NS 0.54 NS 0.55 NS 0.56 NS 
VLC 90th 0.61 0.049 0.58 NS 0.65 <0.001 0.63 <0.001 
WOB 
Skew 
0.49 NS 0.50 NS 0.50 NS 0.51 NS 
ALH 90th 0.62 0.031 0.58 0.049 0.65 <0.001 0.62 0.010 
BCF 5th 0.65 0.012 0.58 NS 0.63 <0.001 0.60 0.019 
UCV 50th 0.63 0.021 0.63 <0.001 0.69 <0.001 0.64 <0.001 
DG=Density gradient cluster, SEM=Semen Cluster, PMC=Progressive Motile Count, TMC=Total Motile Count, 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency, UCV=Uncurving Velocity, NS=Not Significant. 
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Table 9-26 Post freeze motility correlations with pre-freeze motility measures. 
Post 
Freeze 
Parameter 
A Class Motility A+B Class Motility D Class Motility 
37
0
 4
0
 37
0
 4
0
 37
0
 4
0
 
A 0.57 0.78 0.54 0.74 -0.53 -0.69 
A+B 0.40 0.64 0.37 0.63 -0.36 -0.59 
D -0.31 -0.49 -0.34 -0.51 0.33 0.50 
DG 1 -0.46 -0.57 -0.46 -0.60 0.45 0.58 
DG 2 0.56 0.72 0.52 0.68 -0.50 -0.62 
DG 3 -0.03 0.18 -0.03 0.14 -0.01 -0.14 
DG 4 0.04 0.30 0.05 0.27 -0.08 -0.29 
DG 5 0.33 0.46 0.30 0.47 -0.27 -0.44 
DG 6 0.56 0.69 0.51 0.66 -0.48 -0.59 
DG 7 0.02 0.30 -0.01 0.29 0.00 -0.30 
DG 8 -0.13 -0.30 0.01 -0.20 -0.05 0.11 
SEM 1 -0.05 -0.10 -0.08 -0.13 0.10 0.15 
SEM 2 0.32 0.34 0.30 0.31 -0.28 -0.27 
SEM 3 -0.10 -0.04 -0.12 -0.06 0.13 0.09 
SEM 4 0.04 0.31 0.04 0.30 -0.04 -0.30 
SEM 5 0.32 0.56 0.31 0.52 -0.30 -0.46 
SEM 6 0.19 0.47 0.20 0.45 -0.22 -0.45 
SEM 7 -0.42 -0.59 -0.33 -0.51 0.29 0.42 
SEM 8 0.52 0.68 0.46 0.63 -0.44 -0.56 
VLC 90th 0.45 0.65 0.37 0.58 -0.34 -0.52 
WOB Skew -0.51 -0.50 -0.51 -0.50 0.48 0.49 
ALH 90th 0.10 0.22 0.08 0.19 -0.06 -0.17 
BCF 5th -0.01 0.02 -0.06 -0.01 0.09 0.03 
VAP/LIN 50th 0.20 0.31 0.07 0.24 0.02 -0.15 
DG=Density gradient cluster, SEM=Semen Cluster, PMC=Progressive Motile Count, TMC=Total Motile Count, 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency, UCV=Uncurving Velocity, NS=Not Significant. 
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Table 9-27 Significant ROC area under the curve predicting poor freezers from pre freeze parameters 
 
Predicting <25% 
recovery of TMC 
Predicting <30% 
recovery of TMC 
Predicting <40% 
recovery of TMC 
Predicting <50% 
recovery of TMC 
Variable Area p Area p Area p Area p 
Semen Variables Measured 60 minutes after production 
Count 0.72 0.002 0.67 0.014 0.67 0.014 0.69 0.012 
A Mot. 0.66 0.031 0.68 0.012 0.77 <0.001 0.76 <0.001 
B Mot. 0.76 <0.001 0.76 <0.001 0.82 <0.001 0.81 <0.001 
A+B Mot. 0.72 0.003 0.74 0.006 0.82 <0.001 0.81 <0.001 
C Mot. 0.74 0.002 0.74 0.002 0.76 <0.001 0.77 <0.001 
D Mot. 0.25 0.009 0.24 <0.001 0.17 <0.001 0.18 <0.001 
DG 4 0.64 NS 0.72 0.001 0.74 <0.001 0.68 0.019 
DG 5 0.52 NS 0.60 NS 0.63 NS 0.63 NS 
DG 7 0.59 NS 0.64 0.042 0.67 0.016 0.67 0.021 
DG 8 0.44 NS 0.43 NS 0.35 0.023 0.39 NS 
SEM 2 0.36 NS 0.31 0.019 0.28 0.009 0.29 0.003 
SEM 3 0.63 NS 0.64 NS 0.64 0.043 0.62 NS 
SEM 4 0.58 NS 0.62 NS 0.65 0.028 0.65 0.031 
SEM 5 0.61 NS 0.60 NS 0.66 0.022 0.66 0.036 
SEM 6 0.59 NS 0.65 0.032 0.66 0.02 0.62 NS 
SEM 7 0.43 NS 0.39 NS 0.33 0.011 0.37 NS 
VLC 90th 0.58 NS 0.63 NS 0.66 0.025 0.63 NS 
ALH 90th 0.64 NS 0.65 0.033 0.65 0.029 0.65 0.041 
BCF 5th 0.71 0.002 0.70 0.001 0.72 0.002 0.70 0.017 
VAP/LIN 
50th 
0.61 NS 0.66 0.021 0.71 0.004 0.66 0.026 
VCL 5th 0.63 NS 0.69 0.015 0.72 0.006 0.69 0.012 
VSL 5th 0.73 0.002 0.75 <0.001 0.79 <0.001 0.80 <0.001 
VAP 5th 0.73 0.001 0.76 <0.001 0.81 <0.001 0.80 <0.001 
LIN 5th 0.59 NS 0.63 NS 0.72 0.006 0.76 <0.001 
WOB 5th 0.67 0.029 0.73 0.002 0.78 <0.001 0.77 <0.001 
ALH 5th 0.64 NS 0.70 0.003 0.79 <0.001 0.80 <0.001 
BCF 5th 0.71 0.001 0.70 0.001 0.72 0.001 0.70 0.011 
VAP/LIN 
5th 
0.66 0.043 0.70 0.008 0.74 <0.001 0.71 0.002 
Semen Variables measured after 30 minutes at 4
0
 
DG 5 0.35 0.048 0.40 NS 0.45 NS 0.51 NS 
ALH 90th 0.37 NS 0.38 NS 0.36 0.041 0.37 NS 
VAP/LIN 
50th 
0.35 0.049 0.35 0.033 0.38 NS 0.37 NS 
DG=Density gradient cluster, SEM=Semen Cluster, PMC=Progressive Motile Count, TMC=Total Motile Count, 
CV=Coefficient of Variation, VLC=Curvilinear Velocity, VSL=Straight-Line Velocity, VAP=Average Path 
Velocity, LIN=Linearity, STR=Straightness, WOB=Wobble, ALH=Amplitude of Lateral Head Displacement, 
BCF=Beat Cross Frequency, UCV=Uncurving Velocity, NS=Not Significant. 
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Table 9-28 Correlations between deprivation indices and cholesterol measurements in semen and seminal 
plasma. 
Parameter Stat IMD Income Employment Health 
Education 
& 
Training 
Barriers 
to 
Housing 
Crime 
Living 
Environment 
Neat 
Semen 
 
r
2
 0.30 0.33 0.34 0.15 0.25 0.05 0.15 0.09 
p 0.005 0.004 0.002 NS 0.049 NS NS NS 
Seminal 
Plasma 
 
r
2
 0.39 0.40 0.46 0.24 0.24 0.01 0.22 0.14 
p 0.004 0.002 0.002 NS NS NS NS NS 
Semen 
Cell 
Cholesterol 
r
2
 -0.02 0.02 0.05 -0.06 0.08 -0.14 0.16 -0.03 
p NS NS NS NS NS NS NS NS 
IMD=Index of Multiple Deprivations, NS=Not Significant. 
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 ORIGINAL ARTICLE 
 Validation of the sperm class analyser CASA system for sperm counting in 
a busy diagnostic semen analysis laboratory 
 CHEY G.  DEARING 1 ,  SALLY  KILBURN 2  &  KEVIN S.  LINDSAY 1 
 1 Andrology Laboratory, Hammersmith Hospital, Imperial College NHS Trust, London, UK and  2 School of Health Sciences and 
Social Work, Portsmouth University, Portsmouth, UK 
 Abstract 
 Sperm counts have been linked to several fertility outcomes making them an essential parameter of semen analysis. It has become 
increasingly recognised that Computer-Assisted Semen Analysis (CASA) provides improved precision over manual methods but 
that systems are seldom validated robustly for use. The objective of this study was to gather the evidence to validate or reject 
the Sperm Class Analyser (SCA) as a tool for routine sperm counting in a busy laboratory setting. The criteria examined were 
comparison with the Improved Neubauer and Leja 20- μ m chambers, within and between fi eld precision, sperm concentration 
linearity from a stock diluted in semen and media, accuracy against internal and external quality material, assessment of uneven 
fl ow effects and a receiver operating characteristic (ROC) analysis to predict fertility in comparison with the Neubauer method. 
This work demonstrates that SCA CASA technology is not a standalone  ‘ black box ’ , but rather a tool for well-trained staff that 
allows rapid, high-number sperm counting providing errors are identifi ed and corrected. The system will produce accurate, linear, 
precise results, with less analytical variance than manual methods that correlate well against the Improved Neubauer chamber. The 
system provides superior predictive potential for diagnosing fertility problems. 
 Keywords:  Computer-assisted semen analysis ,  validation ,  semen analysis ,  sperm count ,  sperm class analyser 
 Introduction 
 Semen analysis is generally regarded as mandatory in the 
assessment of male infertility. In the United Kingdom 
(UK) the National Institute for Clinical Excellence rec-
ommends semen analysis for all male partners of couples 
who have been unsuccessful with natural conception for 
greater than 12 months (NICE, 2012). The two major 
quantifi able elements of a semen ejaculate are the total 
number of spermatozoa present and the total volume 
of fl uid. While sperm concentration itself is not a direct 
measure of testicular function, since fi nal semen volume 
includes secretions from the seminal vesicles and pros-
tate (Eliasson, 1975), the total ejaculate spermatozoa 
number is related to various fertility endpoints (Bonde 
et  al., 1998; Larsen et  al., 2000; Vanweert et  al., 2004; 
Cooper et  al., 2010; Sripada et  al., 2010). Additionally, 
once this dilution effect and abstinence are accounted 
for, the total number of sperm in the ejaculate does 
correlate with testicular volume (Handelsman et  al., 
1984; WHO, 1987; Behre et  al., 1997) and is indicative of 
the sperm production capability of the testes (MacLeod 
 & Wang, 1979). The sperm count thus is a critical 
parameter in the semen analysis profi le. 
 Sperm counts from 4500 men from 14 countries 
whose partner achieved a pregnancy within 12 months 
exhibit a large range of counts (Cooper et  al., 2010). 
The World Health Organisation (WHO) use the 5th 
percentile from this data as a one-sided reference 
range for sperm counting, though acknowledge that 
the reference range can only be used as a guide, as se-
men characteristics are not exclusive determinants of a 
couple ’ s fertility (WHO, 2010). In addition to counting 
sperm in semen, counting separated samples prior to 
insemination in assisted fertility treatments can offer 
predictive information (Vanweert et  al., 2004). Few 
studies discuss the implications of analytical variance 
on sperm count predictors. 
 In order to quantify spermatozoa, the WHO 
recommends that a minimum of 200 sperm should be 
counted in replicate, and if the replicates are not close, 
new dilutions should be made and the process repeated 
(WHO, 2010). Counting lower numbers proportionally 
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increases the 95% confi dence interval range provid-
ing reduced clinical information. Unfortunately, tech-
niques of semen analysis have previously been shown 
to be poorly implemented in many routine laboratories 
who may fail to understand the implications of smaller 
sample sizes (Matson, 1995; Keel et  al., 2002; Keel, 
2004; Riddell et  al., 2005; Pacey, 2006). The propor-
tion of UK semen analysis laboratories that are actu-
ally counting a minimum of 200 sperm in duplicate is 
unknown, though individual laboratories often admit 
to adopting methods that allow smaller numbers to be 
analysed (KS Lindsay, personal communication, May 
2012). Certainly the UK National External Quality 
Assessment Service (UKNEQAS) laboratory variance 
results suggest that the WHO sperm number recom-
mendations are not universally followed (Pacey, 2006). 
 The WHO recommends counting diluted fi xed sperm 
using a 100- μ m deep haemocytometer chamber and gives 
particular attention to the Improved Neubauer chamber 
(WHO, 2010). However the recommendations are labo-
rious and need to be followed to a high analytical stan-
dard. The WHO recognises that disposable chambers for 
sperm counting are also available (Seaman et  al., 1996; 
Mahmoud et  al., 1997, Brazil et  al., 2004), but warns 
that they may generate signifi cantly different results 
from the Neubauer, and thus need extensive validation 
before use (WHO, 2010). Uneven sperm distribution 
has also been noted with disposable chambers (Douglas-
Hamilton et  al., 2005a, 2005b) and although correction 
factors for this effect are available (Douglas-Hamilton 
et  al., 2005b), they are not universally accepted as 
adequate (Bj ö rndahl  & Barratt, 2005). 
 A solution to some of the uncertainty surrounding 
sperm counting may be the use of Computer-Assisted 
Semen Analysis (CASA). CASA concentration and 
motility data have been shown to relate to various fertility 
measures (Check et  al., 1990; Barratt et  al., 1993; Larsen 
et  al., 2000; Garrett et  al., 2003; Shibahara et  al., 2004). 
Although CASA-specifi c counting overestimations due 
to the recognition of particulate matter as sperm have 
been well documented (ESHRE, 1998), some systems 
have been shown to count sperm accurately (Zinaman 
et  al., 1996; Garrett et  al., 2003; Agarwal  & Sharma, 
2007; Tomlinson et  al., 2010). The WHO recognises that 
CASA offers improved precision over manual meth-
ods and can now be applied to routine semen analysis, 
provided adequate quality control procedures and high 
measurement standards are followed (WHO, 2010). This 
paper aims to illustrate the process validation required 
to assess adequately the commercially available Sperm 
Class Analyser (SCA) CASA system as a counting 
method in an accredited UK semen analysis laboratory. 
 Materials and methods 
 SCA 
 The SCA CASA system ( SCA V 4.0, MICROPTIC S.L. 
Viladomat, 321 - 6 ∞ 4 ª 08029 Barcelona, Spain ) is a PC 
software programme that requires a high-resolution 
camera (minimum 25 frames per second) attached to a 
phase contrast microscope. The SCA system also offers 
sperm motility, morphology, vitality and DNA fragmen-
tation options, though only sperm concentration was 
assessed in this work. No special lighting conditions are 
required though the user is responsible for maintaining 
Kohler illumination, phase contrast and optimal focus 
during analysis which takes 1 second per single fi eld. 
Particle size detected can be adjusted if required though 
only the manufacture ’ s settings were used in this work. 
The user chooses to accept or reject each analysis fi eld 
which can be saved for later quality checking if required. 
Full details including minimum PC requirements are 
available from http://www.micropticsl.com. 
 Population and chamber comparisons 
 Totally 352 patients attending our laboratory for semen 
analysis had their sperm count estimated by both 
the WHO Improved Neubauer method (WHO, 2010; 
Tomlinson et  al., 2012) and SCA CASA. Samples were 
left standing to liquefy (maximum of one hour), and 
then thoroughly mixed on a vortex mixer to ensure a 
homogeneous sample. For Neubauer counts a 1:19 
dilution of sample into 1%  v/v formal saline was made 
using 100  μ l of semen with a positive displacement 
pipette. The dilution was mixed on a vortex mixer and 
transferred with a glass capillary into an Improved 
Neubauer haemocytometer. For Leja and CASA counts, 
samples were mixed on a vortex mixer and transferred 
with a glass capillary into a chamber. All chambers were 
allowed to settle and sperm cells counted by phase con-
trast light microscopy. CASA counts were performed 
uncorrected and corrected. Uncorrected counts are 
achieved by taking the CASA count given by the system 
irrespective of counting errors. Corrected CASA counts 
were obtained by continuously repeating a one second 
video of a random single fi eld of view from the Leja 
20- μ m slide. All the sperm visible on that single fi eld 
are counted manually; dividing this result by a factor 
of six converts the result to 10 6 /ml. All CASA counts 
were performed at 100    magnifi cation. Azoospermic 
samples and post vasectomy samples without sperm 
and samples with high Nucleated Cells Other than 
Sperm (NCOS) counts/debris were used for blank and 
recovery experiments. 
 Accuracy 
 Leja 20- μ m chambers ( 20 m m Leja slides, Leja; Gynotec 
Malden, Nieuw Vennep, The Netherlands ) were prepared 
with two levels of accubead quality control material 
( Hamilton Thorne Biosciences, 100 Cummings Center, Suite 
465C, Beverly, MA 01915 ). Twenty chambers were 
completely fi lled with a well-mixed aliquot of accubead 
quality control material (10 chambers for each con-
centration) and left to stand for 5 min. Each chamber 
was analysed using three and fi ve fi elds of analysis at 
100    magnifi cation. 
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 External quality control 
 UK NEQAS samples used for this project were pooled 
semen fi xed in 10%  v/v formalin prepared by the UK 
NEQAS Reproductive Science Scheme ( Reproductive 
Medicine, Andrology Laboratories, Saint Mary ’ s Hospital, 
Manchester, United Kingdom, M13 9WL ). Sixteen UK 
NEQAS samples refl ecting one year of returns were 
analysed by SCA CASA and compared with the results 
of fi ve trained staff. 
 Precision 
 Single fi eld and means of three and fi ve fi elds of analysis 
were estimated by analysing a minimum of 10 cham-
bers. Each chamber was analysed 10 times to generate 
CV% for two levels of accubead quality control material, 
immotile sperm in semen, motile sperm in semen and 
motile sperm in media. Precision was also calculated 
for varying numbers of sperm (estimated as the mean 
number of sperm per motile sperm fi eld). Precision pro-
fi les were generated for motile sperm and the effects of 
increasing fi eld number examined. 
 Sperm concentration linearity 
 Sperm concentration linearity was estimated on sperm 
in semen and swim sperm in media. A single pool of 
semen was made as a stock solution from the samples 
of 10 men with high (   80    10 6 /ml) sperm counts. The 
pooled sample was serially diluted with pooled cell/
debris free seminal plasma. Pooled swim sperm from 
10 men was centrifuged, the supernatant decanted 
and the pellet re-suspended in 1 ml of fl ushing media 
( Origio 1084 1076  Origio a/s Knardrupvej 2 DK-2760 
M å l ø v Denmark ). The concentrated sample was then 
serially diluted with fl ushing media. Neat and diluted 
samples were analysed by the SCA CASA system using 
means from fi ve fi elds of analysis. 
 Chamber bias, dimensions and Segre-Silberberg effects 
 Nine specifi c areas were identifi ed and counted on 
10 Leja 20- μ m chambers for two levels of accubead 
quality control material. The count on Area 1 was 
repeated at the end to test for dehydration effects that 
may have occurred during the experiment. Slides had 
10 single fi eld analyses made on each area to examine 
if single fi eld precision was different between areas. 
A further test of the Segre-Silberberg (SS) effect was 
performed with 16 semen samples of immotile sperm 
measured for the same nine areas as described above. 
 Recovery experiments 
 Ten separate SCA CASA count recovery estimations 
were made by spiking concentrated pooled semen into 
cell/debris free pooled seminal plasma and sperm free 
seminal plasma with a high concentration of NCOS/
debris. Percentage recovery was calculated for each 
estimation. 
 Clinical decision tables 
 Agreement between the Improved Neubauer and 
the Leja 20  μ m manual method with uncorrected and 
corrected SCA CASA counts for three clinically impor-
tant ranges (1 – 5    10 6 , 6 – 15    10 6 , and    15    10 6 ) were 
made. The number of comparisons, correlation within 
the given range, p value and the percentage agreement 
of results within the range were calculated for each 
separate clinically meaningful range. 
 ROC analysis 
 Totally 1011 intrauterine insemination (IUI) preparation 
results from 530 patients attending the laboratory between 
February 2008 and May 2012 were collated and analy-
sed. Results for all men who achieved a pregnancy with 
their partner after IUI from that or subsequent samples 
(191 semen samples from 102 men) were compared to 
those from all men who did not achieve a pregnancy 
with IUI (823 semen samples from 436 men). Separate 
comparisons were made using SCA CASA data from 
May 2012 until December 2012 (16 successful couples 
and 74 unsuccessful). 
 Statistics 
 Correlations were performed by Spearman ’ s and regres-
sion lines calculated using Deming ’ s regression for all 
analysis between manual counting chambers and SCA 
CASA. Linear regression was used for linearity experi-
ments. Bland – Altman plots were constructed to test for 
bias. Signifi cant differences between counts from nine 
different areas of the Leja 20- μ m chamber were tested 
for by ANOVA with Dunn ’ s as a post-hoc test. Signifi -
cant differences between proximal, central and distal 
areas of the chamber were tested by unpaired t-test. The 
data were analysed using Prism version 4.0 ( GraphPad 
Version 4.01,San Diego, CA, USA, www.graphpad.com ) 
on a Samsung personal computer ( Samsung NC10 
Samsung Electronics, Samsung.com ). 
 Results 
 Chamber comparisons 
 The sperm count results of trained staff from the 
Andrology Laboratory at Hammersmith Hospital (com-
bined results of four operators using both Improved 
Neubauer and Leja 20- μ m manual counting methods) 
showed a strong correlation with SCA CASA (r 2    0.95) 
without correcting for counting errors (see Figure 1). 
A strong correlation with SCA CASA was also evident 
when the two manual counting methods were separat-
ed, Neubauer (r 2    0.94) and Leja (r 2    0.92). However, 
overestimation of low (   15    10 6 ) sperm counts was 
noted and resulted in poor correlations at those concen-
trations: counts below 5    10 6 Neubauer (r 2    0.66) and 
Leja (r 2    0.56), counts 5 – 15    10 6 Neubauer (r 2    0.64) 
and Leja (r 2    0.74). 
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 Figure 1. Correlation of Manual Counting Methods with SCA 
CASA . Spermatozoa counts for patient ’ s samples were measured by 
Neubauer or Leja 20- μ m chambers and by the SCA CASA system. 
 Figure 2. Bland – Altman of SCA CASA bias. (A) Difference (SCA 
count  – Improved Neubauer Count) versus average count. CASA 
results are not corrected for observed counting errors. (B) Difference 
(SCA count  – Leja Count) versus average count. CASA results are not 
corrected for observed counting errors. (C) Difference (SCA screen 
count  – Leja Manual Count) versus average count. CASA results are 
corrected for observed counting errors. 
 Overestimation was demonstrated on Bland – Altman 
plots as a moderate positive bias at low counts compared 
with the Improved Neubauer chamber and a large posi-
tive proportional bias compared with that of the Leja 
20- μ m chamber. The positive bias was increased at 
counts below 30    10 6 and reduced at counts 30    10 6 or 
above (see Figure 2). To correct this bias further tests on 
samples with sperm counts below 30    10 6 demonstrat-
ed that capturing a one-second video from SCA CASA 
and manually counting all the sperm on the computer 
screen correlated highly (r 2    0.99) with the manual 
Leja 20- μ m method. Using this method of performing 
counts from the CASA screen for results below 30    10 6 
combined with uncorrected CASA counts for results 
30    10 6 or above resulted in an excellent overall correla-
tion against the Improved Neubauer method (r 2    0.98). 
There was no bias observed using the one-second videos 
from the SCA CASA screen (see Figure 2). 
 Precision 
 Single-fi eld precision was excellent with mean CV% 
below 1% on latex beads and a mean CV% of 2.4% 
on immotile sperm. Unsurprisingly, analysis of motile 
sperm resulted in higher single-fi eld CV% (mean of 
3.6% for semen and mean of 4.5% for swim sperm). 
Both motile and immotile sperm in semen and swim 
sperm displayed a heteroscedastic precision profi le with 
optimal precision at approximately 200 – 600 sperm per 
fi eld. Multiple fi eld precision was predictably higher 
than single-fi eld precision, though optimal multiple 
fi eld precision was also approximately 200 – 600 sperm 
per fi eld (see Figure 3). Precision decreased markedly 
below 100 sperm per fi eld. Precision improved for each 
increase in fi eld number included in the fi nal analysis, 
though each increase yielded a smaller improvement 
(see Table I). 
 Sperm concentration linearity 
 Pooled semen from 10 men with high (   80    10 6 /
ml) sperm counts serially diluted with pooled cell-free 
seminal plasma and analysed by the SCA CASA sys-
tem demonstrated excellent linearity (r 2    0.99). Pooled 
swim sperm centrifuged to pellet and re-suspended in 
fl ushing media, then serial diluted with fl ushing media 
also demonstrated excellent linearity (r 2    0.95). 
 External quality control 
 SCA CASA achieved the second highest correlation 
(r 2    0.97) against one year of UKNEQAS samples 
when compared to fi ve trained staff (r 2    0.98, 0.93, 
0.92, 0.92 and 0.72) from a laboratory that has never 
been a poor performer. While result bias compared with 
NEQAS consensus values for the Improved Neubauer 
was observed in two of the trained staff on Bland – 
Altman plots, no bias was detected on SCA CASA 
results. 
 Uneven fl ow effects 
 In a series of experiments testing the SS effect the same 
nine areas were counted on 10 Leja 20- μ m chambers 
for both levels of accubead quality control material. 
Distal areas had signifi cantly ( p    0.001) higher latex 
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 Table I. Effects of fi eld number on precision. 
Field number
Category 1 3 5
Accubeads high 14.0 (13.4 – 14.5) 6.8 (5.9 – 7.7) 4.0 (3.5 – 4.5)
Accubeads low 17.9 (15.8 – 20.0) 6.9 (3.3 – 10.4) 6.3 (2.9 – 9.7)
Immotile sperm 18.4 (14.0 – 23.0) 7.6 (6.1 – 9.2) 5.7 (4.4 – 7.0)
Motile sperm in semen 17.2 (7.9 – 26.5) 7.2 (0.3 – 14.2) 3.0 (0.5 – 5.6)
Motile sperm in media 15.7 (8.5 – 22.9) 8.2 (0.5 – 16.0) 6.3 (1.1 – 11.4)
 Ten separate fi elds were analysed per chamber by SCA CASA to generate a multiple fi eld CV%. The CV% 
was calculated for repeat measures of 1, 3 and 5 fi elds. 
 Figure 3. Motile Sperm Precision Profi le . Three or fi ve random fi elds 
were analysed for each Leja 20- μ m chamber by SCA CASA. Mean 
CV% are graphed against the mean number of sperm per fi eld for 
the chamber. 
bead counts than the central and proximal areas. This 
effect became insignifi cant once three fi elds of analysis 
including one proximal, central and distal fi eld were 
included for each count. Further tests of the SS effect 
on immotile sperm in semen demonstrated similar 
insignifi cance once three fi elds of analysis were used to 
calculate a mean count. 
 Recovery experiments 
 SCA CASA count estimations from sperm spiked into 
cell-free pooled seminal plasma and sperm-free seminal 
plasma with a high concentration of NCOS and de-
bris, demonstrated a large increase in sperm counts in 
samples with a high concentration of NCOS and debris 
(mean recovery for cell-free seminal plasma: 98%, mean 
recovery for NCOS and debris: 176%). 
 The observed positive bias with uncorrected CASA 
misidentifi cation of NCOS and debris as sperm, has the 
potential to result in clinically signifi cant misclassifi ca-
tion. Using the SCA CASA with no correction results 
in overestimations of counts at concentrations below 
15    10 6 . Approximately 80% of Neubauer and 33% of 
Leja 20- μ m count results between 1 and 5    10 6 were 
reclassifi ed by the CASA system as being signifi cantly 
higher. The SCA CASA system cannot be used without 
the addition of a corrective step at low concentrations. 
Uncorrected SCA CASA exhibited much improved 
performance at concentrations above 15    10 6 . In con-
trast to the uncorrected SCA CASA counts, the corrected 
SCA CASA counts at concentrations below 15    10 6 
displayed far greater agreement with the manual Leja 
20- μ m method. Using the manual CASA-corrected 
count to calculate sperm concentrations 30    10 6 or 
below and the automatic (uncorrected) CASA count 
for sperm concentrations above 30    10 6 results in high 
correlations (r 2    0.98,  p      0.0001) with the manual 
counting methods. 
 A comparison between the use of Improved 
Neubauer counts and CASA counts demonstrated that 
count data generated by CASA offered superior predic-
tion using ROC analysis. Improved Neubauer counts 
for sperm count gave an area under the curve of 0.50 
(95% CI 0.44 – 0.56), whole ejaculate counts 0.52 (95% 
CI 0.46 – 0.58) and inseminate counts 0.56 (95% CI 
0.50 – 0.62) (see Figure 4). In comparison, CASA sperm 
counts gave an area under the curve of 0.69 (95% CI 
0.57 – 0.81), whole ejaculate counts 0.68 (95% CI 0.56 –
 0.81) and inseminate counts 0.68 (95% CI 0.54 – 0.83) 
(see Figure 5). 
 Discussion 
 This study has provided the process validation required 
to adopt the SCA CASA system as the main method to 
count sperm in a busy UK diagnostic andrology labora-
tory. SCA CASA performed well against the Improved 
Neubauer chamber with the exception of low counts. 
A further method of counting low-sperm numbers 
 Figure 4. ROC analysis of sperm count, ejaculate count and inseminate 
count parameters by cycle. Eighty-six inseminates from men who 
achieved a pregnancy with their partner with IUI from that cycle are 
compared with 735 samples from men who failed to conceive with 
that cycle. All count data was generated from Neubauer. 
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directly from the CASA screen was developed. SCA 
CASA was very accurate with latex bead concentrations 
and correlated against one year of UKNEQAS at least 
as well as trained staff using manual methods without 
observable bias. The technology was generally well 
received by laboratory staff and has provided a rapid, 
precise method which counts far greater sperm numbers 
than are possible with traditional manual methods. 
 There are pros and cons of using Leja style 20- μ m 
chambers with CASA compared with manual haemo-
cytometers when the WHO recommendations (WHO, 
2010) are considered. The SCA CASA system is not 
advanced enough to count only whole sperm, thus all 
cells of similar size to sperm, including sperm without 
tails are counted. However several haemocytometer-
specifi c errors are avoided. The rigorous sperm head 
and tail position rules for counting sperm in relation 
to haemocytometer chamber grid lines are unnecessary. 
The problems associated with coverslips such as, cor-
rect thickness, poor fi t and whether or not to use clamps 
are removed. Likewise, dilution errors and positive 
displacement pipette errors are completely eliminated. 
Other sources of analytical error occurring from vortex-
ing, fi lling chambers, and time frames for analysis are 
also, at least in theory, reduced. 
 Manual semen analysis is a time-consuming process 
that needs to be performed to a high standard with 
trained individuals in laboratories with robust quality 
assurance in order to produce clinically relevant results 
(Tomlinson et  al., 1999; Bj ö rndahl et  al., 2004; Pacey, 
2006; Tomlinson et  al., 2010). However, the current 
cost pressures on laboratories are counterproductive 
to environments that produce such quality. CASA can 
remove some sources of analytical error, dramatically 
increase the number of sperm analysed, provide more 
rapid results than traditional analysis while minimising 
between-operator bias. The training is less intense than 
with manual methods and individuals are likely less 
inclined or able to drift from the method. With time, in-
creases in precision should yield more clinically relevant 
results and may remove some of the current concerns 
about semen analysis. 
 Uncorrected SCA CASA results correlated highly 
with Improved Neubauer and Leja 20- μ m chambers. 
However, low count (   30    10 6 ) correlations were poor, 
caused by erroneous counting of random small NCOS, 
cell debris and tailless sperm heads. This overestimation 
with CASA due to misclassifi cation of particulate debris 
has previously been recognised (ESHRE, 1998; Tom-
linson et  al., 2010) and appears to be a common CASA 
problem. The error still occurs at higher concentrations 
but because of a proportional effect it appears reduced 
in relation to the count. Using a combined approach 
of reporting uncorrected counts 30    10 6 or above and 
counting from the SCA CASA screen for results below 
30    10 6 , bias appeared to be minimal at the critical 
cut-off values for clinical reporting. 
 Precision of SCA CASA was generally excellent with 
optimal precision at 200 – 600 sperm per fi eld. This was 
true for both single and multiple fi eld precision tests. 
Large increases in imprecision were observed at descend-
ing concentrations below 100 sperm per fi eld, though 
it was demonstrated that mean results from three fi elds 
of analysis give acceptable precision for all categories 
tested. While increasing the fi eld number beyond three 
fi elds does decrease imprecision, the gain is not large 
and because of the corresponding time increase may not 
be warranted for routine diagnostic work. 
 In addition to count overestimation errors, several 
other specifi c types of errors were observed from the 
SCA CASA system. Infrequent counting errors oc-
curred when SCA CASA analysed phantom motile 
sperm; this was always graded as WHO class b motility 
and invariably occurs as multiple phantom tracks. This 
error appears to be the result of poor focus/contrast 
or dirty lenses/chamber. An additional infrequent er-
ror related to poor focus/contrast was the counting of 
immotile sperm twice. Both of these gross errors are 
easily identifi ed and removed by re-achieving Kohler il-
lumination/Phase contrast and cleaning and optimising 
the microscope. Additionally, sperm were occasionally 
not detected. However missed sperm were infrequent 
and while the CASA operator has the option of add-
ing the sperm back in manually, at 100    magnifi cation, 
each sperm added only increases the count by 0.2    10 6 
for that particular fi eld. Unless many sperm have been 
missed the error may be considered too small to war-
rant the time to correct. Another source of error pre-
viously described for 20- μ m chambers is the SS effect 
which relates to uneven fl ow of semen into the chamber 
(Douglas-Hamilton et  al., 2005a, 2005b). This current 
work found that by including one 100    magnifi cation 
fi eld from each area (distal, central and proximal) in 
the overall count, the SS effect was not statistically 
signifi cant. Nonetheless the authors believe signifi cant 
errors from the SS effect are still a possibility using this 
technology and should not be discounted. Staff using 
SCA CASA will have to be trained specifi cally to recog-
nise signifi cant errors and correct them. 
 Figure 5. ROC analysis of sperm count, ejaculate count and 
inseminate count parameters by cycle. Sixteen inseminates from men 
who achieved a pregnancy with their partner with IUI from that cycle 
are compared with 174 samples from men who failed to conceive with 
that cycle. All count data were generated from SCA CASA. 
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 The use of the method of performing manual Leja 
20- μ m chamber counts from the CASA screen for results 
below 30    10 6 removed the majority of the overestima-
tion bias, as counts above 15    10 6 were less affected. 
Nevertheless, even occasional counts above 30    10 6 
were signifi cantly affected due to other cells and debris. 
It cannot be overstated that signifi cant error due to mis-
identifi cation is possible at all concentrations using this 
technology. A recovery experiment designed to highlight 
this misidentifi cation error demonstrated a maximum 
count increase of 76%. However, the issue is somewhat 
alleviated by the well-described negative bias between 
20- μ m chambers using motile sperm and the Improved 
Neubauer chamber for fi xed sperm. Proportional overes-
timation by SCA CASA on Leja 20- μ m counts appears 
to produce a result closer to that achieved with Improved 
Neubauer than the Leja 20  μ m. While some overestima-
tion does occur on all samples, the overestimation ap-
pears to be proportional to the count and results in a 
fi nal count that correlates well against the Neubauer. 
 On the basis of this validation data, our laboratory 
adopted the SCA CASA system in May 2012 as the 
main method for counting sperm. It has performed well 
and is used for the vast majority of samples. However 
high-viscosity samples and samples with small NCOS 
or debris occasionally still require manual counting. 
Following up pregnancy success with ROC analysis has 
demonstrated that the predictive potential with the new 
counting system has exceeded the manual methods. 
However, it should be noted that this is not a like-for-
like comparison because the CASA technique had been 
adopted as the main counting method. Further data are 
required but these early results are indeed promising. 
 SCA CASA count technology is not a standalone 
 ‘ black box ’ but rather a tool for trained andrology staff 
that allows rapid, high-number sperm counting. Errors 
will occur and individuals using the system will need 
specifi c training on how to identify and correct these 
errors. Providing errors are corrected, SCA CASA will 
produce rapid, accurate, linear, precise results with 
less analytical variance than manual methods that cor-
relate well against the Improved Neubauer chamber. 
The SCA CASA counts in comparison with manual 
counts on IUI data with ROC analysis indicates that 
the increased analytical precision of CASA may herald 
better predictive outcomes in time. Further data from 
process validated CASA systems correlating CASA 
results with reproductive outcomes are required. 
 Acknowledgements 
 The authors would like to thank the staff of the 
Andrology Laboratory, Hammersmith Hospital, Impe-
rial College NHS Trust, and in particular Mrs Ivy Floyd 
for compiling the IUI data set. 
 Declaration of interest:  The authors report no decla-
rations of interest. The authors alone are responsible for 
the content and writing of the paper. 
 References 
 Agarwal ,  A.  &  Sharma ,  R.K .  (2007) .  Automation is the key to 
standardized semen analysis using the automated SQA-V sperm 
quality analyzer .  Fertility and Sterility ,  871 ,  156 – 162 . 
 Barratt ,  C.L. ,  Tomlinson ,  M.J. ,  &  Cooke ,  I.D .  (1993) .  Prognostic 
signifi cance of computerized motility analysis for in vivo fertility . 
 Fertility and Sterility ,  603 ,  520 – 525 . 
 Behre ,  H. ,  Yeung ,  C. ,  Holstein ,  A. ,  Weinbauer ,  G. ,  Gassner ,  P. , 
 &  Nieschlag ,  E .  (1997) .  Diagnosis of male infertility and 
hypogonadism . In:  Nieschlag ,  E. ,  Behre ,  H.M. (eds.) .  Andrology: 
Male Reproductive Health and Dysfunction .  Berlin: Springer , 
pp.  87 – 111 . 
 Bj ö rndahl ,  L.  &  Barratt ,  C.L .  (2005) .  Semen analysis: setting standards 
for the measurement of sperm numbers .  Journal of Andrology , 
 261 ,  11 . 
 Bj ö rndahl ,  L. ,  Tomlinson ,  M. ,  &  Barratt ,  C.L .  (2004) .  Raising standards 
in semen analysis: professional and personal responsibility . 
 Journal of Andrology ,  256 ,  862 – 863 . 
 Bonde ,  J.P.E. ,  Ernst ,  E. ,  Jensen ,  T.K. ,  Hjollund ,  N.H.I. ,  Kolstad , 
 H. ,  Scheike ,  T. ,  et  al .  (1998) .  Relation between semen quality 
and fertility: a population-based study of 430 fi rst-pregnancy 
planners .  Th e Lancet ,  3529135 ,  1172 – 1177 . 
 Brazil ,  C. ,  Swan ,  S.H. ,  Tollner ,  C.R. ,  Treece ,  C. ,  Drobnis ,  E.Z. , 
Wang ,  C. ,  et  al .  (2004) .  Quality control of laboratory methods 
for semen evaluation in a multicenter research study .  Journal of 
Andrology ,  254 ,  645 . 
 Check ,  J.H. ,  Bollendorf ,  A. ,  Lee ,  M.A. ,  Nazari ,  A. ,  &  Nowroozi ,  K . 
 (1990) .  Correlation of computerized semen analysis with 
successful fertilization of oocytes in an in vitro fertilization 
program .  Archives of Andrology ,  243 ,  229 – 234 . 
 Cooper ,  T.G. ,  Noonan ,  E. ,  Von Eckardstein ,  S. ,  Auger ,  J. ,  Baker ,  H.W.G. , 
 Behre ,  H.M. ,  et  al .  (2010) .  World Health Organization reference 
values for human semen characteristics .  Human Reproduction 
Update ,  163 ,  231 – 245 . 
 Douglas-Hamilton ,  D.H. ,  Smith ,  N.G. ,  Kuster ,  C.E. ,  Vermeiden , 
 J.P. ,  &  Althouse ,  G.C .  (2005a) .  Capillary-loaded particle fl uid 
dynamics: eff ect on estimation of sperm concentration .  Journal 
of Andrology ,  261 ,  115 – 122 . 
 Douglas-Hamilton ,  D.H. ,  Smith ,  N.G. ,  Kuster ,  C.E. ,  Vermeiden ,  J.P. , 
 &  Althouse ,  G.C .  (2005b) .  Particle distribution in low-volume 
capillary-loaded chambers .  Journal of Andrology ,  261 ,  107 – 114 . 
 Eliasson ,  R .  (1975) .  Analysis of semen. . In:  Behrman ,  S.J. ,  Kistner ,  R.W. 
(eds.) .  Progress in Infertility ,  vol. 2 .  Boston, Mass: Little, Brown  & 
 Co., pp.  691 – 713 . 
 ESHRE .  (1998) .  Guidelines on the application of CASA technology 
in the analysis of spermatozoa .  ESHRE Andrology Special 
Interest Group. European Society for Human Reproduction and 
Embryology.  Human Reproduction ,  131 ,  142 – 145 . 
 Garrett ,  C. ,  Liu ,  D.Y. ,  Clarke ,  G.N. ,  Rushford ,  D.D. ,  &  Baker ,  H.W . 
 (2003) .  Automated semen analysis:  ‘ zona pellucida preferred ’ 
sperm morphometry and straight-line velocity are related to 
pregnancy rate in subfertile couples .  Human Reproduction ,  188 , 
 1643 – 1649 . 
 Handelsman ,  D.J. ,  Conway ,  A.J. ,  Boylan ,  L.M. ,  &  Turtle ,  J.R .  (1984) . 
 Testicular function in potential sperm donors: normal ranges 
and the eff ects of smoking and varicocele .  International Journal 
of Andrology ,  75 ,  369 – 382 . 
 Keel ,  B .  (2004) .  How reliable are results from the semen analysis? 
 Fertility and Sterility ,  821 ,  41 . 
 Keel ,  B.A. ,  Stembridge ,  T.W. ,  Pineda ,  G. ,  &  Serafy ,  N.T .  (2002) .  Lack of 
standardization in performance of the semen analysis among 
laboratories in the United States .  Fertility and Sterility ,  783 , 
 603 – 608 . 
 Larsen ,  L. ,  Scheike ,  T. ,  Jensen ,  T.K. ,  Bonde ,  J.P. ,  Ernst ,  E. ,  Hjollund , 
 N.H. ,  et  al .  (2000) .  Computer-assisted semen analysis parameters 
as predictors for fertility of men from the general population . 
 Th e Danish First Pregnancy Planner Study Team.  Human 
Reproduction ,  157 ,  1562 – 1567 . 
 MacLeod ,  J.  &  Wang ,  Y .  (1979) .  Male fertility potential in terms of 
semen quality: a review of the past, a study of the present .  Fertility 
and Sterility ,  312 ,  103 . 
 Mahmoud ,  A. ,  Depoorter ,  B. ,  Piens ,  N. ,  &  Comhaire ,  F.H .  (1997) .  Th e 
performance of 10 diff erent methods for the estimation of sperm 
concentration .  Fertility and Sterility ,  682 ,  340 – 345 . 
 Matson ,  P.L .  (1995) .  External quality assessment for semen analysis 
and sperm antibody detection: results of a pilot scheme .  Human 
Reproduction ,  103 ,  620 – 625 . 
H
um
 F
er
til
 (C
am
b) 
Do
wn
loa
de
d f
rom
 in
for
ma
he
alt
hc
are
.co
m 
by
 U
niv
ers
ity
 C
oll
eg
e L
on
do
n o
n 0
9/0
3/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
44 C. Dearing et al.
Human Fertility
 NICE .  (2012) .  National Institute for Clinical Excellence .  CG11Fertility: 
Assessment and Treatment for People with Fertility Problems  [Online]. 
Available at:  http://www.nice.org.uk. [Accessed 30/07/2012]. 
 Pacey ,  A.A .  (2006) .  Is quality assurance in semen analysis still really 
necessary?  A view from the andrology laboratory.  Human 
Reproduction ,  215 ,  1105 – 1109 . 
 Riddell ,  D. ,  Pacey ,  A. ,  &  Whittington ,  K .  (2005) .  Lack of compliance 
by UK andrology laboratories with World Health Organization 
recommendations for sperm morphology assessment .  Human 
Reproduction ,  12 ,  3441 – 3445 . 
 Seaman ,  E.K. ,  Goluboff  ,  E. ,  Barchama ,  N. ,  &  Fisch ,  H .  (1996) .  Accuracy 
of semen counting chambers as determined by the use of latex 
beads .  Fertility and Sterility ,  664 ,  662 – 665 . 
 Shibahara ,  H. ,  Obara ,  H. , Ayustawati,  Hirano ,  Y. ,  Suzuki ,  T. ,  Ohno , 
 A. ,  et  al .  (2004) .  Prediction of pregnancy by intrauterine 
insemination using CASA estimates and strict criteria in patients 
with male factor infertility .  International Journal of Andrology , 
 272 ,  63 – 68 . 
 Sripada ,  S. ,  Townend ,  J. ,  Campbell ,  D. ,  Murdoch ,  L. ,  Mathers , 
 E. ,  &  Bhattacharya ,  S .  (2010) .  Relationship between semen 
parameters and spontaneous pregnancy .  Fertility and Sterility , 
 942 ,  624 – 630 . 
 Tomlinson ,  M. ,  Harbottle  S. ,  Woodward  B. ,  &  Lindsay  K. (eds.)  (2012) . 
 Association of Biomedical Andrologists Laboratory andrology 
guidelines for good practice .  Human Fertility ,  15 ,  156 – 173 . 
 Tomlinson ,  M.J. ,  Kessopoulou ,  E. ,  &  Barratt ,  C.L .  (1999) .  Th e diagnostic 
and prognostic value of traditional semen parameters .  Journal of 
Andrology ,  205 ,  588 – 593 . 
 Tomlinson ,  M.J. ,  Pooley ,  K. ,  Simpson ,  T. ,  Newton ,  T. ,  Hopkisson ,  J. , 
 Jayaprakasan ,  K. ,  et  al .  (2010) .  Validation of a novel computer-
assisted sperm analysis (CASA) system using multitarget-tracking 
algorithms .  Fertility and Sterility ,  936 ,  1911 – 1920 . 
 Vanweert ,  J. ,  Repping ,  S. ,  Vanvoorhis ,  B. ,  Vanderveen ,  F. ,  Bossuyt ,  P. ,  & 
 Mol ,  B .  (2004) .  Performance of the postwash total motile sperm 
count as a predictor of pregnancy at the time of intrauterine 
insemination: a meta-analysis .  Fertility and Sterility ,  823 ,  612 – 620 . 
 WHO  (1987) .  WHO Laboratory Manual for the Examination of Human 
Semen and Sperm-cervical Mucus Interaction .  Cambridge: 
Cambridge University Press . 
 WHO  (2010) .  WHO Laboratory Manual for the Examination and 
Processing of Human Semen, 5th ed .  Geneva: WHO Press . 
 Zinaman ,  M.J. ,  Uhler ,  M.L. ,  Vertuno ,  E. ,  Fisher ,  S.G.  &  Clegg ,  E.D . 
 (1996) .  Evaluation of computer-assisted semen analysis (CASA) 
with IDENT stain to determine sperm concentration .  Journal of 
Andrology ,  173 ,  288 – 292 . 
H
um
 F
er
til
 (C
am
b) 
Do
wn
loa
de
d f
rom
 in
for
ma
he
alt
hc
are
.co
m 
by
 U
niv
ers
ity
 C
oll
eg
e L
on
do
n o
n 0
9/0
3/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
1ORIGINAL ARTICLE
Trends and usage in a London National Health Service Sperm Bank  
for cancer patients
Chey Dearing1, Danielle Breen2, anne BraDshaw1, Jonathan ramsay1  
& Kevin linDsay1
1Andrology Laboratory, Hammersmith Hospital, Imperial College NHS Trust, London, UK and 2Oxford Fertility Unit,  
Institute of Reproductive Sciences, Oxford Business Park North, Oxford, Oxfordshire, UK
Abstract
sperm cryopreservation is the only method currently available that offers men with cancer insurance against sterilising iatrogenic 
treatments. we carried out two cohort and cross-sectional audits to identify trends with sperm cryopreservation referral rates and 
sample usage rates for men diagnosed with cancer and who banked sperm at The Andrology Laboratory, Hammersmith Hospital, 
Imperial College NHS Trust. these retrospective audits revealed that a total of 4362 men with cancer successfully banked sperm 
between 1976 and 2013. truncating the dataset to 2009 to allow for lag times between storage and use, the overall sample usage 
rate for cancer patients was 6.0% with 75 live births. increased median age at referral influences the cancer profile of men seen at 
the bank, which is highlighted by a disproportionate rise in the number of men with prostate cancer. among men who use banked 
sperm, a large rise in the use of intracytoplasmic sperm injection has occurred over time. the number of patients requiring the 
service is sharply increasing year on year as are the number of patients who go on to use their sample in assisted conception. the 
historical use rates of frozen sperm are likely to be significant underestimations of future use.
Keywords: Cancer, sperm banking, assisted conception
Introduction
sperm cryopreservation is currently the only method 
offering men insurance against sterilising iatrogenic 
treatments, most notably benefiting men with cancer 
requiring chemotherapy, radiotherapy and/or fertility-
affecting surgery (Pacey, 2007). as such, the current 
UK guidelines (rCP, 2007; niCe, 2013) agree that 
sperm banking should be universally available and fully 
funded by the nhs. a recent review (Pacey & eiser, 
2011) established that a significant number of patients 
do use banked samples in assisted conception, though 
this is only a fraction of the total number who initially 
store. however, the benefit from sperm banking cannot 
be measured solely in terms of the numbers of patients 
who go on to use their stored samples. many men, par-
ticularly those who initiate sperm storage themselves, 
gain significant psychological benefit from banking 
sperm, including a positive outlook for survival (saito 
et al., 2005; Pacey & eiser, 2011; eiser et al., 2011).
the poor semen quality of men with cancer referred 
for sperm storage is well established, with certain 
cancers associated with both specific and more pro-
found detrimental effects (Botchan et al., 1997; 
agarwal, 2000; hallak et al., 2000a, 2000b; trottmann 
et al., 2007; emerson & mocanu, 2010; van Casteren 
et al., 2010). apart from testicular cancer, which is 
particularly associated with a pronounced reduction in 
sperm quality due to its negative effects on spermato-
genesis (skrzypek & Krause, 2007; van Casteren et al., 
2010; wiser et al., 2010), the causes of poor semen 
quality in cancer patients are not well understood. 
hypothesised pre-existing defects, systemic cancer 
effects including malnutrition or stress, associated 
metabolic/endocrinal problems including bioactive 
substances or cytokines produced by tumors, hypo-
thalamus/pituitary gland tumour cell invasion and 
immunological disturbances have all been suggested 
(Barr et al., 1993; hallak et al., 1999; agarwal &  
allamaneni, 2005; sabanegh & ragheb, 2009; Dohle, 
2010).
the risk of infertility from the combined effects of 
cancer and cancer treatment can be almost certain for 
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some conditions and treatments: for example, 90% of 
hodgkin’s patients who receive greater than three cycles 
of nitrogen mustard, oncovin, procarbazine and pred-
nisone (moPP) demonstrate azoospermia over one 
year after treatment (lee et al., 2006). even for the few 
patients who do re-establish spermatogenesis af-
ter moPP, recovery may take longer than 10 years 
(marmor & Duyck, 1995). at the other extreme, 90% 
of patients following adriamycin, bleomycin, vinblas-
tine and dacarbazine (aBvD), which has now largely 
superseded moPP, have normal sperm counts after 
one year (tal et al., 2000). however, while the majority 
of patients will recover at least partial spermatogenesis 
following treatment (Bahadur et al., 2005; Pacey, 2007), 
it is not possible to predict accurately how any individual 
will respond to any given treatment.
the primary aim of these audits was to identify any 
trends occurring among cancer patients referred to our 
sperm bank. specifically, we wanted to examine trends 
in referral rates, sample use rates and patient ages. addi-
tionally, we sought to examine the cancer diagnoses that 
lead to sperm cryopreservation referral and the semen 
quality of those patients. to meet these aims, two audits 
were performed. audit one focused on all the men who 
banked sperm following a cancer diagnosis between 
1976 and 2013, to examine specifically the number and 
ages of patients referred for sperm cryopreservation. 
Because of the lag times between storage and sample 
use and the large size of the dataset, a smaller secondary 
audit was undertaken. this included all the men who 
banked following a cancer diagnosis between 1976 and 
2009, to examine (1) the proportion and demographic 
characteristics of men who use their sample in assisted 
conception, (2) the diagnoses leading to sperm cryo-
preservation and (3), the diagnostic relationship with 
semen quality before cryopreservation. the results of 
both audits were then examined to identify any trends 
occurring over time. the results will be used to direct 
efforts to improve our sperm cryopreservation service 
for cancer patients.
Methods
Local policy
the centre operates a “walk in” weekday and emergency 
out-of-hours service for iatrogenic sperm banking. we 
utilise a glycerol based multi-step slow freezing method 
and recommend that each patient stores a minimum of 
three ejaculates before treatment and more if quality is 
severely compromised. the stored samples are reviewed 
biannually, at which time electronic and paper records 
are matched with a physical audit of the samples in stor-
age. the samples continue in storage or are disposed 
within a six-month period after review or after obtaining 
consent for disposal. each patient’s medical require-
ments for extended storage are reviewed before a period 
of 10 years elapses from the initial storage date or last 
review date.
Audit one: Cancer patient referral numbers and ages
all cancer patients’ records from 1976 until 2013 stored 
in the the sperm bank database were downloaded into 
microsoft excel 2010 (microsoft excel v 14.0, micro-
soft, Berkshire, UK). the number of new patients being 
referred was examined over time. age at referral was 
compared over time.
Audit two: Usage, diagnosis and semen quality
the number of men using their stored samples in 
assisted reproductive technology (art) procedures and 
the ratio of patients using their samples to new patient 
referral were examined for the years 1976 to 2009. 
the sperm count of patients storing sperm was also 
collated to examine whether the quality of samples 
being stored changed over time. the median age at 
referral was compared for men who use their samples 
in art procedures, men who do not use their samples 
and men who are azoopsermic.
a summary of the latest available cancer statis-
tics was made from Cancer statistics registrations, 
england (series mB1), no. 42, 2011, released on 26 
June 2013 from the UK office of national statistics 
(o.n.s., 2013). the age ranges of all patients seen at 
the sperm bank were compared with the cancer profiles 
and age ranges for men in england in 2010.
Patients with a clearly identified referral cancer 
diagnosis were matched with pre-freeze semen 
analysis results from the first ejaculate stored. 
Patients without a specific cancer diagnosis but who 
had cancer, chemotherapy or radiotherapy recorded 
in their notes were grouped into an unknown cancer 
group. semen parameters were ranked and compared 
with the 2010 who reference range for fertile men 
(Cooper et al., 2010). identified cancer diagnoses 
(testicular cancers, hodgkin’s lymphomas, non-
hodgkin’s lymphomas, leukaemia’s, melanomas & 
myelomas, brain cancers, prostate cancers) were com-
pared for sperm count, semen volume, total motility, 
whole ejaculate count and total motile count (tmC). 
in addition, rates of cryptozoospermia (sperm only 
seen in centrifuged pellet and/or leja 100 chamber 
(Cooper et al., 2006)), and oligozoospermia (sperm 
count less than 15  106) were compared by cancer 
diagnosis.
Data were analysed from all cancer patients who 
stored and used their samples in art procedures 
between 1976 and 2009. these men transferred their 
sperm samples out of the bank for fertility treatments at 
other clinics. Clinics and patients were contacted to de-
termine which art treatment was used and to follow 
up live birth rates from those treatments. all patients 
had provided written consent to disclosure prior to 
storing their sperm. the semen profiles of the men who 
received fertility treatment with cryopreserved sperm 
were compared for each treatment type, for volume, 
count, total motility, and tmC.
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Statistics
the percentiles of semen analysis parameters were 
calculated for each of the cancer diagnoses and their 
medians were compared with Kruskal-wallis testing. 
semen analysis parameter percentiles were calculated 
for each art. significant differences were tested for with 
the mann-whitney U test. Differences in proportions 
of patients were tested with Fisher’s exact test. linear 
regression was used to examine the yearly increase in 
the number of new referrals, the number of men using 
their samples and the ratio of use to referral. the data 
was analysed using Prism version 4.0 (GraphPad Version 
4.01, San Diego, CA, USA, www.graphpad.com) on a 
samsung personal computer (Samsung NC10 Samsung 
Electronics, Samsung.com).
Ethical approval
all patients consented to their information being used 
for audit purposes. approval for the publication of these 
results was obtained from the Imperial College Healthcare 
National Health Service Information Governance.
Results
Audit one: Cancer patient referral numbers and ages
From 1976 until the end of 2013, the sperm bank at 
hammersmith hospital has frozen or stored after 
transfer a total of 4362 men’s semen samples frozen 
for fertility preservation before beginning cancer treat-
ment. During the first 13 years (1976–1989), sperm 
were banked for only 129 men. From 1990 until the 
end of 2013 the number of new patients increased lin-
early year on year (r2  0.96, p  0.0001) (Figure 1a). 
the magnitude of the increase may be highlighted by 
examining the number of new cases at the start of each 
decade: 45 new cases in 1990, 144 new cases in 2000 
and 310 new cases in 2010. also increasing linearly per 
year was the 25th percentile age (r2  0.46, p  0.0001), 
median age (r2  0.60, p  0.0001) and 90th percen-
tile age (r2  0.47, p  0.0001) of men storing, while 
a non-significant decrease in the minimum age is 
also apparent (Figure 1B). the median age for patients 
storing before 1990 was 26, which rose (p  0.0001) 
to a median age of 32 from 2005 onwards. the oldest 
patient storing sperm at the bank was 73 years old, 
while several 13 year olds represent the youngest 
patients to have banked. 782 teenage cancer patients 
(ages 13 to 19) have banked sperm at the centre.
Audit two: Usage, diagnosis and semen quality
From 1976 until the end of 2009, 3062 cancer patients 
had stored samples and 183 used their samples in art, 
which represents 6.0% of this total. Cancer patients who 
stored and later disposed of their samples are included 
in these figures. excluded from these figures were: 
unrecorded storage reason (171), non-cancer fertility 
or pre-vasectomy storage (126), biopsy cases including 
vasectomy reversal (27), retrograde ejaculation (6), sickle 
cell disease (4), hypergonadotropic hypogonadism (2), 
nephrotic syndrome (1) and ulcerative colitis (1). the 
usage figures varied considerably depending upon the 
time frame examined. a usage rate of 12.4% was seen 
in the cohort who stored from 1976 until the beginning 
of 1990. in contrast, between 2006 and 2009, 992 men 
stored and by the end of this period only 32 had used 
their sample, a usage rate of only 3.2%. examining the 
lag time between storage and use demonstrated that 
the majority of patients who used their stored samples 
did so within a five year period (Figure 2a). however, 
while the cumulative probability of use curve flattened 
after 5 years, a significant proportion (20%) of patients 
still used their samples after this period (Figure 2B). 
the longest time frame between storage and use was 
17 years - the donation from a 24 year old man in 1986.
year on year, the number of art procedures lin-
early increased (r2  0.95, p  0.005) though the ra-
tio of art procedures to new referrals did not. men 
who had stored and used their samples in assisted 
conception were, unsurprisingly, older (p  0.0001) 
at referral (median age 34) than all men who stored 
(median age 31). men presenting with azoospermia 
(10% of all men) were younger (p  0.0001) at referral 
(median age of 27) than men who stored and used their 
samples in assisted conception (p  0.0001) and all men 
who stored (p  0.0143).
Figure 1. (a) the number of new referrals for sperm cryopreservation are plotted by year. (B) the range, 25th, 50th and 75th percentiles of patients 
ages at referral are displayed by year.
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the most common diagnoses associated with sperm 
banking are those which affect men of reproductive age 
(table i). of the 3062 cancer patients, 45% did not 
have a specific cancer diagnosis recorded. these 1364 
patients could be identified from their notes as having 
cancer or receiving chemotherapy/radiotherapy, but a 
specific cancer diagnosis had not been recorded. this 
is unfortunately a major weakness with this dataset as 
the assumption cannot be made that missing diagno-
ses is a random event across oncology disciplines. the 
remaining 1698 patients with an identifiable cancer 
referral diagnoses showed that the greatest single referral 
diagnosis was that of testicular malignancies. the semen 
analysis results of all the 3062 patients demonstrate that 
cancer has a large detrimental effect on male fertility 
parameters including decreased semen volume, count 
and motility (table ii).
a hundred and eighty-three patients who stored 
between 1976 and 2009 before beginning cancer treat-
ment used their samples for assisted conception in 40 
fertility clinics. when contacted, 90% of the clinics and 
60% of the patients were able to provide assisted treat-
ment data. a hundred and nine patients received iCsi 
resulting in 59 live births, 18 received ivF with 7 live 
births while 23 patients received iUi with 9 live births. 
By far the largest group of patients receiving iCsi over 
other assisted conception treatments was of those with 
testicular cancer (96%). after 2004; iCsi also appeared 
increasingly to be the treatment of choice with cryopre-
served sperm (Figure 3). a proportion of this increase 
can be explained by the fact that poor quality samples 
were not stored as often as they are today; evidenced as 
a negative correlation between sperm count and storage 
year (r2   0.09, p  0.02). it must also be noted that 
we were unable to control for the historical availability 
of iCsi at UK clinics. although the majority of patients 
who received iCsi exhibited poorer semen quality with 
lower median sperm counts and motility than patients 
selected for iUi or ivF, a significant number of patients 
with a normal semen profile before cryopreservation 
also received iCsi (table iii).
Discussion
From 1976 until the end of 2013, over four thousand 
cancer patients have successfully stored semen samples 
at the hammersmith hospital sperm bank. this bank 
is thus one of the largest of its kind, with a wide age 
range (13–73 years old) of men storing and sample 
usage rates (6.0%) similar to those reported from 
other centres (ragni et al., 2003; Pacey & eiser, 2011; 
Bizet et al., 2012; Freour et al., 2012; rives et al., 2012). 
several local trends over time are identified: (1) both the 
total number of men referred for sperm banking and 
Figure 2. (a) the number of cancer patients using their sample in art are plotted by the number of years between storage and use. (B) the 
cumulative probability of use by year as a percentage of all patients who use their sample.
table i. median semen analysis parameter values of men with cancer (n  3062) compared by specific cancer diagnosis.
Diagnosis n Crypt. (%) oligo. (%) Count (106) motility (%) volume (ml) ejac. Ct (106) tmC (106)
Unknown Cancer 1364 3.5 25.4 37 37 2.5 93 34
lymphoma 301 2.0 22.3 42 35 2.5 105 36
testicular 617 9.4 40.4 20 36 3.0 60 21
leukaemia 352 11.1 33.2 34 30 2.5 85 25
mel. & myeloma 69 2.9 29.0 38 30 3.5 133 39
hodgkin’s 240 8.3 27.5 36 40 2.5 90 36
Brain 68 0.0 17.6 54 40 2.5 135 54
Prostate 51 0.0 23.5 69 38 1.5 104 39
Kruskal-wallis p 
K-w statistic
 0.0001
(96.7)
 0.0001
(35.9)
 0.0001
(39.6)
 0.0001
(61.6)
 0.0001
(34.6)
*Crypt., Cryptozoospermia (sperm only seen in centrifuged pellet and/or leja 100 chamber); oligo., oligozoospermia (sperm count less than 
15  106); ejac, ejaculate; mel., melanoma
Unknown cancer category not included in the Kruskal-wallis analysis.
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the number using their samples is increasing year on 
year; (2) the ages of men storing are increasing over 
time, which is beginning to influence the cancer pro-
files of patients who store; (3) a large increase in iCsi 
preference over other art for frozen/thawed sperm is 
occurring.
there are likely to be multiple factors responsible 
for the large linear patient referral increases seen at the 
bank. Previous studies have found that the predicted 
numbers of sperm banking patients, taken from from 
population statistics, and the incidence of cancer in men 
of reproductive age (o.n.s., 2013) are always greater 
than the number of patients actually referred for sperm 
banking (gilbert et al., 2010; Pacey & eiser, 2011). 
largely implicated has been under-referral due to a 
lack of information being given to patients, with 30–50% 
of patients not adequately informed about sperm stor-
age services generally (rieker et al., 1990; schover 
et al., 2002; edge et al., 2006). recent criticism of the 
lack of referral and the rising risk of patient litigation 
(lawford-Davies, 2009; gilbert et al., 2010; Pacey & 
eiser, 2011) may now be resulting in greater oncologist 
referral. increases may also be indicative of improve-
ments in cancer survival rates (Dohle, 2010) since with 
increased survival, patients become more concerned 
about quality-of-life issues such as fertility preservation 
(agarwal & allamaneni, 2005). thus, a greater number 
of men may be seeking the service as part of a generally 
improved positive outlook for life after cancer (Pacey 
et al., 2013). increased referral rates may also partially 
be a product of the annual increase of cancer diagnosis 
in men of reproductive age (steliarova-Foucher et al., 
2004); for example, testicular cancer cases in europe 
have roughly doubled in a decade and a half (Bray 
et al., 2006). while identifying which proportion of the 
observed increase in referral can be attributed to any in-
dividual factor is difficult to establish, it is certain that 
year on year a greater number of men access, and thus 
benefit, from the service. one of the reasons for this may 
be changing attitudes to age and reproduction.
the number of men with cancer who store at the 
bank and then go on to use their samples in art pro-
cedures is increasing. encouragingly, three quarters of 
cancer patients are now long-term survivors (Dohle, 
2010). with a greater number of men surviving cancer, 
a greater proportion of those who store wish to become 
fathers. the usage rates are also limited by the time 
frames examined and the ages of the patient storing. 
For example, a 13 year old who stored sperm in the year 
2000 will only reach the average age of first-time UK 
fathers (32; nie et al., 2010) in 2019. the significance 
of this cannot be overstated: 782 of the cancer patients 
storing were teenagers at the time of storage. historical 
usage rates are thus unlikely to be comparable with cur-
rent and future demands, particularly as cancer survival 
rates are likely to continue to improve.
Unfortunately, our 1976–2009 audit could only 
identify a specific cancer diagnosis in 55% of patients, 
thus a risk of bias cannot be removed. the patients sur-
veyed revealed that by far the greatest single referrals 
were from men with testicular malignancies, followed 
by leukaemia, non-hodgkin’s lymphomas and hodgkin’s 
lymphomas; data which are similar to previous reports 
(Dohle, 2010). these cancers represent only a small 
fraction of all diagnosed cancers among males in the 
UK, but are those most associated with reproductive 
age (o.n.s., 2013). however, this cancer profile is now 
being influenced by increasing (p  0.0001) median age at 
referral. this is demonstrated with a greater (p  0.023) 
proportion of men referred with a diagnosis of prostate 
cancer post-2008 compared with pre-2000. also con-
tributing is the improved diagnosis and increased preva-
lence of prostate cancer in young men (o.n.s., 2013). 
these figures may also in part be due to social change, 
with a greater number of older men having younger 
female partners who themselves wish to have children Figure 3. art selection for cryopreserved sperm is plotted by year.
table ii. semen analysis parameter percentiles for men with cancer compared with the who 2010 
reference values for fertile men (Cooper et al., 2010).
semen  
volume (ml)
sperm  
Count (106)
ejaculate  
Count (106)
total  
motility (%)
Percentiles Cancer who Cancer who Cancer who Cancer who
5 1.00 1.5 0.4 15 0.04 39 1 40
10 1.00 2.0 2 22 2.6 69 1 45
25 1.50 2.7 11 41 21 142 17 53
50 2.50 3.7 32 73 79 255 34 61
75 3.50 4.8 73 116 202 455 47 69
90 5.00 6.0 135 169 396 622 55 75
95 6.00 6.8 174 213 574 802 60 78
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and thus influence their partner’s decision on whether 
or not to bank sperm. Partners’ views have previously 
been shown to be important for influencing sperm 
banking decisions (eiser et al., 2011).
this current audit is in agreement with previous 
estimates, in that only about a third of men with cancer 
(van Casteren et al., 2008; Dohle, 2010) have a semen 
profile above the who threshold values (Cooper et al., 
2010). specific cancers are associated with specific 
semen parameter defects which may be of interest to 
sperm banks in selecting the cryopreservation method. 
For example, particularly low semen volumes were 
noted for prostate cancer sufferers and particularly 
low counts for testicular malignancies. the prevalence 
of oligozoospermia was highest for testicular cancer 
patients (40%), followed by leukaemia patients (33%), 
and other cancers (18–29%). this is a hierarchy similar 
to that reported previously though the actual prevalence 
rates differ markedly (Chung et al., 2004; trottmann 
et al., 2007). semen parameter characteristics between 
studies were also not directly comparable: median sperm 
counts from 240 patients with hodgkin’s lymphoma 
were notably higher (36  106) than those reported in a 
previous audit on 202 patients (22.7  106) (sieniawski 
et al., 2008). Differences between the prevalence of 
oligozoospermia or semen parameters may be due to 
differences between fertility-affecting cancer symp-
toms or cancer stages. For testicular cancer patients, 
spermatogenesis defects are higher in tissue in close 
proximity to the tumour (ho et al., 1992): patients with 
larger or more invasive tumours will have higher lev-
els of spermatogenetic defects and a higher prevalence 
of oligozoospermia. Differences in inclusion criteria, 
changes in who reference values and inter-laboratory 
differences are also likely confounders.
For men who store samples with few or even a single 
sperm, iCsi is the only realistic chance for fathering 
their own genetic offspring. in this regard, iCsi has 
revolutionised the value of sperm cryopreservation and 
enabled many men to become fathers who otherwise 
would not. however, while the results of this audit do 
highlight markedly decreased semen parameters for 
men with cancer, not all men with cancer suffer poor 
semen quality. 73% of all patients received iCsi and yet 
the 50th percentile semen parameters were a volume of 
2.5 ml, count of 32  106 and tmC of 27  106. since 
only relatively recent advances in art have enabled 
paternity with very poor quality semen, such samples 
have not historically been stored as often as they are 
today; an increase in iCsi treatments is somewhat an 
expected result. however, even taking this into account 
and considering the well documented negative effects 
of cryopreservation (Keel et al., 1987), iCsi treatment 
selection appears to be occurring for some patients 
irrespective of sample quality. limitations in the quan-
tity of material being stored for cancer patients may be a 
factor. the criteria employed to select patients for iCsi 
have previously been shown to be heterogeneous in 
the UK (Jones et al., 2012) and we are concerned that 
iCsi may be overused in this particular patient group.
10% of cancer patients seen at the bank are azoo-
spermic; a figure similar to previous reports (Dohle, 
2010). these men were younger at referral (p  0.0143, 
median 27) than all those who stored (median 31) 
and those who used their samples in art (p  0.0001, 
median 34). Unfortunately, scenarios like azoospermia 
or non-sample production appear to increase the emo-
tional distress for some young men. however, it is not 
currently possible to predict who is azoospermic or will 
fail to produce a sample. neither is it possible to pre-
dict for an individual, which cancers or treatment will 
result in permanent damage to the gonad (Bahadur 
et al., 2005). additionally, if men find they are infer-
tile after cancer treatment and sperm cryopreservation 
is not offered, litigation may be a real possibility 
(tomlinson & Pacey, 2003; lawford-Davies, 2009; 
Pacey & eiser, 2011). sperm banking therefore has to 
be offered to all men at any risk of infertility.
encouragingly, although sperm banking for cancer 
has historically been underutilised nationally and 
internationally by referring clinicians and patients, the 
local referral rates for sperm cryopreservation are ris-
ing sharply. similarly, the numbers of local men who 
store and then go on to use their samples with art is 
also increasing the historical use rates of frozen sperm 
are therefore likely to be significant underestimations of 
future use. older men are seeking the service, which is 
beginning to influence the cancer profiles of men storing 
samples; a greater proportion of men are storing with 
a diagnosis of prostate cancer. iCsi is overwhelmingly 
becoming the assisted conception treatment of choice 
with cryopreserved sperm. establishing an evidence 
base for art procedure selection following sperm 
cryopreservation and attempting to develop more 
table iii. Percentiles of pre-freeze semen characteristics are compared by post-thaw aFt selection.
volume (ml) Count (106) tot. motility (%) total motile Count (106)
Percentiles iUi ivF iCsi iUi ivF iCsi iUi ivF iCsi iUi ivF iCsi
5 1.0 1.0 1.0 2 3 0.01 3  1  1 0.36  0.01  0.01
10 1.0 1.0 1.5 8 11 0.4 5 5 1 2.25 1.93 0.01
25 2.0 2.0 2.0 36 34 1 29 27 1 21.90 17.64 0.06
50 3.0 2.5 3.0 52 81 18 40 40 20 58.80 72.00 7.20
75 4.0 4.0 4.0 89 112 50 50 55 39 109.26 163.50 35.61
90 5.0 5.3 5.0 150 219 96 60 61 50 167.40 230.55 86.20
95 5.7 6.0 6.0 241 364 134 65 63 53 227.08 340.28 196.40
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patient individualised approaches to sperm cryopreser-
vation may be useful areas to improve future services. 
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